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Abstract  
Introduction: Despite the importance of pharmacokinetic (PK) information for patient 
management there are low numbers of paediatric PK studies and little guidance available on 
optimum study design and conduct.    
Method: Drawing on Implementation Science, a mixed-methods study was conducted, 
including a scoping review (SR) (PK literature: 1990-2015) and quantitative and qualitative 
inquiry (stakeholders: lay population, service users and health-care professionals). Aim: to 
explore the feasibility and acceptability of paediatric PK research. 
Results: The SR (203 papers) highlighted significant problems with participant recruitment, 
retention and sampling. Stakeholders (n=240) added insight into these phenomenon, with 
lack of research staff, additional blood-sampling and appointments highlighted as significant 
barriers to recruitment and conduct. Facilitators included sensitivity and timeliness of 
approach, communication, involvement of child/young person (CYP) in decision-making, 
engagement between research and clinical teams, reassurance of safety, pain minimisation, 
and avoidance/reduction of burden to the CYP and family.   Dedicated research support was 
viewed as critical to success. 
Discussion:  PK research was viewed as feasible and acceptable by service users and health 
professionals, even in the context of critical illness.  Novel, evidence-based, patient-centred, 
recommendations for future PK study conduct and design have been generated which are 
applicable for those designing, approving and implementing PK research.  
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Chapter 1. Introduction 
1.1 Paediatric medicines 
Children and young people (CYP) have a fundamental right to safe and effective medicines 
(Royal College Paedatrics and Child Health, 2004, Choonara and Sammons, 2014).  In the 
past infants and children have suffered serious harm because of exposure to inadequately 
investigated medications (Sutcliffe, 2003, Kemper et al., 2011). A number of studies have 
established the widespread use of off-label medicines (outside of the license with respect to 
dose, route of administration, indication, contraindication or age of a recipient) or as an 
unlicensed preparation (Turner et al., 1996, Turner et al., 1998, Conroy et al., 2000, 't Jong et 
al., 2001, O'Donnell et l., 2002, Barr et al., 2002).  The consequences of this are prescribers 
often have no alternative but to resort to off-label products, without evidence based 
information to guide them in assessment of the risks and benefits of the medicine (Turner et 
al., 1999, Conroy et al., 1999, Conroy et al., 2000, Vermeulen et al., 2017).   This places CYP 
at risk of harm (European Medicines Agency, 2004). Wherever possible, doses should not 
simply be scaled linearly from a known adult dose (Royal College Paedatrics and Child 
Health, 2004, Bartelink et al., 2006, Anderson, 2011, Vermeulen et al., 2017).  Childhood is 
characterised by periods of rapid growth, maturation and development and many 
physiological changes occur which have an impact on the absorption, distribution and 
elimination of medicines (Nunn and Williams, 2005, Kemper et al., 2011, Batchelor and 
Marriott., 2014). Safe and effective prescribing in children is impossible without a 
fundamental understanding of how development influences variables such as hepatic 
enzyme systems, renal clearance of drugs and their metabolites and relative size of body 
compartments (Anand et al., 2005, Tod et al., 2008, Batchelor and Marriott, 2014).  PK 
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research should be performed in different age groups to support formulation development 
and determine the PK parameters to support dosing recommendations (ICH E11 guidelines) 
(European Medicines Agency, 2001). Research is also required in  diseases which are unique 
to CYP, where the relevant knowledge cannot be obtained by research with adults or where 
the trajectory of the disease is different from that in adults (Royal College of Paediatrics and 
Child Health Ethics Advisory Committee, 2000, European Medicines Agency, 2001, European 
Medicines Agency, 2006, Kleiber et al., 2017).     In 2007 European legislation was introduced 
to ensure that medicinal products used with CYP are subject to high quality research and 
improve the information available on their use (Permanand et al., 2007). These legislative 
changes have encouraged the pharmaceutical industry to study medicines in CYP (European 
Parliament and the Council of the European Union, 2006, Kleiber et al., 2017).  As a result 
there are more clinical trials in paediatric patients (Kemper et al., 2011).  However, there are 
concerns that these reflect those that bring the greatest financial benefit to the 
pharmaceutical industry (Choonara and Sammons, 2014) and there is still substantial 
discrepancy between paediatric burden of disease and the volume of clinical trials taking 
place (Bourgeois et al., 2012).  
1.2 Paediatric Intensive Care setting 
The situation is compounded by critical illness.  The proportion of off-label or unlicensed 
drugs can reach up to 70% in Paediatric Intensive Care Units (PIC) (Turner et al., 1996) and 
90% in Neonatal Intensive Care  (Conroy et al., 1999) putting them at greater risk of possible 
treatment failure or toxicity.    In addition, critically ill children can receive up to 18.5 
different drugs during a PIC admission (median 14) with up to 129 drug administration 
episodes (median 58) (McDonnell et al., 2009) putting them at risk of an adverse drug 
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reaction or interaction.  Pasquali et al (2008) highlight that multiple off label prescribing is 
common with 48% (of 31, 432 paediatric patients who had cardiovascular disease) receiving 
two or more cardiovascular drugs off label and 31% receiving three or more medications.  
Organ dysfunction is also common in such groups with 50% of patients in PIC exhibiting two 
or more dysfunctional organ systems (Leteurtre et al., 2006). This may modify drug 
absorption, metabolism, elimination further, altering the expected response to standard 
doses and increase the risk of toxicity and other adverse drug events (Kearns et al., 2003a, 
Thakkar et al., 2017).   In PIC patients at a local level, around 90% of patients experience 
single organ failure, requiring invasive ventilation (PICANet, 2016), and many also require 
additional complex interventions such as Extra Corporeal Membranous Oxygenation (ECMO) 
and renal replacement therapies. ECMO is known to affect pharmacokinetic profiles in 
critically ill patients and guidance for dosing in these patients is challenging (Mousavi et al., 
2011, Thakkar et al., 2017).  It is therefore imperative that the number of trials in children 
continues to grow in order to create a child-specific evidence base which is methodologically 
strong and relevant (Klassen et al., 2009).  Research is needed to improve care in urgent and 
emergency situations but should only be undertaken in these situations if absolutely 
necessary and if non-emergency research will not resolve the uncertainties (Modi et al., 
2014). 
1.3 Pharmacokinetics: what is it and why is it important? 
The scientific study of medicines in children is known as paediatric clinical pharmacology 
(Hoppu, 2008).  Pharmacokinetics is the scientific study of how the body handles a medicine 
and describes the movement of drugs through the body over time and addresses the 
absorption, distribution, metabolism and elimination from the body (Thomson, 2000, 
4 
 
Kanneh, 2002a, Kanneh, 2002b, Vermeulen et al., 2017).  The scientific information 
generated from pharmacokinetic studies and studies of drug toxicity ensure that medicines 
are used rationally in children (Choonara and Sammons, 2014).  Pharmacokinetic studies 
have traditionally required a rigid, experimental design with serial multiple blood sampling, 
usually taken according to a rigidly timed and structured protocol within a relatively small 
patient population (Royal College Paedatrics and Child Health, 2004, Patel et al., 2010, 
Thomson and Elliott, 2011).  Although this conventional approach leads to an accurate and 
precise estimation of PK parameters its feasibility and interpretation are limited by several 
factors, including difficulties in recruitment, patient selection and blood loss (Wurthwein et 
al., 2005).   
1.4 Challenges of conducting pharmacokinetic research 
1.4.1 Consent 
Conducting clinical trials in the Paediatric Intensive Care (PIC) environment is recognised as 
having very specific challenges (Kanthimathinathan and Scholefield, 2014).  Parents need to 
make informed decisions about participation at times of uncertainty and when experiencing 
extreme anxiety (Kleiber et al., 2015).  Historically there has been a reluctance to recruit 
‘vulnerable’ patients to research studies, fearing of adding to the burden families already 
experience (Michelson et al., 2006).  In addition Research Ethics Committees have also 
expressed concerns about involvement of children deemed vulnerable (Angell et al., 2010).     
Clinical trials conducted within life threatening situations are impeded by the difficulty of 
obtaining traditional informed consent during clinical stabilisation.  A number of studies 
have explored the feasibility and acceptability of methods where consent is gained after the 
investigatory treatment has been given (Morris et al., 2004, Morris et al., 2006, Gamble et 
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al., 2012).  In the UK his has been termed ‘deferred consent’ or research without prior 
consent (Woolfall et al., 2015). This approach was legalised in the United Kingdom in 2008 
and was utilised in a large Randomised Controlled Trial (RCT) of Central Venous Catheters in 
14 PICs across England and Wales (the CATCH trial) (Gilbert et al., 2016).  Deferred consent 
was obtained for 84% of families who were approached, indicating that deferred consent 
was an effective strategy for recruitment within the high stress environment of PIC (Harron 
et al., 2015).  Further studies indicate that parents support the approach in a paediatric 
emergency situation such as Status Epilepticus (Chamberlain et al., 2009, Woolfall et al., 
2014) and this could extend to other situations where urgent action is required, such as 
obtaining PK levels of a medication administered within an emergency.  Further work is 
required to explore the perspective of CYP and parents within this specific area.  
1.4.2 Sampling from peripheral vascular access  
Many PK study protocols refer to the use of peripheral vascular access (cannulas) as the 
source for blood sampling.  Not only can initial placement of cannulas in children and young 
people be extremely challenging (Latour, 2000), but obtaining blood samples by ‘bleeding 
back’ cannulas on an on-going basis can be challenging due to distress and the requirement 
to cooperate (Becht and Anderson, 1996, Hands et al., 2010, Thomson and Elliott., 2011).    
In addition, many protocols make specifications that there must be a second cannula 
specifically for sampling. Protocols can stipulate placement in an extremity and in some 
cases require placement in a contra-lateral limb to where an intravenous medication is being 
administered, to avoid ‘downstream contamination’  (Kauffman and Kearns, 1992).  These 
rigid requirements are challenging for CYP, particularly when studies can request 14 samples 
within 24 hours (Su et al., 2010, Kukulka et al., 2014).  
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1.4.3 Pain 
Children’s adverse reactions to medical situations has long been recognised (Prugh et al., 
1953).  Undergoing invasive or painful medical procedures causes distress and anxiety (Duff, 
2003, Dlugos et al., 2005, Hands et al., 2010) and there is also recognition that children can 
become distressed by equipment or the setting or even because of memories of pain from 
earlier experiences (Von Baeyer et al., 2004).  Procedures involving needles seem to be 
particularly difficult for young children (French et al., 1994) and a traumatic experience can 
cause fear and anxiety for future procedures in hospital (Gilboy and Hollywood, 2009).    
1.4.4 Topical anaesthetic agents  
Using topical anaesthetic agents is the gold standard for children who require venepuncture 
for reducing pain (Cordoni and Cordoni, 2001). Use of EMLA cream has been shown to 
significantly decrease pain scores in adults during venepuncture compared with placebo 
(Hijazi et al., 2009) and paediatrics (Hopkins et al., 1988) and topical refrigerant spray has 
also been shown to be effective in paediatric patients for venepuncture (Schlieve and 
Miloro, 2015). However despite the known negative effects of anxiety on the perception of 
pain (Kolk et al., 1999), analgesia is not always used for venepuncture in children  (Hands et 
al., 2010).   
1.4.5 Alternative strategies 
The use of play therapy and other distraction techniques to reduce the distress associated 
with venepuncture has also been described within the published literature (French et al., 
1994, McCarthy and Kleiber, 2006).  Rates of use vary, with techniques used in only  23-28% 
of venepuncture attempts (Ellis et al., 2004, Hands et al., 2010) .  There are suggestions that 
preparing CYP for a procedure is related to less child distress (Kolk et al., 1999), however, 
providing information and preparing CYP is often dependent on parent attitudes. If parents 
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have a favourable attitude towards healthcare, they provide better preparation (Rodriguez 
et al., 2012).  In addition, the attitude of clinical staff can heavily influence the conduct of a 
procedure (Ellis et al., 2004).  Analgesia, distraction, play, parental presence and better 
information about procedures all influence CYP and parent views in clinical practice. It is 
likely that these will also impact on the approach and discussion about research with both 
CYP and parents. Further work is required to determine the optimum combination for 
research participation.  
1.4.6 Use of central vascular access or arterial lines  
To reduce additional painful procedures there is the possibility of using central venous lines 
(CVL) or arterial lines (indwelling lines) to access samples (European Medicines Agency, 
2001, Thomson and Elliott, 2011).  Traditionally many studies have not accepted this 
approach, fearing contamination of samples.  A study comparing readings from paired 
peripheral and central venous line (CVL) samples for Cyclosporin levels found that there was 
no significant difference in the concentration by sampling site.  This meant samples obtained 
from the CVL were reliable and therefore children did not require additional painful 
venepuncture (Senner et al., 2005).   Using existing lines is relatively quick and simple 
allowing timely collection and minimal disruption to patients (Salazar, 2003).  However, 
there are issues associated with staff competence and expertise to access central venous 
and arterial lines (Altamimi et al., 2016). In addition, placement of arterial lines usually 
requires close observation in an area such as PIC (Way, 2000).  
Using analgesia, distraction, play, parental presence, better information about procedures 
and the use of clinically indicated vascular access devices to obtain samples (and avoid pain) 
will impact on the approach and discussion about research with both CYP and parents. 
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Further research is required to determine the optimal combination for research 
participation.  
1.4.7 Anaemia and infection risk  
There are significant concerns about the impact of blood sampling on children for clinical 
indications.  Historically PK studies involved the collection of numerous blood samples (as 
many as 15-20) in addition to clinically indicated blood tests (Choonara and Sammons, 2014)  
This creates concerns for clinical staff about reduction in Haemoglobin from participation in 
a clinical pharmacology study as well as increased infection risk factors associated with the 
frequency with which a central line may be accessed (Cole et al., 2006). There are 
discrepancies in recommendations for acceptable blood volumes for PK research. Blood 
sampling practice varies in published studies from 1ml/kg of total blood volume (Allegaert et 
al., 2008), 1.5 ml/kg if above 12 months of age (Kearns et al., 2000), 1.8ml/kg (Allegaert et 
al., 2007), no more than 1% of circulating volume (Turanlahti et al., 2004), less than 3% of 
circulating volume (Reed et al., 1996, Haig et al., 2001), less than 5% of the estimated 
circulating volume (Ala-Kokko et al., 2005) to a total of 70mls/patient (Agertoft et al., 1999).  
This lack of concordance creates confusion for researchers and for those who regulate 
research from an ethical perspective (Koren et al., 1988, Sammons et al., 2007b).  These 
potential extra risk factors associated with PK research participation may impact on clinical 
staff, parents and children’s decision making about study enrolment.  
In summary, there are indications from the literature that consent, pain, sampling, anaemia 
and infection might all cause issues to PK research studies.  Pharmacokinetic studies have 
tended to involve serial sampling of multiple bloods, usually taken according to a rigidly 
timed and structured protocol within a relatively small patient population (Royal College 
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Paedatrics and Child Health, 2004, Patel et al., 2010, Thomson and Elliott, 2011). It would 
therefore seem likely that recruitment to such studies would be challenging (Wurthwein et 
al., 2005) and researchers need to think creatively to find solutions.  
1.5 Overcoming challenges 
Within the PK literature researchers have identified methods which could potentially 
contribute to overcoming challenges associated with PK trial conduct.     
1.5.1 Population based pharmacokinetic modelling 
Population based pharmacokinetic modelling to support clinical trials can reduce the 
number of samples required from each individual within a population by increasing the 
overall population size (Batchelor and Marriott, 2013). The advantage for paediatric trials is 
that fewer samples are required per individual (a sparse data approach) and there can be 
flexibility in the sampling times (Vermeulen et al., 2017, Barker et al., 2018).  Overall this 
means there is less disruption to the patient and their clinical care (Bartelink et al., 2006, 
Ahsman et al 2010, Thomson and Elliott, 2011).  The population PK approach is generally 
used in patients being given the drug therapeutically and therefore poses fewer ethical 
issues about the exposure of children to experimental medicines (Hawcutt and Smyth, 
2008).  This approach is increasingly evident in the literature (Tod et al., 2008, Barker et al., 
2018) and would seem to overcome some of the issues associated with painful additional 
procedures.  There are also examples of patients being randomised to different sampling 
‘windows’ with a specific regime. For example group 1 has samples at 1 hour and 4 hours 
and group 2 has samples at 30 minutes and 2 hours  (Simpson et al., 2006).  This method is 
felt to be valuable, provided that the actual sample time is accurately recorded (Thomson 
and Elliott, 2011). However, with participants providing fewer samples, there are 
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implications if samples are not obtained. It is not known whether using principles of 
population PK modelling would affect recruitment or how patients and their families make 
sense of this approach.   
1.5.2 Combining research and clinical care  
Studies which are conducted in the context of routine clinical care are much more likely to 
be ethically justifiable and scientifically desirable (Thomson and Elliott, 2011).  It therefore 
follows that arranging for blood samples to be taken for research and for routine purposes 
at the same time is a useful starting point for a study (Wintermeyer et al., 1997, European 
Medicines Agency, 2001, Nielsen et al., 2009, Hawcutt and Smyth, 2008).  Opportunistic 
sampling is not widely described but could contribute to a population PK approach. 
However, if the blood is difficult to draw clinical requirements should take priority, which 
could potentially lead to the loss of research data.  Another approach would be to use 
samples taken for routine clinical monitoring (Saez-Llorens et al., 2009a) so there are no 
‘additional’ samples required or to utilise blood left over after other tests have been 
conducted; opportunistic sampling or ‘scavenged samples’ (Leroux et al., 2015). An 
alternative would be that additional samples, samples taken specifically to measure PK for 
research purposes could be made available for clinical management.  This method does not 
appear to be widely practiced, however, it would be interesting to know the perspective of 
service users and health professionals on this strategy and whether this would be a useful 
addition to clinical management.   
1.5.3 Innovations in sampling  
Traditionally the preferred fluid for obtaining repeated assessments of drug concentration 
has been blood.  However in paediatric patients ethical, physiological and sometimes 
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practical limitations influence the availability of biological samples required for 
pharmacokinetic studies (Kauffman and Kearns, 1992).  Drug assay concentrations from non-
blood samples can be used in some circumstances in order to establish pharmacokinetic 
information.  Approaches such as the use of saliva may offer the possibility of replacing 
blood levels of certain drugs (Wells et al., 2009).  In a study examining parental attitudes to 
DNA studies, after using residual dried blood spots from newborn screening (which had 
already been taken), buccal cell collection was parents’ next preferred method (Jenkins et 
al., 2009).  Whole blood spotted onto filter paper- dried blood samples- is a well-established 
technique for collecting and storing blood in screening newborns for genetic and metabolic 
disorders (Carpenter and Wiley, 2002). However some researchers have utilised the 
technique for drug monitoring in vulnerable groups such as neonates (Patel et al., 2013).  
The main advantage is that samples are micro-volume, stable at room temperature for 
relatively long periods and they present less of a biohazard for transportation (Patel et al., 
2010).  Given the concerns that exist over sampling volumes in vulnerable populations, 
techniques which support micro-sampling, with low volumes of blood are increasingly 
popular.  
Urine has often been included as a potential alternative with studies comparing the results 
obtained with plasma concentrations. However, unless a patient has a medically indicated 
indwelling bladder catheter the collection of timed, quantitative urine specimens could be 
problematic in infants and young children (Walker, 2000).   
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In summary, there are emerging methods to reduce painful procedures, reduce the sampling 
demands and attempts to reduce the invasiveness of PK trials.  The next stage is to assess 
the acceptability of these methods to potential participants and their families.  
1.6 Situation in 2009 
At the time when the PhD funding was awarded for the project research in children of any 
age represented only around 1 in 10 of all applications to the National Research Ethics 
Service, of which less than 10% were trials of an investigational medicinal product (Modi and 
McIntosh, 2011). Protecting children in research seemed to have translated to excluding 
children from clinical trials (Knox and Burkhart, 2007).    Across Europe there was a 
recognition that children were being neglected and that medicines used for children should 
be scientifically evaluated for both efficacy and toxicity (Hoppu, 2008).  European regulations 
had been established requiring  pharmaceutical companies to conduct and share 
information regarding trials in paediatric populations, including encouraging the provision of 
licensing information for older off-patent drugs as well as newly developed medicines 
(Sutcliffe and Wong, 2006, Modi and McIntosh, 2011).      Medicine research in children was 
recognised to be a priority area with the creation of the National Institute for Health 
Research (NIHR) Medicines for Children Research Network (MCRN) (Saint-Raymond and 
Seigneuret, 2005, Duffin, 2007, Sammons and Choonara, 2007, Choonara and Bauchner, 
2008).  The award was made for the PhD, which came to be termed PRESCRIBE; 
Pharmacokinetic RESearch in CRitically Ill children: facilitating the BEst design to review the 
design of PK research.  The focus was on research with acutely ill CYP, therefore the project 
is reflective of academic-led protocols and research, conducted within the NHS. As industry-
sponsored studies can take place within paediatric NHS organisations, study participants 
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could, and did, reflect on these. Industry work conducted within Clinical Research 
Organisations was not included (unless participants’ had specific experience of these and 
chose to reflect on these experiences).  
1.7 Reflexivity 
Qualitative research stresses the importance of reflexivity, whereby the researchers 
recognise they have a social identity and background that has an impact on the research 
process.  Reflexivity will reveal the researchers’ own particular position and the factors 
which may have influenced interpretation should be made clear (Carter and Goodacre, 
2012).  Adopting a review of the researcher (JCM) there were three key aspects which could 
influence the conduct of the research. The influence of the researcher as a nurse (Registered 
Nurse since 1997), research nurse; formerly with the NIHR clinical research network (West 
Midlands) and at the time of the research the PIC nursing research team manager, and the 
influence of being a parent (from 2012). Figure 1 below summarises the key factors 
associated with each role and the positive and negative influence of each. To promote a self-
critical stance to the research the researcher had regular supervision, during which the 
influences of all these components were reviewed.  A summary of the influence of these 
throughout the project is included in Chapter 9 (see 9.3 Reflexivity). 
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Figure 1: reflexivity on JCM as researcher, research nurse and parent   
 
1.8 Evidence based medicine and implementation science 
Evidence based practice (EBP) is the conscientious, explicit and judicious use of current best 
evidence in making decisions about the health care of patients (Sackett et al., 1996). The 
evidence based ‘movement’ has been widely adopted across health and social care as a 
strategy for providing the highest quality of healthcare (Craig and Stevens, 2012).  However 
there is evidence that research has a disappointing impact on practice (Nutley et al., 2000).  
Research cannot change outcomes unless health services and healthcare professionals adopt 
the findings into practice (Eccles and Mittman, 2006).  The basis of PRESCRIBE is about 
understanding factors affecting the conduct of PK research however the output is guidelines 
to assist future researchers in PK study conduct.  How the work would fit into the context of 
care and be of practical utility for staff was therefore fundamental to the project.  The 
literature surrounding EBP was therefore reviewed and identified the relevance of 
implementation Science- associated with the issue specifically of implementing research 
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evidence into practice (Ferlie et al., 2000, Grol and Grimshaw, 2003, Eccles and Mittman, 
2006).   Implementation models are commonly used to describe and guide the process of 
translating research into practice and within these determinant frameworks are those that 
seek to identify barriers or enablers that are important to address  (Nilsen, 2015, Birken et 
al., 2017).  The most widely used of these approaches is PARIHS (Promoting Action on 
Research Implementation in Health Services)  (Kitson et al., 1998a, Kitson et al., 1998b) 
which emphasises the importance of ‘evidence’, ‘context’ and ‘facilitators’.  This was the 
model initially felt to be the most appropriate.  
The scoping review of the literature would provide insight into the facilitators and barriers 
that have been identified with published PK studies (‘evidence’).  The qualitative enquiry 
would provide insight into lay and professional views and attitudes toward PK research 
through targeted stakeholder groups in the context of both ward areas and PIC (‘context’) 
and from all of this the support (‘facilitation’) needed to help people change their attitudes, 
habits, ways of thinking and working identified.   However it became apparent for the 
purposes of PRESCRIBE the model did not give sufficient attention to the stakeholders; the 
people both affected by and who influence potential implementation (Thompson, 2012, 
Rycroft-Malone et al., 2013).  Nor did it help with differentiation between issues at the local 
level and those within the wider organisation.  In recognition of this the i-PARIHS approach 
which has been developed from PARIHS was adopted.  Please see Figure 2 below.  
 
  
 
 
16 
 
Figure 2: I-PARIHS key components (Harvey and Kitson,2016)  
 
 I-PARIHS (Integrated-PARIHS framework) builds on the original approach, developing the 
concepts of evidence to ‘innovation’, context and facilitation and introducing a new 
construct of ‘recipient’ (Harvey and Kitson, 2016).  Facilitation has developed to become an 
active element assessing, aligning and integrating the other three constructs.  Successful 
implementation is defined in terms of the achievement of implementation / project goals 
and results from the facilitation of an innovation with the recipients in their local context.  
The process is represented as a spiral which starts with a focus on the innovation and 
recipients before moving out to consider the context at local and then the wider level.  
Although the model had not been widely implemented at the time it seemed to be 
appropriate to the implementation endeavour.   
1.9 Gaps in the knowledge 
From the literature, it is clear there are a number of gaps in the knowledge. These have been 
identified as: evidence for PK study design, service user perspective, health care 
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professionals’ perspectives and the impact of context, particularly in the face of critical 
illness and facilitators (see Figure 3 below). 
 Figure 3: gaps in the knowledge 
 
 
 
1.9.1 PhD strategy 
Based on the gaps in the knowledge a strategy was devised to gather an evidence base.  The 
chapter structure is outlined below in Table 1.  This highlights the aim of each aspect, the 
underpinning theory and how each addressed a gap in the knowledge.  
Table 1: summary of PhD structure and content 
Study Aims Underpinning theory Gap in knowledge 
Scoping review Identify strategies that:  
I. facilitate recruitment  
II. barriers to conduct of 
PK studies 
Deductive approach: 
scope existing 
knowledge 
 Evidence for PK study 
design 
 Influence of context 
 Facilitation 
Patient & Public 
Involvement (PPI) 
Identify:  
i. stakeholders 
ii. recruitment methods 
iii. methodology 
iv. develop interview 
schedule 
Inductive approach: 
collecting information 
to inform future 
research 
Service user perspective 
18 
 
Study Aims Underpinning theory Gap in knowledge 
Quantitative research: 
  Children & Young 
People (CYP)  
Identify stakeholder: 
I. attitudes 
II. views of barriers 
III. views of facilitators 
& relationships 
Deductive approach: 
Formulating hypothesis 
and proposing 
relationships between 
variables  
 Evidence for PK study 
design 
 Service user’s perspective 
 Facilitation 
 
 
 
Qualitative descriptive 
research with: 
 Children & Young 
People (CYP)  
 Parents 
 Nurses 
 Research personnel 
Understand 
stakeholder:  
i. attitudes 
ii. views of barriers 
iii. views of facilitators 
Inductive approach: 
collecting information 
to develop 
recommendations 
 Evidence for PK study 
design 
 Service user’s perspective 
 Health Care professionals’ 
perspective 
 Influence of context 
 Facilitation 
Recommendations for 
PK study conduct 
Develop 
recommendations for 
future PK studies 
protocol and study 
conduct 
Deductive: strategy 
informed by previous 
work 
Evidence for PK study design 
 
As identified earlier, the work was conducted sequentially with chapters 4 and 5 informing 
the subsequent ones (6-8) (see Figure 4).  Chapters 6-8 were then conducted concurrently in 
an interactive manner with similarities and differences compared and contrasted in chapter 
9. Recommendations were generated and are reported in chapter 10. 
Figure 4: outline of PhD chapters.  
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Chapter 2: Methodology chapter 
2.1 Introduction  
Within chapter 2 the aims of the study, the approaches taken, the rationale behind these 
approaches, the research methods and the analysis are presented.  All methods for chapters 
4-8 are detailed together within this chapter to avoid repetition.  
2.2 Paradigms and approach 
The purpose of this PhD work was to make sense and explore meaning, rather than to test 
theory or explore cause and effect relationships.  The researcher and the project therefore 
sit within an interpretivist paradigm, and the belief that the social world is actively 
constructed by human beings who are continuously involved in making sense of or 
interpreting the social environment (Parahoo, 2014).  Considering the gaps in the 
knowledge, it was necessary to develop a multi-method programme to address the research 
questions   Both qualitative and quantitative methods have been used throughout the PhD, 
an approach referred to as ‘mixed methods’. Mixed methods have been described as 
research in which the investigator collects and analyses data, and draws inferences using 
both qualitative and quantitative approaches and methods in a single study or a programme 
of inquiry (Tashakkori & Creswell, 2007).   Critics of mixed methods approaches argue that 
mixing methods is not feasible because the two paradigms are incommensurate (Turnbull 
and Lathlean, 2015).  However, those who support the approach as feasible believe this is 
possible as long as one approach is dominant, with the theoretical ‘drive’ drawn from this 
paradigm (Morse, 2003, Morse and Niehus, 2009). PRESCRIBE overall has adopted a partially 
mixed, sequential, dominant status, mixed methods typology (Leech and Onwuegbuzie, 
2009).  The dominant approach and therefore the ‘theoretical drive’ (Morse, 2003) is a 
20 
 
qualitative approach.  Parahoo (2014) compares this application of different methods as 
similar to the construction of a whole, complete picture by fitting jigsaw pieces together (see 
Figure 5 below). 
Figure 5: mixed methods approach to PRESCRIBE 
 
The quantitative and qualitative components were conducted independently and 
sequentially, which allowed the different components to remain true to their own paradigm 
and methodology requirements (Cresswell, 2010), without descending into a ‘qualitative 
quagmire’ (Barbour, 1998).  The use of different methods allowed the researcher to study 
the same phenomenon for confirmability or corroboration in an on-going iterative process 
(Sandelowski, 2000a, Moule and Hek, 2011, Parahoo, 2014).   Overall adopting this approach 
using both sequential and concurrent methods (for the qualitative components) allowed the 
researcher to achieve complementarity, completeness and confirmation (Sandelowski, 
2000a, Moule and Hek, 2011, Turnbull and Lathlean, 2015) .   
21 
 
The merits of a number of qualitative approaches were reviewed.  Ethnography focuses on 
culture which was an aspect of interest, however the emphasis on anthropology and world 
view (Polit and Beck, 2010) was not felt to be appropriate.  Action research emphasises 
change, rather than understanding (Dew, 2007) which was also not felt to be the most 
appropriate method.  Phenomenology, with an emphasis on understanding an individual’s 
lived experiences (Ritchie, 2003) was felt to be more appropriate for PRESCRIBE.  However, 
with outcomes from the study wanting to address the implementation of evidence into 
practice this was felt to be the wrong emphasis.  A qualitative descriptive (QD) approach was 
therefore adopted.  This approach is regarded as useful for researchers wanting to know the 
who, what and where of events, and for  gaining insights from participants where a 
phenomenon is poorly understood (Sandelowski, 2000b). Key features of QD design are 
outlined below in Table 2.  
Table 2: qualitative description design issues
1
 
Aspect  Approach 
Philosophy Pragmatic approach 
Reflexivity Important for the researcher to describe their disciplinary affiliation and what 
brought them to the question 
Sampling Purposeful. Maximum variation sampling is especially pertinent 
Data collection Minimum-moderately structured interviews with individuals / focus groups 
Researchers are interested in the who, what, where and why of the experience 
Analysis Qualitative content analysis, can be supplemented with descriptive statistics 
Stay close to the data- low level interpretation 
Outcomes Straight description of the data organised in a way that ‘fits’ the data. Results are 
firmly connected to the data 
Rigour Clear audit trail, consideration of saturation, triangulation 
1
 Caelli et al., 2003, Sandelowski, 2000b, Neergaard et al., 2009  
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In summary, often the phenomenon at the heart of qualitative research has not been 
previously investigated and as Chapter One has demonstrated there are a number of gaps in 
the knowledge surrounding the conduct of PK research.  A mixed methods approach, 
utilising a qualitative descriptive method, which stays close to the data and recognises the 
value of quantitizing qualitative data to add emphasis and provide a measure of scale 
(Tashakkori and Teddlie, 1998) was therefore adopted.  
2.3 Research aims and objectives  
2.3.1 Research aim 
The overall aim of the thesis is to determine the best design features and methods for 
conducting pharmacokinetic research with children and young people (CYP) who are 
critically ill.  
2.3.2 Research objectives 
Objectives for Chapters 3-10 are listed in Table 3 below.  
Table 3: objectives for Chapters 3-8 
Chapter  Objectives 
Chapter 3 To conduct a scoping literature review of paediatric pharmacokinetic research 
studies and identify and quantify:  
a. Strategies that improve recruitment to paediatric pharmacokinetic research  
b. Barriers to recruitment or retention to paediatric pharmacokinetic research 
Chapter 4 1. To develop the research protocol prior to Research Ethics Committee (REC) 
submission in consultation with members of the public, to include:   
a) Identification of the stakeholders1 in paediatric PK research studies 
(potential participants) 
b) Identification of recruitment strategies for future participants 
(recruitment methods) 
c) Identification of the methods to conduct research with future 
participants (methodology) 
d) Identification of questions to utilise with future participants (interview 
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schedule) 
1
stakeholder refers to persons, groups or organisations that are considered to have a 
significant influence on the success of a project and need to be taken into account by 
leaders, managers and front-line staff (Bryson, 2004).   
2. To develop participant information sheet (PIS) and consent / assent forms. 
Chapter 5 Utilising quantitative methods: 
a. Determine the attitudes of a lay paediatric population towards paediatric PK 
studies 
b. Identify what a lay paediatric population perceive to be barriers or 
problematic about the conduct of paediatric PK research studies 
c. Identify what lay paediatric population identify to be enabling or facilitating 
the conduct of PK research studies 
Chapter 6-8 Utilising qualitative methods: 
a. Determine the attitudes of participants towards paediatric PK studies 
b. Identify what participants perceive as a barrier or problematic about the 
conduct of paediatric PK research studies 
c. Identify what participants identify as enabling or facilitating the conduct of 
PK research studies 
Chapter 9 Compare and contrast lay population, service user and health care 
professionals’ attitudes and perceptions of barriers and facilitators to the 
conduct of PK research  
Chapter 10 Using evidence generated from chapters 3-8 develop guidelines for 
pharmacokinetic study design and conduct for future research studies, with a 
focus on the context of CYP who are critically ill.   
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2.4 Research design 
The overall research design and methodologies are summarised in Table 4 below.  
Table 4: summary of research design for all PhD chapters 
Work stream Sampling Method Pilot Approvals Data management Analysis Rigour 
Scoping review 
(SR) (Chapter 3) 
Systematic 
against set 
criteria 
Scoping review 
method 
Preliminary 
searches 
X 
 
Endnote Reviewed against 
inclusion criteria. Results 
themed. 
Adherence to SR method 
PPI (Chapter 4) Purposive Training 
Focus group 
(FG) 
N/A X  Intelligent 
transcription 
 Anonymised 
Thematic analysis  2 separate sessions 
 Member checking 
 Summarising and checking 
within sessions 
School CYP 
(chapter 5) 
Convenience Education 
Vignette 
Questionnaire 
10 CYP (Yr 10) 
5 CYP (Yr 10-11) 
REC not 
required 
√ Head 
teacher 
 Locked office, 
secure corridor 
(for paper 
questionnaires) 
 Anonymised 
 Electronic 
database (NHS 
server) 
SPSS  
Thematic analysis (free 
text) 
 Conducted with variety of 
schools, variety of 
locations 
 Content validated with 
experts 
 
CYP  
(Chapter 6) 
Purposive 
 
Vignette 
FG /Interviews 
Vignette 
developed from 
SR 
 
Piloted within 
school children 
sessions 
 
 
√ REC 
√ R&D 
 
 Recording device 
stored in NHS 
facilities (locked 
corridor) 
 Audio-files 
transferred to 
NHS server (and 
deleted from 
recording device) 
 Intelligent 
transcription  
 Anonymised  
 Imported into 
NVivo 11 
Review of transcript 
(generated from audio-
recording) 
 Coding- structural & 
magnitude coding 
 Mind maps 
 Qualitative Content 
Analysis 
 Framework analysis 
 Descriptive statistics 
(excel) 
 Concurrent analysis within 
groups and between 
groups 
 Researcher triangulation 
 ‘True to participant voice’ 
 Triangulation with 
quantitative statistics 
Parents 
(Chapter 6) 
Vignette  
Interviews 
Nurses 
(Chapter 7) 
Vignette 
FG/ interview 
√ R&D 
 
Research 
Nurses 
(Chapter 8) 
Vignette 
FG/ Interviews 
R&D staff 
(Chapter 8) 
Vignette 
FG/ Interviews 
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2.5 Sampling  
2.5.1 Sample population 
The sample populations for each work stream were developed through consultation and 
engagement with the public (Patient and Public Involvement (PPI). This work is detailed in 
more depth in chapter 4.  The sample populations are defined below. 
2.5.1.1 School children (lay children) 
The key group identified within the PPI work was children and young people: with two 
groups- those with hospital experience and those without (a ‘lay’ group). They felt the best 
way to find and engage with those naïve or less experienced with the hospital setting was to 
recruit CYP in the school setting.  PPI participants felt participants should be years 9-13 (aged 
13-18years). This age was justified as they felt CYP needed to be able to understand the 
concepts of ill-health, decision-making and understand why research is conducted.  Year 9 
was felt to be the year when these topics start to be addressed within science and Personal, 
Social, Health Education (PHSE) lessons.  Screening and recruitment took place through a 
number of methods; schools already engaged with the National Institute for Child Health, 
schools engaged with Birmingham Children’s Hospital and schools engaged with University 
of Birmingham through enrichment events (see Table 5).  A convenience sampling strategy 
was utilised, recruiting all CYP who met the inclusion criteria who attended schools which 
agreed to participate during the period of study.  The pupils were felt to be representative of 
the wider year as there was no chance to self-select or volunteer.  Although this method 
offers the highest risk of introducing bias (LoBiondo-Wood and Haber, 2006), random 
sampling techniques were not feasible due to the challenges of finding sufficient schools to 
engage with.  
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Table 5: summary of inclusion and exclusion criteria: CYP (school setting)  
School children  
Inclusion criteria 
 Head teacher approval for CYP to participate in the study 
 Parents given option to decline their child’s participation 
 CYP in years 9-13  
 No restrictions on health status, medication usage or previous hospital experience 
 CYP consented to participate with questionnaire through ‘tick’ on paper questionnaire 
Exclusion criteria 
 Head Teacher declined school participation 
 CYP whose parent declined their participation in the session. 
 CYP in school years 8 and below and 19years and over. 
 CYP declined consent to questionnaire (verbally or on questionnaire) 
Screening methods: 
1. Identification of school through those already engaged with National Institute for Health Research (NIHR) Clinical Research Networks (3 schools) 
2. Schools engaged with Birmingham Children’s Hospital to attend an outreach event (1 school) 
3. West Midlands schools attending University of Birmingham (UOB) Enrichment Events with School of Pharmacy (6 schools) 
Screening, approach & recruitment 
1. NIHR contacts 
 Schools contacted (Head Teacher) through email introduction from NIHR Clinical Research Network 
 If head teacher agreed to participation then class teachers identified and contacted by the researcher 
 Science and PHSE sessions were targeted (following PPI suggestions). Dates negotiated with individual teacher.   
 Teacher sent out Participant Information Sheet (PIS) to parents of CYP in the class.  PIS informed them of their right to decline consent for their child to 
participate in the session. The school would facilitate attendance at an alternative class.  
 All CYP within the class (Year 9-13) were included (unless parents declined)  
 Contact with schools, liaison with teachers, session conduct, distribution of questionnaire (all JCM) 
 CYP consented through ‘tick’ to indicate consent at the start of the questionnaire 
2. Birmingham Children’s Hospital  
 School that participated in an outreach event at Birmingham Children’s Hospital.  
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 All CYP who attended outreach events eligible for inclusion 
 Liaison with school, session conduct, distribution of questionnaires (JCM) 
 CYP consented through ‘tick’ to indicate consent at the start of the questionnaire 
3. University of Birmingham  
 One-day enrichment events scheduled by School of Pharmacy, UOB.   
 Sessions for PRESCRIBE timetabled within this day.   
 All CYP (years 9-13) who attended sessions eligible for inclusion 
 Liaison with schools (UOB), session conduct, distribution of questionnaires (JCM) 
 CYP consented through ‘tick’ to indicate consent at the start of the questionnaire 
 
2.5.1.2 Children and young people (CYP) and parents within the hospital setting  
CYP and parents with experience of the hospital setting were identified as a key group to interview.  These groups were refined further to 
CYP aged over 8years of age (as advised by the PPI work) and parents of any age of child, with experience of PIC and / or experience of 
participation in clinical trials. Purposive sampling was used to screen and recruit CYP / parents who met one or both of these criteria. In 
purposive sampling decisions are made about which criteria are used for selection early on in the research design stages, shaped by 
hypotheses that the research might want to explore or gaps in the knowledge about the study population (Parahoo, 2014).  These 
strategies were outlined at the outset within the research protocol and Research Ethics Committee (REC) submission and in keeping with 
recommendations, sampling was done as rigorously and systematically as possible (Proctor et al., 2010).   Screening records were kept 
and maintained by the research nurses who worked on Paediatric Intensive Care (PIC) and screened PIC on a daily basis for multiple 
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studies, and the researcher, who maintained screening records for Wellcome Trust Clinical Research Facility (WTCRF).  Inclusion and 
exclusion criteria are defined below (see Table 6 below).   
Table 6: summary of inclusion and exclusion criteria: CYP and parents stakeholders 
CYP Parents 
Inclusion criteria 
 CYP who attend or have attended BCH aged 8-18 years1 
 Attendance at outpatients’ department, research clinic in Wellcome Trust Clinical 
Research Facility (WTCRF) or inpatient on any ward at Birmingham Children’s Hospital 
(BCH) including PIC
2
 
 Siblings or relative of a child who has attended hospital eligible3 
 Members of CYP advisory groups who did not participate with PPI work could be 
invited to participate
4
 
 Parents were involved to assess CYP cognitive ability to participate. 
Inclusion criteria 
 Parents or guardians of children aged 0-18years who attend or have 
attended BCH. 
 One or both parents invited to participate, either at the same time or 
separately 
 Attendance at outpatients, WTCRF or inpatient stay on any ward at BCH. 
 
1 
The age of 8 for CYP with ‘experience’ of health care was recommended by PPI consultation work and Hall et al (2001) 
2 
There are low numbers of PIC admissions aged 8 years +.  Local data suggested <14% were 8 years and the  majority  of  PIC bed  days  nationally are required  by  
children  <1  year of age  (57%) (PICANet National Report, 2015). 
3
PPI participants felt siblings could offer an insight into research.  This was supported by a paper which included siblings in  discussions surrounding participation of their 
brother or sister in research (Snethen and Broome, 2001). 
4 
There were two groups at a local level- NIHR Young Persons Advisory Group (YPAG) (focus on medicines research) and a BCH YPAG (non-research focus).  Members 
who had not participated were invited to participate in the qualitative work.  
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CYP Parents 
Exclusion criteria 
 CYP who could not speak English 
 CYP with insufficient cognitive abilities to participate in focus group discussion 
(determined through sensitive discussions with parents/ clinicians) 
 Members of the YPAG who had previously participated in PPI activity for the study in 
2013 were excluded (n=6) 
Exclusion criteria 
 Parents / carers who could not speak English 
 Parents who do not have parental responsibility for their child or 
where there were shared care arrangements with social services.   
Screening methods: 
 PIC admissions (screening assisted by PIC research team) 
 WTCRF attendance (screening assisted by WTCRF research team) 
 Referral from Family Liaison team on PIC 
 Referral from BCH Specialist Nurses 
 Referral from BCH Patient and Public Experience lead 
Screening, approach & recruitment 
 PIC research team screened all PIC admissions and discharges for eligible CYP/ Parents. Discussed study, provided with PIS, asked for completion of contact details. 
Information supplied to the researcher.  
 WTCRF research team screened specific studies for eligible CYP / parents. Provided researcher with clinic dates of eligible patients. 
 Researcher allowed two mornings / afternoons a week to screen / follow up on those identified through research support 
 Arranged interview / focus group at participant’s convenience 
 Liaised with other sources for referrals, provide them with PIS and follow up. 
 Consent / assent obtained by the researcher (JCM) 
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2.5.1.3 Nursing staff 
The sampling frame was defined as clinical nurses who worked at Birmingham Children’s Hospital, 2013-2014, Bands 5-8, in Paediatric 
Intensive Care (PIC) and High Dependency (HD) ward areas.  Purposive sampling was conducted to sample nurses with experience of 
intensive or high dependency care in ward areas. See Table 7 below.  
Table 7: summary of inclusion and exclusion criteria: nursing staff  
Clinical Nurses 
Inclusion criteria  
 Clinical Nurses working at BCH, Band 5-8. 
 Employed in intensive or high dependency ward areas- PIC, Liver, Cardiac wards.  
 No limitations placed on experience or length of employment in research. 
 Can communicate in English 
Exclusion criteria 
 Unregistered practitioners Band 4 and below 
Screening methods 
 Ward Managers 
 Education links for wards (where they existed) 
 Advanced Nurse Practitioner (ANP) 
 Snowballing- approached by two clinical areas  
Screening, approach and recruitment 
 Purposive sampling to recruit nurses with an email invitation and Participant Information Sheet (PIS) sent via Ward Managers. First approach- April 2013 (PIC), September 
2013 (Wards 8, 11,12), Second approach November 2013 (all wards) 
 Education links for wards (where role existed) contacted.  
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Clinical Nurses 
 Two further wards contacted- Medical Day Care (MDC) and Burns Ward after initiation by individual staff members 
 Advanced Nurse Practitioner (ANP) lead facilitated arrangement of focus group with ANP’s 
 Participants asked to contact JCM directly to arrange focus group attendance 
 Responses could be made by email, answer phone or post indicating their availability and preferences  
 Focus groups were timed to occur alongside staff training / meetings  
 Facilities were booked to ensure private, quiet and confidential surroundings. 
 Discussed study with participants, provided with PIS, given opportunity to ask questions. 
 Consent taken by JCM  
 All focus groups and interviews conducted by JCM  
 If a participant was unable to attend the focus group, arranged interview at participant’s convenience 
 
2.5.1.4 Clinical Research staff and Managers 
The sampling frame was identified as those with research expertise- research staff (within NHS organisations) and those reflecting a 
hospital management perspective on the conduct of research- ‘hospital managers’ (see Table 8 below).  Research staff were staff Band 5-
8 employed at Birmingham Children’s Hospital, 2013-2014, in a department specific research role or within the National Institute for 
Health Research (NIHR) Research Network role.  Additional study sites were added in order to add different research perspectives, 
responding to emerging themes. The NIHR Clinical Research Network South West team covered a large number of vaccine studies, which 
involved additional painful procedures and blood sampling, so it was therefore felt to be useful to add their perspective (following REC 
and local R&D approvals).  The inclusion of neonates within research appeared to be an area of concern across participant groups, 
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therefore the research team at Birmingham Women’s Hospital NHS Trust (following additional approvals) were purposively invited to 
participate.  It was initially difficult to define who represented the management perspective towards research, but after consultation with 
the R&D Manager and Deputy Chief Nurse the R&D committee were felt to be the best representatives.  The sampling frame was 
therefore members of the BCH R&D panel who reviewed the approval and conduct of all research at BCH.   
Table 8: summary of inclusion & exclusion factors: research staff  
Clinical Research Staff Hospital Managers 
Inclusion criteria 
 Clinical Research Staff working at BCH 2013-2014, Band 5-8. 
 No limitations placed on experience or length of employment in research, 
including experience outside of the NHS setting with Pharmaceutical companies 
 No limitations on professional background 
 National Institute for Health Research (NIHR) Medicines for Children Research 
Network (MCRN) West Midlands research team
1
.   
 Extended to staff within NIHR MCRN South West team2  
 Staff within the NIHR networks could be based throughout the West Midlands or 
the South West, although their base and place of employment was BCH and 
United Hospitals Bristol (UHB). 
 Birmingham Women’s Hospital (BWH) neonatal research team. A team of research 
nurses who cover studies within the neonatal unit.      
Inclusion criteria 
 Member of BCH Research and Development Facilitation Committee (responsible for 
approval of all research at the BCH NHS Trust)
3
.  
 Attendance at monthly meeting on the day of the planned focus group.   
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Clinical Research Staff Hospital Managers 
1
 Now termed NIHR Clinical Research Network (West Midlands) 
2
Now termed NIHR Clinical Research Network (South West) 
3
The panel includes representatives from the NIHR Clinical Research Network, R&D manager, R&D finance, pharmacy, labs and radiology
 
Exclusion criteria 
Staff with job descriptions ‘data managers’, ‘research administrators’ or ‘trials 
managers’; roles which did not have direct influence over trial design or patient 
contact within clinical trials. 
Exclusion criteria 
No exclusions criteria on the basis of professional background. 
R&D panel at BWH not eligible
4 
4
BWH and BCH are now one Foundation Trust (2017). At the time of the research these were separate organisations with separate R&D approvals processes. Approval was only 
granted to include BCH R&D teams 
Screening, approach and recruitment 
 Purposive sampling to recruit NIHR Clinical Research Network staff with an email invitation and Participant Information Sheet (PIS) sent via Managers. 
 Screened total staffing records (provided by managers) to review response rates. 
 Focus groups were timed to occur alongside staff training / meetings  
 Facilities were booked to ensure private, quiet and confidential surroundings. 
 Discussed study with participants, provided with PIS, given opportunity to ask questions. 
 Consent taken by JCM  
 All focus groups and interviews conducted by JCM  
 If a participant was unable to attend the focus group, arranged interview at participant’s convenience 
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2.5.2 Sample size 
Recommendations for sample size in the majority of qualitative studies generally follow the 
concept of reaching saturation; that any new data does not shed any further light on the 
issues under investigation (Glaser and Strauss, 1967).  Data saturation however is difficult to 
define and there is little practical guidance for researchers on actual sampling sizes.   A 
sample size of 20 was considered to be appropriate, as little ‘new’ information is felt to 
emerge after this (Green and Thorogood, 2009, Mason, 2010, Snelgrove and James, 2011), 
although there was flexibility in this, recognising that there was uncertainty about the 
influence of different ward contexts on reaching data saturation (Glaser and Strauss, 1967).  
Within paediatric qualitative studies similar numbers appear to have been consulted; 17 CYP 
and 22 parents (Farrington et al., 2016), 25 CYP  (Luchtenberg et al., 2015) and 23 caregivers 
and 29 CYP (Patterson et al., 2011, Patterson et al., 2015).   Within PRESCRIBE the notion of 
20 participants per group was outlined. Once no ‘new’ information was being yielded, 
saturation would be deemed to have occurred (Parahoo, 2014).  A single site approach was 
felt to be appropriate for most participant groups. The exception was the Clinical Research 
Nurses where further sites were added in light of emerging themes.  
2.6 Approvals  
Ethical approval is not required for the active involvement element of the research, where 
people are involved in planning or advising on research, nor are researchers required to 
obtain written informed consent from patients and members of the public (National 
Research Ethics Service and INVOLVE, 2009, Boote et al., 2010).  REC approval was therefore 
not obtained for the PPI activity but Good Clinical Practice (GCP) recommendations in 
dealing with CYP and parents were adhered to (National Institute for Health Research, 
2016a). Research Ethics Committee (REC) approval was also not required for the work 
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within schools as it was classed as an ‘educational intervention’.  The University Research 
Ethics Committee and Sponsor (University of Birmingham) were satisfied with this.  No 
formal consent process by CYP and parents was therefore required.  Research involving NHS 
patients and their families does however require the approval of a REC (Gelling, 2015, Lacey, 
2015) as well as approval by research governance from the site where the research will be 
conducted (Department of Health, 2005). See Table 9 below.  
Table 9: summary of approvals for PRESCRIBE project 
Approval Reference number and date 
NHS REC approval: NRES Committee South Central- 
Oxford A 
 
Ref No. 12/SC/0051 
Approval date: 18.01.2012.   
Extension applied for until 31.12.2015.   
University approval: University of Birmingham 
 
Reference Number: ERN_11-1275 
Sponsorship: University of Birmingham 
 
Ref RG_11-208 
Approval date: 05.04.2012 
Research & Development approval:  
Birmingham Children’s Hospital NHS Foundation 
Trust 
 
Birmingham Women’s Hospital NHS Trust  
 
 
United Hospitals Bristol (UHB) 
 
 
Reference number: 12/SC/0051 
Approval date: 05.04.12 
 
Ref Number: 62998 
Approval date:20.09.2013 
 
Ref Number: CH/2013/4416 
Approval date: 24.10.2013 
Research Ethics Committee approval is not required for research conducted with NHS staff 
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2.7 Data collection methods 
2.7.1 Vignette  
A vignette was used throughout the work streams to prompt people to respond to a 
hypothetical specific situation (Arthur and Nazroo, 2003).   The same one, modified to the 
knowledge and orientation of the participants, was used throughout interviews and focus 
groups, to promote continuity (Wilson and While, 1998). This also facilitated comparison 
between participants and participant groups.   Although vignettes provide more context  
than questions alone they can be criticised for being uni-dimensional and cannot predict 
how people might react in real life situation (Moule and Goodman, 2009).  However, this 
was felt to be the best method available to use within the time and circumstances available. 
The vignette was developed to represent a ‘typical’ PK study protocol, based on information 
gained after reading over 1000 paediatric PK publications for the scoping review. Key 
features identified were samples were usually blood, most commonly from peripheral 
vascular access (from a cannula specifically inserted as ‘extra’ for sampling purposes) and 
most sampling took place within the first 24 hours, with approximately 8 in total.  These 
features were incorporated within the vignette (see Appendix 1).  Variables were then 
changed to elicit information about respondents’ perceptions and opinions (Polit and Beck, 
2010), for example the type of vascular access was changed to a central venous line or the 
context was changed from a ward area to PIC.  Vignettes were utilised for all qualitative 
work and within all methods.  The vignette was developed from feedback from the pilot for 
the questionnaire (15 CYP).  The vignette was the core component of introductory material 
(for all participant groups, including CYP and parents). This material provided information 
about what pharmacokinetics was and why measurements were required, before 
introducing the vignette.  This material was displayed electronically or on a paper handout 
(dependent on the location and facilities available).  Provision of this type of information is 
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vital for participants who undertake a PPI role (Telford et al., 2004, Staniszewska and 
Denegri, 2013, Bagley et al., 2016).  Training needs to be relevant, interesting, but also age 
and developmentally appropriate (Kirby, 2004, INVOLVE, 2016a, INVOLVE, 2016b). PPI 
participants suggested that similar material should be provided at the start of focus groups 
and interviews to provide background to the work and clarity on the purpose of the study. 
The background information was therefore developed through feedback from the PPI group 
(6 CYP) and piloted with 5 CYP from a school Young Person Advisory Group. Minor 
amendments to this were conducted to ensure clarity of message.   
2.7.2 Interview schedule  
The interview schedule was recognised to be a key element to ensure the central research 
question was addressed, while also allowing new and interesting responses to be explored 
(Tod, 2010).  Development of the schedule was therefore recognised to be a crucial aspect 
of the PPI work to ensure not only the clarity of questions for participants, but also the 
sequencing of questions was appropriate.  Sensitivity was also required, particularly when 
discussing potentially emotive topics (Polit and Beck, 2010), such as conducting research 
with CYP who are not expected to survive.  The schedule was essentially the same for all 
participant groups to permit exploration of the same issues and examine similarities and 
differences, but the language was modified and oriented to the particular position of the 
respondents (Glaser and Strauss, 1967).  (Please see Appendix 2 for the interview schedule 
utilised with CYP). Prompt questions were identified for each group to encourage 
participants if they lost their thread or to re-engage them with the interview (Tod, 2010). 
Efforts were made to follow question wording precisely and in the same order. However, if a 
participant appeared to find an aspect of conversation distressing and indicated they wished 
to move on, or appeared not to understand an area of questioning, the researcher moved 
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the schedule along, recognising the responsibility of the researcher to make the interview a 
pleasant and satisfying experience (Polit and Beck, 2010).  The interview schedule was 
reviewed by the supervision team, by two Registered Children’s Nurses and by two Patient 
and Public Involvement experts.  It was piloted with two participants and found to require 
no amendments, therefore these respondents are included within the analysis.  
2.7.3 Questionnaire 
Questionnaires are self-report forms that are useful to elicit information about beliefs, 
attitudes or opinions (Burns and Grove 2011).  A questionnaire refers to when respondents 
complete the instrument themselves, usually in a paper format (Polit and Beck, 2010). This 
method was selected for the work conducted with school children because a structured, 
standardised, pre-determined approach with the same questions in the same order asked of 
all respondents was required (Parahoo, 2014).   Sessions were time-restricted and an 
approach was required which could ensure that the work was conductible within the 
available time.  Researchers are advised that wherever possible, an existing questionnaire 
with established reliability and validity should be utilised  (Jones and Rattray, 2010). 
However, one did not exist exploring attitudes towards PK studies therefore a questionnaire 
was developed with questions which could be asked within the subsequent qualitative 
work, to allow comparison and facilitate triangulation.  Demographic data were gathered at 
the beginning of the questionnaire to prompt respondents to report on their medication 
use, health status and hospital experience.  Likert scales were used to measure attitudes 
with a range of 5 pre-coded options, ranging from strongly agree to strongly disagree 
(Hassan et al., 2015).  Multiple choice formats were used to allow respondents to select the 
one (or more) options that best applied to them (Parahoo, 2014).  The questionnaire was 
composed of pre-dominantly closed-ended or fixed-alternative questions. This approach is 
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more efficient and is also useful with groups who may not feel confident answering more 
open-ended questions (Polit and Beck, 2010).  The disadvantage of this approach is that 
omission of potentially important alternatives might occur or answers might be relatively 
superficial.  Participants are also deprived of the opportunity to express their own opinions 
or to elaborate on responses (Polit and Beck, 2010).  In order to overcome this free text 
options were offered in each domain to allow participants to expand upon answers (Jones 
and Rattray, 2010).  The questionnaire was completed at the end of an interactive 
discussion which introduced the concept of research with children, children’s medicines and 
pharmacokinetics, a similar strategy to prepare and set the scene to a study with CYP about 
unlicensed medications (Mukattash et al., 2012).  The questionnaire was distributed in 
paper form as computers were not widely available and the researcher was available to 
assist with answering questions, which is associated with a higher response rate (Moule and 
Goodman, 2009).  The PIS emphasised the voluntary nature of completion of the 
questionnaire. In order to reduce pressure upon students as the work was conducted in 
classroom settings, the questionnaire began with a simple consent statement students 
‘ticked’. This meant they had a discrete method of declining participation if they did not 
want to participate and allowed response rates to be monitored.  The questionnaire was 
piloted with 10 CYP from a year 10 Science class in January 2012.  Feedback predominantly 
focused on the layout, lack of pictures and terminology. Following modification this was 
then re-piloted with a small group of CYP (5) within a school. No further modifications were 
required to the questionnaire.  
2.7.4 Focus groups 
Focus groups were the preferred method for the patient and public engagement work, as 
well as the qualitative work with CYP, parents, nurses and research staff.  The benefit to 
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focus groups is the emphasis on moderated group discussion; with research participants 
enabled to exchange, discuss, agree or disagree about opinions, attitudes and experiences 
(Kitzinger 1995, Parahoo 2007). They are felt to be less intimidating and time intensive than 
one to one interviewing and encourage attempts to identify, describe, analyse and resolve 
key issues (Kitzinger, 1994, Ritchie, 2003, Goodman and Evans, 2010).  The size of a focus 
group varies typically from between 5- 12 members (Goodman and Evans, 2010) (Krueger 
and Casey, 2000). There are challenges for all groups in availability and a pragmatic 
approach was adopted, recognising that sessions would be run with fewer if changes to 
availability occurred. All focus groups were set up and moderated by the researcher (JCM) 
with field notes taken by an independent research nurse (where available) following training 
by JCM.  New purpose built, accessible, research facilities, separate from clinical care areas 
were booked for sessions (Marlowe, 2008, Bell, 2009) and service user participants were 
offered refreshments and travel costs  (Edmunds, 1999, Marlowe, 2008).  Consent was 
taken immediately prior to the session commencing by JCM for all participants to indicate 
they were satisfied with the information they had received and were happy for sessions to 
be audio-recorded and transcribed.  For CYP, informed consent was taken from parents with 
assent from CYP, (or consent directly from the CYP if they were aged over 16years). Please 
see Appendix 3 for a full list of PIS and consent and assent forms developed for PRESCRIBE.  
The PIS provided to parents of CYP who were eligible for participation and for CYP and the 
consent and assent forms are included (Appendix 3a-e).  Clear ‘ground rules’ for the focus 
group were established at the outset and the sessions were facilitated to try to ensure all 
participants were given the opportunity to contribute (Rennie et al., 2002, Shaha et al., 
2011).  Sessions were planned for relatively homogenous participants, for example a group 
of children with the same rare disease, in the same clinical trial. Homogenous groups are 
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generally preferable to ensure free discussion and enable cross-group comparisons 
(Morgan, 1997, Goodman and Evans, 2010).  Using pre-existing groups or groups of people 
who are already meeting for another purpose, is also useful to ensure participants are 
relaxed and facilitates participation. This also reduces the challenge of bringing people 
together at the same time (Kitzinger, 1994, Parahoo, 2014).   
2.7.5 Interviews 
Interviews are known to have a number of advantages: higher response rates, allowing 
clarification, permitting more in-depth questioning and probing and allowing the 
interviewer to judge the respondents’ level of understanding (Polit and Beck, 2010).  This 
approach is particularly useful when little is known about an area.  However, this method is 
extremely time-consuming and does not facilitate the stimulation of discussion through 
participant interaction as happens within a focus group (Kitzinger, 1994). The decision was 
therefore made to promote focus groups as the predominant method, with one to one 
interviews offered to participants (CYP, nurses and research staff) in the event of 
unavailability for focus group attendance or personal preference.  This allowed us to engage 
with ‘hard to reach’ groups; people who would be reluctant or unable to participate using 
other methods (Tod, 2010).   This proved essential for the successful recruitment of parents.  
The same interview schedule was utilised for all participants (focus group or interview) to 
allow comparison between group participants.  These sessions were also audio recorded 
and transcribed following consent and assent.  
2.8 Data Analysis 
2.8.1 Data management 
The questionnaires were transported to and stored in a locked office in line with Data 
Protection Act requirements (Data Protection Act, 1998).   These were then entered into a 
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database manually, given a unique study number to ensure participant anonymity before 
importing into SPSS for statistical analysis.    
The recorded audio files from PPI work and qualitative interviews / focus groups were 
transferred to a secure NHS password protected computer and deleted from the recording 
device.  They were transcribed and all identifying information was deleted with a unique 
study number allocated.  These were then imported into NVivo for qualitative analysis.  
2.8.2 Analysis- questionnaires 
Data yielded from the questionnaires was predominantly nominal and ordinal.  Nominal 
variables were compared using Fisher’s exact test, an alternative to the Chi-square test, 
which gives exact p-values, rather than relying on an approximation (McDonald, 2014).  The 
ordinal variables did not meet the assumptions for parametric analyses, since they followed 
skewed distributions and so non-parametric analyses were used (Hicks, 1999). Where 
ordinal variables were compared between two groups, Mann Whitney U tests were used 
(Freeman and Walters, 2010), with Kruskal-Wallis tests used for comparisons between three 
or more groups (Hicks, 1999).  For all of the analyses, the null hypotheses were that there 
was no difference between the groups being compared. Two-sided p-values were reported, 
as the direction of any effect had not been pre-specified (Hicks, 1999), for example, it would 
be of interest if male school children were either more or less likely to agree with PK 
research on children than females.  Using a two-tailed hypothesis was judged as appropriate 
because there was little background information to inform specific predictions.  Throughout 
the analysis, a critical p-value of 0.05 was used, meaning that any p-values that were <0.05 
were deemed to be indicative of a significant effect (Freeman and Walters, 2010).  
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Where a significant difference was detected in a comparison of more than two groups, post-
hoc tests were performed, in order to identify which of the individual pairs of groups the 
observed differences occurred between. For significant Kruskal-Wallis tests, this was 
achieved using Dunn’s test (also known as Bonferroni adjustment). This allowed comparison 
between each pair of groups separately with the p-values Bonferroni corrected (Dinno, 
2015). Bonferroni correction is appropriate when there are a relatively small number of 
comparisons being made and only a small number are likely to be significant (McDonald, 
2014).  
Some of the questions were not answered by all respondents, resulting in missing data, 
although the numbers of missing values were very small. These cases were treated as 
‘missing at random’, whereby it was assumed that those respondents that did not answer 
questions were not a biased sample of the cohort as a whole (Carpenter and Kenwood, 
2017).  Respondents with missing data were therefore excluded from the analyses relating 
to the questions where answers were not recorded, but remained in the analyses for the 
other questions for which data were available (McCormick et al., 2015).  All analyses were 
performed using IBM SPSS 22.  
2.8.3 Analysis- interviews and focus groups 
2.8.3.1 Transcription 
Transcription has been described as central to the process of analysis. It refers to the 
process of reproducing spoken words into written text and it represents what the 
researcher and the transcriptionist preserve from the taped speech (Maclean et al., 2004).  
The decision was made to use ‘intelligent transcription’ rather than ‘verbatim transcription’ 
which removes the conventions of dialogue e.g. pauses which can be difficult to read (Gale 
et al., 2013).  Although verbatim transcription has been cited as central to the reliability, 
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validity and veracity of qualitative data collection, drawbacks to this approach reflect the 
time and human resources required to capture these nuances (Wellard and Mckenna, 
2001). Researchers must focus on their research objectives and make appropriate decisions 
about the level of transcription required (Bird, 2005, Oliver et al., 2005, Davidson, 2009) and 
the decision was made that intelligent transcription was sufficient. The first 5 transcripts 
were conducted by the lead researcher JCM and following this were outsourced to a 
transcription service with a signed confidentiality agreement in place.  As recommended 
within the literature (Maclean et al., 2004, Halcomb and Davidson, 2006, Davidson, 2009), 
clear guidelines were provided to clarify the documentation of emotion, inaudible sections, 
medical terminology and conversation fillers.  Following transcription there was a phase of 
data cleansing where the transcripts were reviewed alongside the audio and the 
authenticity verified.   
2.8.3.2 Field notes 
In studies which involve using recording equipment, field notes provide an opportunity to 
record what researchers see and hear, their thoughts about the dynamic of the encounter, 
ideas for inclusion in later fieldwork and issues that may be relevant at the analytical stage 
(Arthur and Nazroo, 2003).  Field notes were recorded during focus groups by an 
independent research nurse (where available) and by JCM after the sessions. This enabled 
clarification of participant’s speech, correct attribution to participants and notes on emotion 
and non-verbal behaviours helped clarify meaning. Notes were not made during 1:1 
interviews due to feasibility, but were made as soon after as possible by JCM.  
2.8.3.3 Coding 
Coding is an interpretive act which enables the researcher to organise and group similarly 
coded data into categories and make sense of patterns (Saldana, 2013).  This is an iterative 
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process and recoding occurs with a more attuned perspective so eventually some first cycle 
codes will be subsumed by other codes, relabelled or dropped altogether.  Abbott (2004) 
likens the process to decorating a room: you try it, step back, move a few things, step back 
again and so on.  A structural coding approach was utilised; a basic but focused, content-
based approach to coding (Saldana, 2013). This is consistent with qualitative content 
analysis of staying close to the description of the data (Sandelowski, 2000b, Neergaard et 
al., 2009).  Structural coding is particularly appropriate for studies with multiple participants 
as it can act as a labelling indexing device.  This allows researchers to quickly access data 
likely to be relevant from a large data set and serves as a categorisation technique (Namey 
et al., 2008).  Quantitative applications are then possible and data can be quantified with 
code frequencies explored to identify which themes, ideas or domains were common, and 
which rarely occurred (Tashakkori and Teddlie, 1998).  A second coding strategy of 
magnitude coding was utilised, coding for attitudes in a simple manner as ‘positive’, 
‘negative’ and occasionally ‘neutral’ codes.    Magnitudinal codes add adjectival or statistical 
texture to qualitative data and assist with mixed methods or quantitative studies by 
indicating intensity or frequency as well as weight and importance (Saldana, 2013).    
2.8.3.4 Qualitative content analysis 
Qualitative analysis is based on a common set of principles: transcribing the interviews, 
immersing oneself in the data to gain detailed insights into the phenomena, developing a 
data coding system and linking codes or units of data to form categories or themes that lead 
to the development of theory (Morse and Richards, 2002). The analysis method was 
qualitative content analysis.  Analysis focused on coding interview material, looking for 
commonalities and differences in the data (Miles and Huberman, 1994) and developing 
themes.  A theme captures something important about the data in relation to the research 
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question and represents some level of patterned response or meaning within the data set 
(Braun and Clarke, 2006, Fereday and Muir-Cochrane, 2006).  This method also supports the 
supplementation of qualitative analysis with quasi-statistical analysis, summarising some 
data with descriptive statistics (Neergaard et al., 2009).  This  quantifying can help to 
confirm suspicions and can assure readers that researchers’ assumptions are valid 
(Tashakkori and Teddlie, 1998).  The objectives of PRESCRIBE were to understand more 
about the barriers and facilitators to conducting PK research. Providing an idea of the 
magnitude of these through quantifying was felt would avoid too much weight being given 
to dramatic or vivid accounts or too little weight to disconfirming cases (Sandelowski, 2001).  
2.8.3.5 Framework analysis 
The Framework Method for the management and analysis of qualitative data is a matrix-
based analytical method which facilitates systematic, rigorous and transparent data 
management.  It allows the analyst to move back and forth between the raw data and cross-
link initial categories (Ritchie et al., 2003, Gale et al., 2013).  While in depth analysis of 
themes can take place across the whole data set, the views of each research participant 
remain connected to other aspects of their account so that the context of the individual’s 
view is not lost.  Data can be compared and contrasted across cases as well as within cases 
and the method is recognised as particularly useful for managing large data sets.   A series of 
main themes emerge, subdivided by a succession of related subtopics.  This method enables 
the researcher to explore the data in depth whilst simultaneously maintaining an effective 
and transparent audit trail, enhancing the rigour of the analytical processes (Ritchie, 2003, 
Smith and Firth, 2011).   
This method was felt to be appropriate due to the large volume of planned interviews and 
focus groups and the ability to compare and contrast cases. This also assisted with 
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quantifying the data (Tashakkori and Teddlie, 1998) and confirming the  impression of an 
association (Sandelowski, 2000a, Sandelowski, 2001).   
2.8.4 Analysis approach 
One of the criticisms of qualitative approaches is the lack of transparency in how the 
researchers have made sense of their data.  In order to minimise this, the approach to 
analysis is detailed, with supplementary material available in Appendix 4. The process as a 
whole is summarised in Figure 6.  
Figure 6: summary of the qualitative analysis process 
 
Initial coding was conducted within NVivo software. These were reviewed; combined, 
subsumed in other codes or removed.  Mind maps were used to make sense of nodes and 
themes were identified.  Some nodes fitted into more than one category, so there was some 
fluidity about their placement.  However, all nodes could be categorised into these seven 
themes and there were no outliers.  Each theme and the sub-codes were then used to 
create a template framework for each participant group and each individual’s responses 
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were plotted. The matrix served as a means to ensure key messages were kept and the 
essence of each individual’s responses was represented.  This was particularly helpful as a 
number of these participants were interviewed in focus groups and it was sometimes 
difficult to separate individual voices.  This also served as a reminder where there were 
particularly useful quotes.  
Within NVivo 2nd line magnitude coding then took place where there were attitudinal 
responses to different codes.  Each code had notes made (paper records), to detail how 
many positive / negative comments there were and the number of people making these 
comments.  All comments were traceable to the individuals.  These figures were plotted in 
excel to provide quantitative data on the magnitude of participant opinion.  All reporting 
featured both the number of comments and the number of participants to avoid misuse of 
the numbers and the influence of one person dominating a topic.  The number of 
participants was not reported alone as participants could comment both positively and 
negatively and it was felt the volume of comments was a stronger measure of magnitude.  
2.9 Ethical considerations 
2.9.1 CYP and parents 
There were deemed to be minimal potential risks of undertaking this study for all 
participants.  The main concern was the possibility that taking part might raise distressing 
memories of events for CYP or parents from previous hospital attendances.   In recognition 
of this the PIS highlighted key topics such as blood sampling and medicines would be 
discussed in order that potential participants could make an informed decision about 
participation. Participants were reassured throughout the process that they could stop the 
interview at any time and the PIS outlined that they had a week after the interview to 
withdraw consent. If this happened the interview would be deleted. It was recognised that 
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parents could become distressed reflecting on their past situation or there was the potential 
to identify a family in need of additional support.  In recognition of this a support algorithm 
was devised which identified sources of support CYP and parents could be referred to (see 
Appendix 5).   
2.9.2 Clinical and research staff 
The PIS highlighted to staff that if they made a disclosure or a statement which highlighted 
unsafe practice or practices which contravened hospital policy this information would be 
shared with their line manager. In all other situations anonymity and confidentiality were 
assured. If any distress was experienced a referral to on site psychology services would be 
made recognising the right of all participant groups to have their wellbeing protected 
(Department of Health, 2005, National Institute for Health Research, 2016a).   
2.10 Reliability and validity- quantitative work 
Reliability is defined as the extent to which results are consistent over time and an accurate 
representation of the total population under study (Golafshani, 2003). Within this is the 
concept of the repeatability of a questionnaire; that it will measure what it is supposed to 
measure in a consistent manner (Jones and Rattray, 2010).   Test-retest reliability can be 
done to check consistency over time, however this was not feasible within the time 
constraints of classroom sessions or outreach events.  Reliability was therefore addressed 
through alternate-form test or equivalence,  where small changes of wording assess the 
consistency of participants’ responses (Parahoo, 2014). Validity refers to whether the 
questionnaire measures what it is supposed to measure and if it measures it correctly and 
accurately (Golafshani, 2003).  Through two sets of pilot tests with CYP, the items appeared 
relevant and unambiguous and all respondents appeared to follow the instructions in the 
same way. Face validity was therefore felt to have been addressed. Content validity was 
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enhanced through consultation with pharmacology experts outside of the research team to 
ensure that the questionnaire items represented the constructs to be measured (Polit and 
Beck, 2010).  Although the group discussion sessions with CYP in schools were not audio 
recorded, field notes were recorded (Watson et al., 2010). These served to summarise 
observations from the session, including overall attitude from the group, feelings of 
understanding and comprehension and any areas of confusion.  These reflections helped to 
promote criterion related validity, the extent to which a measure relates to an outcome. Key 
features are summarised in Table 10 below.  
Table 10: summary of methods used to ensure reliability and validity of the research 
Term Method employed Strategy  
Reliability-  
questionnaire 
Alternate form re-retest Concepts checked within questionnaire 
Validity- questionnaire Face validity 
 
Content validity 
Criterion validity 
Pilot test / re-test 15 CYP 
Review ability answer questionnaire 
Expert consultation 
Triangulation with field notes 
Dependability-  
qualitative methods 
Audit trail 
Triangulation 
Reflexivity 
Coding trail 
Sources, methods, coding methods, researcher 
Researcher position and perspective disclosed 
Trustworthiness- 
qualitative methods 
Thick description 
Member checking  
Triangulation 
Negative case analysis 
Participant voice, methods and analysis 
In interview checking 
Sources, methods, coding methods, researcher 
Review of examples which do not ‘fit’ 
 
2.11 Dependability and trustworthiness- qualitative 
research 
The term dependability is used instead of reliability in qualitative research (Lincoln and 
Guba, 1985). Dependability is demonstrated through a clear audit trail to enable the reader 
to review the decision-making process, the context of the research and demonstrate how 
the researcher reached their conclusions.  The summary diagram Figure 6 and additional 
information within Appendix 4 provide detail of the data analysis process.  Lincoln and Guba 
(1985) also demand confirmability, with the audit or decision trail tracing the data directly 
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to the sources.  Utilising the framework approach enabled each code to be cross-referenced 
to each individual.  This also allowed discrepancies amongst an individual’s responses to be 
reviewed, for example a participant who was coded as being very anxious about pain, 
stating they would definitely agree to participate in a PK study might seem at odds, but then 
this is modified by a statement that helping others is extremely important to them and to 
overcome their concern about pain they would request local anaesthetic cream.  Having a 
transparent sequential process to coding enabled us to review alternative cases or 
discrepant voices and ensure interpretations were the most valid and plausible (Holloway 
and Wheeler, 2002).   
Validity is linked to how ‘true’ or credible the findings of the study are and whether they 
accurately reflect the aims of the research and the social reality of participants (Hollaway 
and Wheeler, 2010).  This concept of trustworthiness denotes how confident the reader can 
be in the findings (Lincoln and Guba, 1985).  Remaining true to participants’ experiences 
though ‘thick description’ is a fundamental principle within qualitative content analysis 
(Sandelowski, 2000b, Snelgrove and James, 2011). The results are therefore rich in 
participant accounts with coding grounded in participants’ responses.  Member checking of 
interpretation by participants is recognised as a strategy to enhance the validity of a study  
(Lathlean, 2010).  This was not possible with the resources available of a lone researcher. 
Instead member checking took place within the interviews and focus groups by 
summarising, repeating or paraphrasing the participants words (Holloway and Wheeler, 
2002).  Participants will receive a copy of the results and be invited to provide comments. 
These will be taken into account in the write up for publication.     
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Triangulation, the process by which the phenomenon or topic is examined from different 
perspectives, has been achieved through  methods triangulation (Holloway and Wheeler, 
2002, Parahoo, 2014),  with the five qualitative work streams all simultaneously recruiting, 
conducting, transcribing and analysing. In addition, researcher triangulation took place with 
initial coding and analysis by the researcher (JCM), with a second investigator (HPD) coding 
independently, reviewing codes and themes (see Figure 7 below)  Researcher triangulation 
allows for cross checking to ensure that key themes are not missed (Giles, 2002, Rennie et 
al., 2002). 
Figure 7: sequential analysis, with triangulation from methods, sources and coding methods 
 
2.12 Conclusion 
Chapter 2 has provided a summary of all the research design considerations made 
throughout the multiple work-streams of this project.  There are a number of strategies 
researchers can use to ensure the dependability and trustworthiness of a qualitative 
research project.  The predominant strategies utilised were a strong reflexive stance, 
member checking within the interview process, thick description of data, a clear audit trail 
with strong links to the data and methodological and data triangulation.    
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Chapter 3: A scoping review of recruitment 
of paediatric participants to 
pharmacokinetic research studies 
3.1 Introduction 
Pharmacokinetic studies are essential in paediatric patients as they help determine the 
correct dose and medication regimen (Thomson, 2000).  However, less than a third of 
pharmaceutical trials conducted with adult participants funded by the UK’s Medical 
Research Council (MRC) and Health Technology Assessment (HTA) programme recruited 
their original target within the time originally specified (Campbell et al., 2007).  This is of 
concern because failure to recruit to target compromises the ability of the research to draw 
conclusions about a medication dose and regime (Campbell et al., 1997).    In the context of 
Randomised Controlled Trials (RCTs), difficulty with patient accrual is the most commonly 
cited reason for discontinuation (Kasenda et al., 2014, Pica and Bourgeois, 2016).  But even 
in this field little literature exists to guide researchers seeking to optimise recruitment 
(Patterson et al., 2015) or to reduce attrition from a study (Shilling et al., 2011, Tishler and 
Reiss, 2011).  Pharmacokinetic studies have traditionally involved a rigid, experimental 
design with multiple blood samples from venepuncture (Patel et al., 2010, Choonara and 
Sammons, 2014).  There is evidence CYP and parents find procedures involving needles 
particularly upsetting (French et al., 1994) so there are likely challenges to recruitment 
associated with this type of research. A systematic review of these challenges has not 
previously been conducted.  In addition, alternative ways of conducting PK studies which 
minimise the number of blood samples or the total volume of blood required using micro-
analytical techniques and population PK methods have been developed (Altamimi et al., 
2016).  The impact of these on recruitment and study retention has not been reviewed.  
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It is vital that future pharmacokinetic research is informed by systematic evaluation of past 
research. This will ensure that future research can build upon success in trial strategies and 
design in paediatric PK research, to minimise or address barriers to study recruitment and 
conduct.  There is currently a gap in the knowledge surrounding the evidence for 
pharmacokinetic research design (see Figure 8). The first priority of PRESCRIBE was 
therefore to understand the current situation in pharmacokinetic research recruitment and 
trial conduct through a scoping review of the topic and integration of the research evidence.   
Figure 8: gap in the knowledge: evidence for PK research design 
 
3.2 Aims and objectives 
The aim of this literature review was to explore what was known about the challenges and 
facilitators to recruitment and conduct of paediatric pharmacokinetic research within the 
published literature.  
Objectives: Through a systematically conducted literature review, identify and quantify:  
a. Strategies that improve recruitment to paediatric pharmacokinetic research studies 
b. Barriers to recruitment1 and conduct of paediatric pharmacokinetic research studies 
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1
Barriers to recruitment are taken to include reasons why trials fail to recruit, including why potential 
participants decline participation within a study (Houghton et al., 2017)  
3.3 Method 
3.3.1 Search methods 
3.3.1.1 Scoping review 
A Systematic literature review allows for objective appraisal of the evidence by identifying 
relevant studies, appraising their quality and summarising their results using a scientific 
methodology (Khan et al., 2003).  Whilst systematic reviews are regarded as being one of 
the highest form of evidence that can be generated, this proved challenging to conduct 
where many of the trials being reviewed were classed as low levels of evidence.  To achieve 
the objectives a scoping review was therefore adopted. Scoping reviews map the key 
concepts underpinning a research area and the main sources and types of evidence 
available. This approach can be used to examine the extent, range and nature of research 
activity and to identify gaps in the existing literature (Arksey and O'Malley, 2005).  They can 
be useful where an area is complex or has not been reviewed comprehensively before 
(Mays et al., 2001). They are also useful at the first stages of a research project to inform the 
subsequent work by providing the researcher with relevant and quantified results about the 
knowledge on a particular topic (Hidalgo et al., 2011, Duffett et al., 2013).   
3.3.1.2 Refining search terms 
Mind mapping was used to generate possible search terms by consideration of the PICO 
format (population, intervention, control, and outcomes) a widely-used strategy for framing 
a research question (Sackett et al., 1997).  The mind map informed several scoping searches 
conducted to identify if the terms were generating relevant articles (see Figure 9 below).  
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Figure 9: mind map of preliminary scoping review searches 
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Where possible MeSH headings (Medical Subject Headings) were utilised (National Library 
Medicine, 2015) which is a controlled vocabulary thesaurus to promote accuracy of 
literature searching.  From 1966 – 1988 ‘Kinetics’ was suggested for pharmacokinetics and 
‘pharmacology’ for pharmacodynamics.  These produced an unmanageable quantity of 
irrelevant references, therefore the search was restricted to Pharmacokinetics. Defining the 
search terms for population was initially difficult. Using limits to restrict searches was not 
always successful at screening out adult and animal papers.  The databases also had 
variations in the age categories the search could be limited to therefore limits were not 
used.  Infant and child were universally accepted terms across the databases and proved 
relatively successful at screening out papers in adults and healthy volunteers and Pediatric 
was a MeSH heading which captured a vast range of terminology associated.  The most 
difficult terms to refine were those capturing recruitment and study retention.  The 
suggested MeSH heading was ‘patient selection’ however this failed to capture the 
phenomenon of trial recruitment alone.  Although terms such as blood samples, drug study 
and research yielded a large number of papers when in conjunction with pharmacokinetics, 
many were not relevant and failed to discuss the phenomenon of recruitment.    
Once the mind map was completed, scoping searches were conducted to determine 
whether the terms were generating relevant articles and were sufficiently comprehensive.  
A number of techniques were explored within the preliminary searches, before 
Pharmacokinetics was decided to be the most applicable.  Recruitment and enrolment were 
selected to capture the phenomenon of recruitment. After this refinement process, the final 
search terms used for the review are defined in Table 11 below. 
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Table 11: final search terms utilised for the scoping review   
Search term:  
1. pharmacokinetic*  ti,ab 
2. pharmacokinetic*.af 
3. Recruit*. Ti, ab 
4. Recruit*. Af 
5. Enrol*. Ti, ab 
6. Enrol*. Af 
7. paediatric* OR pediatric* OR infant* OR child*. Ti, ab 
8. paediatric* OR pediatric* OR infant* OR child*. Af 
9. 3 OR 5 
10. 4 OR 6 
11. 1 AND 7 AND 9 
12. 1 AND 7 AND 10 
13. 2 AND 8 AND 10 
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3.3.1.3 Inclusion and exclusion criteria 
To avoid bias in the selection process, inclusion and exclusion criteria were defined a priori.   See Table 12 below for full details of the inclusion 
and exclusion criteria.  
Table 12: Inclusion & exclusion criteria for the scoping review 
Component Inclusion criteria Exclusion criteria 
Population 1. Children and young people (0-18 years old) who had 
participated in pharmacokinetic research.   
2. No limitation on the number of participants per study.  
3. No limitation on underlying disease process, type of 
medication, method or route of delivery. 
4. No limitation on the type of samples analysed  
1. Adult studies (over 18 yrs) 
2. Studies in adult and paediatric patients where recruitment figures 
could not be separated for the two groups.  
3. Animal studies 
4. Studies in healthy volunteers 
Intervention  1. Pharmacokinetic (PK) research 
2. Population PK research 
 
1. Pharmacodynamics studies  
2. Pharmacogenomics 
3. Genetics research 
4. ‘Routinely collected’ therapeutic drug monitoring with no additional 
sampling for research purposes.   
5. PK studies which measure non-therapeutic interventions, for example; 
environmental exposure to pollutants / toxic substances 
6. PK studies which measure medication levels following indirect 
administration e.g., through the placenta or breast milk.   
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Outcome:  
a. Facilitating 
strategies 
 
 
 
 
b. Barriers 
 
1. Proportion of eligible individuals recruited reported, e.g. 
10/ 12 participants.  
2. Proportion of eligible participants whose data was not 
included in the analysis reported 
3. Identification of a facilitator that influenced potential 
trial participation to participate or stay participating in 
the study 
4. Identification of a barrier that influenced potential trial 
participant to decline participation or be unable / 
unwilling to continue to the end of the study.  
1. No failure to recruit e.g. 12/12 participants approached and 
consented or ’12 people’s data reported’, with no indication of total 
sampling frame. 
2. No loss of participants reported at the end of the study period e.g., 
12/12 participant’s data included 
3. No report of facilitators which were attributed to success of 
recruitment 
4. No report of barriers to recruitment or factors that led to the loss of 
participant data 
5.     No report of withdrawal and /or loss to follow up 
Study design 1. Prospective experimental studies with / without 
randomisation.  
2. Observational studies.  
3. Studies conducted within phase(s) I- IV, including 
commercially funded and conducted studies 
4. Qualitative studies of participation in pharmacokinetic 
research study  
5. Papers reported in abstract only 
6. Abstracts reported in English language 
7. All reporting contained within the paper 
1. Review papers 
2. Studies which utilised therapeutic drug monitoring samples with no 
additional research specific sampling.    
3. No abstract available in English language. 
4. No direct contact to authors- detail had to be available within the 
published papers 
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3.3.1.4 Study design 
A scoping review adopts an inclusive approach to studies (Arksey and O'Malley, 2005, 
Hidalgo et al., 2011). All studies that met the inclusion criteria were therefore considered for 
the review, regardless of study design.  
3.3.1.5 Language 
The plan was to screen non-English papers on their abstract. If the paper was not eligible on 
this basis then the reason was recorded as per other criteria. If the paper appeared to be 
eligible then attempts would be made to have these translated utilising local resources. If it 
was not possible to translate then their existence would be documented and ‘language’ 
recorded as the reason for exclusion (Centre for Reviews and Dissemination, 2009). 
3.3.1.6 Year of publication 
Searches were restricted to publications from 1990. A recent systematic review of 
invasiveness of PK studies (1967-2015) (Altamimi et al., 2016), found the majority of PK 
studies occurred from 1985 onwards (497/ 549 studies; 91%) which supported this strategy. 
3.3.1.7 Electronic searches 
Following preliminary searches, the electronic databases searched were: 
 MEDLINE (1990- 8th August 2015) 
 CINAHL (Cumulative Index to Nursing and Allied Health Literature) (1990- 8th August 
2015) 
 EMBASE (1990- 8th August 2015)  
 ISI Web of Science (including Science Citation Index) (1990 –8th August 2015) 
 Database of Abstracts of Reviews of Effects(DARE) (Centre for Reviews and 
Dissemination) (until April 2016 when funding ceased) (accessed 8th August 2015) 
 Health Technology Assessment (HTA) database (online) (last updated October 2016) 
(accessed 8th August 2015) 
 Cochrane Database of Systematic Reviews (accessed 8th August 2015) 
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The search strategy was reviewed and validated by two librarians who assisted with the 
decisions about using MeSH terms, the Boolean operators and the databases to access; a 
role recognised as an integral part of the review process (DeLuca et al., 2008).  Eventually 
references to the same studies began to appear repeatedly and it was deemed reasonable 
to conclude that saturation had been reached.  Duplicate citations were screened and 
removed as a function within EndNote software, a computer programme for reference 
management, with a system for storage and reference (Hidalgo et al., 2011),   although 
deduplication by hand was also necessary.  
3.3.1.8 Other searches 
Although scoping reviews support the inclusion of literature identified through other 
strategies, such as citation searching, searching the reference lists of included retrieved and 
relevant studies and hand-searching key journals, the decision was made that this was not 
feasible.  This was because included studies covered a variety of medications, locations, 
were conducted in a range of countries and published in 98 different journals.  This 
heterogeneity reduced the feasibility of this method.  
3.3.2. Data collection and analysis 
3.3.2.1 Selection of studies 
During the early scoping searches terms were searched in ‘title and abstract’ as well as ‘all 
fields’ for each of the key elements in Medline, Cinahl and Embase, to determine if 
searching in title and abstract alone was sensitive. The numbers for most searches were 
very similar therefore the decision was made to search title and abstract.   Citations were 
imported into EndNote and tracked into categories for inclusion or exclusion. Potentially 
eligible papers were screened by the author (JCM), with independent screening of a sub-set 
of these (10%) by a second reviewer JFM (Supervisor). Full copies of potentially eligible 
studies were then obtained, reviewed by JCM, decision made on inclusion or exclusion of 
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papers based on the predefined criteria, with independent review by JFM. In the case of any 
differences of opinion a third reviewer KPM (second supervisor) reviewed and made the 
decision. There was no blinding to the journal, the authors or the institution.   
3.3.2.2 Data extraction 
A data extraction form was adapted from Polit & Beck (2010) (See Appendix 6). Data was 
extracted on the country in which the lead author was based, the setting, the nature of the 
medication under investigation, the nature of the included population, the number of 
participants recruited, the study design, the route and regime for medication 
administration, the sampling protocol and reasons for recruitment failure or data loss.    
3.3.2.3. Analysis 
The factor(s) that made the study eligible were extracted and then grouped together where 
they were similar in form and content.  Broad categories were then shaped from the 
emerging themes and further delineation into sub categories by (JCM) with theme 
verification by (JFM).   A study was eligible if it met one or more categories for inclusion 
therefore trials could appear in more than one category.  
3.4 Results: included studies 
The search strategy resulted in 4082 records being identified through database searches and 
a further 198 by other search methods, including the preliminary searches (Figure 10 
PRISMA diagram below). Following the removal of duplicates (2493), 761 records were 
excluded based on review of title and abstract and 1026 articles were reviewed in full. 823 
were excluded, 610 of these because there was no reported participant loss or account for 
loss of participant data.  203 studies were eligible for inclusion (see Table 13 below).  
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Figure 10: PRISMA diagram of reviewed studies 1990-2015  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Codes for Table 13 below.  
1
Study design: 1: RCT, 2: Open label study  
2
PK approach: C: ‘classic’ PK approach, P: Population PK, C&P: both 
3
Category of medication: A: Analgesia/ sedation, B: Chemotherapy, C: Anti-infective, D: HIV, E: psychiatric disorders, F: 
anti-convulsant, G: Acid suppression, H: asthma, I: other 
4
Category of barrier:  
A: Recruitment, B: Medication- B1. Drug dose error, B2 Vomiting / expulsion, B3 Delivery issue, C: Sampling, D: 
Processing- D1. Clerical errors (includes labelling & discrepancies in drug history and collection times), D2: Technical 
failure, assay difficulties and preparation failure, D3 Storage and transportation. E: Withdrawal.
Electronic searches:  
4082 potentially relevant citations 
Other sources:                                                     
Reference lists, alerts, early scoping 
searches: 198  
1787 records after duplicates 
removed 
(n = 2493 duplicates) 
1787 records screened 
1026 full‐text articles assessed for 
eligibility 
 761 Records excluded: 
Adults (n=413)                     
Paediatrics, but no PK (n=204)      
Not PK study* (n= 104)                 
Review papers (n=40) 
823 full‐text articles excluded: 
                                               
1. No loss of participants OR 
unable to account for loss 
(n=610)                         
2. Adults (n = 19)                          
3. Not PK (n= 104)                                   
4. Review paper (n=6)                             
5. No differentiation between 
adult and paed data (n= 30) 
6. Duplicate publication (n= 54)          
203 papers included  
(3 from reference lists, 1 from 
alert, 27 from early scoping 
searches, 172 from main search) 
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Table 13: table of all included studies within the scoping review 
Authors Yr 
published 
Country Study 
design
1 
PK 
approach
2 
No. 
centres 
Category of 
medication
3 
Study 
 population 
No. 
eligible 
for PK 
No. 
included 
in PK 
analysis 
Age of 
CYP 
No. samples & 
timeframe 
Category
 
Kinney et al  1991 USA 1 C 1 I Sepsis in NIC 170 35 <72hrs 
age 
4 per infusion (0-
7days). Max 12 
samples/ pt 
B1 
Saxen et al  1993 Finland 2 C 1 C NICU Patients 16 10 Neonates 
< 24hrs 
age 
7 (0-72hrs) D1, D5 
& D7 (total 21) 
C 
Fritz et al  1994 USA 2 C 1 I Nocturnal enuresis 18 16 7-15yrs 4 (Wk 5, 7, 9, 11) E 
Husson et al  1994 USA 2 C 2 C HIV 25 19 0.25-18yrs 9 (0-24hrs) D2 & 
D6. 10 (0-24hrs) 
D10 (total 28) 
C 
Blumer et al  1995 USA 2 C MC: not 
listed 
C Infection 73 63 0.16 -
12yrs 
7 (0-8hrs) C, D2 
Force et al  1995 USA 2 C 1 C Otorrhoea after 
tympanostomy tube 
placement 
10 7 3-8yrs 2 (pre-and 1 hr post 
dose) D7 
C 
Gaedicke et 
al  
1996 Germany 2 C 3 B Malignant tumours 49 24 3-15yrs 10 (0-24hrs) E 
Malinovsky 
et al 
1996 France 2 C 1 A Urology surgery 32 30 2-9yrs 13 (0-6hrs) C 
Reed et al  1996 USA 2 C 1 A Sedation on PIC 29 19 0-18yrs 18 (0-24hrs) C, D2 
Birmingham 
et al  
1997 USA 1 C 1 A Orthopaedic surgery 28 28 2-12yrs 16 (0-16hrs) C 
Carlsson et al  1997 Sweden 1 C 1 I Haemophilia A 21 14 >8yrs-
42yrs 
8 (0-48hrs) A 
Geiduschek 
et al  
1997 USA 2 C 1 A NICU patients on 
Extra-Corporeal 
Membrane 
Oxygenation (ECMO) 
16 11 Neonates 4 (0-3 hours) C 
Gorodischer 
et al  
1997 Canada 2 C 1 F Epilepsy 170 128 0.3-18yrs 1 sample, no 
standardised time 
schedule (blood and 
saliva) 
C, D2 
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Authors Yr 
published 
Country Study 
design
1 
PK 
approach
2 
No. 
centres 
Category of 
medication
3 
Study 
 population 
No. 
eligible 
for PK 
No. 
included 
in PK 
analysis 
Age of 
CYP 
No. samples & 
timeframe 
Category
 
Mendelsohn 
et al  
1997 USA 2 C 2 I Congestive cardiac 
failure 
9 6 2-18yrs 5 (0-2.5 hrs) C 
Stevens et al  1997 USA 2 C 2 C Febrile neutropenia 28 23 0.5-16yrs 12 (0-120hrs) & 12 
samples on D5 
(total 24) 
C 
Reynolds et 
al  
1997 USA 2 C 1 I Elective surgery 29 28 0.25-5yrs 6 (0-4hrs) C 
Wintermeyer 
et al  
1997 USA 2 C 1 D HIV 16 13 0.25-18yrs 4 (1 per outpt visit) C 
Canafax et al  1998 USA 2 C 1 C Otitis media 34 30 0.25-5yrs 2 (0.5-4hrs) E 
Lindsay et al  1998 USA 1 C 2 I Septic shock 12 11 0.5-
18years 
6 (0.5-8hrs) C 
Peytchev et 
al  
1998 Bulgaria 2 C 1 F Epilepsy 59 48 1.7-12yrs "steady state" no 
further info 
E 
Agertoft et al  1999 Denmark 2 C 1 H Chronic asthma 13 10 3-6yrs IV: 8 (0-3hrs), oral: 
8 (0-6hrs) (total 16) 
A, B3, E 
Findling et al  1999 USA 2 C 1 E Depression 30 23 5-17yrs 11 (0-24) & urine 4 
(0-24hrs) 
E 
Crawley et al  2000 UK 1 C 1 F Cerebral malaria 440 23 0.75-13yrs 8 (0-48hrs).   A, C, D2, 
E 
Dallas et al  2000 Canada 2 C 1 D HIV patients 6 3 0.33-5 yrs 8 (0-8hrs) E 
Hahn et al  2000 Denmark 2 C 1 A Post-surgery 23 17 0.17 - 
11yrs 
5 (0-5 hrs) saliva 
and blood 
C, D2 
Kearns et al  2000 USA 2 C 3 C Gram positive 
infection 
57 54 0.25-16ys <12mths: 8samples 
>12 months: 
10samples (0-
24hrs). 
(Total 10) 
Urine 4 samples (0-
24hrs) 
C 
Nahara et al  2000 USA 2 C 1 A Sedation in PIC 23 22 0.02 -
16yrs 
"steady state" no 
further info 
C 
Scheepers et 
al 
2000 Canada 2 C 1 C Dental surgery 11 10 2-6yrs 12 (0-2hrs) C 
Stevens et al 2000 USA 1 C 27 D HIV 106 77 0.25-18yrs 8 (0-4hrs) C, D1 
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Authors Yr 
published 
Country Study 
design
1 
PK 
approach
2 
No. 
centres 
Category of 
medication
3 
Study 
 population 
No. 
eligible 
for PK 
No. 
included 
in PK 
analysis 
Age of 
CYP 
No. samples & 
timeframe 
Category
 
Wulf et al  2000 Germany 2 C 1 A Inguinal hernia 
repair 
25 20 0-5yrs 9 (0-2hrs) C 
Johnson et al  2001 USA 2 C 7 I Radiocontrast agent 43 40 0-12yrs 5 (0-32hrs) C 
Tod et al  2001 France 2 C&P MC: not 
listed 
C Herpes simplex & 
Varicella Zoster 
Virus 
85 79 <2yrs 5 (0-8hrs) D1 
Reed et al  2001 USA 1 C 8 A Sedative pre-med 
for day surgery  
111 89 0.5-16yrs 13 (0-10hrs) B2, C 
Ross et al  2001 USA 2 C 2 A Surgical patients 42 34 0-18years < 2yrs: 10 samples 
0-1hr  
>2 yrs 12 samples 
(0-4hrs) (total 12) 
C, D2 
Dsida et al  2002 USA 2 C 1 A Orthopaedic / 
urology pts 
43 36 1-16yrs 16 (0-10hrs) C 
Furman et al  2002 USA 2 C MC: not 
listed 
B Refractory 
leukaemia 
49 33 <21yrs 4 (0-24hrs) C 
Guay et al  2002 USA 2 C 1 I Prevention HIV 
vertical transmission  
29 21 Newborn 4 (1hr- 14weeks 
age) 
C 
Gremse et al  2002 USA 1 C 11 G Gastro oesophageal 
reflux 
60 53 1-11yrs 13 (0-24hrs) B1, C, D3 
Lipman et al  2002 Australia 2 C 1 C Sepsis 20 17 0.25-5yrs 9 (0-12hrs) D0, D2, 
D6-8 (Total 27) 
C, D1 
Marina et al  2002 USA 2 C MC: not 
listed 
B Solid tumours 22 10 <21yrs 7 (0-48hrs) D1 
Orenstein et 
al  
2002 USA 1 C 6 G Gastro oesophageal 
reflux 
29 25 4-11yrs 10 (0-6hrs) C 
Rahman et al  2002 USA 1 C 1 I Malnourished 
children 
411 339 1-2.1 yrs 3 (D0, D21, 3 
months) 
E 
Rongkavilit 
et al  
2002 Netherlands 2 C 1 D Neonates exposed 
to HIV 
24 22 <0.08yrs 6 (0-12hrs) D14 & 
D28 (total 12) 
D2, E 
Best at al  2003 USA 2 C 5 I Children with 
Kawasaki disease 
24 10 0.5-5 
years 
D1:6 (0-5hrs), D6: 4 
(0-3hours) (total 10) 
B1, C, E 
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Authors Yr 
published 
Country Study 
design
1 
PK 
approach
2 
No. 
centres 
Category of 
medication
3 
Study 
 population 
No. 
eligible 
for PK 
No. 
included 
in PK 
analysis 
Age of 
CYP 
No. samples & 
timeframe 
Category
 
de Wildt et al  2003 Netherlands 2 C 1 A Sedation in 
Paediatric Intensive 
Care (PIC) neonates 
21 20 0.005-
17yrs 
3 samples (loading 
dose), 1 sample 
/day on infusion, 9 
(0-24hrs) post 
infusion  
(total: min 13) 
E 
Fraaj et al  2003 Netherlands 2 C 1 D HIV 35 6 0.2-
13.6yrs 
8 (0-8hrs) D1 & D2 
(total 16) 
C, E 
Gajjar et al  2003 USA 2 C MC: not 
listed 
B Glioma with 
concomitant enzyme 
inducing anti-
convulsant 
35 18 3-21yrs 7 (0-6hrs) D5 and 
D12 (total 14) 
E 
Howel & 
Patel  
2003 UK 1 C 1 A Elective spinal 
surgery 
24 22 >25kgs 4 (2-5hrs) B1 
Kearns et al  2003 USA 2 C 1 A Healthy children 12 12 5-15yrs 12 (0-9.6 hrs) C 
Sallas et al  2003 USA 1 C&P 47 
centres 
in 8 
countries 
F Epilepsy 138 109 3-17yrs 4 (visits 5,6,7,8) C 
Wu et al  2004 USA 2 C 1 I Neonatal Intensive 
Care (NICU) 
59 22 <1 month 2 (D14 & D 28) A, E 
Aquino et al  2004 Canada 2 C MC: not 
listed 
B Refractory solid 
tumours 
23 22 <21yrs 13 (0-6hrs) D1 
Conway et al  2004 UK 2 C 1 C Cystic Fibrosis 5 4 <16yrs & 
>16yrs 
8 (0-12hrs) D1 & 
D14. 2 (0-2hrs) D8 
& D11 (total 20) 
A, E 
Fletcher et al  2004 USA 1 C 48 D  HIV 21 18 3-14yrs 7 (0-8hrs) C 
Goren et al  2004 USA 2 C 1 B Tumours 14 11 1-18yrs 8 urine D1 and D5 
(total 16) 
C 
Lebovitz et al  2004 USA 2 C 1 H Asthma in PIC 56 50 0.5-16yrs 13 (0-72hrs) B1, C 
Neville et al  2004 USA 2 C MC: not 
listed 
B CNS tumour 26 25 <22yrs 11 (0-48hrs) 16pts. 
9 pts had additional 
3 (8-12hrs) 
C 
 
 
69 
 
Authors Yr 
published 
Country Study 
design
1 
PK 
approach
2 
No. 
centres 
Category of 
medication
3 
Study 
 population 
No. 
eligible 
for PK 
No. 
included 
in PK 
analysis 
Age of 
CYP 
No. samples & 
timeframe 
Category
 
Oliver et al  2004 USA 2 C 1 I Cardiopulmonary 
bypass for 
congenital heart 
surgery 
30 28 <16yrs 8 (0-4hrs) C 
Quinn et al  2004 Canada 1 C 3 E ADHD 32 31 9-12yrs 9 (0-10hrs) E 
Stewart et al  2004 USA 2 C 4, 2 
Countries 
B Medulablastoma & 
supratentorial 
tumour 
44 36 3-21yrs 6-8(0-6hrs) B3 
Wagner et al  2004 Germany 2 C MC: not 
listed 
B Progressive glioma 9 7 3-18years 7 0-24hours C, E 
Wheeler et al  2004 USA 2 C 1 A Elective surgery 10 10 5-11yrs 16 (0-10yrs) C 
Bergschoeff 
et al  
2005 Netherlands 1 C 2 D HIV 24 20 2-13yrs 8 (0-12hrs) wk 4 & 
Wk 8 (Total 16) 
B1 
Capparelli et 
al  
2005 USA 2 C MC: not 
listed 
C Bacterial infection 111 98 0.5-16yrs 12 (0-24hrs) B2 
Chalkiadis et 
al  
2005 Australia 2 C&P 8 A Surgical infants 22 12 <0.25 
years 
5 (0.5-4hrs) C 
Chien et al  2005 USA 2 C 5 C Bacterial infection 85 80 0.5-16yrs IV: 2 (0-24hrs) oral 
1 (0-24) + 36 and 
48hr samples (total 
5) 
B2, D1, E 
Daw et al  2005 USA 2 C MC: not 
listed 
B Malignant solid 
tumour 
17 17 <22years 7 (0-24hours) A 
Jacobs et al  2005 USA 2 C 3 C IV in Inpatient / 
outpatient  
32 29 0.5-16yrs <2 yrs:7, >2: 9. 
(0=168 hrs) 
C, E 
Kyllonen et 
al  
2005 Finland 2 C 1 A Minor surgery/ 
orthopaedic surgery 
24 20 0.02 - 
1year 
10 (0.3-10hrs) B2 
Saul et al  2005 USA 1 C 48 
centres, 
7 
countries 
I Cardiac arrhythmias 32 25 0.08 - 
16yrs 
Loading dose: 5 
samples (0-2hrs), 3 
(0-24hrs), washout 
9 (0-30days) (total 
17) 
C 
Veal et al  2005 UK 2 C 7 B Chemotherapy 31 16 <21yrs 8 (0-24hrs) C 
Ward et al  2005 Canada 1 C 1 I Osteogenesis 
Imperfecta Type 1 
25 24 4-16yrs Urine: 3 (0-24hrs) B2 
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Authors Yr 
published 
Country Study 
design
1 
PK 
approach
2 
No. 
centres 
Category of 
medication
3 
Study 
 population 
No. 
eligible 
for PK 
No. 
included 
in PK 
analysis 
Age of 
CYP 
No. samples & 
timeframe 
Category
 
Bomgaars et 
al  
2006 USA 2 C 1 B Refractory solid 
tumours 
23 11 1-21yrs 15 (0-24hrs) C 
Cormack et 
al  
2006 UK 2 C 1 A Chronic Liver disease 17 16 3-15yrs 6 (0-8hrs) C 
Dupuis et al  2006 Canada 2 C 1 I Stem cell transplant 80 24 0.5-
16.9yrs 
8 (0-12hrs) A, B2, C, 
E 
Fouladi et al  2006 USA 2 C MC: not 
listed 
B Refractory solid 
tumours 
18 12 <22yrs 11 (0-6hrs) Wk 1 & 
Wk3 (total 22) 
c, D3 
Heresi et al  2006 USA 2 C MC: not 
listed 
C Premature neonates 
in NIC 
23 19 premature 
infants  
6 (0-12hrs) C 
Johannsen et 
al  
2006 USA 2 C 13 B Malignancy 31 26 <21yrs 15 (0-96hrs) B2, C 
Kokki et al  2006 Finland 2 C 1 A Surgery 34 30 0.5 -7.6yrs 10 (0-12hrs)  A, B2, C 
Muller et al  2006 Germany 2 C 1 A Post-operative pain 
in PIC 
41 39 0-4yrs 8 (012hrs) Urine 4 
(0-12hrs) 
C 
Mehta et al  2006 USA 2 C 1 C Stem cell 
transplantation 
14 12 0.38 -9yrs 14 (0-168hrs) Wk 
1& 4. (Total 28) 
C 
Rodriguez-
Galindo et al  
2006 USA 2 C 1 B Refractory solid 
tumours 
11 10 <21yrs D1-5: 4 samples 
/day 0-6 hrs. (total 
20) 
E 
Simpson et al  2006 Australia 2 C&P 5, 4 
countries 
I Malaria 86 70 1.3-10yrs 3 (0-24hrs) B2 
van der Lee 
et al  
2006 Netherlands 2 C 1 D HIV 19 18 1.4-
12.9yrs 
8 (0-24hrs) D14 E 
Zhao et al  2006 USA 1 C 1 G Gastro oesophageal 
reflux 
30 27 1-11yrs 9 (0-6hrs) E 
Zuppa et al  2006 USA 1 C 1 I Neonatal cardiac 
surgery 
16 15 Neonate 13 (0-24hrs) C 
Aman et al  2007 USA 2 C 1 E Psychiatric / 
neurodevelopmental 
conditions 
19 12 4-15yrs 4 (0-7 hours) C 
Broniscer et 
al  
2007 USA 2 C MC: not 
listed 
B Recurrent brain 
tumours 
50 28 <21yrs 7 (0-6 hrs) A, C 
Diaz et al  2007 USA 2 C 1 A  Surgical patient on 
PIC 
10 10 0.3-7.9yrs 12 (0-8hrs) D1 
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Fouladi et al  2007 USA 2 C 1 B Refractory solid 
tumours 
26 18 3-22 yrs 9 (0-24hrs) A, D2 
Horton et al  2007 USA 2 C MC: not 
listed 
B Refractory 
leukaemia 
11 5 1-21yrs Unable to 
determine 
A 
Kulkarni et al  2007 India 1 C 1 A Children undergoing 
minor surgery 
50 29 3-12years 9 (0-12hrs) A, C 
Lynn et al  2007 USA 1 C&P 1 A Elective surgery 25 15 0.5-1.5yrs 5-7 samples (0-
12hrs) 
B1, C 
Quinn et al  2007 Canada 1 C 1 E ADHD 18 14 6-12yrs 11 (0-24hrs) B1 
Veal et al  2007 UK 2 C 9 B Neuroblastoma 29 28 <18yrs 5 (0-6hrs) D1 and 
D14 (total 10) 
C 
Zhang et al  2007 USA 2 C&P 8 in USA  D  HIV 52 43 5-17yrs 5 (0-12hrs) & 4 
trough levels (wk2, 
8, 16 24) (total 9) 
D1 
Abdel-
Rahman et al  
2008 USA 2 C MC: not 
listed 
C Gram positive 
infection 
25 22 2-17yrs 10 (0-24hrs) B3, C 
Almeida et al  2008 Portugal 2 C 1 F Epilepsy 31 26 2-17yrs 7 (0-12) E 
Bomgaars et 
al  
2008 USA 2 C 1 C Children receiving 
chemotherapy  
37 32 2-18yrs 8 (0-8hrs). Urine 0-8 
hrs 
C, D3 
Danne et al  2008 Germany 1 C 1 I  Type 1 Diabetes 32 30 6-17yrs 14 (0-16hrs) C 
Findling et al  2008 USA 2 C 4 E Psychiatric disorder 21 19 10-17yrs 9 (0-24hrs) D 14 E 
Glade Bender 
et al 
2008 USA 2 C MC: not 
listed 
B Malignant solid 
tumour 
10 8 <22years D1: 4 (0-5hrs), D2-
14: 5 samples (total 
9) 
C 
Goto et al  2008 Japan 2 C 1 I Liver transplant 44 39 0.25-14yrs 2 samples D3 and 
D7 (total 4) 
E 
Gururangan 
et al  
2008 USA 2 C MC: not 
listed 
B Recurrent brain 
tumours 
41 23 <21yrs 8 (0-4hrs) A, C, D2, 
E 
Hammer et al  2008 USA 1&2 C MC: not 
listed 
I Surgical patients 77 76 0.06-12yrs <2ys 3 (0-post 
infusion), >2yrs: 4 
samples (0-post 
infusion) (total 4) 
B3 
Neville et al  2008 USA 2 C 2 H Asthma  25 24 <16yrs 14 (0-60Hrs) C 
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Standing et 
al  
2008 UK 2 P 1 A Day surgery 74 70 1-12yrs 3 samples: insertion 
of cannula, end of 
surgery & removal 
of cannula 
A, B2 
Van Ommen 
et al  
2008 Netherlands 2 C 1 I Veno-
thromboembolic 
disease 
84 76 0-18yrs 1 (4 hrs) and if dose 
altered (min 1) 
C 
Almenrader 
et al 
2009 Italy 2 C 1 A Induction of 
anaesthesia for 
umbilical procedures 
13 10 1.8- 7 yrs 8 (0.33-12hrs) C 
Baruchel et 
al  
2009 Canada 2 C 5 B Recurrent CNS 
tumours 
7 5 2-18yrs 10 (0-48hrs) E 
Beghetti et al  2009 Switzerland 2 C 11 in 7 
countries 
I Pulmonary 
hypertension 
36 35 2-12yrs 6 (0-12hrs) B1 
Chadwick et 
al  
2009 USA 2 C 9 in 2 
Countries 
D Infants with HIV  10 9 >14days - 
<6 weeks 
5 (0-12hrs), 4 (8-24 
Wks) (total 9) 
B2 
Gonzalez et 
al  
2009 USA 1 C 1 E  ADHD 27 23 6-12yrs 9 (0-16hrs) C 
Hahn et al  2009 Germany 2 C&P 14 sites 
in Europe 
& 
Canada 
I MRI contrast agent 138 130 2-17yrs 4 (0-8hrs) B1, C, D2 
Jacquemin et 
al  
2009 France 1 C 1 I Chronic cholestasis 
or Cystic Fibrosis 
12 11 0-18yrs 6 (0-24hrs) C 
Malloy et al  2009 USA 1 C 5 I Type II diabetes 13 6 10-16yrs 3 (0-8hrs) D2 
McGregor et 
al  
2009 USA 2 C MC: not 
listed 
B Refractory solid 
tumours 
13 6 1-22yrs 5 (0-14days) A, D2 
Nielsen et al  2009 Sweden 2 C&P 1 C Neonates 61 61 0-45 days 2 (0.25-8hrs) D2 & 
D5 & routine 
measurements (min 
4) 
D1 
Pollock et al  2009 UK 2 C 1 D HIV 43 37 0-16yrs 5 (0-12hrs) B1, C 
Saez-Llorens 
et al  
2009 USA 2 C MC: not 
listed 
C Herpes simplex or 
Varicella Zoster 
Virus 
51 50 1-12yrs 6 (0-5hrs) B1 
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Saez-Llorens 
et al 
2009 USA 2 C 8 in 3 
countries 
C Infants with 
candidiasis  
18 17 <0.25yrs 1 dose: 3 samples 
(0-24hrs), multiple 
doses: D1 5 samples 
(0-24hrs), D4 (2: 1 & 
24hrs) (total 10) 
C 
Beaty et al  2010 USA 2 C 8 B Refractory solid 
tumours 
124 49 <21yrs 4 (0-7days) A, D2 
Blumer et al  2010 USA 2 C&P 5 C Herpes simplex  18 17 0.08-1yr 4 (0-6hrs) B2 
Fouladi et al  2010 USA 2 C MC: not 
listed 
B Refractory CNS 
tumours 
59 33 <21yrs 7 (-0-8hrs) A, C 
Gururangan 
et al  
2010 USA 2 C MC: not 
listed 
B Malignant glioma 31 12 <21years 3 (0-16days) B1 
Kimberlin et 
al  
2010 USA 2 C 15 C Herpes simplex 112 98 0.08-11yrs 6 (0-6hrs) B2 
Mckibbin et 
al  
2010 USA 2 C 1 B Medullablastoma 49 33 3-21yrs 8 (0-3hrs) after 1st 
& 2nd doses (total 
16) 
A, D2 
Musiime et al  2010 Uganda 2 C 2 D Children with HIV 41 36 3-12yrs 7 (0-12hrs) + D28 8 
(0-24) Total = 15 
D1 
Standing et 
al  
2010 USA 2 P 1 A Cranioplasty 7 7 0.3-1yr 11 (0.08-4.5 hrs) C 
Su et al  2010 USA 2 C&P 1 A Cardiac surgical 
patients on PIC 
38 36 Infants 14 (0-24hrs) C 
Aplenc et al  2011 USA and 
Canada 
2 C 21 B Solid tumours 39 19 1-21yrs 10 (0-24hrs) A 
Berg et al  2011 USA 2 C MC - not 
listed 
B Solid tumours 49 29 1-21yrs 9 (0-D14) A 
Chadwick et 
al  
2011 USA 2 C 17 D Infants with HIV 31 20 0-0.5yrs 5 (0-12hrs) B1, C, E 
Fillekes et al  2011 Uganda 2 C 2 D HIV 41 39 3-12yrs 9 (0-4wks) D1 
Forbes et al  2011 USA 2 C 11 I Intravascular 
procedures 
110 106 0-16yrs 6 (0-30mins after 
stop infusion) 
C 
King et al  2011 USA 2 C 1 D HIV patients 50 47 8-18yrs 7 (0-24hrs) & 3 
Urine (0-24hrs) 
C 
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Kiser et al  2011 USA  2 C MC- not 
listed 
D Children with HIV 195 172 0.24-21yrs 9 (0-24hrs) B1, B2, 
C, D3 
Knoderer et 
al  
2011 USA 2 C 1 C Post cardiac surgery 
on cardiopulmonary 
bypass 
16 15 0.08-3yrs 7 (0-12days) B1 
Lynn et al  2011 USA 1 C&P 1 A Post-surgery 25 14 0.17-
0.5yrs 
5-7 samples (0-
12hrs) 
C, E 
McJunkin et 
al  
2011 USA 1 C MC- not 
listed 
C La Crosse 
Encephalitis 
15 9 5-14yrs 6 (0-4 days) D1 
Mugabo et al  2011 South Africa 2 C 1 D Premature infants 
born to HIV-infected 
women 
68 58 Infants 
<37wks 
gestation 
7 (0-21days) C 
Piper et al  2011 USA 2 C 1 C Infants with 
suspected 
candidiasis 
10 8 0.0005-
0.16yrs 
8 (0-5 days) B1, D1 
Raber et al  2011 USA 2 C 12 sites 
in 6 
countries 
I Glaucoma 47 46 0-18yrs 5 (0-1hr)  D3 
Rakh-Manina 
et al  
2011 USA 2 C 1 D HIV 50 44 4-18yrs 7 (0-12hrs)   B1, C 
Warren et al  2011 USA 2 C MC - not 
listed 
B Brain tumour 23 18 0-21yrs 6 (0-24hrs) A, B1, 
B3, C 
Wigal et al  2011 USA 2 C 1 E ADHD 32 28 6-12yrs 8 (0-11.5hrs) C 
Ademisoye 
et al  
2012 Nigeria 2 C 1 I Sickle cell disease 15 10 10-13yrs 14 (0-28days) E 
Chamberlain 
et al  
2012 USA 2 C&P 10 F Status epilepticus 69 63 0.25-17yrs 13 (0-48hrs) C, E 
Cohen-
Wolkowiez 
et al  
2012 USA 2 C&P 5 C Premature neonates 
in NIC 
32 31 <32weeks 5 (0-24hrs) + 1 (pre-
last dose) 
D1 
Drover et al  2012 USA 2 C 1 A Post-operative 
Adolescents 
20 18 12-17yrs 10 (0-24hrs) B1 & C 
Fillekes et al  2012 Netherlands 2 C 1 D Infants with HIV 16 15 0.08-25yrs 4 (0-12hrs) B1 
Jimenez et al  2012 USA 2 C 1 A Tonsillectomy 70 68 3-17yrs 6 (0-240mins) B1 
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Malhotra et 
al  
2012 USA 2 C 7 I Overactive bladder 21 16 8-17yrs 4 (0-4hrs Wk 4) + 4 
(8-20hrs Wk 8) = 8 
total 
B1, C 
Manitpisitkul 
et al  
2012 USA 1 C&P 17 in 5 
countries 
F Epilepsy 50 35 0.1-2yrs 4 (0-10hrs) B1, C 
Mcgregor et 
al  
2012 USA 2 C 1 B Solid tumours 20 11 0-21yrs 7 (0-6hrs) on D1 
and last day course 
1 = 14 total 
A 
Norman et al  2012 Unknown 2 C Not 
specified 
I Type 1 Diabetes 16 13 10-17yrs 12 (0-4hrs) B3 
Oudijk et al  2012 Zambia 2 C 1 D Children with HIV 29 22 0.7-3.2 yrs 4 (0-6 hrs) B1 
Varendi et al  2012 Estonia 2 C 1 A Clinically indicated 
paracetamol 
39 30 0-2yrs Up to 5 (no time 
frame specified) 
A 
Autmizguine 
et al  
2013 Canada 2 C 1 C Osteoarticular 
infections 
12 11 0-18yrs 5 (0-6hrs)   C 
Blaney et al  2013 USA 2 C MC- not 
listed 
B Neoplastic 
meningitis 
19 6 3-22yrs 2 (Wk 1& 3) CSF  A 
Cohen-
Wolkowiez 
et al  
2013 USA 2 C&P 3 C Premature neonates 
in NIC 
24 23 <32weeks 5 (0-8hrs) C 
Demirjian et 
al  
2013 USA 1 C 1 C Infection 61 46 2-18yrs 4 (0-32hrs) C 
Glade Bender 
et al  
2013 USA 2 C MC - not 
listed 
B Solid tumours 51 43 2-22yrs 11 (0-24hrs) A, C 
Gore et al  2013 USA 2 C MC- not 
listed 
B Refractory solid 
tumours 
15 13 1-18yrs 27 (0-4 wks) E 
Hummel et al  2013 USA 2 C MC- not 
listed 
B Brain tumour 19 16 12-21yrs 9 (0-24hrs) A 
Kilburn et al  2013 USA 2 C MC- not 
listed 
B Brain tumour 24 9 3-21yrs 8 (0-10hrs) + 1 (D7) 
+ 1 (D21) = 10 total 
A, B3,  
Kim et al  2013 USA 2 C MC - not 
listed 
B Neurofibromatosis  9 4 3-18yrs 7 (0-8hrs) C 
Kimberlin et 
al  
2013 USA 2 C 16 C Influenza 87 77 0-2yrs 5 (0-12hrs) A, C, E 
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MacDonald 
et al 
2013 USA 2 C MC- not 
listed 
B Glioma    30 24 <22yrs 4 (0-6hrs) A 
Min et al  2013 Korea 2 C 1 I Post kidney 
transplant 
38 34 5-15yrs 15 (0-24hrs) on D7, 
D14 & D28 (total = 
45) 
C 
Muscal et al  2013 USA 2 C MC -not 
listed 
B Solid tumours 23 6 12-22yrs 13 (0-72hrs) A 
Salzer et al  2013 USA 2 C MC- not 
listed 
B Leukaemia 59 41 2-18yrs 12 (0-24hrs) D1 B1, D1 
Shah et al  2013 UK 2 c 6 F Epilepsy 102 100 0-17yrs 3 (0-8 wks) C 
Smith et al  2013 USA 2 C MC- not 
listed 
I Urea cycle disorders 15 13 0.08-6yrs 4 (0-24hrson D1) + 
4 (0-24hrs on D10) 
= total 8. Urine 3 (0-
24hrs D1) + 3 (0-24 
on D10) = 6 
C 
Stricker et al  2013 USA 2 p 1 I Craniofacial surgery 39 18 0.5-2yrs 10 (0-15hrs after 
end of infusion) 
A 
Sugita et al 2013 Japan 2 C 1 C Otitis media 23 20 0.4-
5.25yrs 
2 (0-4.8hrs) Blood & 
ear effusion 
C 
Thompson et 
al  
2013 USA 2 C MC - not 
listed 
B Refractory solid 
tumours 
20 18 >1-<22yrs 8 (0-48hrs) E 
Veal et al  2013 USA 2 P MC - not 
listed 
B Neuroblastoma 103 73 0-21yrs 6 (0-14days) C 
Vrooman et 
al  
2013 USA 2 C 10 B Leukaemia / 
Lymphoma 
30 23 1-17yrs 4 (0-72hrs) B1, C 
Walson et al  2013 USA 1 C 1 A Temperature 
prophylaxis 
30 26 0.25-
0.5yrs 
3 (0-8hrs)  B1, C 
Weinstock et 
al  
2013 USA 2 C 24 F Epilepsy 50 49 0.08-16yrs 3 (0-8hrs)  B3, C 
Zorzi et al  2013 Canada 2 C MC- not 
listed 
B Solid tumours 12 5 >1-<18yrs 8 (0-24hrs) + 1 
(D15) = 9 total 
A 
Altcheh et al  2014 Argentina 2 P 1 C Chagas Disease 40 37 2-12yrs 3 (0-6hrs) A, E 
Boddy et al  2014 UK 2 C&P MC- not 
listed 
B Cancer 101 96 Not 
specified 
8 (no range) E 
Bradley et al  2014 USA 2 C 8 C Bacterial infection 24 19 0.25-2yrs 6 (0-12hrs) C 
 
 
77 
 
Authors Yr 
published 
Country Study 
design
1 
PK 
approach
2 
No. 
centres 
Category of 
medication
3 
Study 
 population 
No. 
eligible 
for PK 
No. 
included 
in PK 
analysis 
Age of 
CYP 
No. samples & 
timeframe 
Category
 
Bunupuradah 
et al  
2014 Thailand 2 C 2 D HIV 20 18 6-18yrs 8 (0-24hrs) B1 
De Bruyne et 
al  
2014 Belgium 2 C 1 I Nocturnal enuresis 23 22 5-8yrs 3 (1-6hrs) B3 
Desai et al  2014 USA 2 C 1 B Neuroblastoma 14 14 0-15yrs 15 (0-28days) C 
Garcia et al  2014 Argentina 2 P 5 C Chagas Disease 81 76 0-12yrs 5 (no times 
provided) 
B1 
Hiruy et al  2014 USA 2 C 1 I TB 36 31 <10yrs 6 (0-24hrs) A 
Kukulka et al  2014 USA 2 C 3 G Gastro oesophageal 
reflux 
36 31 1-11yrs 14 (0-24hrs) C, E 
Musiime et al  2014 Uganda 1 C 2 D HIV 79 59 0.25-13yrs 7 (0-12hrs Wk1), 7 
(0-12hrs, Wk8) 
(total =14) 
B1, B2, 
C, E 
Oualha et al  2014 France 2 C 1 I Post cardiac surgery 
low cardiac output 
55 39 0-18yrs 3 (0-6 hrs post 
infusion 
commencing) 
C 
Ramos-
Martin et al  
2014 UK 2 P 1 C Infection 39 39 0-16yrs 4 (1-24hrs) & 4 
after last dose (1-
24hrs) (total 8) 
C, D1 
Thompson et 
al  
2014 USA 2 C MC- not 
listed 
B Cancer 107 98 0-21yrs 20 (0-72hrs) E 
Zongo et al  2014 Burkina 
Faso 
2 C 3 I Malaria 379 365 >0.5-10yrs 2 (D7) B1, B2, E 
Woloszczuk-
Gebicka et al  
2014 Poland 2 C 1 A Abdominal surgery 20 20 0.3-3yrs 3 (0-48 hrs) + 3 (3-
18hrs post infusion) 
= 6 
C 
Hahn et al  2015 USA 2 P 1 C Infection 15 13 0-18yrs 2 additional (1 hr 
post, & 3/ 4 hrs 
post) 
C 
Kilburn et al  2015 USA 2 C MC- not 
listed 
B CNS tumour 33 16 0-22yrs 8 (0-72hrs) + 6 (0-
24hrs on D28) = 14 
total 
A 
Kim et al  2015 USA 2 C MC - not 
listed 
B Solid tumours 20 10 2-21yrs 2 (0-12hrs)  A 
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Munoz et al  2015 USA 2 C 40 in 3 
countries 
C Influenza 17 16 0-12yrs 8 (D1- 0-12hrs), 4 
(D3- pre-8 hrs) (12 
total) 
C 
Stricker et al  2015 USA 2 P 1 I Posterior Spinal 
Fusion Surgery 
21 20 12-17yrs max 11 (0-6 hrs 
post infusion) 
A 
Young et al  2015 USA 2 C 23 in 8 
countries 
I Haemophilia A 71 51 0-12yrs Unclear (0-48hrs) A, C, E 
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3.4.1 Details of the included studies 
Journal: The included studies were reported in 99 journals, making hand searching 
unfeasible.  The highest numbers were from the Journal of Clinical Oncology (n=12), 
Antimicrobial Agents and Chemotherapy (n=10), Clinical Cancer Research (n=10), Pediatric 
Blood and Cancer (n=10) and Pediatric Infectious Disease Journal (N=10).  
Country of origin: Just under two-thirds of the papers originated from USA 65% (n= 132), 5% 
from the UK (n=11) and 5% (n= 11) from Canada.  The remaining 25% originated from 24 
other countries.   In one paper, the country where the study was conducted could not be 
determined.  
Number of sites: The included studies were single site studies in 48% of cases (n=98).  A 
number were reported to be multi-centre but the exact number of sites was indeterminable 
(n=43, 21%).  The highest number of sites was a multi-centre study with 48 centres in 8 
countries.   
Trial design: 170 were classified as observational studies (84%) and 31 (16%) occurred in the 
context of an RCT. Most described a ‘classic’ approach to PK with a predetermined sampling 
regime (n=178, 88%), 9 studies utilised a population PK modelling approach only (4%) and 16 
studies (8%) used a combination of the two approaches.  
Subject area: Medications within the included studies were classified according to 8 main 
classifications. Analgesia / sedative medications (n=49, 24%), anti-infective medications 
(n=38, 19%) and chemotherapy (n=32, 16%) were the biggest categories.    
Year of publication: The number of publications (which met the inclusion criteria) had 
increased significantly over the past seventeen years.  89% (n=181) of papers came from 
 
 
80 
 
2000 onwards and 69% (n=141) of papers came from 2005 onwards, possibly reflecting 
changes in legislation internationally. The reduction in numbers for 2015 reflects the 
searches running until 5th August 2015.   
Number of participants: The number of patients included within the PK study varied widely 
from 3 to 365 (median of 23).  15% of the studies (n=30) had 10 or less participants in the 
study, 45% (n=91) had 20 or less participants and 84% of the studies (n=165) had below 50 
patients in them.  Only 9 studies (4%) had 100 or more participants.   
Age of participants: Studies were categorised into those involving infants (under 1 year of 
age) (n=108, 53%), children (1- 12 years) (n=181, 89%) and adolescent studies (age 13years 
plus) (n=123, 61%).  Many studies had broad inclusion criteria and crossed several age 
classifications and were counted in each category (therefore these figures do not add up to 
203).  
Sampling period: There was wide variation in the sampling schedule of the included studies, 
with some studies sampling for as short a period of time as one hour (Raber et al., 2011)  
through to studies that required samples until 24 weeks (Zhang et al., 2007, Chadwick et al., 
2011).   Eleven studies had an unclear sampling period or a regime that varied per individual.  
In 41% of studies (n= 84) the period of obtaining samples was 12 hours or less.  66% of 
studies required samples for a period of 48 hours or less.  
Number of samples: Over all time periods the range of samples taken per patient was 1- 45, 
with a median of 8 samples / patient.   78% of studies (n=158) required 12 or less samples 
from patients.  
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Type of samples: The majority of PK studies sampled blood from patients (n=201, 99%).  A 
small number of studies compared or measured PK within blood and another bodily fluid: 
urine (6), saliva (4) and ear effusion (1).  Two studies sampled urine alone (Goren et al., 
2004, Ward et al., 2005). 
Language: No papers were specifically excluded on the basis of language.   
3.4.2 Classification of results 
There were no papers that reported recruitment strategies in a systematic manner 
(objective 1).  Reporting of barriers to recruitment was variable and inconsistent (objective 
2).  The results which emerged have been classified into five broad categories, with a 
number of sub sections within each.  The table of all included studies (Table 13) featured 
lists under which category(ies) each is eligible (final column- ‘Categorised’). 
3.5. Results: themes 
3.5.1 Recruitment 
There were 38 papers in total which reported the sampling size and the number who 
consented or refused (see Table 14 below).  Refusal rates ranged from 3% - 76% with a 
median of 41%. Overall there was very little information provided about refusal to 
participate, despite the fact that studies experienced up to 76% refusal rates. 
Table 14: included studies which reported consent or refusal rates 
Refused Number of 
identified papers 
References 
Reported refusal 
(numerical figure 
only) 
31 Crawley et al., 2000, Wu et al., 2004, Daw et al., 2005, Broniscer et 
al., 2007, Horton et al., 2007, Fouladi et al., 2007, Kulkarni et al., 
2007, Gururangan et al., 2008, Standing J., 2008, McGregor et al., 
2009, Beaty 3rd et al., 2010, Fouladi et al., 2010, McKibbin et al., 
2010, Aplenc et al., 2011, Berg et al., 2011, Warren et al., 2011, B 
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In 31 / 38, this was the only detail provided.  Of the 7 papers that provided any further 
information about refusal, 3 specifically stated that there were issues related to blood 
sampling or the placement of an IV cannula (Agertoft et al., 1999, Conway et al., 2004, 
McGregor et al., 2012).   One paper (Dupuis et al., 2006) reported an inability to recruit 
based on parents’ unavailability or the patients themselves declining assent. One paper 
reported refusal due to not wanting to change medication regime (Carlsson et al., 1997) and 
two studies referred to the burden of additional hospital visits  (Kokki et al., 2006, Altcheh et 
al., 2014). Amongst the studies reporting recruitment rates, 58% (n=22/38) involved a 
chemotherapy agent.  This could reflect improved reporting amongst this group of 
medications, although with reporting rates so poor it is difficult to draw conclusions.    
3.5.2 Drug administration /delivery problems  
There were 52 papers which reported issues associated with drug administration or delivery 
in Children and Young People (CYP) (see Table 15 below). These results were classified into 
those where there was an error in the dose delivered, non-adherence or an issue with the 
formulation and dose-delivery failure.   
 
Varendi et al., 2012, Blaney et al., 2013, Glade et al., 2013, Kilburn 
et al., 2013, Stricker et al., 2013, Hummel et al., 2013, Macdonald 
et al., 2013, Muscal et al., 2013, Kimberlin et al., 2013, Zorzi et al., 
2013, Hiruy et al., 2014, Kim et al., 2015, Kilburn et al., 2015, 
Stricker et al., 2015, Young et al., 2015    
Reported refusal 
with additional 
information  
7 
 
Carlsson et al., 1997, Agertoft et al., 1999, Conway et al., 2004, 
Dupuis et al., 2006, Kokki et al., 2006, Altcheh et al., 2014, 
McGregor et al., 2012   
Total 38  
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Table 15: included studies which reported drug prescription, administration and delivery problems 
Factor No. of 
identified 
papers 
References Scale 
Bi: Drug dosing error  21 Kinney et al., 1991, Gremse et al., 2002, Best et al., 
2003, Howell and Patel, 2003, Lebovitz et al., 2004, 
Bergshoeff et al., 2005, Lynn et al., 2007, Quinn et 
al., 2007, Beghetti et al., 2009, Hahn et al., 2009, 
Pollock et al., 2009, Saez-Llorens et al., 2009b, 
Gururangan et al., 2010, Knoderer et al., 2011, Piper 
et al., 2011, Kiser et al., 2011, Warren et al., 2011, 
Jimenez et al., 2012, Manitpisitkul et al., 2013, Salzer 
et al., 2013, Musiime et al., 2014   
0.7-12%, 
median 3% 
Bii: Non-
adherence/Formulation 
issue 
29 Reed et al., 2001, Capparelli et al., 2005, Chien et al., 
2005, Kyllonen et al., 2005, Ward et al., 2005, 
Dupuis et al., 2006, Johansen et al., 2006, Kokki et 
al., 2006, Simpson et al., 2006, Standing J., 2008, 
Chadwick et al., 2009, Blumer et al., 2010, Kimberlin 
et al., 2010, Chadwick et al., 2011, Kiser et al., 2011, 
Rakhmanina et al., 2011, Warren et al., 2011, Drover 
et al., 2012, Fillekes et al., 2012, Oudijk et al., 2012, 
Malhotra et al., 2012b, Kilburn et al., 2013, Walson 
et al., 2013, Vrooman et al., 2013, Bunupuradah et 
al., 2014, De Bruyne et al., 2014, Garcia et al., 2014, 
Musiime et al., 2014, Zongo et al., 2014   
1-23%, 
median 5% 
Biii: Equipment failure 6 Agertoft et al., 1999, Stewart et al., 2004, Abdel-
Rahman et al., 2008, Hammer et al., 2008, Norman 
et al., 2012, Weinstock et al., 2013   
1-19%, 
median 4% 
Total 52 papers Kiser et al (2011), Warren et al (2011), Zongo et al 
(2014), Musiime et al (2014) in two categories 
0.7-23%, 
median 4% 
Drug dosing: 21 studies reported that incorrect doses had been administered, which meant 
blood samples had to be disregarded and excluded from the study.   In the papers that 
recognised and reported this problem the problem ranged from 0.7% to 12% with a median 
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of 3%.   PK studies are dependent on accurate prescribing and administration and errors lead 
to loss of participants’ data.  
Non-adherence / formulation issues:  29 papers reported problems related to adherence to 
the medication regime or problems associated with the formulation utilised within a study.  
These could reflect vomiting, spitting medications out or expulsion of rectally administered 
medications.  Seven studies reported participants being unable to ingest the medication 
under investigation,  because they were unable to swallow the tablets (Ward et al., 2005, 
Johansen et al., 2006, De Guchtenaere et al., 2011, Warren et al., 2011, Kilburn et al., 2013, 
Musiime et al., 2014) or because the route of delivery was too challenging (Kokki et al., 
2006).  Overall issues associated with tolerance and compliance led to researchers having to 
disregard data from 1%- 23% of recruited participants, (median of 5%) due to large variation 
in the results.   
Drug delivery:  Six studies reported a pump delivery problem that affected 1 – 19% of 
participants, with a median of 4%. If the drug fails to be delivered then the pharmacokinetic 
measurements have the potential to be misleading and lead to participant data being 
withdrawn.  
3.5.3 Obtaining samples  
The most common problem cited within the published literature was that of issues 
associated with obtaining the required samples (n=112).  See Table 16 for a full list of these 
studies.  
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Table 16: included studies which reported problems associated with sampling 
Factor No. of 
identified 
papers 
References Scale 
Sampling 
problems 
112 Saxen et al., 1993, Husson et al., 1994, Blumer et al., 1995, 
Force et al., 1995, Malinovsky et al., 1996, Reed et al., 1996, 
Birmingham et al., 1997, Carlsson et al., 1997, Geiduschek et al., 
1997, Gorodischer et al., 1997, Mendelsohn et al., 1997, 
Reynolds et al., 1997, Stevens et al., 1997, Wintermeyer et al., 
1997, Lindsay et al., 1998, Crawley et al., 2000, Hahn et al., 
2000, Kearns et al., 2000, Nahara et al., 2000, Scheepers et al., 
2000, Stevens et al., 2000, Wulf et al., 2000, Johnson et al., 
2001, Reed et al., 2001, Ross et al., 2001, Dsida et al., 2002, 
Furman et al., 2002, Guay et al., 2002, Gremse et al., 2002, 
Orenstein et al., 2002, Lipman et al., 2002, Best et al., 2003, 
Fraaij et al., 2003, Kearns et al., 2003b, Sallas et al., 2003, 
Fletcher et al., 2004., Goren et al., 2004, Lebovitz et al., 2004, 
Neville et al., 2004, Oliver et al., 2004, Wagner et al., 2004, 
Wheeler et al., 2004, Chalkiadis et al., 2005, Jacobs et al., 2005, 
Saul et al., 2005, Bomgaars et al., 2006, Cormack et al., 2006, 
Dupuis et al., 2006, Fouladi et al., 2006, Heresi et al., 2006, 
Johansen et al., 2006, Kokki et al., 2006, Mehta et al., 2006, 
Muller et al., 2006, Zuppa et al., 2006, Aman et al., 2007, 
Broniscer et al., 2007, Kulkarni et al., 2007, Lynn et al., 2007, 
Veal et al., 2007, Abdel-Rahman et al., 2008, Bomgaars et al., 
2008, Danne et al., 2008, Glade Bender et al., 2008, Gururangan 
et al., 2008, van Ommen et al., 2008, Neville et al., 2008, 
Almenrader et al., 2009, Baruchel et al., 2009, Hahn et al., 2009, 
Nielsen et al., 2009, Jacquemin et al., 2009, Pollock et al., 2009, 
Saez-Llorens et al., 2009a, Standing et al., 2010, Fouladi et al., 
2010, Su et al., 2010, Chadwick et al., 2011, Forbes et al., 2011, 
King et al., 2011, Kiser et al., 2011, Lynn et al., 2011, Mugabo et 
al., 2011, Rakhmanina et al., 2011, Warren et al., 2011, Wigal et 
al., 2011, Chamberlain et al., 2012, Drover et al., 2012, Malhotra 
et al., 2012a, Autmizguine et al., 2013, Cohen-Wolkowiez et al., 
2013, Demirjian et al., 2013, Glade et al., 2013, Kim et al., 2013, 
0.3-80%, 
median 
10% 
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Kimberlin et al., 2013, Manitpisitkul et al., 2013, Min et al., 
2013, Shah et al., 2013, Smith et al., 2013, Sugita, 2013, Veal et 
al., 2013, Vrooman et al., 2013, Walson et al., 2013, Weinstock 
et al., 2013, Oualha et al., 2014, Desai et al., 2014, Ramos-
Martin et al., 2014, Kukulka et al., 2014, Bradley et al., 2014, 
Musiime et al., 2014, Woloszczuk-Gebicka et al., 2014, Hahn et 
al., 2015, Munoz et al., 2015, Young et al., 2015a   
Sampling problems were referred to in a number of ways within the published literature. For 
some studies this was reported as ‘incomplete’ sampling, for example Bradley et al. (2014) 
reported 5/24 participants had incomplete sampling and were excluded from analysis. Other 
studies reported ‘Intravenous catheter malfunction’, (Drover et al., 2012) or ‘vascular access 
unavailable’ (Mendelsohn et al., 1997).  ‘Insufficient sampling volume’ was referred to by 
some authors; e.g. 7/100 participants had insufficient blood volume withdrawn (Mugabo et 
al., 2011).  Several studies also highlighted patients’ results having to be excluded because of 
‘incorrect sampling’. These included samples not being collected (Zuppa et al., 2006), being 
taken on the wrong day (Pollock et al., 2009) or being taken from the wrong place (Abdel-
Rahman et al., 2008).  The significance of sampling errors / problems varied significantly 
within the literature, ranging from a loss of 0.3% - 80% of participants, (median of 10%).  The 
study which reported a loss of 80% of participants, found 16/20 patients had missing 
samples at 18 hours because of blood sampling issues (Woloszczuk-Gebicka et al., 2014).  
Overall although sampling and obtaining PK samples with CYP was identified as challenging, 
it was difficult to determine which aspect was the most challenging aspect due to the 
variance in reporting.  
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3.5.4 Processing problems 
34 studies reported problems associated with the processing of samples and obtaining 
results. These problems were classified as clerical, technical and those associated with 
storage and transportation (see Table 17 below).  
Table 17: included studies which reported processing problems 
Factor No. of 
identified 
papers 
References Scale 
Di: Clerical errors 16 Stevens et al., 2000, Tod et al., 2001, Lipman et al., 2002, 
Marina et al., 2002, Aquino et al., 2004, Chien et al., 2005, 
Diaz et al., 2007, Zhang et al., 2007, Hahn et al., 2009, 
Nielsen et al., 2009, Musiime et al., 2010, McJunkin et al., 
2011, Piper et al., 2011, Cohen-Wolkowiez et al., 2012b, 
Salzer et al., 2013, Ramos-Martin et al., 2014  
1-44%,  
median 5% 
Dii: Technical 
failure 
14 Blumer et al., 1995, Reed et al., 1996, Gorodischer et al., 
1997, Crawley et al., 2000, Hahn et al., 2000, Ross et al., 
2001, Rongkavilit et al., 2002, Fouladi et al., 2007, 
Gururangan et al., 2008, Malloy et al., 2009, McGregor et 
al., 2009, Beaty 3rd et al., 2010, McKibbin et al., 2010, 
Raber et al., 2011   
2-54% 
Median 12% 
Diii: Incorrect 
storage / 
transportation 
4 Gremse et al., 2002, Fouladi et al., 2006, Bomgaars et al., 
2008, Kiser et al., 2011    
1.5-25% 
Median 6% 
Total  34 0 papers in more than 1 category 1-54% 
Median: 
7.5% 
Di. Clerical errors: 16 studies reported issues associated with documentation of sample 
collection times or conflicts between dosing history and the recorded samples’ collection 
times. The number of samples affected by documentation problems was not large (median 
of 5% amongst the 16 studies which reported problems. However, it does highlight an 
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avoidable problem that researchers need to address to ensure that samples taken for 
research purposes are handled and labelled appropriately.  
Dii. Technical failure:  14 studies were classed as experiencing ‘technical issues’. These 
included  mishandling of serum and saliva (Hahn et al., 2000), improper sample preparation 
(Beaty et al., 2010) and difficulties with the assay (Ross et al., 2001).  Reed et al (2001),  
highlighted that all of the data from the first 9 patients / 29 were invalidated after 
interfering substances were discovered in the stopper of the blood collecting tubes.  This 
highlights that when there are technical issues they can have a sizeable impact on the results 
obtained.   
Diii: Storage and transportation:  4 studies reported a loss of samples due to storage or 
transportation issues, affecting a median of 6% of samples to be lost from analysis.  This 
could have a profound impact on the results if there is a lack of systems in place to detect 
these issues.   
3.5.6 Withdrawal  
43 studies reported loss of participants due to withdrawal and loss to follow up and 
therefore did not complete the study they were recruited to (Table 18 below).   
Table 18: included studies which reported consent withdrawal 
Factor No. of identified 
papers 
References Scale 
Consent 
withdrawn 
 
43  Fritz et al., 1994, Gaedicke et al., 1996., Canafax et al., 
1998, Peytchev and Chakova, 1998, Agertoft et al., 1999, 
Findling et al., 1999, Crawley et al., 2000, Dallas et al., 
2000, De Wildt et al., 2003, Rahman et al., 2002, 
Rongkavilit et al., 2002, Best et al., 2003, Fraaij et al., 
2003, Gajjar et al., 2003, Conway et al., 2004, Quinn et al., 
0.7-100% 
Median 8% 
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2004, Wu et al., 2004, Chien et al., 2005, Jacobs et al., 
2005, Dupuis et al., 2006, Rodriguez-Galindo et al., 2006, 
van der Lee et al., 2006, Zhao et al., 2006, Almeida et al., 
2008, Findling et al., 2008, Goto et al., 2008, Gururangan 
et al., 2008, Baruchel et al., 2009, Gonzalez et al., 2009, 
Chadwick et al., 2011, Lynn et al., 2011, Ademisoye et al., 
2012, Chamberlain et al., 2012, Gore et al., 2013, 
Kimberlin et al., 2013, Thompson et al., 2013, Altcheh et 
al., 2014, Boddy et al., 2014, Musiime et al., 2014, 
Thompson et al., 2014, Wagner et al., 2004, Kukulka et 
al., 2014, Zongo et al., 2014, Young et al., 2015    
 
Consent withdrawal:  Withdrawal rates ranged from 0.7-100% of participants withdrawing 
consent for studies, (median of 8%).  The study that reported 100% withdrawal of consent 
included seven participants, none of whom had their 48 hour blood sample taken as 
permission was withdrawn (Baruchel et al., 2009).  Unfortunately, no further explanation 
was provided so the aspects surrounding this attrition are unknown.    The highest 
withdrawal after this study was reported to be 33% (Dallas et al., 2000) so it would appear 
unusual for 100% of participants to withdraw from a study.   Similar to the reporting of 
recruitment to pharmacokinetic research there is little detail why parents withdrew consent 
for their child to participate.  28 / 43 reports reported only a numerical figure on how many 
parents withdrew or how many patients were lost to follow up, with no further information 
to explain this loss.  Of the 15 studies where information was provided, the biggest issue 
identified was that of blood sampling requirements (11/15) and extra clinic attendance 
(4/15), the same factors which gave rise to concerns about recruitment.   
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Table 19 below provides a summary of the results from each theme. Overall, sampling 
problems were the most common barrier reported, however recruitment problems had the 
greatest impact with the loss of approximately 41% of participants.   
Table 19: summary: studies which experienced loss of participants’/ participants’ data (by theme) 
Category Number of studies Range Median 
A: recruitment (refusal rates) 38 3-76% 41% 
B: medication 52 0.7-23% 4% 
C: sampling 112 0.3-80% 10% 
D: processing 34 1-54% 7.5 
E: withdrawal 43 0.7-100% 8% 
 
The key barriers identified from the scoping review are summarised in Table 20 below.  No 
papers identified facilitators to PK research.  
Table 20: summary of barriers and facilitators (scoping review results) 
3.6 Discussion  
3.6.1 Facilitation strategies 
The primary objective of the review was to identify and quantify strategies to improve PK 
trial recruitment and no papers reported this information.  This finding was disappointingly 
low; however, this seems in keeping with current understanding about successful trial 
 Barriers Facilitators 
Recruitment Refusal 
Additional blood sampling / vascular access 
Additional hospital attendance 
Lack of published detail about recruitment / refusal 
X 
Medications Drug dosing error 
Non-adherence to medication regime/ formulation issues 
Equipment failure / delivery failure 
X 
Sampling Inadequate / incomplete / insufficient sampling  X 
Processing Clerical errors 
Technical failures in the process of sample analysis  
Incorrect storage / transportation 
X 
 Outcomes 
 
Consent withdrawn 
Lack of published detail about withdrawal / loss to follow up 
 X 
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recruitment.  A study which explored the outcomes of Medical Research Council (MRC) and 
Health Technology Assessment (HTA) funded trials found only 55% of studies recruited to 
their target sample size and 45% needed an extension of time and / or funding (Sully et al., 
2013).  A US study found a third of trials at one centre (260 trials) recruited zero or only one 
participant at a cost of $1 million (Kitterman et al., 2011).  Understanding more about 
strategies that improve recruitment has therefore in recent years come to be recognised as 
important.  Research in this area is emerging but even where research has been undertaken 
there are very few interventions which have evidence to support a claim for increasing 
recruitment to trials (Treweek et al., 2010).  This Cochrane review focused on the 
quantitative impact of measures to increase recruitment but a newly registered qualitative 
synthesis is suggesting that alongside this there is also a requirement to explore how 
potential and actual trial participants and trial recruiters perceive and experience 
interventions  (Houghton et al., 2017).   In summary, whilst there is clearly a need to 
understand more about facilitation strategies for paediatric pharmacokinetic research, 
quality research into this area has yet to be conducted.  Where the scoping review was able 
to add more insight was into the situation surrounding barriers to PK research.  
3.6.2 Barriers to pharmacokinetic research 
203 studies were included within the scoping review which quantified and described 
problems in the conduct of pharmacokinetic studies.  It therefore appeared that elucidating 
the barriers to conducting PK research was better-reported.  This was reflected in expert 
review papers and commentaries which highlight that conducting PK research with CYP is a 
challenging area to research (Smyth, 2001, Baber, 2005, Kemper et al., 2011). Anderson et al 
(2007) recognised that the material reported in a paediatric pharmacokinetic publication 
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often did not include the tribulations endured by the authors during the study.  These 
problems and pitfalls are therefore repeated by others in further paediatric studies and are 
rarely reported.  Indeed their own publications  surrounding trials of Ketamine (Herd and 
Anderson, 2007) and Clonidine (Potts et al., 2007), feature no reference to the issues of 
recruitment, blood sampling & laboratory handling which are referred to in their review 
paper (Anderson et al 2007).   Reasons for this are unclear.  A recently published systematic 
review examined the invasiveness of PK studies in CYP confirms the lack of change in PK 
research practice (Altamimi et al., 2016).  Increasing numbers of PK studies are being 
conducted which is encouraging. However, reporting is inconsistent, often results are not 
reported for different age or weight groups and despite the rise of population PK methods, 
there was no change in the overall volume of blood being collected from patients over a four 
decade period (Altamimi et al., 2016).  It is essential that problems and pitfalls researchers 
experience are identified to allow the identification of appropriate strategies to tackle them 
appropriately.  Although reasons for this are unclear, the lack of transparency in reporting is 
likely to be a factor in perpetuating study design issues.  
3.6.3 Recruitment and study retention 
With 41% (median) of patients declining to participate and 8% (median) withdrawing from a 
PK study, the most sizeable challenge to undertaking PK research in paediatrics related to 
recruitment and retention.   Despite the magnitude of this problem there is very little 
information to inform researchers why parents refuse consent to participate or withdraw 
from a study.  Current reporting makes it extremely difficult to determine whether all 
patients were approached, how many declined and if so why they declined.  Only 7 /38 
studies (Carlsson et al., 1997, Conway et al., 2004, Agertoft et al., 1999, Kokki et al., 2006, 
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Dupuis et al., 2006, Altcheh et al., 2014, McGregor et al., 2012) provided any further insight 
into the factors that influenced recruitment.  These reflected blood sampling requirements 
(n=3) or additional visits (n=2). This is supported by literature which highlight parents’ 
refusal because of additional venepuncture or capillary sampling (Dlugos et al., 2005, 
Anderson et al., 2007, Jenkins et al., 2009).  Berg et al (2010) identified that the most 
common reasons for not participating with a PK study (amongst 50 participants) were the 
requirement for extra time at hospital and requirement for an extra cannula, similar to the 
findings from the scoping review. Participants within this survey were a mix of adult 
subjects, 4 adolescents and 38 parents of children in a phase one oncology study and there 
was no separation of paediatric responses from the adult participants, therefore the study 
was excluded from the scoping review (as per the exclusion criteria in Table 12). The study 
reported that 36/ 50 participants had consented to an optional PK study (consent rate of 
75%).  This figure seems higher than the median found within the scoping review of 59%, 
however, this could reflect the fact that the survey was conducted in the context of a phase 
1 oncology study, where there are often no further treatment options.  This has been linked 
to higher rates of enrolment (Kim et al., 2008, Kim et al., 2009).   Only 15 papers included 
any information about why participants withdrew from research and again the commonality 
was related to blood sampling requirements (11) or extra visits (4).  Researchers cannot 
ignore the fact that parents find blood sampling extremely stressful and it features highly in 
the decision about whether to participate and whether to continue in a study.  Few trialists 
describe how they overcome recruitment barriers and this reporting needs to improve if 
future research is to demonstrate increased accrual and reduce attrition (Shilling et al., 2011, 
Tishler and Reiss, 2011).  In addition, reporting of the patient journey, including the number 
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of eligible patients, the number invited to participate, those who refuse and those who were 
included is important to describe the characteristics of those who participate.  This is 
recognised within several reporting standards such as the Consolidated Standards of 
Reporting Trials (CONSORT) (Moher et al., 2001b, Schulz et al., 2010) and Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) (Vandenbroucke et al., 2007).   
There should also be sufficient information reported about withdrawals and intention to 
treat analysis to allow assessment of attrition bias. According to one of the widest used 
quality assessment scales (Jadad et al., 1996), this should not only include the number of 
patients lost or excluded but also the reasons for the exclusion.  This is poorly described 
within the published PK literature currently.   
3.6.4 Sampling problems 
The largest volume of problems reported by published PK trials related to obtaining 
sufficient sample numbers and volume from participants at the correct time points.  This 
problem meant a number of participants’ data had to be excluded (median 10%). Since 99% 
of the studies involved blood sampling it can be reasonably concluded that most of the 
problems experienced occurred in obtaining paediatric blood samples.   The challenge of 
obtaining blood samples from CYP is recognised within paediatric literature  (Kauffman and 
Kearns, 1992, Becht and Anderson, 1996, Jenkins et al., 2009) . However, there was a lack of 
published details about the sampling techniques utilised which makes further interpretation 
challenging.   Papers often did not state where blood was sampled from, whether it involved 
an indwelling intravenous catheter, the location of the line, the type of line utilised, the 
proximity of the line to the drug administration, whether the line lasted for the whole study 
duration or needed to be replaced, the volumes of blood taken and even the sampling 
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regime was not always explicitly stated.  This was confirmed in a study which found 32% of 
published studies did not state the method of blood sampling (Altamimi et al., 2016). 
Without this detail, it is difficult to determine strategies that contribute to obtaining any 
required study samples.    
A small number of studies featured non blood sampling, usually in the form of urine (Findling 
et al., 1999, Kearns et al., 2000, Goren et al., 2004, Ward et al., 2005, Muller et al., 2006, 
Bomgaars et al., 2008, King et al., 2011, Smith et al., 2013) or saliva  (Gorodischer et al., 
1997, Hahn et al., 2000, Aman et al., 2007, Weinstock et al., 2013).  There are suggestions 
from the literature that non-blood sampling can be appropriate and useful in paediatric 
patients to avoid the use of blood sampling  (Jenkins et al., 2009, Wells et al., 2009) however 
there is a lack of qualitative review of participants’ views on this.  Few studies have also 
undertaken paired PK readings to compare the accuracy of non-blood alternatives so the 
feasibility of this type of analysis is unknown for many medications. 
3.6.5 Processing issues 
Overall there were the fewest reports concerning processing problems (n=34 studies). 
However, there were cases where problems affected up to 54% of participants’ data (Malloy 
et al., 2009) which has a huge impact on the results and conclusions of studies.  Although the 
issues encountered were specific to the individual studies, it highlights the importance of 
ensuring that researchers have done sufficient preparatory work to establish stability, the 
process of sample preparation and development of the assay and have produced clear 
guidance on storage and transportation of samples.  Processing relies on the administration 
of a known dose, at a known time which can be a major limitation in the clinical setting since 
the dosing regimen the patient receives does not necessarily coincide precisely with the 
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prescribed regimen. Documentation of the exact time of administration and of sampling is of 
paramount importance otherwise the observed and predicted concentrations could become 
quite discrepant (Brundage et al., 2004). The same degree of rigour must be addressed to 
the data recording as would be demanded in a more traditional clinical research study.   
3.6.6 Reporting  
The main difficulty the review encountered was the lack of detail that was included within 
PK publications on the conduct of the study.  In other types of study design there are clear 
published standards for reporting results, such as the Consolidated Standards of Reporting 
Trials (CONSORT) (Schulz et al., 2010) or STrengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) statement (Von Elm et al., 2007) which enable the reader 
to determine participant flow at all stages of the trial.  Guidelines and checklists help to 
improve the transparency and presentation of studies and therefore have the potential to 
improve the impact and implementation of scientific research (PLOS Medicine Editors, 
2013).  Evidence suggests that adoption of guidelines is associated with improvements in the 
quality of trial reports (Moher et al., 2001a).  This review found it difficult to determine in 
much of the published PK literature the total eligible population screened, the proportion of 
these successfully recruited to a PK study and the number who successfully completed the 
study.  This situation requires urgent attention so that readers can follow what was planned, 
what was done, what was found and what conclusions were drawn and assess the research 
critically.   
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3.7 Limitations of the review 
3.7.1. Type of review 
Although the initial intention was to conduct a systematic literature review, recognising this 
as being at the top of the hierarchy of evidence (Khan et al., 2003), this was not felt to be 
appropriate in this subject area.  Systematic reviews generally recommend ensuring the 
trials included are of the highest quality and most recommend inclusion only of RCTs (Egger 
and Davey Smith, 2001, Juni et al., 2001).  Randomisation is not appropriate for PK studies, 
which often take place in the context of phase 1 and 2 trials.  In fact, only 15% of the studies 
within the review took place in the context of an RCT. If all other study methods were 
excluded there would have been little to inform the review.    A decision was made by the 
researcher to include all levels of evidence and generate understanding of the current 
situation surrounding PK studies, rather than to state that no evidence was available (Ogilvie 
et al., 2005).  Conclusions are based on the best available evidence, but caution is advised 
against over-interpreting the incidence data related to specific barriers to PK research.  
3.7.2 Search terms 
Refining the search terms to capture recruitment, barriers to study completion and retention 
to a study was challenging.  Recruitment captured aspects associated with agreeing to 
participate with research but aspects related to participant retention within a study were 
more difficult.  Initial scoping searches found retention was sensitive within psychology 
studies, but less so in clinical trials and participation tended to be utilised more within 
consumer involvement work. Loss to follow up was also not a MeSH term and proved to be a 
very insensitive term for papers of interest.  Conclusions from the scoping review are 
therefore focused on barriers to recruitment, although aspects associated with retention 
have been identified during these searches.  Limited conclusions can be drawn about 
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barriers to study retention specifically because the search strategy was challenging to refine.  
Despite the difficulties in defining sensitive terms, screening on title and abstract appeared 
to be effective in screening out irrelevant papers because only 12% of those reviewed in full 
were ineligible on population (Adult study, n=12), or on study design (not PK study, n=104) 
(123/1026 papers reviewed in full).  Most importantly most papers were excluded on the 
basis that they did not experience or report any difficulties with recruitment of participants 
or did not acknowledge the loss (n=610).  This information would not have been known 
without reviewing the full paper. The search strategy therefore did highlight relevant papers; 
however, this highlights the challenges in finding the information of interest to this review.  
‘Neonate’ (which is defined as the first 28 days of life) was not included within the search 
terms. The initial scoping searches indicated ‘infan*’ was sensitive to studies relevant to the 
neonatal period.  Studies which specifically stated they recruited neonates (n=13) were 
captured within the review, therefore papers relevant to this population were identified.   
Pharmacokinetics as a MeSH term was operational from 1988. However, searches were 
conducted from 1990 onwards.  It is therefore acknowledged that the search strategies 
would have been better to have extended to 1988. The paper by Altamimi et al. (2016) 
provides confirmation that searching before 1976 yields 0 papers. In addition 91% of papers 
came from 1985 onwards, but for completeness searches will be conducted for this period 
when the work is written up for publication.  
3.8 How does the scoping review address the gap in 
knowledge surrounding pharmacokinetics?  
The scoping review is the first review the researcher is aware of to appraise systematically 
the published paediatric literature and address questions associated with recruitment to 
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pharmacokinetic research.   However, no papers identified methods to improve recruitment 
to PK studies.  The gap in knowledge surrounding facilitators to recruitment therefore 
continues.   The review has however addressed the gap in knowledge surrounding the 
barriers to PK research conduct.  From 203 papers, there is evidence that 41% of approached 
CYP will not consent to PK research and a further 8% will withdraw from the study.  The 
predominant reason for both non-recruitment and attrition appear to be due to the 
requirements associated with blood sampling and additional visits to hospital.   However 
large numbers of studies also experience loss of data due to issues associated with the 
practicalities of venous access and blood sampling.   This is the first account to provide a 
sense of scale to the problems researchers can encounter with PK study conduct at all 
stages.  The participant data loss identified has huge implications for researchers seeking to 
ensure they recruit to time and target. With this knowledge researchers can ensure they set 
realistic targets as well as optimise their trial design by consideration of problems at all 
stages of research conduct.  
3.9 Conclusion 
The scoping review was undertaken to address the gap in knowledge associated with the 
conduct of PK studies.     Despite wide inclusion criteria and over 4000 studies being 
identified by the search strategies there were no studies which reported strategies to 
improve recruitment to paediatric PK studies.   Studies were included within the review 
based on reported problems associated with the conduct of PK studies; the most common 
issue appeared to relate to blood sampling, but the biggest challenge related to recruitment.  
Understanding more about the barriers to recruitment is essential as many studies fail to 
recruit their target sample size, or are discontinued early (Sully et al., 2013, Kasenda et al., 
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2014, Pica and Bourgeois, 2016).  Understanding the perspective of potential study 
participants and those who conduct PK research was therefore identified as essential and 
contributed to the development of Chapters 4-8.  This is the first review, to the researcher’s 
knowledge, to explore paediatric pharmacokinetic research and quantify and systematically 
categorise the barriers that exist with trial conduct. This is essential if strategies to improve 
the situation are to be developed.   
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Chapter 4: patient and public involvement 
and engagement in the design and 
development of the PRESCRIBE study 
4.1 Background 
4.1.1 Definition and purpose of patient and public involvement 
In the UK there has been an increasing focus on patient, public and service user involvement 
in health and social care policy (Staniszewska, 2009, Department of Health, 2009, 
Department of Health, 2010) and health and social care research (Stewart et al., 2011, 
Staniszewska et al., 2011a).  This approach, often described as Patient and Public 
Involvement or PPI, is defined as research being carried out ‘with’ or ‘by’ members of the 
public, rather than ‘to’ or ‘for’ them.  The critical feature is that they are involved in research 
design and process rather than as subjects in the research project (INVOLVE, 2012).  Public 
involvement in research is founded on the core principle that people who are affected by 
research have a right to have a say in what and how research is undertaken(Hewlett et al., 
2006, Staniszewska, 2009). The benefits of consumer involvement are that researchers are 
assisted to understand the human aspect through patients’ experiences and expertise, 
knowledge of issues is more complete, good practices are validated, communication 
becomes more patient-friendly, the right issues are addressed and the quality, relevance and 
acceptability of research is enhanced (Ali, 2006, Royal College Nursing, 2007, Staniszewska, 
2007, Staniszewska et al., 2011a, Brett et al., 2012).  It ensures that issues which are 
important to consumers and therefore to health resources as a whole are identified and 
prioritised; it ensures that money and resources are not wasted on research of little value 
and it encourages consumers to push for outcomes that may have greater relevance than 
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those considered by professionals (Boote et al., 2002). Research regulators and a growing 
number of commissioners of publicly funded health research now ask applicants to describe 
how they plan to involve the public in their research (Telford et al., 2004, Stewart et al., 
2011, Staley et al., 2012, Jones et al., 2015, Bagley et al., 2016)  and researchers applying 
through the Integrated Research Application System (IRAS) have to state their plans for 
involvement (Tarpey and Bite, 2014, IRAS, 2015).  The NIHR Strategy document ‘Going the 
Extra Mile’ (National Institute for Health Research, 2015a) consolidates the place of PPI as a 
core component of good research practice and recognises the experience of patients and 
service users as a fundamental and valued source of knowledge.    
4.1.2 PPI with Children and young people (CYP) 
The United Nations Convention of the Rights of the Child (1989) gives children a right to be 
involved in decisions that affect their lives and for their views to be listened to.  The principle 
of ‘no decision about me, without me’ is central to this and applies as much to children and 
young people as any other patient group (Weil et al., 2015). The  Department of Health 
(2003) state explicitly that  CYP should be consulted and involved in all aspects of their care, 
including decision making about research participation.  There is a growing recognition that 
children have knowledge that is separate from their parents’ and carers’ knowledge and that 
this knowledge is worthy of consideration (Bird et al., 2013).  This should extend to inclusion 
with PPI activities, to enable researchers to design studies that are more acceptable and 
relevant to service users themselves, not just parents (National Children's Bureau, 2010, 
INVOLVE, 2016a).  However, despite this a recent survey of  National Institute Health 
Research (NIHR) funded trials (2006-2010) found declining rates of PPI within paediatric 
trials (Gamble et al., 2014).  This is of concern because conducting clinical trials in CYP is 
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generally regarded as more challenging than those in adults and omitting PPI could affect 
recruitment, appropriate design and prioritised outcomes (Caldwell et al., 2004, Tishler and 
Reiss, 2011, Menon et al., 2012).  In paediatric studies, Research Ethics Committees (RECs) 
require evidence that consultation with service users has taken place to ensure that a study 
design is appropriate; risks and burdens have been minimised and information materials are 
comprehensible to their target audience (Nuffield Council Bioethics, 2015a).  In the case of 
specific populations with serious and rare conditions, specialised input from relevant 
representatives becomes even more important (Nuffield Council Bioethics, 2015a).  
Although PPI with CYP has had a raised profile through the National Institute for Health 
Research (NIHR) (National Institute for Health Research, 2015c, National Institute for Health 
Research, 2016f) there remain few published accounts of Young Persons Advisory Group 
(YPAG) activities. In particular, there are few accounts of involvement within high 
dependency and Paediatric Intensive Care (PIC) research studies. 
Although PPI has become increasingly prevalent in health service development and research, 
there is a gap in the knowledge about which approaches work best, when or why, or under 
what circumstances.  Some of these uncertainties relate to difficulties with the involvement 
evidence base, which is relatively poor (Staniszewska, 2009).  Research in this area has often 
been of poor quality with no specific way of evaluating the quality of PPI within a study.  Also 
there have been difficulties attributing changes to user involvement (Crawford et al., 2002).  
Staley (2012) highlights that researchers’ accounts of involvement have not been sufficiently 
detailed; often not describing the context, mechanism and expected outcome of any chosen 
approach.  More detail is needed about where the researcher started- their original plans, 
priorities, values and assumptions, what recommendations were made by the public and 
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why, what changes were made in response and why, what outcomes were expected and 
what outcomes were observed by researchers and the public.  This will assist researchers to 
understand how involvement works in different contexts and understand how outcomes are 
achieved (Staniszewska et al., 2008, Staniszewska and Denegri, 2013). Chapter 4 therefore 
aims to address the gap in knowledge related to service user perspectives in the context of 
paediatric PK research (see Figure 11 below)  
Figure 11: gap in the knowledge- service user perspective 
 
4.2 Aims 
1. To develop the research protocol prior to Research Ethics Committee (REC) submission in 
consultation with members of the public, to include:   
a) Identification of the stakeholders in paediatric PK research studies (potential 
participants) 
b) Identification of recruitment strategies for future participants (recruitment methods) 
c) Identification of the methods to conduct research with future participants 
(methodology) 
Gaps in the 
knowledge 
Evidence 
for PK 
design 
Service user 
perspective 
Health care 
Professionals 
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Influence of 
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d) Identification of questions to utilise with future participants (interview schedule) 
2. To develop participant information sheet (PIS) and consent / assent forms. 
4.3 Method 
 
Please see chapter 2 for full details of the method. Aspects specific to identification of 
participants for PPI work are detailed below.  
4.3.1 Participants 
The plan was to work with existing service user groups, recognising that there was 
insufficient time, networks or resources to establish new groups of service users, specifically 
for the purposes of PRESCRIBE as a standalone project.  These factors have been identified 
as barriers to involving service users (Staniszewska, 2007).  Membership was conceptualised 
as being two core groups: children and young people (CYP) and parents. A systematic 
literature of public involvement in research design identified that conducting focus groups 
within the context of existing support groups (Boote et al., 2010) was a successful approach 
to follow.  In light of this, existing resources were therefore sought. 
Children: National Institute for Health Research (NIHR) Medicines for Children Research 
Network (MCRN) in the West Midlands agreed to facilitate access to an established Children 
and Young Person’s Advisory Group (YPAG) with a remit to advise on the development and 
conduct of research  (Dudley et al., 2015, National Institute for Health Research, 2015c, 
National Institute for Health Research, 2016f).  The group was composed of around 18 
members (8-18years) and met every six weeks.  The session was planned for 26th April 2011, 
with participants those who attended on this day.  See Figure 12 below.  
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Figure 12: recruitment of CYP & parent participants for PPI work 
 
Parents:  Consultation with a group representing parents of hospitalised children was the 
aim, however this proved difficult to achieve.  The research networks did not have a specific 
group of parents to advise on the conduct of research, nor did Birmingham Children’s 
Hospital (BCH) or the Paediatric Intensive Care Unit.  The Patient Experience and 
Participation team at BCH agreed to facilitate access to parents they had contact with but 
after several months of contact and negotiation this did not come to fruition (Oct 11-Jan 12). 
This struggle to obtain access to service users through gatekeepers is recognised as a 
significant barrier to PPI conduct in the literature (Smith et al., 2009).  Partnership with 
parents who are in a similar situation to potential study participants will help to ensure that 
important aspects of the research question have been considered (Nuffield Council 
Bioethics, 2015a).  However, the concept of ‘similar situation’ is challenging in the PIC 
context as patients can be 0-18years of age and there is a broad case mix of underlying 
diseases and  diagnosis (Kleiber et al., 2015). Approximately 50% of admissions to PIC are for 
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children with a cardiac condition post-surgery (PICANet, 2016) and therefore parents’ of 
children with cardiac conditions were felt to be the most representative ‘group’.  A local 
(Birmingham) Children’s Cardiac Charity was approached and a session was planned with the 
board of the charity in November 2013.  This was then rescheduled twice before this line of 
enquiry was abandoned.  
4.3.2 Model of involvement  
The involvement of consumers in research activity has been viewed on a continuum ranging 
from a low to a high level of activity. Consultation is regarded as the lowest level of 
involvement, with service-user led projects the highest  (Boote et al., 2002, Staniszewska et 
al., 2011a).  For the purposes of a single site, PhD project with no funding available for 
ongoing consultative approaches, consultation was felt to be the most appropriate 
approach. The project went through stringent peer review process in the funding application 
and this approach was supported.  
4.4 Analysis 
The plan was to use mind mapping on large A1 sheets, which would then serve as the field 
notes from the session. Thematic analysis and simple descriptive statistics would then be 
conducted.  However, during session one with CYP the group struggled initially with this 
format.  Notes were therefore made by the researcher during the session.  The subsequent 
session was audio-recorded, transcribed intelligently  (Gale et al., 2013) and analysed using 
thematic analysis.  Participants were given a unique number and anonymised quotes are 
reported.  
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4.5 Results  
4.5.1 PPI Participants 
The first session was held in April 2011.  Participants are summarised in Row 1, Table 21 
below. A second session had to be planned as the session ran out of time and the same six 
participants were scheduled for a session in July 2011.  There were no changes in the 
constitution of the group.  The third session was conducted separately to develop project 
artwork for the Participant Information Sheet (PIS). 
Table 21: summary of PPI participants’ demographic data 
Date No. 
participants 
Age 
(yrs) 
School 
Yr 
Gender Experience
1 
Method Location of 
interview 
April 2011 6 10-16 8-12 Male: 1 
Female: 5 
0-3 Focus groups: 
A1 paper notes 
for mind 
mapping  
Wellcome 
Trust Clinical 
Research 
facility 
(WTCRF) 
July 2011 6 (same) As 
above 
As 
above 
As above As above  Focus group: 
Audio-recorded 
session 
As above 
September 
2011 
8 8-16 6-12 Male: 2 
Female: 6 
No records Project artwork 
and PIS 
development 
As above 
1
Experience: 0= No experience, 1= visitor to hospital setting, 2= experience of outpatients / ED, 3= experience 
as an inpatient 
 
4.5.2 Protocol development 
4.5.2.1 Research participants 
The YPAG identified six key groups with whom it was essential to engage about future PK 
studies.  Following PPI there was a substantial increase in the stakeholder groups from the 
original plan (Figure 13) to what was actually conducted (see Figure 14).  The purple boxes 
denote work PPI participants felt could be conducted, but did not take place.   
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Figure 13: PRESCRIBE planned research activity (pre-PPI)  
 
Figure 14: post-PPI research conduct for PRESCRIBE 
 
Additional stakeholders identified were nurses, hospital managers and research personnel. 
In addition, consumers- CYP and parents- expanded from those with PIC experience, to those 
with wider hospital experience and to the lay population, in order to review the influence of 
experience on participants’ views and attitudes.  There were three key areas where the 
advice of the YPAG was not followed (the purple boxes on Figure 14)- the lay parent group, 
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Doctors and REC committee members.  Engaging with parents connected to the hospital 
environment was extremely challenging and efforts were channelled in to ensuring those 
with experience of the hospital setting were recruited.  After initial attempts to engage with 
Doctors across the Trust, the decision was made to follow this group up at a later stage.  This 
group were challenging to engage with due to their workload and rapid changes to their 
availability.  A survey with REC members was developed but was not conducted because of 
time constraints. Overall the impact of PPI was to significantly broaden our participant 
groups and widen the inclusion criteria for the future qualitative studies.   
4.5.2.2 Recruitment methods 
The YPAG identified that for health professionals and REC members, invitation to participate 
could be undertaken by email. See Figure 15 below for a summary of their views on 
recruitment of participants.   For CYP and parents however recruitment was felt to be best 
conducted face to face, to ensure that the timing was appropriate.  Recruitment could take 
place in a variety of areas, provided there was sensitivity to the individual’s circumstances, 
particularly those in Emergency Department (ED) or PIC.  To capture the perspective of those 
with no experience of the hospital setting, they felt this work would be best conducted in 
the school setting.  
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Figure 15: planned method of recruitment for each participant group 
 
Overall recruitment methods did not change as a result of PPI but the impact of PPI was to 
verify the planned approaches. These plans continued through to implementation of the 
research protocol.     
4.5.2.3 Methodology 
The planned methodology was envisaged to be focus groups. Overall this approach was 
supported by the PPI collaborators, with focus groups viewed as the best methodology to 
conduct with nurses, Research Network staff and Hospital managers. The YPAG did however 
caution that this could be problematic for CYP and parents, citing challenges with child care, 
travel and working patterns.  To overcome this, they suggested discussion of preferences 
with participants at the time of approach, with the offer of an interview if the CYP or parent 
preferred (protocol amended to reflect this choice).  There was a potential place for 
questionnaires / e-surveys, although there were recognised limitations for both methods. 
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The impact of PPI was to confirm the selection of methodologies for some groups and to 
make modifications to allow for participant choice.  
4.5.2.4 Interview schedule 
Key topic areas to address within the interview schedule were discussed with the YPAG, see 
Table 22 below.  These generated questions to be posed within the interviews or aspects 
they felt would need to be addressed.  Examples raised are listed below in Table 22, along 
with quotes from participants. The impact of PPI was therefore in the generation of topics 
for discussion. 
Table 22: interview topics and questions generated by PPI participants’ 
Group Topic Questions 
CYP  Type of sample 
 Blood sampling 
 Sampling regime 
 Risks of participation 
 Pain 
What type? Where do you take it from? How much? What happens if 
they can’t obtain the sample? Extra attendance at hospital? How long 
for? Are there alternatives? Scarring? Side effects? Safety? What 
happens to the samples after? Will it hurt? What can you do to 
minimise pain? 
Parents As above, plus  
 Longer term effects  
 Commitment 
 Benefits of 
participation 
How long do we need to do this for? How much extra is this to normal? 
Do you ‘share’ the results? Will this benefit care?  
Nurses  Time 
 Workload  
 Blood sampling 
 Gatekeeper 
 Results  
How much time is required? Is there help available? What is involved? 
What does this mean for medications? Where do we take samples 
from? How many? Which patients? Is this safe for them? What happens 
to results? Will this change patient care? 
Hospital 
Managers 
 Invasiveness 
 Impact on patients 
 Medicines 
management 
 Cost implications 
How many invasive procedures? Where will this take place? How will 
this affect patients?  What is the impact on prescribing? Could this avoid 
other procedures? Are there cost savings to be made?  
                                                                                             
“What happens if you don’t bleed?  Is there a maximum 
number of times they’ll stab you?” (YPAG-4) 
“Parents might think more long term.... like what’s the period of the study? How long 
is it going to be going on? How long are you going to want the bloods? “(YPAG-3) 
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4.5.3 Participant Information Sheet (PIS) and study paperwork 
The YPAG highlighted that they felt it was important for a study to have an identity or a logo 
and for this to be used consistently throughout the study. The YPAG therefore produced the 
prototype PRESCRIBE logo (final results produced by a graphic designer). In addition, they 
provided feedback on the content and readability of the PIS.  The impact of PPI was the 
restructuring of information into shorter paragraphs, clarification of study activities and 
highlighting where graphics would be of benefit.  Comments on the consent and assent 
forms reflected the need for short sentences and ensuring the language was appropriate for 
the age bracket for which it was designed.  See Appendix 3 for copies of PIS.   
4.6 Discussion  
4.6.1 Consultation  
PRESCRIBE utilised a consultation approach to PPI, with engagement focused at the pre-
protocol development stage.  This approach has been criticised as being the lowest level of 
PPI engagement, with participants often passive in the research process (Boote et al., 2002).  
However, early PPI at the pre-REC submission stage is recognised as being the most credible 
and useful, as it optimises the impact and relevance of research (Buck et al., 2014).  At this 
stage, many decisions are made that determine the relevance and conduct of the research 
question, the precise specification of the research question, methods of data collection, 
recruitment and consent procedures (Staniszewska, 2007, Boote et al., 2010, Brett et al., 
2012).   In addition, although activity is defined as one-stage PPI, it was not a once-only 
event.  Consultation with the YPAG took place on three occasions: twice in relation to the 
protocol development and once in relation to the PIS and artwork.  There is also a danger of 
PPI profligacy, the encouragement of elaborate plans for PPI that are disproportionate to the 
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needs of a trial (Buck et al., 2014). For the purposes of this project, consultation focused on 
the pre-protocol stage was felt to be appropriate. 
4.6.2 Engaging with the ‘right’ people 
Despite efforts to conduct PPI with parents who understood the PIC setting, strategies were 
unsuccessful.  Finding and engaging with the right people with an interest in and 
understanding of the research is recognised as a major hurdle for researchers (Buck et al., 
2014).  Efforts were made to utilise existing resources within the local NHS Trust but there 
were challenges with Hospital gatekeepers and a reluctance to ‘share’ databases of parents.  
Many researchers conduct PPI with patients known to the researcher through clinical care 
(Mathie et al., 2014). In fact a study exploring PPI training with 31 researchers from 28 trials 
found that only one Chief Investigator sent out an advert inviting people to volunteer for the 
role of PPI contributor (Dudley et al., 2015).   This can create challenges for researchers of 
managing ‘known’ patients and there can be issues for participants about raising aspects 
which imply criticism of their clinicians or services (Buck et al., 2014).   Given that CYP who 
utilise PIC services are, by nature critically ill, it was felt inappropriate to conduct PPI with 
families of CYP who were current service users.   
Unlike other disease-specific support groups, there are no national support groups that 
specifically exist for parents of former critically ill children (Menzies et al., 2016).  It is 
therefore difficult to reach and engage with parents in the design and conduct of trials 
carried out in the PICU environment.  Tume et al (2015), despite using a variety of 
recruitment strategies locally and nationally over a 6 month period, were only successful in 
engaging in PPI with two parents of children who had been PIC service users.  They report 
that the actual consultation work was relatively straightforward but the main challenge was 
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in the recruitment of parents to the consultation process.  This mirrors experiences of 
consultation with parents of children who had experienced a PIC admission for Refractory 
Status Epilepticus. Of 56 families approached for participation in a focus group, there were 
47 non-responders and only representatives from 5 families went on to be involved in a 
focus group (Menzies et al., 2011).  Even when the method was a telephone interview, only 
35% (12/34) of parents approached agreed to participate (Agrawal et al., 2009).  There is 
significant effort required to conduct this type of ‘stand-alone’ consultation, where 
participants are sought for a specific focused project.  Within the time restrictions of a PhD 
project the decision was made to find an existing group of parents who already met for a 
specific purpose. In addition, because of the context under consideration it was decided that 
the group needed to have some understanding of the challenges involved with having a child 
admitted to hospital and being prescribed medications.   This is in keeping with PPI guidance, 
that wherever possible, utilise existing PPI resources (Morrow et al., 2012).  Social media 
offers new avenues and opportunities but these were limited in 2011-2012.  
4.6.3 Impact: recruitment rates, documentation and approval 
One of the commonly reported impacts of involvement is an increase in recruitment rates 
(Vale et al., 2012, Ilife et al., 2013).  This is complicated because studies have often 
compared one group of projects with some kind of involvement, with another group of 
projects with no involvement, without controlling for other contextual factors that might 
influence recruitment (Staley, 2015).   In the case of PRESCRIBE it is difficult to measure the 
impact because recruitment to all groups was considered within the PPI consultation and 
there was no other ‘similar’ project with which to compare it.  In addition, gains provided 
from PPI are often diffuse and hard to quantify (Fudge et al., 2008). There was also no 
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particular anticipated problem with recruitment.  However, recruitment as a process went 
smoothly and exceeded target sample size for many of the participant groups.  Contributing 
factors were felt to be the consideration of recruitment strategies and the most appropriate 
methodologies for each participant group.  PPI verified the planned approaches and 
identified new groups with which to engage.  Whilst recruitment to time and target cannot 
be directly attributed to one factor, the care and consideration taken at the pre-protocol 
stages were felt to have contributed to the smooth progress of the study.   
Involvement of consumers in studies has been identified as contributing to improvements in 
the study documentation, including protocol development and Participant Information Sheet 
(Vale et al., 2012, Mathie et al., 2014).  This is reflected in PRESCRIBE, with contributions to 
PIS for parents (for CYP focus groups), CYP aged 8-10years, CYP aged 11-16years, a PIS for a 
parent focus group as well as consent and assent forms.  Measuring the impact of these 
changes is again challenging but as these are key documentation reviewed by the Research 
Ethics Committee (REC), it can be seen as positive that there was only one additional 
sentence required by the REC to any of the study documentation.  
Research Ethics Committees require researchers to demonstrate evidence of PPI activity to 
ensure that a study design is appropriate, risks have been minimised and information 
materials are comprehensible to their target audience (Nuffield Council Bioethics, 2015b).  
The impact of involvement is therefore that ethically acceptable research is designed and 
the approvals process is facilitated (Staley, 2015). Following submission, the study was 
approved (subject to the one amendment about the use of quotes) within six days.  Whilst 
this cannot be fully attributed to the PPI conducted as proportionate review,  an expedited 
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review of research studies which raise no material ethical issues (Health Research Authority, 
2014) was applied for.    However, the PPI work impacted on the overall standard of the 
application, which was felt to have facilitated the speed of approval.   
4.6.4 Impact: on the researcher 
Whilst PPI was planned from the outset, the value of PPI was under-estimated. A review of 
documented PPI plans in funding applications found this was a common fault (Buck et al., 
2014).   Planned PPI activity for PRESCRIBE went from being a two-hour once-only activity to 
help populate the protocol, to contributing to three sessions, with the development of 
project related artwork and logo, the development of the interview schedule and vignette as 
well as the details required for the protocol regarding recruitment and methodology.  A 
thesis chapter specifically on PPI also evolved, a future publication about the conduct of PPI 
with CYP is drafted as well as a publication about the challenges of PPI within the PIC context 
(Menzies et al., 2016). De Wit et al (2014) highlight that one of the most important  
outcomes from involvement is the reality check for the researcher and the challenge that 
involvement makes to their thinking, planning, values and communication.  This is equated 
to a form of experiential learning for researchers (Staley, 2015).  One of the biggest impacts 
of PPI for PRESCRIBE is therefore the experiential knowledge gained by the researcher about 
the potential contribution of PPI through direct experience of working with the public.   
4.7 How does PPI work conducted address the gap in 
knowledge?  
The narrative review, conducted to explore PPI within the PIC setting, demonstrated the lack 
of published examples of PPI engagement in this context (Menzies et al., 2016).  In 2016 
there was only one paper which described PPI within Paediatric Intensive Care trial design 
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(Tume et al., 2015), rather than research on trial design.  Researchers working in PIC are in 
the woeful position of having few options to guide them in their own research design and 
conduct.  This runs the risk of perpetuating more badly designed studies or trying to answer 
questions which patients and their families do not view as important.  Staniszewska et al 
(2011b) describe the current evidence base as like an iceberg, only partly visible within the 
literature, with much information hidden, either not reported or poorly reported.  The 
recently published article makes the important step towards consolidating and highlighting 
the literature surrounding PPI in the PIC context (Menzies et al., 2016). There is also a need 
to understand the impact of PPI on any aspect of trial design (Staley, 2015).  Researchers 
need to publish their experiences to encourage this transparency and ensure others can see 
the nature and value of the contribution PPI has made to the study (National Institute for 
Health Research, 2015a).  In recognition of this, the next step is to contribute to the 
evidence base of PPI with CYP by developing the abstract (Menzies et al., 2013) to a full 
paper.   
4.8 Limitations 
A major limitation was the underestimation of challenges of undertaking PPI activity with 
parents.  Navigating consumer networks and organisations can be difficult as can the process 
of communicating goals and intentions to gatekeepers and facilitating access to potential 
participants (Smith et al., 2009). In future projects, negotiation with a number of 
gatekeepers and the pursuit of several options simultaneously is recommended. 
There were many benefits to consulting with the NIHR Clinical Research Network YPAG.  
They were accessible, met regularly and were well facilitated (National Institute for Health 
Research, 2016f).  They lived locally and therefore represented service users within the local 
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geographical area and some were service users at the local hospital.  They were also already 
trained to some extent in research terminology and could comprehend the concepts under 
debate.  This is important because researchers have identified that PPI contributors should 
be confident, motivated, intelligent and have relevant experience (Dudley et al., 2015).  
However, there is a question about whether they represent the authentic patient 
perspective.  Indeed, this difficulty of ensuring that participants are representative of the 
wider public is often cited (Boote et al., 2010).  Within the adult PPI literature it has been 
identified that individuals who are educated and articulate are more likely to volunteer as 
PPI contributors and are also more likely to identify with the perspectives of the researchers 
(Enany et al., 2013).   The researcher acknowledges that consulting with an existing panel of 
CYP with an established remit to advise on paediatric research does not ensure 
representation of the West Midlands CYP population but in 2011, there were very few other 
opportunities.  The YPAG was felt to be diverse enough to represent different ages, gender, 
ethnicities and experiences of hospital services including high dependency areas.  In 
addition, the group were briefed on the PIC environment by the PPI leads, including a visit to 
PIC to understand the context of the research studies.     
The researcher was not able to take on board all the YPAG’s suggestions due to the timelines 
of the PhD and the resources available.  Guidance documents have stated that researchers 
must value the contribution of CYP and highlight that overlooking comments can lead to CYP 
withdrawing from projects (Bird et al., 2013, INVOLVE, 2016a, INVOLVE, 2016b).  In line with 
recommendations, feedback was provided about why suggestions were rejected to 
demonstrate transparency in the decision making process (Telford et al., 2004, Snow et al., 
2015). The YPAG reported feeling positive about the experience of consultation and future 
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collaboration with the researchers and this is viewed as another successful outcome of the 
work.   Pharmacists were not identified by the PPI work as a group to engage with. The 
pharmacy team locally were a very small team and extremely busy, so after consideration 
the decision was made to not engage with this group for PPI purposes. 
4.9 Conclusion 
PPI conducted for PRESCRIBE contributed to improvements in the protocol design and 
paperwork as well as timely ethical approval. It also contributed to the researcher’s 
knowledge and professional development and confirmed the value of PPI within paediatric 
research.  One of the strategic goals of the NIHR is that by 2025 the evidence base for PPI 
will be strengthened through published accounts of what works (National Institute for 
Health Research, 2015a).  The next step is to share the experiences of PRESCRIBE and 
contribute to this evidence base, highlighting the impact and value of meaningful PPI.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
121 
 
Chapter 5: The attitudes of school children, 
years 9-13 towards pharmacokinetic 
research  
5.1 Introduction 
The NHS research strategy is to improve the health and the wealth of the nation through 
high-quality research (Department of Health, 2006).   There is evidence that patients cared 
for in research-active hospitals have better outcomes (Ozdemir et al., 2015), but the 
viewpoint of the wider public about research is still relatively under-researched.  Amongst 
adults there are generally high levels of support for research activity (Madsen et al., 1999),  
particularly in the presence of major diseases (Kemp et al., 1984) or critical illness (Burns et 
al., 2013).  Within the lay paediatric population, two notable studies were identified; one 
comparing attitudes towards health research of lay children compared to those with a 
chronic health condition (Cherrill et al., 2010) and a second reviewing the attitudes of school 
children towards the use of unlicensed medications  (Mukattash et al., 2012). However, 
within paediatrics overall there very few published accounts of engagement with lay children 
and young people (CYP) (Hill, 2006).   Patient and public involvement (PPI) consultation work 
outlined in Chapter 4 advised that work should be directed towards understanding the 
perspective of the lay paediatric population, rather than just those with first-hand 
experience of the hospital sector.  No publications about the views of lay CYP towards 
pharmacokinetic research were identified within the published literature.  There was an 
identified gap in the knowledge surrounding the service user or potential future service user 
perspective which this body of work set out to address (see Figure 16 below).  
 
 
 
122 
 
Figure 16: gaps in knowledge surrounding the ‘lay’ CYP perspective  
 
5.2 Aims 
Utilising quantitative methods: 
a. Determine the attitudes of a lay paediatric population towards paediatric PK studies 
b. Identify what a lay paediatric population perceive to be barriers or problematic about the conduct 
of paediatric PK research studies 
c. Identify what lay paediatric population identify to be enabling or facilitating the conduct of PK 
research studies. 
For all information related to method and analysis see Chapter 2- Method.   
5.3 Results 
5.3.1 Schools  
The set up and conduct of this work was initially extremely challenging. Of three schools in 
the West Midlands contacted on two different occasions, there was no response from any of 
them. Of two further schools contacted through the South West Medicines for Children 
Research Network (MCRN), one did not respond after an initial expression of interest (see 
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Figure 17). One school was included through an event at BCH and an enrichment programme 
at University of Birmingham (UOB) provided access to six schools (West Midlands)  
Figure 17: summary: method for how schools were accessed  
 
5.3.2 Participants 
134 participants took part in the sessions.  No parents declined for their child to participate. 
Thirteen were 19-21 years old, and so were excluded (from the sessions at UOB).  One 
declined to complete the questionnaire so responses from 120 participants are included 
within the results (response rate 99%).  See Table 23 below for details of the sessions and 
the number from each school year.  
Table 23: summary of lay CYP recruits by school year 
School year Location Date No. participants 
Year 9 School, West 
Midlands 
School, Bristol 
Feb 14 
March 14 
29 (subgroups of 7-8) 
22 (1 session) 
Year 10 School, Bristol 
UOB, West Midlands
1
 
Feb 14 
July 14 
5 (1 session) 
8 (1 session) 
Year 11 UOB, West Midlands
1
 July 14 18 (1 session) 
Year 12 & above UOB, West Midlands
1
 
 
August 14 
 
52 (sub groups of 12-13) 
Total respondents   134 (120 included) 
 
1
Attendees were from approximately six different schools across the West Midlands 
Further details about the participants are presented in Table 24 below.  The largest group of 
participants was students in year 9 (n=49, 42%).  14% (n= 17) of participants classified 
themselves as having no experience of the hospital sector, whilst 34% (n=41) reporting to 
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have had at least one inpatient stay (excluding birth).  25% (n=30) reported taking 
medications and 28% (n=34) classified themselves as having a health problem.   Respiratory, 
skin and hay fever / immune system issues were the three highest reported problems, see 
Table 24 and Table 25 below. This correlates with their medication use with 9% (11) 
reporting using inhalers and 5% (6) using antihistamines.   
Table 24: summary of lay participant characteristics 
  
Characteristics Frequency Percentage 
Gender 
Male 
Female
1
 
 
43 
77 
 
36 
64 
Total 120 100 
School year  
Year 9 
Year 10/11 
Year 12/13 
 
49 
29 
39 
 
42 
25 
33 
Total 117 100 
Medication use
2
 
Yes 
No 
Unsure 
 
30 
88 
2 
 
25 
73 
2 
Total 120 100 
Medical condition 
Yes 
No 
 
34 
85 
 
29 
71 
Total 119 100 
Hospital experience
3
 
None 
Visitor 
Outpatients / ED 
Inpatient 
 
17 
10 
52 
41 
 
14 
8 
44 
34 
Total 120 100 
1
One of the schools was a comprehensive school for girls only, all the other schools were mixed comprehensive 
schools.  
2
At time of completion of questionnaire 
3
Respondents’ answers were coded to reflect their highest level of experience.  Visitor coded as 1, outpatient/ 
ED visit coded as 2, Inpatient stay coded as 3. 
System No. Total % 
Respiratory
1
 11 119 9 
Skin 10 119 8 
Hay fever/ Immune 
system
2
 
6 119 5 
Bones / mobility 4 119 3 
Blood 3 119 3 
Heart 3 119 3 
Hormone 1 119 1 
Cancer 1 119 1 
Metabolism 1 119 1 
Sickle cell 1 119 1 
Diabetes 1 119 1 
Liver 1 119 1 
Kidneys 1 119 1 
Mental health 1 119 1 
1
Inhalers: N= 11 (9%) 
2
Hay fever/ antihistamines: N=6 (5%)  
 
Table 25: summary of health issues of lay participants' 
(self-reported) 
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5.3.3 Attitude towards PK research 
99% (n=119) of participants either agreed or strongly agreed that it is important that Doctors 
make sure they give people the right amount of medicine.  This factor was found to be 
significantly correlated with experience of the hospital setting (p= 0.026). When asked 
whether this type of research should take place with CYP, the number who responded 
‘agree’ and ‘strongly agree’ dropped to 80% (n= 96) and reduced to 30% (n=37) when the 
participants were changed to babies and young children (displayed in Figure 18 below).  
 
Figure 18: lay CYP views on acceptability of PK research in adult, children and infants 
   
 
15% of participants made additional statements about the conduct of research with children 
(18/120), or babies (17/119) or both (8/119).  Some made additional comments because 
they were uncertain about whether research should take place: 
  “Babies that are very, very young are likely to have a weaker immune system” 
(‘Unsure’: S- 33) 
Others added clarification to statements to emphasise their reasons for disagreeing / 
strongly disagreeing: 
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“I think babies are too vulnerable to be tested on” (‘strongly disagree’ S-8)  
“They can fall ill too fast” (‘strongly disagree’, S-22). 
School year was found to have a significant association with whether research should take 
place in children and young people (p<0.001).   Year 9 students were the most positive about 
this research taking place, with the level of agreement reducing as the participants got older. 
Post-hoc analyses found the year 12 and 13 students to have significantly lower agreement 
with the statement than those from either year 9 (p<0.001) or year 10/11 (p=0.040) (see 
Figure 19 below).  
Figure 19: lay CYP views on the acceptability of PK studies in children   
 
5.3.4 Participants attitudes towards personal participation   
When asked about whether they would take part in the study described within the vignette 
(please see Appendix 1), only 19% (n=23) said ‘No’ outright.  32% (n=38) felt unsure about 
personal participation and 49% (n=59) said ‘Yes’.   Personal participation was not associated 
with gender, school year, medication use, health conditions or experience of the hospital 
sector.  
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5.3.5 Motivational factors for participation in a PK study 
When asked about the factor(s) which would make them consider taking part in a PK study, 
the biggest influencing factor was to help others (76%, n= 91), followed by the belief that it is 
important to do research n=59 (49%) (all options are displayed in Figure 20 below). 
Figure 20: lay CYP reasons for considering participation in a PK study  
 
 
Helping others was associated with a number of factors.  Females were significantly more 
likely than males to report being motivated by helping others (84% vs. 60%, p=0.007). School 
year was also significantly associated with being motivated to help others (p=0.040), with 
the proportion of participants agreeing with this statement increasing from 67% in Year 9 to 
90% participants in years 12 and 13. Increasing experience with the hospital setting was also 
significantly associated with the motivation to help others (p=0.002).   Post-hoc analysis also 
found that those with experience as an inpatient were over twice as likely to be willing to 
help others than those with no hospital experience (88% vs. 41%, p=0.003). 
5.3.6 CYP concerns about PK research and positive influences to 
participation 
Participants were asked to identify the aspects of a PK research study that gave them 
concerns about participation.  Their biggest concerns are listed in Table 24 below. 
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Table 24: CYP concerns about participation in PK research (L) and positive influences on participation (R)   
1
Participants were allowed to tick as many answers as 
was applicable.   
 
Pain was the highest ranked concern and was correlated with gender, with females more 
likely to report being worried (p=0.015) (see left side of Table 24).  ‘Parents having to make a 
decision about participation on their behalf’ was the second highest ranked concern. Those 
participants with this concern (n=59) were found to be significantly more likely to report the 
use of medications (p=0.047), and having a medical condition (p=0.034).  
The provision of simple, clear information about the study was the highest ranked 
influencing factor for CYP (see right of Table 24 above).  It was significantly correlated with 
school year (p=0.047), with 90% (n=35) of year 12 and 13 students reporting this as an 
influencing factor, compared to 67% of those in year 9.  Given that decision-making about 
participation was a significant concern it is notable that being asked directly about 
participation was the second highest rated facilitating factor.  Using left-over blood was 
regarded as a positive factor for those with experience of being an outpatient (55%, n= 28) 
or inpatient (35%, n=14), rather than those with no hospital experience (19%, n=3) 
Concerns
1 
Frequency % 
 
Pain 74 62 
Parental decision 
making 
59 49 
Personal decision 
making 
53 44 
Extra cannula 52 43 
Extra bloods 47 39 
 
Extra visits 42 35 
Scarring 39 33 
Understanding what is 
being done & why 
39 33 
Making extra work for 
staff 
19 16 
Positive influences to 
participation
1 
Frequency % 
Provide clear information 88  75 
Ask me directly about 
participation 
87  75 
Use local anaesthetic agents 83  72 
Use a central line where 
possible 
66  56 
Take smallest amount of 
blood 
60  52 
No extra visits 55  47 
Use urine or saliva 51  44 
Use 'leftover' blood only 48  41 
Take only alongside routine 
bloods 
38  32 
Minimise extra work for 
staff 
37  32 
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(p=0.018).  Those with hospital inpatient experience (n=22) were more likely to find ‘no extra 
visits’ important than those with no experience (n=6) (55% vs 38%) (p=0.03). 
5.4 I-PARIHS 
Using the integrated PARIHS framework (I-PARIHS) (Harvey and Kitson, 2016) outlined in 
Chapter 2, the key aspects for the ‘recipients’ -lay CYP-  have been mapped out in relation to 
the ‘innovation’ PK research studies (see Figure 21 below).  This demonstrates that there 
was little consideration of context specific factors and CYP were more focused on the direct 
impact of research to recipients.   
Figure 21: lay CYP responses mapped to I-PARIHS 
 
5.5 Discussion 
5.5.1 Participation with PK research 
CYP within this study were overwhelmingly supportive of the idea of ensuring medicine 
optimisation.  However, this support diminishes when research potentially involves younger 
children and infants, particularly amongst older children.  This is in keeping with one of the 
few studies to explore school children’s attitudes towards clinical trials.  Within the study 
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conducted by Mukattash et al (2012) the general view, particularly amongst older children, 
was not in favour of children taking part in trials unless they were seriously ill.  Concerns 
about vulnerability appeared to be the main reason although this could also reflect concerns 
that they have a right to make decisions for themselves (Balen et al., 2006).    
Respondents within the PRESCRIBE study were also hesitant when they were asked about 
personal participation in a PK study, with 49% saying yes and 32% unsure from across all the 
age groups.  This potential consent rate is supported by the fact that 50% of children aged 
11-16 also agreed to participate in a theoretical trial to assist with the licensing of medicines 
(Mukattash et al., 2012).    However, there is some indication that this consent rate could be 
higher in trials conducted with CYP with health conditions.  97.4% (n=112) of children who 
had participated in a trial reported they were happy about participation with the study and 
91.3% (n=105) would agree to be in a future study (Fogas et al., 2001).  Whilst this positivity 
is encouraging, this was a population PK study of steady state methylphenidate with only a 
single venepuncture and does not represent the requirements of many more complex PK 
studies.   
5.5.2 Motivation 
The biggest motivational factor amongst CYP was to help others; particularly for females, 
those with experience of the hospital setting and older CYP in school years 12-13.  This is in 
keeping with published literature, which has found that CYP are capable of altruism 
(Wendler and Jenkins, 2008, Wendler et al., 2012) and that those with chronic illness might 
be more motivated to participate (Cherrill et al., 2007, Cherrill et al., 2010).  In one of the 
few studies to explore attitudes towards PK studies in children with a chronic condition, self-
interest was a larger motivator (47%) than altruism (39.1%) (Fogas et al., 2001).  However, 
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only 61% of those who participated with the PK study consented to be interviewed so it is 
unclear if this was the motivation for all study participants. In addition, participants were 
interviewed over 8 months after participation so there is a question about the reliability of 
children’s recollection surrounding their decision making.  The concept of decision making 
about participation is hugely important and research which provides insight into this 
phenomenon is clearly useful.  Year 9 students were the most open to inclusion of all patient 
groups to the research and showed a trend towards being the most likely to consent to 
participation (although this figure did not reach statistical significance). These differences 
highlight the need for approaches to consider the influence of age as well as health status.   
Overall the findings add weight to the notion that CYP are capable of altruistic behaviours.  
However, the study only included those in year 9 and above (aged 13 and over).  Other 
published literature has similarly excluded younger children so there is a dearth of 
information about the perceptions of younger school age CYP.  Future research therefore 
needs to explore this notion with a younger population. It would also seem wise to explore 
differences in school year as this might determine information needs and the pitch of 
participant information sheets (PIS).   
5.5.3 Concerns and anxieties about PK research 
Pain was the highest ranked concern of lay CYP in the school setting.  This is supported by 
literature which highlighted that fear of phlebotomy is the principle reason for refusal for 
research (Dlugos et al., 2005) and venepuncture is the most distressing aspect of a hospital 
admission (Duff, 2003, Hands et al., 2010).  Factors that reduce pain such as the use of 
topical local anaesthetic, use of a central venous line (where possible) and the use of leftover 
blood were ranked as positive influences by CYP within the questionnaire.  These results 
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demonstrate that lay CYP recognised the value of approaches which reduced or avoided 
painful procedures, such as using scavenged samples (samples obtained without obtaining 
additional blood) (Cohen-Wolkowiez et al., 2012a) or the use of local anaesthetic to 
minimise pain (Cordoni and Cordoni, 2001).   
The other big concern expressed by CYP was decision making, either their parents making 
decisions without their involvement or a concern about how they themselves would make 
decisions whilst unwell. This is validated by the fact that the biggest facilitators to PK 
research were the provision of clear information, particularly for older students, and being 
asked directly about participation.   CYP indicated they wanted to be involved in the 
decision-making process and worried about not understanding what was required of them in 
a study. There is some evidence in studies with parents that a lack of experience with 
research heightened parents’ anxiety levels (Langley et al., 2003).  Another study found the 
more experienced parents are with science and medicine, either professionally or as a 
consumer of health services,  the more open they are to the prospect of their child taking 
part in vaccine research (Chantler et al., 2007).  Familiarity did not predispose to enrolment 
in research, but did contribute to parents’ confidence in decision making, acceptance and 
judgement of the research.  Given that the CYP in this study placed such importance on 
information and rated not understanding what is going on amongst their biggest concerns, 
this would suggest that CYP also value science and medicine and the ability to make sense of 
what a study requires.  There is a growing recognition of the importance of beginning this 
education within the school setting.  Education about research would contribute to 
enhanced awareness and understanding about research amongst a lay population of CYP  
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(National Institute for Health Research and GenerationR., 2014, National Institute for Health 
Research, 2015c).  
5.5.4 Experience and health status  
Those with experience of health care settings were more likely to be motivated to help 
others; with those had been an inpatient over twice as likely to be motivated than those 
with no hospital experience.  Cherrill et al (2010) similarly found CYP with a chronic illness 
were more likely to support children’s involvement in clinical trials than those without.  CYP 
in PRESCRIBE with inpatient experience were also more likely to regard having to attend 
hospital for extra visits as a negative influence on their decision making and rated the use of 
approaches which utilised leftover blood samples.  Health status appears to have a large 
influence on CYP decision-making, however this is challenging to capture in a non-health 
care setting.  Within the questionnaire CYP reported medication use at 25%, and the 
presence of a medical condition in 28%, which seems in line with the estimate of 31% of 
children are affected by a chronic condition (Newadreck & Taylor 1992).  Other studies 
conducted within the school setting have reported 11% of pupils took regular prescribed 
medicine, although no further detail about their health status was reported (Mukattash et 
al., 2012) and Cherrill et al (2010)  reported 23% children took regular medication, with 20% 
classed as having a chronic condition.   Findings from PRESCRIBE suggest that health status 
and experience of the hospital setting are influential factors but it is difficult to capture 
detail about episodes with self-reporting.    
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5.6 Limitations of the study 
5.6.1 Method  
Utilising the format of a questionnaire did limit the opportunity for the researcher to clarify 
meaning and question participants further. Participants were instructed to seek help or 
advice if they did not understand but there were some discrepancies, for example; people 
who reported they took medication but did not disclose a medical condition.  Focus groups 
would have been beneficial in allowing in depth discussion, however our PPI participants 
advised that CYP in school setting might find it intimidating having open discussions with 
classmates.  Furthermore, they advised that questionnaires would allow people to make 
confidential disclosures regarding their health and medications which might not otherwise 
be reported.  The difficulty was making sense of these revelations.  In future research, 
clarification from parents could be justified to ensure illness and injury are classified 
appropriately.  Alternatively gathering more information from CYP to allow a clearer picture 
of their health status would be beneficial, although there is the possibility that participants 
may then have questionnaire fatigue.  
5.6.2 Time 
Time constraints meant that the sessions lasted between 35-55 minutes, as sessions had to 
fit with school timetabling.  All sessions were conducted in the same manner and same 
format however the available time did mean there were constraints on the level of 
discussion possible which could have led to differences in responses.  Unfortunately, 
because the questionnaires were anonymised and entered manually after the session it was 
not possible to examine whether this was a factor in shaping perception.  The sessions that 
were held at University enrichment days had attendees who were aged up to 21 years of 
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age.  Their responses were discounted but it is possible that they influenced the discussion 
prior to questionnaire completion and may have influenced younger fellow attendees.   
5.6.3 Comprehension 
Preparatory information was provided to the participants about the process of research, the 
nature of PK research and the nature of hospital experiences however it was not possible to 
prepare them through visualisation of areas such as PIC. They were able to comprehend that 
when seriously ill they could be asked about participation in a trial however within group 
discussions they struggled to understand that illness or medical treatment might render 
them unconscious and therefore unable to join in the consent process.   
5.7 How does this work with lay CYP address the 
knowledge gap surrounding pharmacokinetics? 
Very few health research studies have been conducted within the context of the educational 
setting with a lay paediatric population.  This is the first study the researcher is aware of to 
engage with CYP from a number of schools to identify their attitudes towards PK research. 
The study provides evidence that CYP are willing to consider participation in research and 
are motivated by the idea of helping others, as well as to improve their own health in line 
with other published literature undertaken with CYP (Cherrill et al., 2007, Cherrill et al., 
2010, Mukattash et al., 2012).  This is most apparent in year 12 and 13 students and 
amongst those of any age who had experienced a hospital admission. Although altruism 
appears to increase as CYP progress through school, so does concern about the recruitment 
of infants and young children.   Factors that appear to facilitate participation are the 
provision of clear information and being involved in the decision-making process, although 
as this work was conducted using a hypothetical situation caution about over interpretation 
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is advised.  Understanding more about lay perspectives is vital if a trial is to benefit future 
patients or the wider public  (Piko and Bak, 2006). This work makes an important 
contribution to understanding more about the perspective of CYP who are current, or 
potential future service users.   
5.8 Conclusion 
Lay concepts of health and illness give additional important information to health 
professionals (Lawton, 2003).  Very few studies have been conducted to explore ‘healthy’ 
CYP perceptions of research and none have specifically reviewed the topic of PK trials.  CYP 
in this study were supportive of the idea of PK research and would consider personal 
participation, despite concerns about pain and decision making.  As children age they appear 
to become more altruistic but also become increasingly concerned about the inclusion of 
those they viewed as ‘vulnerable’.  Those who had experience of the hospital setting 
appeared to be more likely to want to help others but researchers must take care in the 
design of future research to ensure material provides sufficient, clear information to CYP and 
that they are directly involved in decision making. Addressing pain, information needs and 
involvement in decision making are likely to be the most effective ways of improving 
receptivity to PK research.  Although only 19% of this lay population included in this work 
would decline immediately, there was a high level of uncertainty, possibly reflective of a lack 
of education about research and an understanding of what is involved. This study found 
there was an enthusiasm for debate and to learn about hospital care and research amongst 
school age CYP.  There is a possibility that through educating and informing an openness to 
research can be cultivated which will influence future public support for research.  
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Chapter 6: Exploring children, young 
people and parents’ perspectives on 
Pharmacokinetic research in critically ill 
children 
6.1 Background 
6.1.1 Paediatric research 
The strategy ‘nothing about me, without me’ emphasises the importance of decision-making 
in partnership with patients and families about health care (NHS England, 2017).  This 
extends to decision making about research participation (Department of Health, 2003).  
There is a growing recognition that children may be able to express their own opinions about 
participation if these are sought, using appropriate methods to elicit them  (Hart and 
Chesson, 1998).  Despite this very little research exploring children’s perspectives of health 
research has been conducted (Cherrill et al., 2007, Woodgate and Edwards, 2010).  With 
increased understanding of their perspectives, their concerns and their motivations 
researchers can work to design studies which are acceptable to CYP and parents.   
6.1.2 What is known about CYP attitudes towards pharmacokinetic 
research?  
In a systematic review of the factors that motivate and discourage CYP and parents to 
participate in pharmacological research, less than half of the studies had considered the 
perspective of CYP than parents (16 compared to 37) (Tromp et al., 2016).  There were also 
concerns that several populations were under-represented, including the views of healthy 
children, children with chronic diseases and critically ill children.   When the field of 
pharmacokinetic (PK) studies specifically is considered, there were only three studies 
identified.  Whilst Berg et al (2010) reported high levels of support for PK studies, only four 
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of the participants were actually CYP. The rest (n=46) were adult participants or parents.  
Errington et al (2016) had a higher participation rate with 23/ 100 participants being CYP. 
However Berg et al (2010) and Errington et al (2016) conducted the work by survey which 
limited the opportunities for further exploration of views.  Only one study involved CYP 
being interviewed directly (by telephone) (Fogas et al., 2001). 91% of Participants within this 
study were supportive of PK research and would participate in a further PK study if asked.  
However, this may not represent the experience of all PK studies, as this study involved a 
single additional venepuncture and was conducted in an outpatient setting, with no 
requirement for additional visits or admission to hospital.  Overall there is a lack of research 
exploring the perspective of CYP surrounding participation in PK research and no research 
addresses the question of conduct within an emergency or time sensitive situation. Future 
research must focus on the factors that shape the decision of children themselves (Tromp et 
al., 2016) and how these perspectives change in the context of hospital admission and in the 
face of critical illness.   
6.1.3 What is known about parents’ attitudes towards pharmacokinetic 
research?  
Research surrounding parents’ consent to participate in research has often focused on their 
understanding of randomisation and the consent process (Snowdon, 1997, Tait et al., 2002, 
Kodish et al., 2004).  Whilst such research is relevant it cannot tell us what parents consider 
important about how information about clinical trials is communicated and their perspective 
of the recruitment process (Shilling et al., 2011).  The systematic review conducted by Tromp 
and colleagues (2016) found  the biggest factors for parents to consider participation in drug 
research was benefit for the child, altruism, a general trust in the safety of research and a 
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relationship with researchers. Discouraging factors were a fear of potential risks, a general 
distrust in research (their child as a ‘guinea pig’), logistical aspects of the study and the 
disruption to daily life.  Studies reviewing PK trials have focused on the attitudes of parents 
within the oncology speciality (Berg et al., 2010).  However, these trials often take place in 
the context of phase I/ II trials and it is unclear the degree to which access to novel 
treatments influences decision-making.  No studies have been conducted with parents 
within the PIC population and the influence of context and acute health deterioration on 
decision making has not been well-described.   There are therefore large gaps in the 
knowledge base surrounding the perspective of CYP and parents, the factors that facilitate 
recruitment and also the influence of context on decision-making (see Figure 22).   
Figure 22: gaps in the knowledge- CYP and parents’ perspective 
6.2 Research aims 
As outlined in Chapter 2 the aim of this work was to determine the attitudes of participants 
towards paediatric PK studies, identify what participants perceived to be a barrier or 
problematic about the conduct of paediatric PK research studies and identify what 
participants’ identify as enabling or facilitating the conduct of PK research studies. Please see 
Chapter 2 for full details of the methods undertaken.   
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6.3 Results 
6.3.1 Demographics 
Screening and recruitment took place from July 2013- July 2014. Table 25 below includes details on where CYP were recruited from, their 
reported experiences and location of the interview / focus group. Table 26 summarises the key information of age, gender and experience 
Table 25: recruited CYP demographics  
Participant Age 
(yrs) 
School 
Yr 
Gender Screened by Recruited Reported experience Current 
medication 
Experience
1 
Method Location  
56A 11 7 M PIC PIC Nystagmus operation/ 
Sibling child on PIC 
No 3 Joint Interview 
(56B) 
Home 
56B
2 
15 10 M PIC  PIC Patient on PICU Yes 3 Joint interview 
(56A) 
Home 
70A
2
 10 6 F WTCRF WTCRF Rare disease Yes 3 FG 1 WTCRF 
70B
2 
12 8 F WTCRF  WTCRF Rare disease Yes 3 FG 1 WTCRF 
70C
2 
10 6 M WTCRF  WTCRF Rare disease Yes 3 FG 1 WTCRF 
70D
2
 12 8 M WTCRF WTCRF Rare disease Yes 3 FG 1 WTCRF 
75A 10 6 M WTCRF WTCRF Fractured finger / sibling 
child in trial 
No 2 Joint interview 
(75B) 
Home 
75B
2 
7 3 M WTCRF WTCRF Cerebral Palsy Yes 3 Joint interview 
(75A) 
Home 
81A
2 
15 10 M WTCRF WTCRF Diabetes Yes 2 Joint interview 
(81B) 
Home 
81B
2 
17 13 M WTCRF WTCRF Diabetes Yes 2 Joint interview 
(81A) 
Home 
82A 14 9 F PPI lead YPAG Nil reported Not asked 0 FG 2 WTCRF 
82B 17 13 M PPI lead YPAG Asthma Yes 3 FG 2 WTCRF 
82C 17 13 F PPI lead YPAG Minor op Not asked 0 FG 2 WTCRF 
82D 15 11 F PPI lead YPAG ‘Ill’ as a child Not asked 2 FG 2 WTCRF 
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Participant Age 
(yrs) 
School 
Yr 
Gender Screened by Recruited Reported experience Current 
medication 
Experience
1 
Method Location  
82E 15 11 F PPI lead YPAG Skin allergies Not asked 3 FG 2 WTCRF 
82F 13 8 M PPI lead YPAG Bone marrow donor Not asked 0 FG 2 WTCRF 
82G 12 8 F PPI lead YPAG Asthma Not asked 2 FG 2 WTCRF 
82H 17 12/13 F PPI lead YPAG Asthma Not asked 2 FG 2 WTCRF 
82I 17 12/13 M PPI lead YPAG Cardiology Not asked 3 FG 2 WTCRF 
101A 12 8 M Burns team Burns Burns HDU No 3 Joint interview 
(101B) 
BCH 
101B 11 7 M Burns team Burns Burns HDU No 3 Joint interview 
(101A) 
BCH 
104
2 
10 6 F PIC  PICU Renal /PICU Yes 3 Interview Home 
117A 17 13 F Patient 
Experience Lead 
(PIL) 
YPAG Nil reported No 2 FG 3 BCH 
117B 15 11 F PIL YPAG Chronic renal Yes 2 FG 3 BCH 
117C 14 9 F PIL YPAG Nil reported No 0 FG 3 BCH 
117D 12 8 F PIL YPAG Nil reported No 2 FG 3 BCH 
 
Total 26 participants 
1
Experience: 0= No experience, 1= visitor to hospital setting, 2= experience of outpatients / ED, 3= experience as an inpatient 
2
Has been / currently in a research study (n=9/ 26) 
Table 26: summary of recruited CYP demographics 
Demographic Participants 
Age Range 7-17 years (median 13.5). Child aged 7 years old specifically wanted to take part)
 
Gender 13 Males, 13 females= 26 participants 
Medication use 7: No, 11: Yes. 8: did not disclose 
Hospital experience None (4), visitor only (0), outpatient / Emergency Department (ED) visit (9), Inpatient (13); PIC admission (3) 
Research experience  9: patients currently in / has been in a research study at some point 
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PIC: screening records were maintained by JCM and PIC research team.  Records for a 
7month period (September 2013- April 2014) reflect 850 PIC admissions (see left hand side 
of Figure 23).  122 admissions were over the age of 8 years (14%).  Of these 44(36%) were 
ineligible due to pre-existing learning difficulties or acquired difficulties due to their illness / 
injury (discussed with parents and clinical teams) or child protection issues which made 
consent difficult.  63 (52%) were missed due to rapid discharge before the study could be 
discussed. 15 (12%) were provided with the Participant Information Sheet (PIS), 11 of which 
were happy to consider participation but did not respond to follow up.  As a result, only one 
person was consented through this process.  The other 2 participants with PIC experience 
(one former patient, one sibling) were identified through the PIC Family Liaison team. 
WTCRF: research participants were screened and recruited from WTCRF by JCM, following 
liaison with WTCRF staff.  15 CYP were screened, of which 11 were provided with a PIS.  
Ultimately six consented to participate with the study (all in clinical trials) (see right hand 
side of Figure 23). 
Figure 23: screening records for CYP admitted to PIC and attendees at Research Facility (WTCRF) 
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Table 27 provides details of parent/ carer participants, with summarised details of their research and health care experience in Table 28.   
Table 27: recruited parent participant demographics  
Participant Gender Child's age 
(currently)
1
 
Level of 
experience 
PIC/ NIC 
experience 
Research 
experience
3 
Recruited from Screened by Interview location 
71 F 10& 12 3 Yes Yes WTCRF WTCRF WTCRF 
85 F 6 3 Yes Yes PIC / Cardiac Family liaison Home 
86 F 6 3 Yes No PIC / Cardiac PIC team BCH 
87 M 0.5 3 Yes No NIC/ Surgical day case PIC team Home 
89 F 1.5 3 No No Respiratory Specialist nurse Home 
92 F 6 3 Yes No PIC/ Cardiac PIC Home 
102 M 10 3 Yes No PIC/ Burns Specialist nurse WTCRF 
105A
2
 F 10 3 Yes Yes PIC/ Renal PIC Home 
105B
2
 M 10 3 Yes Yes PIC/ Renal PIC Home 
107 M 10 3 Yes No PIC/ Renal PIC Home 
108 F 5&1.5 2 No No Surgical day case/ A&E Family liaison WTCRF 
109 F 4 3 Yes Yes PIC PIC WTCRF 
111 F 7 3 No Yes WTCRF WTCRF WTCRF 
113 F 16 & 14 3 Yes No PIC/ Cardiac Family liaison WTCRF 
114 F 4 3 Yes Yes PIC Family liaison Home 
115 F 7 3 No Yes WTCRF WTCRF WTCRF 
121 M 4 3 Yes Yes PIC/ Cardiac PIC WTCRF 
122 F 7 3 Yes Yes PIC/ Cardiac PIC WTCRF 
1
Child’s current age.  For many their first point of contact with BCH was when the child was a new-born so they had been service users for a number of years.
  
2 
Married couple- interviewed together  
3
Level of experience- 2= experience of outpatients / ED, 3= experience as an inpatient 
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Table 28: summary of parent participant demographics 
Participants 18- Mothers (13) Fathers (5) 
Hospital 
experience 
17 participants had experienced an inpatient stay in hospital with their child.  
12 PIC/ HDU / NIC admission with their child (2 at other sites) 
1 ED/ outpatient visits 
Research 
experience 
Participated in a research study (10) 
WTCRF (3) (rare diseases with PK sampling) 
PIC (6): 4 (observational studies), 1 (genetic study with blood sampling) 1(RCT with blood 
samples) 
Neonatal care setting (1) (genetic study with blood sampling) 
Recruited parents / carers varied in the age of their child at the time of the interview (0.5-16 
years) and their child’s diagnosis (although there was a high proportion of parents of 
children with congenital heart disease, reflecting that 50% of PIC admissions are for heart 
surgery).  17/18 (94%) had experience of an inpatient admission to hospital with their child, 
compared with 13/26 (50%) of CYP.    
With limited resources, the focus was placed on screening for CYP as this was recognised as 
being the more challenging group to recruit to.  The PIC Research team screened for families 
where it was appropriate to consider a home visit on grounds of distance, child’s prognosis 
and lone working for the researcher.  See Figure 24 below for a summary of recruitment. 
Figure 24: screening and recruitment records for parents (2013-2014) 
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6.3.2 Themes 
There were six key themes identified within participants’ responses, reflecting the journey 
of the patient and their family through the research process see Figure 25  below.  Running 
throughout these was the influence of context at the local level, the wider organisational 
level and beyond.  This reflected aspects identified within the I-PARIHS model (Harvey and 
Kitson, 2016).   
Figure 25: thematic analysis results: core themes 
   
                                                    
Attitudes towards PK research are highlighted first. Then within each theme problems or 
barriers to conducting PK research and factors which enabled or facilitated conduct were 
identified.  Barriers are discussed first with facilitators summarised at the end of each 
theme. As facilitators could address a number of barriers there was some cross-referencing. 
Quotes from CYP are cited as CYP- then individual study number. If this was conducted as 
part of a FG there is an additional letter to differentiate participants. Parents are cited as P-
individual study number.   
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6.3.3 Attitudes towards PK research 
6.3.3.1 Parents’/ carers’ attitudes 
Parents and carers attitudes reflected the influence of multiple factors during their 
assessment of the risks and benefits of participation (see Table 29 below).   
Table 29: summary of influential factors on parents’ attitudes towards PK research  
Positive comments (50%) Negative comments (50%) 
 Nature of the disease 
 Experience/expertise (chronic 
illness) 
 Group affinity 
 Act in best interests of child 
 
 Vulnerability /fear 
 Health status 
 ‘Experimentation’ 
 Study requirement  
 Child with communication/ comprehension 
difficulties 
Positivity towards PK research was particularly evident from families with experience of a 
child with a rare disease, in situations where there were few treatment choices and best 
interests were therefore felt to be clearer or where families felt an affinity to a community 
of children with a chronic disease:     
“I think in our case we would because we would already have had the background 
of knowing that they’d got a rare condition that there wasn’t a treatment for, so 
we would already have had the mindset of promoting research really.” (P-71) 
Concerns about PK research tended to focus on the requirements of a protocol and the 
impact of this for the individual CYP.  This was of particular concern when the CYP was 
acutely unwell: 
 “...however pro-research you are, it becomes difficult when it is your own child, 
which is terrible to say; that’s my baby... I think it is a big issue.” (P-86) 
It was also an issue for families of a child with communication or comprehension difficulties. 
There were comments from such families that preparing for and managing routine 
investigations / health monitoring was already challenging, without additional burdens from 
research: 
“My son is not going to tolerate anything- he’s autistic, he’s very stuck in his 
ways.  He doesn’t communicate or talk... he hates anything new… he won’t sit still 
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for long, he gets distressed, he gets sick... and he doesn’t like pain, he doesn’t like 
anything with needles...” (P-107) 
Some parents reported that there was stress about the uncertainty research raised; both 
from decision-making about whether to participate, but also from the realisation that 
Doctors did not have all the answers to managing their child’s condition 
 “I understand that my daughter wouldn’t be here if it wasn’t for people in the 
past that have progressed, so that’s where you're caught.  Totally, you have to do 
this.  You have to it, but I'm just saying as a parent, it is extra stress.  It’s extra 
stress because you don’t know if you're doing the right thing” (P-121) 
Overall parents’ attitudes reflected a risk: benefits assessment about participation of their 
child in PK research. Most were willing to consider participation (see 6.3.8.2.3) 
6.3.3.2 Children’s attitudes  
CYP were less focused on risk: benefit analysis about PK research than parents and instead 
focused on aspects influencing their decision-making (see section 6.3.4.1 below).  CYP 
appeared to think more positively about PK research with increasing age, with increased 
experience of health care and when they had expertise in the management of chronic 
health conditions. There were also comments about the positive attitude towards research 
held by those with chronic health conditions or who felt affiliated to a ‘group’ (See Table 30 
below).   
Table 30: summary of CYP attitudes towards PK research 
Positive comments (58%) Negative comments (42%) 
 Age 
 Experience/ expertise 
 Identify with a group 
 Vulnerability / fear 
 Age 
 Health status 
Negative comments reflected that being older and more experienced did not necessarily 
equate to increased receptivity to research, particularly in the context of being acutely 
unwell. Understanding and comprehension about PK research could be challenging for CYP, 
particularly the rationale for additional unpleasant procedures.  
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Overall CYP appeared to be supportive of PK research, particularly amongst those who feel 
they have benefited from other’s participating in research and were willing to consider 
participation in a PK study (see section 6.3.8.2.3).   
6.3.4 Recruitment                                            
The recruitment process was by far the most discussed aspect of PK research conduct 
amongst CYP and parents. Within this sub-theme many discussions focused on factors 
influencing the decision-making process. 
6.3.4.1 Decision-making about participation in PK research 
Overall there was a high level of congruence between CYP and parents, with 5 / 6 sub-
themes the same (see Figure 26 below). Where the groups differed was the focus of parents 
on the influence of novel treatments, the value of personal benefit and the emphasis CYP 
placed on joint decision-making.  
1. Helping others 
Overall both sets of participants were supportive of the idea of taking part in research which 
would help improve care for others in the future:   
“Because I’d want to think that people are getting the same support as me or 
even better support, being able to get the right medicines and all that because it’s 
not fair when children are ill, especially at such a young age” (C-104)  
Some accepted that involvement might not bring any personal benefit, but this was 
acceptable as long as there was none - minimal pain or inconvenience to the CYP.  Others 
would consider participation, even when this involved extra blood samples: 
“All these samples... all these studies eventually join up into a bigger picture... 
and that’s how you’ve got to sell it... “yes, your blood sample, it’s not going to 
change the world, but it’s going a long way towards it, without yours it’s one 
less.” (P-107) 
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Figure 26: number &distribution of comments made by CYP & parents about decision-making (DM) 
 
The degree of altruism therefore varied and where participants made negative comments, these tended to reflect inconvenience or discomfort 
to the child: 
 “I know people do want to try and help in those situations but I mean when you're in that specific situation. You’re not really thinking 
about other children, you're just trying to focus on your own child” (C-82H) 
2. Pain and distress 
For both CYP and parents the idea of pain and distress was hugely influential when considering participation.  Both CYP and parents 
highlighted the stress and upset having a cannula sited or having a blood test taken could bring: 
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“I would never, I don't do blood tests unless they're absolutely necessary.  I won't 
take part in any trial or anything like that.  I'd love to you know, have the 
confidence to do it but I've got a fear of needles and I can't take an injection or 
you know, or do a blood test, I can't do it...” (C-82B). 
“Yes, he gets very distressed with having cannulas put in and I mean every visit 
that we have to the hospital, he always says, “Mummy, have I got to have a 
cannula?”  Even for a check-up” (P-92) 
If the study involved additional painful procedures which were not clinically indicated many 
felt this was too much and stated this would influence them to say no.  However, if the child 
was sedated and had good pain management or already had lines in place for sampling then 
additional sampling was regarded as more acceptable: 
“And if he was on morphine or something, or strong drugs, then he wouldn’t 
really have been too aware of it happening and I would say yes, they could put 
another cannula in to take the bloods.” (P-92) 
3. Personal benefit  
There were a large number of comments from 13 parents about the motivating influence to 
participate in PK research if there was personal benefit for their child.   Most viewed this 
participation as an enhanced form of care or an extra level of reassurance:  
“We want to make sure he has the best antibiotics or the best pain relief possible 
and if to achieve that... we have to measure blood levels, fine.  It's making sure 
that he gets the absolute best.” (P-102) 
10 CYP acknowledged that they would be motivated to take part in research to benefit their 
own care, of which six were in a clinical trial at the time of the interview.  However overall 
there were fewer comments from CYP reflecting the personal benefits of participation, 
suggesting that personal benefit was not the most motivating factor for them.   
4. Age of the child 
Both CYP and parents commented on the influence of age on decision-making about 
whether to participate or not. Despite concerns about the involvement of infants, there was 
recognition from participants (both groups) that conducting PK research with infants could 
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be ‘easier’ as they had less anticipatory anxiety, less understanding of what was taking place 
and also would not remember procedures such as blood sampling: 
“If anything, babies are the easier ones to do the study on… because the older 
ones have more objections. “(P-109) 
Participants were not specifically asked at what age they felt CYP could join in with decision-
making process, but many did suggest or debate ages.  Suggestions from CYP ranged from 6-
11 years and parents ranged from age 5 - 16 years of age, although there was widespread 
recognition that this would vary according to the individuals concerned.  Age could serve as 
a guide but ultimately much would depend on the individual child and family: 
“I could have signed up for either of my children but I know they would have 
responded differently and so for one child, I could see that I would have gone 
through with it but for another, it would have been more difficult to stick with 
that” (P-86)  
5. Involve CYP  
The main area the two groups differed on was the relative prioritisation of joint decision-
making with the CYP; this was the 3rd most commented on aspect for CYP and the 9th for 
parents.  21 CYP (81%) made reference to the fact that CYP should be involved in decision 
making about participation in research and should be asked directly wherever possible: 
“If they were asleep or ill, I'd probably like wait until they were like better or 
woken up so then they could... know what they were going to be going through. 
You need to get their opinion, instead of the parents' opinions because you don't 
know if they want to do it or not” (C-75A) 
6. Health Status 
A number of comments reflected the influence of the child’s health status at the time of 
being eligible for research.  Parents’ concerns tended to focus on the invasiveness or 
relevance of the study to the CYP current condition.  CYP focused in on more specific 
aspects of health and wellbeing such as feeling ill, feeling tired and the influence of 
medications on an ability to make decisions: 
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“Not really because you are not in the best state of mind, kind of, you just want 
some privacy and to be left alone.” (C-56B) 
These were the main themes influencing CYP. For parents, other influences such as ‘novel 
treatments’, uncertainty, time, experience, the prioritisation of the child were identified, 
however these were in smaller numbers.   
6.3.4.2 Barriers to recruitment 
Overall the biggest barriers to decision-making about PK study participation from CYP and 
parents’ perspective were pain and distress, the age of the child and their health status at 
the time of approach.  In addition, other barriers / issues were identified during discussions 
surrounding recruitment (see Table 31 below for a summary of barriers and facilitators). 
Table 31: summary of barriers and facilitators to recruitment (CYP and parents) 
 Barriers Facilitators 
R
ec
ru
it
m
en
t 
‘Vulnerable’ individuals  Having a choice 
 Personal benefit 
 Helping others 
 Levels made available for care1 
 No additional samples / sampling procedures 
 
Severity of health status Deferred consent
1 
Pain / distress  Analgesia 
 Use of indwelling lines for sampling2 
 
Age: both younger and older  Appropriate communication 
 Personal benefit 
 Involve CYP 
Communication/ comprehension difficulties  Preparation 
 Communication 
 ‘The approach’ 
 Support joint decision-making 
Extra appointments 
Missing school 
Missing work 
Travel and parking  
Reduce impact for individuals 
o ‘Piggy backed’ appointments 
o Flexibility 
o Home visits 
1 
Discussed in 6.3.4.3.9, 
2 
Discussed in 6.3.6.2  
6.3.4.2.1 Vulnerable study participants 
Both CYP and parents were mostly positive (62% of CYP, 89% of parents) about being 
inclusive about who was approached to participate in PK research, recognising the need to 
include different types of people in PK research: 
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 “...the way I look at it is the disease or whatever, that’s not going to choose 
which age group to affect, so you’re going to have to test the medication in all 
ages.” (P-105B) 
However, there were concerns about patients they felt were ‘vulnerable’; in particular 
infants (CYP) and those on palliative care pathways (CYP and parents). These 3 sub-themes 
are identified in Figure 27. Positively themed comments about their inclusion are 
summarised on the left and negatively-themed comments to the right.   
Figure 27: summary CYP & Parents attitudes towards PK study participants 
 
Concerns about infants reflected their perceived vulnerability, their limited communication 
capabilities and the ethical difficulties associated with being unable to involve them in 
decision-making:   
“It’s hard to ask for a baby (agreement from all). It is all right if they’re older and 
you can ask them as well as their parents but obviously, the babies, you can’t.  
And then you don’t understand the pain that they’re going through because they 
can’t speak.” (C-117D) 
There were also some concerns about inviting patients on a palliative pathway to participate 
because of a lack of personal benefit and a concern about adding burden or distress: 
“I would say if you know the wee child is not going to make it the last thing that 
parents need is to think of their kid as a lab guinea pig... respect the child” (P-121) 
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6.3.4.2.2 Hospital appointments 
The subject of hospital appointments specifically for research yielded a high number of 
comments from CYP and parents which were felt to influence decision-making (Figure 28). 
Figure 28: CYP and parents’ attitudes towards research appointments 
 
Overall extra appointments were viewed negatively by parents, particularly those whose 
children who already required multiple attendances at hospital. Responses ranged from 
classifying these as inconvenient to annoying, disruptive and time consuming:   
 “I think it’d be incredibly hard dealing with the whole extra hospital visits.  It’s 
hard enough being on a trial and having *’s other hospital appointments at 
<names another tertiary children’s hospital>... It’s draining.  It’s not just a five-
minute appointment...  Generally, it’s a whole day, which is time consuming and 
quite hard.” (P-115) 
Parents of children with chronic conditions recognised that a certain amount of school 
would be missed. However, there were thresholds of acceptability and extra visits posed a 
problem: 
“...she's in year 6 and she starts secondary school in September, and she's lost a 
lot of school already so that would be a concern for me” (P-105B) 
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Although CYP were less negatively opinionated than parents about the idea of extra visits, 
they became more concerned if attendance required them to miss school.  There were 52 
comments by 20 CYP identifying the importance of education, particularly for children who 
had to attend hospital regularly. The issue also increased in significance as pupils progressed 
through school, with CYP identifying the challenges of catching up on lessons missed:  
“I used to love missing school for my appointments.  I used to drag it on, ask 
pointless questions [laughter] but now, I try and get in and out because I can't 
catch up otherwise.” (C-82B) 
Parents were also extremely concerned about missing work to attend hospital 
appointments with their child and there were accounts of parents stopping work due to the 
amount of appointments some families were required to attend.  There were also 
comments about the need to prioritise appointments and although managers were 
sympathetic to parents’ situations there was a finite limit to how much time could be taken 
off work: 
“...if it was an essential appointment you get time off work but I don’t think your 
managers will be happy if it is just for research purposes. Sorry!” (P-109) 
Parents were also extremely concerned about the travel and parking associated with 
attending a hospital appointment: 
 “For us it is a nightmare because we live in *.  To drive it is an absolute bloody 
nightmare, quite honestly.  You know all the way in, where am I going to park?  
Will I get a parking space?  How much is this going to cost me?  I’ve come here 
before and it costs me nearly £10 just to park the car for a few hours.  That’s a lot 
of money when it’s regular” (P-113)  
Offering to reimburse parking or travel expenses to compensate for extra research 
requirements was felt by some to assist with this, however, for many the message was 
clearly that research alone would not be sufficient motivation to have to attend for more 
appointments.   
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6.3.4.2.3 Summary barriers to recruitment 
In summary, there were many issues surrounding recruitment to PK research for CYP and 
parents. Decision-making was felt to be negatively influenced by the potential for pain and 
upset to the child and the requirement to make decisions at a time of deteriorating health 
status. Both groups were concerned about vulnerable populations, with CYP concerned 
most about the inclusion of infants and parents most concerned about palliative patients. 
Both groups felt additional hospital appointments were problematic, particularly missing 
school and parents also commented on the problems of missing work and the challenges of 
travel.   
6.3.4.3 Facilitators surrounding recruitment 
Facilitators identified by CYP and parents are discussed below.  
6.3.4.3.1 Having a choice  
Despite concerns about the inclusion of infants and palliative patients deemed vulnerable, 
very few participants made generalisations about their exclusion from research.  Many felt 
families valued having a choice and the opportunity to contribute to future health care as 
well as the potential for personal benefit, such as improved pain management. There were 
also comparisons to that of organ donation; recognising that conversations about donation, 
whilst extremely difficult, are now recognised as accepted practice. Over time, being 
approached about research could also be normalised and become more acceptable:  
 “...like when you do organ donors… there are questions that are going to be 
asked.  Their child’s too poorly and they’ve done everything they can so you have 
to ask about organs, don’t you?  It is the same as asking about organs.” (P-107) 
6.3.4.3.2 Emphasise the benefit of participation (personal /for others) 
CYP and parents highlighted the importance of offering some form of personal benefit or 
enhanced level of care for the child from participation:  
 
 
157 
 
“I think people are more likely to agree to taking part in the studies if they see a 
benefit to them... an extra review afterwards... and review the bloods...  I don’t 
know why anybody would say no to that.” (P-114)  
 
This seemed to be a particular priority for parents. Both CYP and parents were also highly 
motivated by altruism.  If a study could outline the impact of research for other CYP and 
families many participants felt this was a motivational factor, even for young CYP: 
“I think all children understand the concept of helping other people... If we said 
this is going to make you a little bit uncomfortable now but it will help lots of 
other children, I think even from a young age they could understand that...” (P-
71)  
6.3.4.3.3 Communication and ‘the approach’ 
Communication is fundamental for all aspects of care, but parents specifically highlighted 
the importance of getting the level and depth of communication about research right to aid 
decision making about participation. This took the form of both verbal and written 
communication in simple and easy to understand formats:  
 “You give them the leaflet, this is what you’re signing up for, parents know if they 
can commit to 18 hours of sitting around in hospitals, or they can’t” (P-107) 
There was also specific reference to the importance of the initial contact with families about 
a PK research study.  These highlighted that it was not just what was said but also the timing 
and sensitively of the approach: 
“Yes.  I think it is in the manner it’s done and the timing.  That’s the big thing, 
when is the right time to approach the parents and ask them really?  I think once 
you’ve got that balance, you’re more likely to get parents’ consent.” (P-108) 
Crucial factors related to the personal skills of the researcher and their ability to interpret 
the situation.  Key elements are listed in Table 32 below.   
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Table 32: ‘the approach’: influential personal skills and situational factors  
‘The Approach' 
Personal skills Situation 
Trustworthy Timing 
Courteous ID badge 
Personable Clear role 
Clear explanations Relationship with clinical team 
Tactful Visible liaison with clinical team 
Correct ‘pitch’  
Receptive  
Sensitive  
Provision of appropriate information  
(from 16 parent participants) 
6.3.4.3.4 Involvement of significant people 
Recognising that CYP were extremely concerned about being excluded from decision-
making about research, a key facilitating factor was to ensure that involvement of CYP was a 
priority for researchers:   
“I’d be a bit annoyed... I know that you’re only doing it for the best but I’d be like 
“Why are you taking things from me?” ...  I know I’m in a state at the moment 
and like I could die...  But then at the end of the day it’s my personal information, 
you know?” (C-104) 
Parents also recognised the importance of facilitating the CYP’s involvement to make shared 
decisions with them (although less so than the CYP themselves), but they also wanted to 
consider shared decision-making with spouses/partners.  They highlighted that making 
decisions about research was challenging and the consent process needed to involve other 
people deemed important to the parent with parental responsibility.  
6.3.4.3.5 Preparation 
Parents felt that informing people as early as possible about the PK research taking place 
would help to prepare and support them with decision-making. This extended to preparing 
families prior to their admission, particularly for those having elective surgery:  
“...if his operation was in 3 months’ time, and this information came through in 
the envelope with the appointment letter and it gave me the option to have a 
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think about it, read about it and do some research into the research study, then 
yes, it is definitely something that would be helpful to me.” (P-87) 
Parents recognised that this information might not be thoroughly ingested if it was 
perceived not to be relevant, however it might help at least prepare families for being 
approached about a research study.  Some parents also highlighted the value of other 
sources of information to help families make decisions, such as websites featuring accounts 
from other families: 
“That would help me immensely because if I was willing to take part in the 
research. it would be good for me to go on to a website and just have a look at 
what other people’s experiences are and it might help me make my decision that 
bit quicker.” (P-87) 
6.3.4.3.6 Analgesia and distraction techniques 
Recognising the negative influence of anticipated pain, CYP and parents recommended the 
usage of topical analgesia to reduce pain. Provision for local analgesia should be 
incorporated within a study protocol to help address anxieties associated with procedural 
pain.     Seven parents also made reference to the use of distraction and play therapy to help 
their child to cope with procedures required for routine hospital care: 
“the play specialists were fantastic.  Absolutely fantastic...  They play a very 
important part, they really do.  Because once we got over that, it was plain 
sailing.” (P-113) 
This suggests that play therapy and distraction techniques could play a role in facilitating 
patient and family engagement with research.    
6.3.4.3.7 Reassurance about safety 
Confidence in the safety of a study is fundamental for CYP and parents.  Parents identified 
that if research and clinical teams had a good relationship and could be seen working 
together this was viewed positively: 
 “If the doctors on the round says we spoke and it seemed to be more of a team 
affair rather than just a lone person walking around doing things then that would 
be good.” (P-109) 
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Seven CYP and thirteen parents reported that guidelines which referenced acceptable blood 
sampling volumes would provide reassurance that a trial was safe and therefore increase 
their likelihood of participation:  
 “...if they said well yes, these are the national standards or the agreed limits for 
taking blood from children and this is within that range, then that would give you 
a bit more confidence.” (P-71) 
However, there was a recognition this should still be reviewed for each individual CYP, to 
ensure their individual situation was considered.    
“…at the end of the day, they're only guidelines, they're not applied to every... 
individual person.  It says there's a certain number of units of alcohol you can 
have before you drive, but I would never have any alcohol before I drive...  So 
<reference to guidelines> wouldn't give me any confidence whatsoever” (C-82B).   
6.3.4.3.8 Avoid / combine research appointments 
Extra hospital visits, travel and parking expenses, missing school and missing work were 
significant issues for CYP and particularly parents, even those strongly supportive of 
research.   Facilitation measures therefore need to reduce the impact for the individual and 
their family. See Figure 29 below for a summary of participants’ views on different 
approaches.   From these the top three preferences for each group were compiled after 
ranking the percentage of positive to negative comments. These are summarised in Table 
33.   
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Figure 29: CYP (L) and parents’ (R) perspectives on alternative approaches to research appointments 
 
Table 33: top 3 preferences for research appointments (CYP & Parent) 
CYP Parents 
1. Piggy backed to clinical care 1. After school 
2. Weekends 2. Piggy backed to clinical care 
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1. ‘Piggy backed’ research 
Overall the concept of adding research appointments to routine clinic appointments was 
viewed extremely positively. 100% CYP (n=13) and 90% parents (n=10) supported the 
approach: 
 “I think you could arrange it so it coincides with another appointment that you 
already have.  So, you’re not missing any more school, then that might be better” 
(C-117A).   
2. Flexibility with appointments 
Weekend appointments were the second most positively viewed approach by CYP and after-
school appointments the second most positively viewed by parents.  Although the groups 
differed slightly in their preferences, the rationale for both was to avoid missing school,  
therefore, flexibility in appointments appeared to be the key message.  
3. Home visits 
Eight CYP and eleven parents were supportive of the idea of home visits from research staff, 
based on rationale that this was better for the individual and offered enhanced privacy.  
However, this was not universally popular, particularly from a safety perspective:  
“I’d feel safer in the hospital because I know then you’ve got intensive care 
upstairs so you could just go there if anything happens. Whereas here, you’ve got 
to get the ambulance and if anything, is to go wrong, it could be life 
threatening…” (C-104) 
 
6.3.4.3.9 Consider different approaches to traditional PK approaches 
In order to overcome some of the issues and concerns raised, alternative approaches from 
the PK literature were discussed.  Figure 30 below summarises both groups’ attitudes 
towards a number of these, with Table 34 summarising the top four approaches.  Overall 
the groups rated the approaches very similarly and were relatively positive to all alternative 
methods.   
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Figure 30: alternative approaches to traditional PK studies (CYP and parent)    
 
Table 34: summary: alternative approaches to PK studies (CYP & parent)  
CYP Parents 
1. Opportunistic sampling / Levels available for routine care  1. Levels available for routine care 
2. Scavenged samples 2. Other bodily fluids 
3. Deferred consent 3.  Scavenged samples 
4. Other bodily fluids 4. Opportunistic sampling 
 
 
 
 
164 
 
1. ‘Research’ levels made available for clinical care 
CYP and parents felt that if PK measurements were taken for research care, these should be 
made available for clinicians managing their clinical care, particularly if this was not normally 
available.    Although there were not large numbers of comments about this approach, there 
were no negative comments about this approach:   
“So, you just say look, this is the graph of the results we took... and it shows you... 
the pain he was in, this shows what drug he had and what happens as he came 
off... And it's kind of like, if the results are there available in their notes to use... to 
say this is the results we've got that helps.” (P-102) 
2. Opportunistic sampling  
Opportunistic sampling, or sampling alongside clinically indicated bloods, did not receive 
any negative feedback from CYP and overall was rated positively by 8 CYP and 9 parents:   
“Yes, that would definitely be better because then you have less chance of 
infection.  Because infection control is very important. * did actually get an 
infection from the line that he had put into him.” (P-87) 
Negative comments reflected a concern that it must be clear what the samples were being 
taken for, as well as recognising that these were still in addition to clinically indicated bloods 
and therefore still had the potential to lead to anaemia.   
3. Scavenged samples 
Overall the use of ‘leftover’ samples rated highly amongst parents and CYP.  Participants 
liked the idea of avoiding waste of samples which had already been taken for routine 
purposes:  
“Yes, I think you should.  I think if it is already out, you may as well use it for other 
things.” (C-56B) 
Concerns related to why there was any excess blood to be able to measure levels from.  
Participants felt this could create some concerns and uncertainty for CYP and families: 
“I think some parents might be a bit sceptical I guess, “Did you do that on 
purpose?”” (P-108) 
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4. Other bodily fluids 
The use of saliva or urine instead of blood was another popular alternative approach, with 
74% of CYP comments and 93% of parents’ comments positive to the idea.  It was regarded 
as easier, less painful and a productive use of a waste product: 
“I think I’d rather go to the toilet than have something stuck in me” (C-82A) 
 Negative comments related to the difficulty of obtaining time specific samples, the issue of 
children who cannot void on demand, issues related to embarrassment as well as some of 
the practicalities associated with obtaining samples: 
 “But then some people don’t know like weeing into a pot, ‘cos I don’t. It’s hard. 
Particularly if you’re a girl!” (C-104) 
5. Deferred consent 
Within both CYP and parents there was some support for the idea of deferred consent.  
Those that spoke positively recognised that admission to PIC was an extremely stressful 
time and appreciated the fact this method would not delay treatment or require them to 
make a decision about research immediately: 
“I think when your anxieties are very high and you are not sure what is 
happening, you are so out of control aren’t you? All you can think about is your 
child and their safety and their health, so I think like you say, when it has calmed 
down it is a very different kettle of fish isn’t it, because your anxieties pass, you 
can think more rationally.” (P-85) 
CYP and parents who were unsure about this approach were those who felt strongly that 
they should be able to consent to everything being done to their child before it was done, 
rather than afterwards: 
 “I think for most parents the issue would be with taking it in the first place, not 
the using it.” (P-71) 
Overall approaches which avoided additional blood sampling, made use of samples already 
taken or were perceived to offer an enhanced level of care were the most valued by CYP 
and parents.   
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6.3.4.3.10 Summary of facilitators 
Appropriate communication, preparation and consideration of ‘the approach’ by research 
professionals have all been identified as positively enhancing the recruitment process.  The 
optimum study design would offer some form of personal benefit to participation as well as 
a clear outline of how this will benefit other CYP in the future.  Addressing these factors 
would help to mediate concerns about vulnerable populations.  Ideally, additional painful 
procedures are avoided, taken alongside clinically indicated samples or utilise leftover 
samples. Alternatively, procedures are undertaken whilst receiving analgesia and the use of 
distraction and play therapy is recommended.  Researchers need to facilitate the 
involvement of significant others in decision-making about research, including CYP.  To 
reduce the burden of research, researchers need to minimise or avoid additional hospital 
appointments through ‘piggy-backing’ them to clinically indicated appointments or offering 
flexibility in their timing.  
6.3.5 Medication 
6.3.5.1 Barriers/ challenges with medicines 
Taking a medication in a prescribed manner is a key aspect of a PK study. Despite only 11/ 
26 of CYP reporting being on medications at the time of the interview, 18/26 (69%) CYP and 
13/18 (72%) of parents identified issues surrounding the administration of medicines to 
children, (see Table 35 below). 
Table 35: summary of barriers and facilitators associated with medications (CYP & parents) 
  Barriers Facilitators 
Medications Administration 
Tablets 
Palatability  
Changing meds for research purposes 
 Check individual preferences 
                                                                     
Problems related to being able to take medicines in the form dispensed, knowing what to do 
if the CYP vomited as well as difficulties obtaining prescriptions:   
 
 
167 
 
“when we went to the chemist, the pharmacy to get the renewal prescription, 
they wouldn’t give it to us because the steroids were... the dosages were more 
than an adult would have. And they actually had to query it and had to double 
check it before they would give it to us.” (P-113) 
Both groups recognised that taking tablets and the palatability of medicines were significant 
issues (see Figure 31 below), with 80% of parents asked (12/15) highlighting concerns.   Even 
parents of adolescents cited examples of their children struggling to take them:  
“Get him to swallow something whole?  No.  No chance.” (P-102. Parent of a 12-
year-old) 
This was confirmed by adolescent participants themselves:  
“...I physically can't swallow a big tablet.  I just literally regurgitate. I’m not 
scared of taking tablets, I just can’t swallow them.  I’m such a baby” (C-117B, 
aged 15 years).  
Where palatability was discussed (9/26 CYP and 10/18 parents) it was identified as a 
significant issue (67% of CYP and 80% of parents):   
“It tasted like strawberries mixed in with poison” (C-75A discussing 
Benzylpenicillin) 
This would be an issue for participants in future PK studies, particularly if a study involved a 
new preparation which had not conducted consultation over taste, colour and smell. 
Despite issues identified with medications, there was some reluctance amongst participants 
to change medications for a research study: 
“I think I’d want figures, to be honest.  I think I’d be more protective from now on 
just because of what he’s been through really.  I don’t like the idea of new drugs 
being tested.  Old drugs with different doses, change in the dosage, I wouldn’t be 
so alarmed about really.  Definitely a new drug, I’d be a bit apprehensive.” (P-
122) 
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Figure 31: experiences and attitudes towards medications (CYP & parent) 
 
6.3.5.2 Facilitators associated with medications 
The main facilitator identified from participants’ responses was to engage with CYP and their families about medications before embarking on 
a research project.   Studies need to address medications which actually pose an issue for CYP and also ensure that the proposed alternatives 
are available in appropriate, palatable formulations. 
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6.3.6 Sampling 
Participants made many comments about issues surrounding sampling for PK studies. 
Barriers and facilitators are summarised in Table 36 below.  
Table 36: summary of barriers and facilitators related to sampling (CYP & parents) 
 Barriers Facilitators 
Sampling Capillary 
Cannulas 
Use of indwelling lines  
 
Blood volumes  
Frequency 
Sampling regime 
 Guidelines for safe volumes1 
 Engagement with clinical teams1 
 Consider alternative methods to reduce sample 
volume and number
2
-  
o opportunistic sampling 
o scavenged samples 
o other bodily fluids 
 
1
See 6.3.4.3.7  
2 
See 6.3.4.3.9 
6.3.6.1 Barriers / challenges to sampling  
6.3.6.1.1 Vascular access 
Within the vignette different types of vascular access were discussed and compared.  These 
included arterial lines, Central Venous Lines (CVL) and peripheral vascular access devices- 
cannula and capillary samples (see Figure 32 below). 
Figure 32: CYP and parents’ attitudes towards vascular access 
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Overall capillary sampling, was unpopular with both groups.  Negative comments reflected 
the side effects of the capillary sampling procedure, such as scarring and the distress 
associated with handling, pain and the squeezing action required:  
“...you can still feel the scars, or still see the scars on his heels now.  He had quite 
a few as you can imagine.” (P-87; son was admitted to NICU as a new born) 
Sampling from a cannula was even more unpopular.  Both groups commented that cannulas 
were painful, restrictive and also a source of distress for the CYP:   
 “…if you’ve got a cannula in the back of your hand… it’s no good the nurse saying, 
“It can’t be hurting you, it doesn’t hurt.”  Or, “It’s only plastic.  It’s not a needle in 
your arm.  It’s only a little bit of plastic.”  It’s something alien to you, isn’t it?” (P-
113) 
There were also specific challenges to cannulation related to individual’s anatomy and 
physiology, particularly those with a chronic condition or rare disease, such as smaller 
vessels, thickened skin or saturated skin secondary to renal failure. Both CYP and parents 
were cautious about who could undertake these tasks, recognising the additional challenges 
these features posed:  
“The problem is I must have about three good veins in my body and that’s it. 
Hopefully I’ll be able to use that one there because I’ve got one there and one 
there (gestures location of veins) but they’re really hard to find” (C-104) 
“you need someone who is very experienced at doing it... I have found in the past 
that it helps if it is the same person doing it every week because with their 
particular condition, their veins are a bit small and a bit wiggly and that makes it 
even harder. If you have got someone coming in as a one off, they are not going to 
have any previous knowledge of how easy or difficult it is to find a vein.” (P-71) 
6.3.6.1.2 Obtaining samples 
There were a large number of comments relating to ‘obtaining samples’, with three sub-
themes:  blood volume, frequency and the sampling regime (see Figure 33 below).  The 
volume of blood being sampled was the most commented on aspect by both groups; 
although parents tended to be more positive about the issue of blood volume than CYP.  
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Concerns (mostly from CYP) focused on safety, the impact of blood sampling, as well as the 
associated discomfort:   
“They filled up five bottles from one arm on my blood test...  I was there for like a 
good minute and that minute feels like, ages.  You want to be over and done with 
not like sit there for five minutes pulling blood out” (C-82B). 
Figure 33: CYP and parent perspectives on study sampling requirements 
 
 
Although the number of blood samples being taken did not appear to be a large concern for 
most participants, comments were predominantly negative.  These reflected concerns about 
the number of occasions the CYP would be approached and the potential this gave for 
distress to the CYP: 
“If you were doing it when she was conscious and there was an ordeal attached to 
it, definitely less the better.” (P-114) 
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“if you came in and said I need to wake him up now to take that, I am not sure. I 
think my answer would depend on how the day had gone, because would I want 
you to wake him up if he had been awake for 6 hours? Possibly not.” (P-89) 
6.3.6.2 Facilitators associated with sampling  
In contrast to comments about accessing peripheral vascular access or conducting capillary 
samples participants were extremely positive about the concept of sampling from indwelling 
vascular access.  Arterial lines were viewed extremely positively by all participants with 15/ 
17 (88%) comments positive from CYP and 24 /25 (96%) comments positive from parents on 
their use.  CVLs were also popular- 34/41 (83%) positive comments from CYP and 35 /37 
(95%) positive comments from parents.  Positivity related to the fact that these devices were 
clinically indicated and there was no additional pain / discomfort involved in their 
placement: 
“...it is in, it is not going to hurt them when you are doing it, it is already 
established, so I kind of think why not?” (P-89) 
Several participants had port-a-cath’s (permanent venous access devices) in situ and the 
placement of these had been a huge improvement from both a parent and child perspective: 
 “So, you know, before we had ports, we used to have cannulas.   You know why 
we just changed to ports, because our veins … 
Our veins wouldn’t stand out” (C- 70A&B siblings discussing why they had port-a-
cath central lines inserted) 
As outlined in 6.3.4.3.9, different approaches which reduced the sampling volume, the 
frequency of sampling or meant there was flexibility in the sampling regime were valued. 
6.3.7 Processing    
Overall CYP and parents did not recognise there to be many areas of concern related to the 
processing and interpretation of results from PK studies. See Table 37 below.  
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Table 37: summary of barriers / facilitators to processing (CYP & parents) 
 Barriers Facilitators 
Processing Care taken with handling  
Documentation accuracy 
Adequate staffing (research or clinical) 
CYP reflected on the need for care with participants’ samples to avoid waste and repetition.  
 “Really annoyed.  So, I've also had like, they were taking, they dropped the blood.  
They actually dropped it on the tray and they had to take some more... They 
wouldn't like it if they had to do it.” (C-82E) 
Parents in contrast were concerned about the accuracy of documentation required for a PK 
study and whether this would be to the standards required:  
 “Without implicating people, you probably can see this going on, yes I should 
have been here at 1 o'clock but it's actually ten past one. Mmmm, that's 1 o'clock.  
“(P-102) 
The main factor identified by CYP and parents to avoid / address issues with processing and 
reduction in waste was adequacy of staffing.  With appropriate resources accuracy could be 
maintained.   
6.3.8 Outcomes 
6.3.8.1 Barriers / challenges associated with outcomes from PK research 
‘Outcomes’ was used to collate codes equating to results, outputs or consequences of PK 
research. Key barriers and facilitators are outlined Table 38 below. 
Table 38: summary of barriers and facilitators related to study outcomes (CYP & parents) 
 Barriers Facilitators 
Outcomes Increased staff workload  Research culture 
 Engage with clinical staff 
 Support from research staff   
 The right research design 
6.3.8.1.1 Increased staff workload 
Both CYP and parents had mixed feelings about the extent to which clinical nurses could be 
involved in research activities alongside clinical care. Although they were felt to be well-
placed to assist with research activities, there was a recognition that this was not feasible.   
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Negative comments reflected concerns over their ability to comply with research regimes 
and requirements and a concern over adding to their workload 
 “Yes, I don’t think they’d have the time or I think it would be delayed…I don’t 
think it would work at all.” (P-114) 
Both groups expressed concerns that this could diverting clinical staff away from key aspects 
of their job. The consequence being that not only could research conduct be compromised 
but clinical care could also suffer: 
 “Then you might think it might change your care.  She’s already got all these 
things to do and she’s got all these things to do for research.  It might put pressure 
on her and affect your care ‘cos she’s rushed” (C-117B) 
6.3.8.2 Facilitators associated with successful study completion 
6.3.8.2.1 Research engagement and support 
As identified in 6.3.4.3.7 engagement of research and clinical teams was regarded as 
essential at all stages of research conduct. CYP and parents were not concerned about 
additional people coming to the bedside to carry out research activity, provided there was 
clear communication about what they were there to do and how their role fitted alongside 
clinical care provision.  Some parents commented that this would actually be a reassurance 
and perceived this as offering a higher level of care: 
 “...actually, I’m getting a double whammy because the research nurses are still 
nurses and should anything, God forbid, happen, they’re not going to say. I’m 
going to stand back, I’m here for my research only … In an emergency situation, it 
doesn’t matter, they’re all going to work together” (P-108) 
6.3.8.2.2 Research culture 
Many participants referred to the importance of research to improve health care.  For some, 
this was related to a recognition that their child had benefited from previous research: 
“It has also been explained to me that 20 years ago, nothing could have been 
done for *, so if somebody hadn’t taken those first steps 20 years ago...  and still 
in some parts of the world, babies born small like * was with these issues, they 
would say it’s not possible.  And yet * is a living example that it is.” (P-86) 
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Others could see that innovative work and research had been going on even whilst their 
child had been a patient, which was altering contemporary care and management. They 
therefore felt they were benefiting from fellow patients.   Most people referred to research 
contributing to improvements for other CYP in the future: 
 “we wouldn't be where we are now without research.  So, my personal view is the 
only way to go forward is research and if we can help, then absolutely” (P-105B) 
There was even some recognition of the issues faced in prescribing and using medications 
for children with three parents commenting on the use of off-label and unlicensed 
medications: 
“most of *’s medication I noticed it says ‘unlicensed’ and that often makes me 
think, oh there’s not been research into that medication used on children.” (P-92) 
One child also reflected on a medication she was receiving and the concerns she felt about 
receiving it:  
“Yeah… I just know that it’s a highly toxic drug being administered.  That kind of 
makes you think, “Hang on a minute.  What are they injecting in to me?”  Is it life 
threatening?  It could be. If something went wrong with it or a wrong dose, this 
worries me a bit” (P-104) 
Understanding how care has been informed by previous research and how future care will 
be shaped was an important motivating factor for many CYP and parents. This information 
could be utilised to set the background and context to a PK study.  
6.3.8.2.3 The right research design 
Despite all the concerns raised throughout the interviews and focus groups, at the end of the 
session 18/22 CYP (82%) (4 CYP not specifically asked) and 17/18 parents (94%) said yes, 
they would consider participation in a PK study.  Only four people (3 CYP and 1 parent) 
specifically said ‘No’, and three would reconsider this if the tests could be done on an 
alternative sample such as urine or saliva or on blood that had already been taken:  
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“If the people came and said that we could use the blood that’s already been 
used, yes, 100% yes.” (P-121)  
This indicates that if a PK study is designed with CYP and parents’ involvement, recruitment 
and study retention can be addressed.  
In summary, there were high levels of support for research from both CYP and parents and 
this extends to consideration of PK research.  Successful retention of participants in a PK 
study could be facilitated by engagement with clinical staff and the provision of research 
support as well as a research design which allows for the utilisation of scavenged samples or 
non-blood sampling.   
6.3.9 Context  
6.3.9.1 Barriers/ problems with the context of research 
Participants made many comments reflecting the location or context of PK research conduct. 
(See Table 39 below for a summary of barriers / facilitators). 
Table 39: summary of barriers and facilitators to the context of research (CYP & parents) 
 Barriers Facilitators 
Context Wards  WTCRF
1
: outpatient basis 
 PIC: inpatient admission 
 Adequate staffing (research or clinical) 
1 Wellcome Trust Clinical Research Facility (WTCRF) 
 
Figure 34 below summarises attitudes from both participant groups towards PK research in 
different clinical areas. Conducting PK research within ward areas was clearly felt to be 
problematic with concerns reflecting the demands of the environment and the staffing 
ratios:   
“If you’ve got one nurse to four children, then that’s a bit difficult especially if one 
has to have extra treatment done.” (P-107) 
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Figure 34: CYP and parent attitudes towards the context of PK research 
 
 
6.3.9.2 Facilitators associated with context  
If a PK study was to be conducted on an outpatient basis, Wellcome Trust Clinical Research 
Facility (WTCRF) was felt by both CYP and parents to be a safe, appropriate place to do this: 
“I mean here it’s like they know exactly what they’re doing, when they have to do 
it”  
“Yeah, they know exactly how to look after you and what ways to do it in” 
(Exchange between Participants C-70C and C-70D) 
It is worth noting that this was conditional on activity being conducted within office hours as 
overnight stays for research purposes were extremely unpopular with CYP. Many CYP and 
parents felt that PK studies could be conducted on PIC as children would have analgesia and 
sampling would be facilitated due to the presence of arterial or CVL devices: 
“I think just do it in intensive care because it is the best time... And you’re not 
really too aware of what’s going on anyway, so it doesn’t really affect you in any 
way” (C-75B) 
In addition, the staffing ratios of one: one staff: patient ratios would facilitate the timely 
conduct of study requirements. There were comments about the vulnerability of families 
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and the immense pressure they are under, but overall there was support for PK research 
within the PIC context.  
6.4 Mapping to I-PARIHS 
Using the integrated PARIHS framework (I-PARIHS) (Harvey and Kitson, 2016) the key aspects 
for the ‘recipients’ -CYP and parent groups- have been mapped out in relation to the 
‘innovation’ PK research studies.  See Figure 35 and Figure 36 below.  
Figure 35: summary of CYP responses mapped to I-PARIHS 
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Figure 36: summary of parents’ responses mapped to I-PARIHS 
 
6.5 Discussion 
6.5.1 Decision-making 
There was a high level of congruence between the two participant groups about factors 
influencing decision making. The main motivation for both CYP and parents was altruism and 
to receive personal health benefits.   This is in keeping with a systematic review of adults 
with emergency medical conditions (Limkakeng et al., 2014), a qualitative meta-summary of 
research with CYP and their parents about participation (Tromp et al., 2016) and a 
systematic review of consent to clinical trials with pre-term or sick neonates (Wilman et al., 
2015); all of which highlight the top motivations for research participation as altruism and 
personal benefit.  Despite the fact many PK studies offer no possibility of personal benefit 
from participation participants in PRESCRIBE indicated that they would be willing to consider 
participation in research. This is similar to Wendler et al (2012) who reported 90.4% of 
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adolescents and 91.6% of parents were willing to allow extra blood to be taken, even when it 
was of no direct benefit and may even tolerate minimal risk   (Wendler and Jenkins, 2008). 
There is evidence that people can find meaning or benefit when researchers do not perceive 
there to be any.  Patients with chronic health conditions can feel motivated by a strong 
sense of belonging to a particular group that would benefit from the research (Pletsch and 
Stevens, 2001, Limkakeng et al., 2014).  In addition, individuals who have spent more time in 
research may have increased trust in researchers, increased comfort with research 
procedures and increased recognition of the value of research, so there may be gains which 
researchers themselves do not value (Wendler et al., 2012). Luchtenberg et al (2015) 
similarly found that there were subcategories to participation benefit, including 
improvement in dealing with their disease, getting closer attention and monitoring as well as 
learning about themselves and gaining confidence in managing their disease.   PRESCRIBE 
provides evidence that CYP and parents will consider participation in paediatric PK research 
studies, motivated for personal benefit and to help others. This is consistent with literature 
that exists surrounding CYP participation in other types of research.   
6.5.2 Consent rates 
Two studies have explored the experiences of children with cancer participating in optional 
non-therapeutic studies, where patients will not benefit directly from inclusion. These 
studies were PK (Berg et al., 2010) and PK and pharmacogenetic (Errington et al., 2016).  
Both report high levels of altruism to help others and to help researchers learn more about 
the drug, with Berg et al (2010) reporting a consent rate to PK studies of 72%.  Errington et al 
(2016) explored attitudes from 100 patients but it was unclear what the overall consent rate 
was.  Participation rates to the theoretical PK study in PRESCRIBE were 82% CYP (18/22) and 
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94% of parents (17/18). Whilst these figures are encouraging and highlight support for PK 
research, the mean recruitment rates to PK studies identified in Chapter two were around 
59%.  It is therefore likely that these figures would be much lower outside of a ‘theoretical’ 
study.   
6.5.3 Pain & distress  
Most participants (CYP and parents) commented that additional painful procedures, 
particularly the insertion of a cannula, would mean declining participation.  This is in keeping 
with other research studies which found that parent attitudes towards capillary puncture or 
venepuncture for research purposes were overwhelmingly negative (Seemann and 
Reinhardt, 2000, Jenkins et al., 2009, Abernethy et al., 2013).  There was also a preference 
for strategies which minimised painful procedures and reduced waste.  This is supported by 
studies in which parents rated the use of residual blood spots from new-born screening as 
their preferred method (Jenkins et al., 2009) or approved an extra sample taken alongside 
routine bloods (Freibott et al., 2016).  In a US study of optional PK studies 83% of 
participants ranked it as very important that participation would not cause additional pain or 
harm to the child and 43% were concerned about the placement of an additional IV cannula 
for sampling blood  (Berg et al., 2010).  In a similar UK study, only 8% of parents and 9% of 
children felt that too many blood samples were taken (Errington et al., 2016).  However, 
patients in this study had all samples taken from central lines which may have contributed to 
the positivity of parents and children towards participation. Participants in PRESCRIBE 
agreed with this approach, preferring that PK studies are conducted whilst the child has 
optimum pain management, is sedated and / or has a clinically indicated CVL or arterial line.  
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This means during admission to PIC is regarded as the optimum time, despite the associated 
stress PIC admission brings.  
Avoiding or minimising pain was extremely important to participants from both participant 
groups in PRESCRIBE and the use of topical analgesia was advocated.  This is well recognised 
as valuable in clinical care (Cordoni and Cordoni, 2001).  A number of parents also referred 
to play therapy and distraction.  Although there is reference to the use of these services in 
clinical care (French et al., 1994, McCarthy and Kleiber, 2006) there is no reference 
specifically to the research setting. Given the huge impact of pain and potential distress on 
decision making by the CYP and parents, future research design must consider the concept 
of invasiveness within a study protocol (Altamimi et al., 2016).    
6.5.4 Involvement of the CYP 
Involvement of children in decision making about participation in research was highly rated 
by CYP within this study.   Previous studies have suggested that adolescents often abdicate 
decision-making to their parents (Hinds et al., 2005) but findings from PRESCRIBE are in 
keeping with a recent study of decision-making on participation in paediatric oncology, 
which found that adolescents preferred a collaborative role in decision-making (Ingersgaard 
et al., 2017).  Although this was recognised by some parents, there was a marked difference 
between the extent to which this was a priority between CYP and parents.  Age of the CYP 
was identified as an influencing factor but similar to the published literature (Broome et al., 
2001, Abernethy et al., 2013) there were different suggestions from participants at what age 
involvement should start to occur.   The Children’s National Service Framework (Department 
of Health, 2003) states that all children should be consulted with and involved in all aspects 
of their care, including research.  In addition, there are suggestions that being consulted, 
 
 
183 
 
leads to enhancement of wellness in children and positively influences health outcomes 
(Coyne, 2006).  This seems to suggest that regardless of age, all CYP should be facilitated to 
be involved in decision making about research.    Researchers need to ensure that the 
communication needs of both CYP and their parents are addressed, rather than making 
assumptions based on age.  Without this there is the potential to cause conflict between 
CYP, parents and clinicians during the consent procedure.   
6.5.5 Vulnerable groups & health status 
CYP and parents recognised the need for PK studies to be inclusive in invitation to 
participate, however they had some reservations about the approach and recruitment of 
those they viewed as ‘vulnerable’.  Parents were more concerned about CYP who were not 
expected to survive, whereas CYP were most concerned about the inclusion of young 
infants, although they also had concerns about palliative patients. This concept of protecting 
vulnerable or critically ill populations from the demands of clinical trials has been noted 
amongst health professionals (Nicklin and Spencer, 2004, Macrae, 2009) and Research Ethics 
Committees (Kreicbergs et al., 2004, Angell et al., 2010).  PRESCRIBE identifies that CYP and 
parents can also have strong opinions on research conduct and potentially oppose research 
with those viewed as vulnerable.  This is despite the fact that parents can find research 
participation positive, even in times of bereavement (Dyregrov, 2004) and participation is 
rarely regretted (Newman and Kalouek, 2004). The evidence surrounding parents’ attitudes 
to research with neonates and infants is less clear. In the Neonatal Intensive Care Unit 
(NICU) setting there is evidence that mothers of pre-term infants were twice as likely as 
mothers of term infants (48% vs 23%) to consider participation in a research study (Maayan-
Metzger et al., 2008).   However in a study of consent rates to research in the PIC setting, 
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there was a trend toward lower consent rates in younger children and also in those 
undergoing cardiac surgery  (Menon et al., 2012).   It appears that within the neonatal 
setting parents might be more willing to consider research when their child is premature and 
/or low birth weight, whereas in PIC being younger or having a congenital problem such as a 
cardiac anomaly might make parents less likely to participate (Slosky et al., 2014).  This 
would seem to support the finding within PRESCRIBE that neonates were viewed with 
concern. However, in none of these situations is the concept of immediacy in the critical care 
setting addressed.     
CYP and parents in the PRESCRIBE study commented that decision making about research 
during a perceived life-threatening episode was difficult.  Within the adult literature this 
acuity was actually highlighted as a reason to participate as participants  did not want to 
delay treatment (Limkakeng et al., 2014).  However similar to Morris et al. (2007), 
participants in PRESCRIBE were concerned that participation in research might divert the 
clinician’s attention from their child.  The hypothetical requirement to make decisions 
quickly challenged many of them and the default position seemed to be to decline, rather 
than consent to research, which has implications for research studies with a time sensitive 
eligibility.   A PIC admission is known to be incredibly stressful for parents (Colville et al., 
2009) and being too stressed to make a decision has been identified  as the biggest reason 
for declining participation in PIC studies (Menon et al., 2012).  Morris et al (2007) also found 
there was a far lower level of support for research in emergency situations than research in 
non-emergency settings, although it was not clear whether it reflects a perception that such 
research is not valuable or whether it is not appropriate.  Parents in PRESCRIBE could see a 
place for research in emergency situations but concerns seemed to focus around 
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appropriateness, particularly when the vignette highlighted a time limited situation and also 
the concept of uncertainty.  This seems to suggest that conducting PK research in a time-
sensitive situation, with infants, admitted to hospital in a critical condition could be 
particularly challenging.   
6.5.6 Facilitators: communication and the approach 
One of the biggest facilitating factors for CYP and parents within PRESCRIBE was effective 
communication, particularly at the recruitment stage. Families rated communication as one 
of the most important skills of physicians, especially during critical illness (Meyer et al., 
2006).   Research staff need to gauge the right level of communication and for each 
individual family.  Families are more likely to participate if they have a greater understanding 
of study concepts and study specifics (Tait et al 2003, Hoberman et al 2014).  Studies have 
also shown that subjects who were well-informed and received adequate communication 
also had better compliance and a reduced premature withdrawal rate (Lynoe et al., 1991). 
Communication therefore has an important impact on recruitment and study retention.  
However, CYP and parents within PRESCRIBE also highlighted that recruitment is reliant on 
more than just communication skills, particularly at the stage of initial contact. Crucial 
elements included professionalism, tact, courteousness as well as communication elements 
such as clarity and provision of appropriate information.  This view of the researcher is 
crucial because positive parental perception of the researcher is associated with greater 
likelihood to assent (Tait et al 2003, Hoberman et al 2014), particularly at the initial 
encounter (Perez et al 2010).  Mothers of diabetic children similarly defined a ‘good 
paediatric researcher’ as approachable, responsive and dedicated (Pletsch and Stevens, 
2001). These are key aspects researchers can focus on to improve the recruitment process.   
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One of the biggest challenges for researchers in neonatal settings is approaching families at 
an appropriate time (Wilman et al., 2015). This is also reflected in PRESCRIBE participants’ 
concerns about approaching families about PK studies in a PIC setting.    Liaison and close 
partnership with health colleagues is recognised as effective to enhance recruitment to trials 
(Gooch, 2000, Wilman et al., 2015) and helps to reduce inappropriate and poorly timed 
approaches. Knox and Burkhart (2007) also suggest that developing relationships with 
colleagues can lead to improved referral and potential recruitment as the CYP and family 
trust and respect their health care provider’s opinion.  Researchers therefore need to 
demonstrate a visible relationship with clinical colleagues and ensure the timing and 
approach are optimised.   
6.5.7 Personal impact 
Extra visits to hospital were a huge concern for parents within PRESCRIBE, with the 
associated implications of missing school, work, travel and parking costs.  Indeed spending 
extra time in the hospital was identified as a reason by 50% of those who declined 
participation in a PK study (Berg et al., 2010). Research highlights that when a child 
participates in research much of the burden falls on the shoulders of parents, including 
hospital attendance, work absences and research requirements to complete paperwork.  
These can be hugely draining for parents (Tromp et al., 2016). However, children also feel 
the impact of research as a burden (Pletsch and Stevens, 2001, Hein et al., 2015).  Strategies 
for reducing this burden for CYP and families could include on-line visits and telephone 
interviews to reduce the burden of research visits.  Indeed 83% of parents in an ED study 
would consent to a study that involved a telephone follow up.  This figure reduces to 58% 
when an additional appointment is proposed (Abernethy et al., 2013).  Preferred options 
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raised by CYP and parents in PRESCRIBE were flexibility, with suggestions of after school or 
weekend appointments and home visits.  This is supported by Knox & Burkhart (2007) 
observation that the single biggest factor for retention of children in research studies is to 
allow for flexible scheduling.  Volmer et al (1992) found that scheduling clinic visits in the 
late versus the early afternoon resulted in better participant attendance.  Saturday 
appointments were identified as useful for some participants but were also the most 
commonly missed appointments.  However, the most preferred option amongst participants 
in PRESCRIBE was to ‘piggy back’ appointments to clinically indicated appointments, so 
clinical and research care are conducted side by side.  There are no published accounts of 
this to allow the evaluation of the utility and cost-effectiveness of such a strategy.  This 
requires further exploration.    The message overall was that CYP and parents felt the impact 
of clinical care and are reluctant to add burden through research participation. The best 
strategy was to avoid extra demand altogether.    
6.6 Limitations 
6.6.1 Participants 
There were multiple sibling pairs interviewed together (at the family’s request) which may 
have influenced respondent’s answers. However, the presence of a sibling was sometimes 
useful to add clarity or to remind the other of a specific occasion.  Interviews were held at 
the participants’ homes so it was also difficult to exclude parents from the process, although 
they were discouraged from being present and participating.   One interview was cut short 
when a clinical situation occurred during a child’s clinic visit. A follow-up time to complete 
the interview was unable to be scheduled as both the researcher and the parent were then 
on maternity leave.  
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The CYP who had experienced PIC were knowledgeable and insightful but there were low 
numbers interviewed. In part, this was because there were low numbers of eligible CYP to 
interview, but in addition, there were a number who declined at the point of invitation and 
after being discharged home.   Purposive sampling of CYP with experience of clinical trials 
was more successful.  However, for some the visits to the hospital had come to be their way 
of life, so caution is required in the interpretation and transferability of the results to a wider 
population.   
6.6.2 Subject matter 
PK research as a concept was deemed ‘complicated’ by the PPI participants, particularly for 
CYP.  Despite the use of props and aids and the vignette, it was unclear at times if 
participants had understood the questions fully or if things were not important as their 
answers were limited in depth.  To overcome this the researcher did summarise responses 
and check participant agreement and was satisfied with comprehension.  The use of the 
vignette was also valuable as it enabled the discussion to remain focused, particularly when 
exploring alternative methods for conducting PK research.   
There were some situations where not all participants were asked the exact same questions.  
Participants were purposively sampled to have a wide range of experiences and it seemed 
illogical to press participants to discuss research care in WTCRF when they had experience of 
care on PIC and vice versa.  For transparency, response rates are reported to enable the 
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6.6.3 Interview conduct 
A purposive sampling strategy of parents of children who had experienced PIC or clinical 
trials meant that many were parents of children with complex health conditions. Timing of 
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interviews was extremely challenging. Conducting them whilst the CYP was still in hospital 
meant interviews were frequently postponed due to changes in the child’s clinical condition. 
In addition, parents were anxious about leaving their child.  Conducting interviews once 
families were discharged, meant some then failed to respond to contact or there were 
challenges about arranging home visits around parent’s work and other commitments.   This 
therefore did lead to some families not responding to follow up.  
6.7 How does this qualitative work with CYP and parents 
address the knowledge gap surrounding 
pharmacokinetics? 
This chapter set out to address gaps in knowledge associated with the service user 
perspective, the influence of context and facilitation and has addressed all three aspects.   
1. There is a paucity of research conducted with CYP to understand their views on research 
and trial design generally and within the PK literature very little was known about attitudes 
of CYP and parents.  Where research had been conducted it was specifically related to PK in 
phase 1 /Phase 2 studies in oncology (Berg et al., 2010, Errington et al., 2016) or a study in 
CYP with Attention-Deficit Hyperactivity Disorder (Fogas et al., 2001).  This is the first study 
to address the subject of PK studies outside of a specific diagnosis or speciality and utilise 
face to face methods to conduct the research.  New knowledge has been gained to show the 
negative influence of additional painful procedures and additional hospital appointments on 
the decision to participate in PK research. In addition, there is a clear discrepancy between 
current PK study protocol recommending the placement of a peripheral cannula for 
sampling and participant’s expression of this as their least preferred method. Factors such as 
the influence of blood volume, the number of samples and the sampling regime and new 
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approaches for conducting PK research have not previously been explored.  PRESCRIBE 
therefore provides insight into the feasibility and acceptability of novel study design. 
2. This is the first study to explore the influence of context and the considerations of 
conducting PK research in an emergency / intensive care environment.  Historically there 
have been concerns about approaching families to consider research, particularly when CYP 
are acutely ill (Kanthimathinathan and Scholefield, 2014).   However, PRESCRIBE has found 
that CYP and parents will not only consider research within the PIC context, but may actually 
prefer it to take place in this context when their pain is well controlled and they have 
vascular access for sampling.  There are also important messages about the value of 
designated research areas for research conduct.  There is little formal evaluation of the roles 
and utility of facilities such as Wellcome Trust Clinical Research Facilities.  PRESCRIBE 
provides evidence that these are an important resource for CYP and families in the context 
of PK studies.   
3. The third gap in the knowledge PRESCRIBE addresses is the identification of facilitators to 
aid researchers with future study design and conduct.  PRESCRIBE has systematically 
reviewed all stages of the PK research process, identifying not only barriers and challenges at 
each stage but also enabling factors / facilitators to overcome these. These facilitators 
address psychological, social, emotional and financial needs of CYP and parents.  
Recruitment and retention to paediatric studies is recognised to be challenging (Caldwell et 
al., 2004, Tishler and Reiss, 2011, Menon et al., 2012).  With enhanced understanding, 
measures to assist with research conduct can address both PK recruitment and study 
retention.   
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6.8 Conclusion 
Conducting interviews and focus groups with CYP and parents was a challenging 
undertaking, requiring reflexive sampling and study methods. Valuable information to 
inform the design of future research was obtained.  CYP and their families will consider 
participation in PK studies, even when there is no direct benefit to themselves, provided 
there is minimal or no additional painful procedures, or analgesic measures are put in place. 
Ideally this type of research will take place when CYP are inpatients, with clinically indicated 
intravascular access in place for sampling.  Provided there is sensitivity to the circumstance 
and the timing of approach PIC is regarded as an optimum time to carry out this type of 
research.  CYP and parents prefer strategies which minimise the disturbance to them such as 
samples taken alongside clinical care and scavenged samples or would like the results to be 
made available to clinicians so they feel they have ‘gained’ from their involvement.  Overall 
CYP and parents are willing to consider participation in PK studies, although this may depend 
on the medication under investigation and the perceived benefit for their clinical condition.   
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Chapter 7: Exploring the attitudes of 
nursing staff towards Pharmacokinetic 
studies in critically ill children  
7.1 Introduction 
7.1.1 What is known about clinical staff attitudes towards 
pharmacokinetic research?  
There is evidence that clinicians can heavily influence recruitment to research through 
expressing their preferences (Mansour, 1994) and non-invitation of potentially eligible 
patients (Nicklin and Spencer, 2004). Amiel et al (2007) reported not inviting eligible 
paediatric patients, driven by ethical concerns related to the study design, the severity of the 
underlying disease and anticipation of families refusing to participate. Shilling et al (2011) 
also found that practitioners can regard approaching families about trials as an unwelcome 
burden and some felt personally uncomfortable and awkward about recruiting children to 
trials.  This reluctance of clinicians to participate can be a greater obstacle to successful 
completion of a trial than the reluctance of patients (Fallowfield et al., 1997).   However, the 
majority of this work has been undertaken with adults and within the oncology field.   Little 
research has taken place surrounding attitudes towards research in trials of medications.  
There is some evidence that health care professionals may not recognise that the 
medications they are prescribing are being prescribed off-label (Chalumeau et al 2000) 
which is of concern.  However other studies show that health care professionals are aware 
and are concerned about the safety (77.8%) and the efficacy (87.9%) of unlicensed / off label 
prescribing in children (Mukattash et al., 2011). Despite these concerns though, there can be 
a reluctance to undertake trials of medicine in children (McLay et al., 2006). Reasons for this 
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reluctance were unclear but are concerning given that clinical trials of medications are 
dependent on support from clinicians.   
7.1.2 What is known about nurses’ attitudes towards pharmacokinetic 
research?  
Nurses occupy a key role in the contemporary drive to develop and maintain evidence-based 
health care across the UK (Department of Health, 2006).  There is evidence to suggest that 
nurses have positive attitudes towards research, however the research in this area has 
tended to focus on exploring barriers to research utilisation and implementation (Nilsson et 
al., 1998, Bjorkstrom and Hamrin, 2001, Snelgrove and James, 2011).   Paediatric nurses can 
be present at the time of recruitment of patients to trials, be involved with data and 
sampling collection and the following of trial protocols (Knox and Burkhart, 2007).  However, 
little is known about the attitudes of clinical nurses towards research, particularly studies 
with pharmacokinetic (PK) sampling requirements.  Chapter 7 aims to address the gap in 
knowledge related to clinical nurses’ attitudes towards PK research, explore the influence of 
context on nurses’ attitudes and identify facilitators (see Figure 37 below).  
Figure 37: identifying gaps in the knowledge- nurses 
 
 
 
194 
 
7.2 Research aims 
The aim of this work was to determine the attitudes of nurses working in a Paediatric 
hospital setting, towards paediatric PK studies, identify what they perceived to be a barrier 
or problematic about the conduct of paediatric PK research studies and identify what nurses 
identified as enabling or facilitating the conduct of PK research studies.  Please see Chapter 2 
for full details of the methods undertaken. 
7.3 Results 
7.3.1 Demographics 
Recruitment to focus groups and interviews took place between 01.04.2013 and 28.02.2014.  
At the time of the initial approach in April 2013 the total number of eligible staff (Registered 
Nurses) on each ward (Band 5-8) was: PIC- 272, Ward 11 (Cardiac)- 30, Ward 12 (Cardiac)- 
30, Ward 8 (Liver)- 30, Burns ward- 25.   
26 PIC nurses from a UK PIC and 7 Ward Nurses (Burns Ward, Liver Ward and Cardiac wards) 
(n=33) participated in five focus groups (n=29), two interviews with two participants (n=4)  
and one to one interviews (n=4).  One focus group (4 cardiac staff) had to be excluded due to 
poor sound quality, therefore total number of participants = 29 Registered Nurses.  
Participants included Band 5 (n=18), Band 6 (n=4), Band 7& 8 (n=7), with 15months -18years 
PIC experience.  Participants are summarised in Table 40 below, which features their place of 
employment, gender and level of paediatric experience.  * Indicates nurse had undertaken 
Good Clinical Practice (GCP) training (n=3) 
Table 41 provides details on the codes used within Table 40.  Quotes from nurses are cited 
as N- individual study number. If this was conducted as part of a FG there is an additional 
letter to differentiate participants.  
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Table 40: summary of nurse participants’ age, gender, band and experience 
Participant Age Gender Band Department Paeds experience PICU experience Method 
49 2 F 5 PICU 2 2 Interview 
57A 2 F 5 PICU 2 2 FG 1 
57B 2 F 5 PICU 2 2 FG 1 
57C 1 F 5 PICU 2 2 FG 1 
57D* 1 F 5 PICU 2 2 FG 1 
57E* 4 F 6 PICU 4 4 FG 1 
57F 2 M 5 PICU 2 2 FG 1 
61A 4 F 7 PICU 3 3 FG 2 
61B 4 F 7 PICU 5 5 FG 2 
61C 4 F 8 PICU 5 4 FG 2 
61D 5 M 8 PICU 5 5 FG 2 
61E 2 F 7 PICU 3 3 FG 2 
73 5 F 7 PICU 4 4 Interview 
74 5 F 6 PICU 5 5 Interview 
80A 4 F 7 PICU 5 5 Interview 
with 80B 
80B 3 F 6 PICU 4 3 Interview 
with 80A 
98A 2 F 5 PICU 2 2 FG 3 
98B 2 F 5 PICU 2 2 FG 3 
98C 2 F 5 PICU 2 2 FG 3  
98D 1 F 5 PICU 2 2 FG 3 
98E 3 F 5 PICU 2 2 FG 3 
98F 2 F 5 PICU 2 2 FG 3 
106A 2 F 5 PICU 2 2 FG 4 
106B 2 F 5 PICU 2 2 FG 4 
106C 2 F 5 PICU 2 2 FG 4 
106D 3 M 5 PICU 3 2 FG 4 
97* 2 F 5 Liver 2 0-ward Interview 
99A 3 F 6 Burns 4 0-ward Interview 
with 99B 
99B 1 F 5 Burns 2 0-ward Interview 
with 99A 
* Indicates nurse had undertaken Good Clinical Practice (GCP) training (n=3) 
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Table 41: codes for nurses’ age and level of experience (in Table 42) 
Age Experience 
1= 21-24 years 1= </=2 yrs 
2= 25-29 years 2= >2 years- 4.99yrs 
3= 30-35years 3= 5- 9.99yrs 
4= 36-40years 4= 10- 14.99 yrs 
5= 41-50 years 5= >/=15 yrs 
 
All participants (n=29) had experience of PK in clinical practice and most were able to 
provide examples of medications that required levels taking as part of routine care.  4/29 
(14%) had experience of sampling PK levels as part of a research study.   However, only 13/ 
29 (45%) were able to define what they thought pharmacokinetics was, possibly reflecting a 
lack of confidence in the terminology: 
“I suppose I have not heard it in those terms before but I mean, you know, it is 
about how the drugs react in the body is what I would think” (N-73) 
Participants could however provide a variety of clinical applications of PK in practice. This 
seems to indicate that they understand the principles of why PK is of importance clinically, 
particularly senior staff (Band 6-8).   
“That’s why we have our liver protocols for things like paracetamol where you 
give the patients a reduced dose because they can’t break it down as efficiently as 
if they hadn’t had a transplant” (N-57B) 
7.3.2 Themes 
Coding was condensed to the six core themes referred to within chapter 6.  
7.3.3 Attitudes of nursing staff  
During discussions about PK research conduct, nurses were relatively positive about the 
concept of PK research and generally rated families as having a positive attitude towards 
research (see Table 42 below).  
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Table 42: summary of nurses' attitudes towards PK research with CYP 
Positive comments (76%) Negative comments (24%) 
 Inclusive approach 
 Families value choice & opportunity 
 
 Vulnerability  
 Experimentation 
 Health status  
 Impact on staff 
Nurses felt many families would appreciate, or at least consider the choice and opportunity 
of participation:  
“I’ve never had a parent complaining or say that they want to withdraw from a 
trial or anything like that and especially from parents whose children have passed 
away” (N-49) 
However, they also identified that some families will have concerns over the vulnerability of 
their child, being approached during critical illness, the concept of experimentation and the 
impact of protocol requirements on staff: 
“I think that they won’t see the value of the overall goals of the study.  They’ll just 
think what it comes down to is them personally having to do extra... in an 
environment where morale is not particularly high.” (N-62C) 
Despite recognising the importance of families’ views, there were very few comments about 
the views of CYP towards research or the importance of researchers involving or considering 
the views of CYP in discussions about research.   
Overall despite large numbers of negative comments about the potential challenges of 
conducting PK research alongside clinical practice, all nursing staff were willing to support a 
PK study (see section 7.3.8.2.3) 
7.3.4 Recruitment 
7.3.4.1 Nurses’ perspectives on parents’ decision-making 
One of the most discussed aspects within Chapter 6 was factors which influenced decision 
making by CYP and parents about participation in research. Some of these factors were also 
raised by nurses, although there were far fewer comments overall (see Figure 38 below).   
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Figure 38: number and distribution of comments on parental decision-making (DM) by nurses 
 
*
Age was discussed in more detail but with regards to safety of sampling rather than in relation to decision making about 
participation 
**
Routine Vs Novel treatment: The vignette was described as a ‘routine’ medication, rather than a ‘novel’ treatment.  Only 
one participant made any comments about rare diseases and novel treatments.  
***
Time: there were references to ‘time’, but all in relation to the nurses’ time to undertake the research, rather than time 
required by participants to consider recruitment.  
1. Helping others 
The motivation of CYP and their families to help others was referred to by 14 nurses, the 
most commented on factor influencing decision-making.    Nursing staff felt there was a high 
level of altruistic feeling towards research amongst parents, even when they were in an area 
such as PIC: 
 “Parents like to feel like they can help or prevent another child going through 
something. Parents feel quite helpless in those circumstances so the idea of 
actually helping by giving consent is usually something that really benefits them.” 
(N-98A) 
2. Health status  
A number of staff commented on the influence of the child’s health status at the time of 
being approached for research.  Some comments focused on the challenge for parents 
having to make a decision when their child was extremely unstable.  However, others 
recognised that the reason for the child’s admission could impact on whether the CYP could 
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actually participate, for example whether it would be possible to site a peripheral vascular 
access device if the CYP was shocked and peripherally shutdown: 
“I think it would be difficult for most of our patients because they come in shut-
down and with circulatory collapse and we’ve got difficulty with access anyway” 
(N-49) 
3. Pain and distress 
Eight nurses recognised the pain and distress associated with invasive procedures such as 
blood sampling.  Comments reflected that CYP and parents could experience concerns about 
additional requirements which could influence their decision-making:  
 “.. there are so many kids that come in to outpatient’s clinics now that literally 
because they’ve had so many bloods taken, so many stabs, so many times with 
cannulas, they literally scream as soon as they come in because they just don’t 
want to be there…” (N-57B) 
4. Improving personal care 
A number of nurses felt parents were motivated to participate in research as an opportunity 
to improve the care of their own child: 
 “Parents, I don't think anyone would say no, really, to improve their child's care.” 
(N-98B) 
Some felt that even when there was no immediate direct benefit, some parents would still 
consider research, recognising their child could benefit during a future admission to hospital 
or in their future management.    
7.3.4.2 Barriers to recruitment 
The factors that influence decision-making by CYP and parents were not widely discussed by 
nursing staff.  However, where comments were made there was a recognition of the 
altruistic nature of many parents. Other perceived barriers and facilitators are summarised 
in Table 43 below.  
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Table 43: summary of barriers and facilitators to recruitment (nurses) 
 Barriers Facilitators 
R
ec
ru
it
m
en
t 
Vulnerable patients, particularly Infants  Personal benefit to research 
 Benefit for others 
 Education / training 
 Safety 
-Education and training of staff 
-Reference to guidelines 
 No additional samples /sampling 
procedures 
Severity of health status  Deferred consent
1 
Pain / distress Use of indwelling lines for sampling
2 
Safety  
1
Discussed in section 7.3.4.3.3, 
2 
Discussed in section 7.3.6.2.1 
7.3.4.2.1 Vulnerable study participants 
Nursing staff were generally supportive of broad inclusion criteria (see Figure 39 below).  
Although age was not felt to be grounds to exclude patients from a study, neonates were 
raised as a concern by 12 people, with two people specifically stating they should be 
excluded:  
“But if you've got a little weeny one, like our ITU one and you're taking that, it's 
quite a significant amount, isn't it?” (N-99A) (ward nurse) 
Figure 39: vulnerable study participants’: nurses’ views 
 
There were no blanket comments about exclusion for patients who were not expected to 
survive or who were on a palliative pathway.  In fact, the majority of comments (29/30) were 
positive to inviting them to participate, recognising that participation might even offer a 
0 5 10 15 20 25 30 35
Palliative
Neonates
All ages included
No. comments 
Positive refs negative refs
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form of benefit.  However, this was cautioned with the need to liaise with clinical staff about 
all patients; both to check if inclusion was clinically acceptable and also to determine the 
appropriateness and timing of the approach:   
“I think in some families it might be that if you came in at that point that you 
might completely derail all the withdrawal talks, so I think it is just about having 
some form of liaison” (N-61E) 
There was also a recognition that palliative care could mean different things for different 
patients and families and did not necessarily mean the CYP was going to die imminently:  
“You are going to get some parents whose kids are on this palliative care 
pathway, but they have been on it for five years. They know this is going to 
happen and they are prepared and they are not jolly, but they are accepting of it, 
so you could approach them.” (N-106D) 
7.3.4.2.2 Hospital appointments 
All the nurses interviewed worked on inpatient wards, with the majority (26/29) on PIC.  
Participants were asked about the impact of a PK study on families but there were no 
specific mentions of factors related to the impact of extra appointments, school, work and 
travel.  
7.3.4.2.3 Summary of barriers to recruitment 
There was a recognition that research staff should take an inclusive approach to patients on 
the basis of age and diagnosis, although liaison with clinical staff (identified as both medical 
and nursing staff) was vital to check individual circumstance.  Decision-making was felt to be 
negatively influenced by the potential for pain and the requirement to make decisions at a 
time of deteriorating health status but overall there was less consideration about 
recruitment than from CYP and parents.   
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7.3.4.3 Facilitators to recruitment 
7.3.4.3.1 Emphasise the potential benefit of participation  
Although there were few blanket rules of exclusion, many nurses were concerned about the 
inclusion of neonates in PK research which offered no personal benefit.  To address this a 
study would ideally offer some form of benefit to the CYP participating or would outline the 
benefit for CYP in the future 
“If they think they’re contributing to something that might not make a difference 
to their child at that moment in time, but for children in the future, they don’t 
have a problem.” (N-80A). 
7.3.4.3.2. Reassurance of safety 
Safety of the research study for the individual patient was paramount to nurses.  Two key 
components to this were the education and training for staff and reference to guidelines or 
standards.  Education and training were crucial to ensure staff understood the purpose 
behind the study, what they were required to do and what to do in the event of any 
problems: 
  “It took quite a lot of drilling in how much you need to take and which bottle to 
put it in and it was very much ‘this is an idiot’s guide’... And there is definitely a 
place for idiots’ guides for things” (N49) [Talking about a trial which involved a 
very specific management plan]  
18 people made reference to the value of guidelines to provide guidance on safe volumes for 
sampling, particularly if there were stratifications identified for different ages and /or weight 
groups: 
 “...as a bedside nurse it’s drilled into you about protocols, procedures, 
prescriptions... and you’ve got something in front of you that says it’s safe to take 
X, Y, Z amount of blood off a 3-kilo patient, then it would make you feel very 
slightly more comfortable about the responsibility of doing that.” (N-73) 
7.3.4.3.3 Alternative approaches to PK conduct 
In order to overcome issues and concerns associated with the sampling requirements of a 
traditional PK study alternative approaches were discussed. Figure 40 below summarises 
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nurses’ attitudes towards a number of alternative PK methods.  Table 44 then summarises 
the top four approaches.  
Figure 40: alternative approaches to conducting PK studies (nurses) 
 
Table 44: top 4 preferences for alternative approaches to PK study conduct (nurses) 
Nurses preferences 
1. Opportunistic sampling 
2. Deferred consent 
3. Scavenged samples 
4. Population PK  
1. Opportunistic sampling  
PK samples taken alongside routine bloods or as clinical need dictated was the highest rated 
approach, with 96% of comments from 20 staff positive.  Nurses felt this reduced the 
infection risks associated with accessing lines and also minimised any extra work as it was 
taken alongside ‘normal’ care:  
“I don’t think it’s unreasonable for us to assist when we are doing routine bloods 
and I think that you know just filling an extra blood bottle, nobody has got a big 
problem with” (N-74) 
0 10 20 30 40 50 60
Other bodily fluids
Scavenged samples
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Randomised sampling windows
Opportunistic sampling
Levels available for routine care
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2. Deferred consent  
Deferred consent was discussed in the context of an emergency situation or the need to 
start a ‘routine’ medication quickly.  A sample would be taken prior to administration as well 
as ‘post’ samples, until discussion with the family and informed consent could be obtained.   
Overall staff were supportive of this approach, with comments reflecting the fact that 
families would struggle to concentrate on any discussions at this difficult time. 
3. Scavenged samples 
Many nursing staff (n=15) approved of the idea of using blood ‘leftover’ after routine tests 
had been conducted and which would normally be disposed of as clinical waste for 
measurement of PK levels.  Support reflected the fact this was not adding to nursing 
workload and avoided ‘waste’:  
“I see no reason why they wouldn’t really, because it is only going to get discarded 
if it’s not needed for anything else.  So, I see no reason why they would” (N-73) 
Where there were negative comments, these related to the question of why there was 
additional blood left after routine tests:  
 “It certainly raises issues with me because I never knew there was blood left over.  
Why are we taking all that blood when they are throwing it in the bin?”  (N-106D) 
4. Population PK 
Population PK approaches which are facilitated by sparse sampling methods were as a whole 
viewed positively.  Nurses liked the idea of fewer samples per patients. They also thought 
families would prefer this approach:  
“I think you’re more likely to get patients and parents... signing up for four 
samples than... for the other regime where you’re looking at seven or eight” (N-
80B) 
However, negative comments reflected concerns about the accuracy and completeness of 
data.  If there were any doubts, they preferred traditional methods with smaller numbers of 
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patients contributing more data, conducted with full supervision, to ensure patients’ data 
did not go to waste: 
 “So as long as it was scientifically valid and we knew we could get the answers so 
that data didn't go to waste” (N-98D). 
 
7.3.4.3.4 Summary of facilitators  
Nursing staff were reassured by approaches to PK sampling which avoided additional blood 
sampling or made use of samples that were already taken.  The optimum study design would 
ensure there was some form of personal benefit for patients or emphasised the value for 
future patients. In emergency or time-pressured situations nurses were supportive of 
deferred consent for PK research. 
7.3.5 Medication  
7.3.5.1 Barriers / challenges with medications                                                            
Nurses were asked about their experiences of prescribing and administering medications to 
CYP. There were 61 comments made by 23/29 participants; making it the second most 
commented on topic by nursing staff.  The majority of these comments reflected problems / 
challenges (see Table 45 below). The volume of comments about these issues are 
summarised in Figure 41. 
Table 45: summary of barriers and facilitators to medication administration (nurses) 
 Barriers Facilitators 
Medications Accuracy with administration  Training 
 Trial paperwork 
 Research support  
Tablets/ palatability / changing for research 
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Figure 41: experiences and attitudes towards medications (nurses) 
 
There were references to the challenges of monitoring medication levels even as part of 
routine patient management, with staff concerned about the potential for both under- and 
over-dosing patients:  
“I think we probably under dose a lot of children, particularly antibiotics I would 
have thought because ...you are not necessarily alerted to the level.  So, if you are 
busy, you might not get the level until a couple of hours after and I think kids end 
up having doses delayed” (N-61C)  
“I find the opposite – I think that we overdose a lot of them because we don’t take 
into account their renal function and when you get a high level back obviously, 
you’ve given them the next dose anyway” (N-61D) (Dialogue between two ANPs 
on PIC) 
 
Other issues affecting the timely administration included: staffing levels, workload and 
patient acuity, medications prescribed for ‘busy times’, intravenous access availability, 
multiple and competing drug requirements, staff having the skills to administer medications 
and waiting for medical team input.  Staff also identified issues about where PK 
measurements would be obtained from, particularly with limited vascular access which 
could create issues for both the administration of the medication (if IV) and sampling: 
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“You may have to prioritise drugs over other drugs as well.  A drug that's once a 
day versus one that's four times a day, you might have to prioritise getting that 
one in first and maybe not start the study one at that time.” (N-98A) 
There were also specific issues for oral medications, including ‘nil by mouth’ status, patient 
refusal and difficulties with compliance.  Despite these concerns there were comments that 
changing medications might not be appropriate. Some felt CYP and parents had strong 
preferences and would therefore be resistant to change, others commented that there may 
be safety issues changing from one formulation to another: 
 “We have seen it on the unit where different drugs – the same name drug – is 
given in a different form and it is less effective or more effective… just changing 
something as simple as a liquid to a tablet could actually have a big consequence” 
(N-106D)  
Overall the majority of comments from nursing staff about taking medications were 
negative, reflecting multiple challenges in routine practice. In the context of a PK study these 
challenges could be enhanced by the need for timely and precise administration.  
7.3.5.2 Facilitators to medication issues 
In order to ensure the timeliness of administration of medications and accuracy of 
documentation staff training was felt to be important: 
“...what it boils down to is education and communication I think.” (N-80A) 
In conjunction with this was simple, trial paperwork which prompted accuracy in 
documentation: 
“Your prescription chart can have a little slip stapled to it that quite clearly says 
they are in this trial, please just write down the time you have given that drug.  To 
the minute.” (N-106C) 
However, there was a recognition that with conflicting demands staff could struggle to 
comply with study protocols. Therefore, research staff support should also be available to 
help support staff with administration requirements.  
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7.3.6 Sampling 
Participants made many comments about issues surrounding sampling for PK studies. 
Barriers and facilitators are summarised in Table 46 below.   
Table 46: summary of barriers and facilitators related to sampling (nurses) 
 Barriers Facilitators 
Sampling Capillary 
Cannulas 
 Use of indwelling lines  
 Conduct on PIC1 
Blood volumes & frequency  Guidelines 
 Consider alternative methods to reduce 
sample volume and number
2
  
 opportunistic sampling  
 scavenged samples 
 population PK 
Sampling regime  Communication with clinical teams- 
verbal and written 
 Training 
 Support from senior staff / research 
teams 
1 See section 7.3.9, 2See section 7.3.4.3.3   
7.3.6.1 Barriers /challenges to sampling 
7.3.6.1.1 Vascular access 
All nurse participants commented on different types of vascular access in relation to 
sampling requirements for PK monitoring.  (See Figure 42 below for a comparison of 
comments).  
Figure 42: views on vascular access & sampling (nurses) 
 
Overall capillary sampling and sampling from a cannula were not regarded as reliable or 
pleasant methods for obtaining blood samples.  All comments about capillary sampling were 
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negative, reflecting on the pain, distress, scarring and the time-consuming nature of this 
method for obtaining blood samples:  
“I think when people come in and they have had a lot of heel pricks, their heels 
are...(N-61B).  
They’re a mess, aren’t they (N-61A).  
It looks excruciating to be fair, some of them” (N-61B) (exchange between PICU 
nurses N-61A&B) 
The majority of comments about obtaining samples from cannulas were also negative, 
relating to the pain and discomfort for CYP from the placement and manipulation.  Other 
difficulties related to the specificity of the protocol with the location of vascular access or 
the achievement of required sampling volumes: 
“And the differing limbs?... If both had to be venous cannulas, for some of our 
patients you don’t have that luxury of being able to pick where they are placed.” 
(N-80B)  
In fact, only one nurse had experience of being able to reliably obtain blood samples from a 
cannula that ‘bled back’ and this was in older CYP on an adolescent ward 
“Well in my experiences, cannulas don’t always bleed back and once you start, 
you might be okay for the first couple of samples but they won’t stay the course 
and then what happens to you? You have started this pathway then what happens 
to the trial really, if you haven’t been able to take the rest of them?  Does that 
mean it’s abandoned then?” (N-73) 
7.3.6.1.2 Obtaining samples 
Three key sub-themes were discussed about obtaining samples: the blood volume a study 
protocol requested, the number of samples (frequency) and the specific regime or study 
protocol. Comments are summarised in Figure 43 below. 
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Figure 43: views on study sampling requirements (nurses) 
 
The volume of blood (16mls in total) was regarded as an issue by a number of the nurse 
participants.  Negative comments reflected concerns about the impact of this volume for 
patients on PIC who were commonly under one year of age, underweight, unstable, 
vulnerable to anaemia and the potential need for a subsequent transfusion. 
  “And you run the risk they become anaemic because of that much sampling you 
are exposing them to – that’s a big issue really, isn’t it?” (N-61B) 
Nurses made fewer comments about the number of samples being taken, so it appeared 
that this was less of an issue than the overall sampled volume. However, all the comments 
made on this topic were negative.  Staff concerns reflected the impact of extra sampling on 
workload as well as the enhanced infection risk for patients: 
“In effect, you are quadrupling their infection potential... If two days down the line 
your patient’s gone septic, you could quite reasonably say has that got something 
to do with it? Has that sampling regime jeopardised our patient?” (N-57F) 
There were a large number of comments about the blood sampling regime outlined within 
the vignette.  For many the regime was felt to be too rigid, unrealistic and too difficult to 
achieve due to the unpredictability of the clinical environment: 
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 “I think especially on PICU, I don’t think we’d ever be able to be compliant with 
those time frames unless you have got a nice level one steady patient...  If you 
have got a level four patient, you are going to really struggle to get that in.” (N-
57A) 
7.3.6.2.3 Summary of barriers 
Overall cannulas were perceived as unreliable for obtaining samples and capillary sampling 
was negatively viewed. Nurses were concerned about the volume of blood being sampled 
and the regime requirements more than the number of samples. However there were 
concerns about the impact of all three aspects for both the patient and the staff.  
7.3.6.2 Facilitators 
7.3.6.2.1 Use of indwelling, clinically indicated vascular access  
Nurses commented positively about the use of arterial lines to obtain study samples, due to 
their ease of use, speed and reliability. Where negative comments were made these 
reflected concerns about increased infection risk, the potential for lines to be left in longer 
than was clinically required and staff having the required competency to obtain the samples:  
“They can't access central lines or arterial lines without having a competency 
signed off for a start.  So therefore, they'd have to be competent.” (N-98A) 
There were a similar number of positive comments about the use of CVL, again reflecting the 
ease of use.  However, there was a slightly higher proportion of negative comments 
identifying that not all patients would have a CVL, the challenge of conflicting drug regimens 
and competing requirements for sampling: 
 “If it is an IV <intravenous> drug that you are giving, there is a high degree of 
probability, especially on ITU, that it will be given centrally.  So therefore, if your 
protocol says that you can’t sample from the same line that you gave it, then 
automatically you have an issue there already” (N-57A) 
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7.3.6.2.2 Reference to guidelines  
As outlined in 7.3.4.3.3 alternative approaches which reduced the number or volume of 
additional blood samples were valued.  However, nursing staff also felt reference to 
guidelines to demonstrate the safety of a study protocol was important.  
7.3.6.3.3. Communication and engagement  
Communication was viewed as essential throughout the conduct of a PK study to convey 
exactly what was required.  This covered both verbal and written communication with 
clinical teams.  Written communication in the form of simple, clear trial documentation were 
felt to be an important facilitating factor: 
“As long as we knew what we were doing... we've got a tick-list... to look at, this is 
what we need to do when there's no one here, then I think we'd be fine” (N-99A). 
However, ultimately this was dependent on nursing staff having time to undertake the 
activity.  Therefore, the crucial factor was felt to be support from dedicated research staff to 
support staff with sampling requirements.   
7.3.7 Processing 
Overall nurses did not recognise there to be many areas of concern related to the processing 
and interpretation of results from PK studies. See Table 47 below.  
Table 47: summary of barriers / facilitators in relation to processing (nurses) 
 Barriers Facilitators 
Processing Documentation accuracy  Training 
 Trial related paperwork / documentation 
                        
In contrast to CYP and parents there were a number of accounts by nursing staff of issues 
related to the processing of PK samples in routine clinical care.  Issues involved accounts of 
blood being put in the wrong bottles, problems with the opening times of the laboratories or 
issues with delays in obtaining results. One respondent summarised the situation: 
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 “Yes, lots [of problems] [Laughter].  That’s because the sample isn’t taken at the 
right time, or put in the right vial, or sent to the right place at the right time or if 
they say it’s gone, it hasn’t arrived there. Or the results have come back late or the 
results haven’t been phoned through or somebody’s had the results and haven’t 
conveyed it to the doctors. So, there are, lots and lots of challenges...” (N-73) 
One of the issues raised about current practice was that in order for methods such as the 
use of scavenged samples or opportunistic sampling alongside routine bloods to work, 
documentation in relation to both medication administration and sampling would have to 
improve: 
“We are notorious for the six o’clock bloods being six o’clock-ish, which is 
somewhere between half four and half seven, whilst still being ‘the six o’clock 
bloods’... (N-74) 
Although this topic received fewer comments than other aspects of PK research by nursing 
staff, staff recognised that these issues would create significant issues for a PK study.  They 
identified that key facilitators to overcome this was training and the creation of trial-specific 
paperwork which prompted accuracy in documenting the sampling times.  
7.3.8 Outcomes  
7.3.8.1 Barriers / challenges associated with outcomes from PK research 
Key barriers and facilitators are outlined in Table 48 below. 
 Table 48: summary of barriers and facilitators related to study outcomes (nurses) 
 Barriers Facilitators 
Outcomes Nursing workload, prioritisation & 
responsibility 
 
 Engagement with clinical teams 
 Support 
 senior staff   
 outreach research 
 department specific team 
Lack of feedback from research  Research is important 
 
7.3.8.1.1 Nursing workload, prioritisation and responsibility  
Throughout the discussions nursing staff referred to their workload and stated that many 
nurses already felt overloaded and working at capacity.  If a family consented to a study they 
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would strive to comply with the protocol requirements, feeling a sense of personal 
responsibility as a 1:1 caregiver.  Negative comments reflected a sense of concern that they 
did not want to be the person who caused a study to ‘fail’:  
“...you don’t want to mess everything up, especially if it is something that has 
been run for the last four days very well... you don’t want to be the person who 
has then messed it up” (N-57F) 
This was counterbalanced by a recognition that although they thought research was 
important, their priority had to be the clinical care requirements: 
 “I have got to do what we need to do to save the child’s life and then if I possibly 
can I’ll take your samples… I did try hard to accommodate requirements for the * 
trial but if it had been impossible then I wouldn’t have given it a second thought” 
(N-74) 
Staff experienced a dilemma of wanting to support research but recognising there were 
insufficient resources.  This situation was summarised by one participant:  
 “We’re willing, but not able” (N-49).  
7.3.8.1.2 Lack of feedback from research 
Three nurses highlighted the frustration when the results of research were not shared with 
staff.  One highlighted the frustration she felt when a protocol for managing a particular 
group of patients was amended following an RCT on the ward, but the reasons for the 
change was never disseminated to the nursing staff:  
“I’ve got no clue what came out of it, other than the fact they <patients> are not 
on steroids now.  From the wards point of view, that’s the extent of our 
knowledge. They shouldn’t be on steroids, that’s it. As to why, I don’t know… So, 
it’s not really kind of communicated and filtered down.” (N-97) 
7.3.8.2 Facilitators for successful outcome 
7.3.8.2.1 Research is important 
Despite all the issues identified by nursing staff, there was a general sense from many staff 
that research contributed to improvements in patient care.  11 staff highlighted that PK 
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research could lead to optimised medicines management, improve the patient journey as 
well as potentially reducing the length of stay:  
“if you find that measuring drug levels, I don't know, every 8 hours or whatever, 
gives you a better control over the trough levels and therefore infections clear up 
quicker or something, then that becomes standard practice... wouldn't it?” (N-
98F) 
Nursing staff wanted to understand more about the impact of research on practice, what 
evidence supported changes and how that information had been gained. Feedback from 
each study to staff was therefore identified as important.  
7.3.8.2.2 Support 
The biggest facilitating factor for the conduct of a PK study was support.  Some nursing staff 
felt this could take the form of involvement of team leaders or the nurse in charge.  Senior 
staff were identified as useful as they could provide reminders and practical support to 
junior staff:   
“...if you inform the team leader or the Band 7 at least they can say at handover 
time, “Don’t forget that this patient has to have samples done.”  And then they 
can go and try and follow it up.” (N-57A) 
However, there was a recognition that support from trained research staff was the ideal 
method of study support, reflecting that responsibility for following the research protocol 
then shifted to the research staff: 
“...if you have an independent person who is from the research team, that is 
purely there to take those bloods and they will turn up at that time, they’ll bring 
whatever they need to take the bloods, they will sample independently.  It means 
the bedside nurse can almost forget about it... Therefore, your odds of it being 
missed, your odds of there being a problem, are cut down because you have got 
that independent person”. (N-57F) 
Where staff were less clear was on the place of trained research staff who were external to 
the department- outreach support.  17 people felt any support was valuable, however 14 
people expressed concerns.  These concerns reflected that external staff would not be 
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competent in sampling and therefore their role would be to dictate the protocol to bedside 
staff, without providing any practical assistance.  Others reported a degree of suspicion in 
the competence of the research staff and would want to watch them closely to ensure they 
were satisfied with their technique, even when staff had evidence of training:  
“I think we would be more suspicious, I think you’d want to watch them a couple 
of times... If there is some person you’ve never met before… they can have 
something signed but I’d want to see for myself” (N-61C) 
When the research team was composed of internally-trained staff, for example, a PIC 
specific research team, staff had far fewer concerns. They felt a PIC specific team were more 
familiar with the environment and could interpret the clinical situation better:  
“Every situation I've been in where I've had a critically unwell patient and one of 
the PIC research team wants to talk to them, if you've said actually, I really don't 
think it's a good time, they've always listened... and they've walked away... I'm 
very conscious that you've got time limits to get these patients recruited but 
actually it kind of proves that their wellbeing was at the forefront of your minds as 
well.” (N-98F). 
7.3.8.2.3 Model of support 
Despite all the concerns, all 29 participants agreed that they would care for a patient in a PK 
study and assist with the study protocol where required (although only three nurses had 
actually undertaken GCP training).  Where staff differed was in the level of research support 
they felt should be provided.  Only 3 people (10%) felt research staff should undertake all 
study-related activity and 55% (n=16) felt a model of 50:50 shared responsibility between 
research and clinical staff was appropriate (see Figure 44 below).  
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Figure 44: 'ideal' research nurse involvement in a PK trial (nurses views) 
 
However, of the 55% who stated the study should be run on a 50:50 basis, 3 specifically 
stated this support should be split over the 24-hour period, 7 days / week with the ability to 
flex according to unit need which has implications for research service provision:  
“50/50 split but you want that 50/50 split to cover the whole 24-hour period 
because you want to have the choice of you doing it or them doing it” (N-106D) 
Overall there appeared to be high levels of support for the conduct of PK research but this 
was dependent on support being available over a 24-hour period, 7 days a week which 
exceeds current provision.   
7.3.9 Context of research 
A number of nursing staff expressed concerns about the conduct of PK studies in the context 
of inpatient wards and PIC.   As none of the staff had worked within a research facility they 
were not asked specifically about this context. (See Table 49 below for a summary of barriers 
/ facilitators and Figure 45 to show the distribution of comments). 
Table 49: summary of barriers / facilitators to the context of research (nurses) 
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Figure 45: the influence of context on the conduct of PK research (nurses) 
 
In contrast to CYP and parents, nursing staff had reservations about PK research taking place 
on PIC.  Concerns reflected the workload, the acuity of the patients and also the challenge 
for staff of complying with multiple study requirements: 
 “It’s hard from a bedside nurse’s point of view, when you’re bombarded with four 
or five clinical trials that your patient could potentially be a part of...” (N-49) 
The ward context was also highlighted as challenging because staff to patient ratios were 
lower and there were issues about staff training and the lack of Registered Nurses assessed 
as competent to administer medications intravenously or sample blood:   
“I have worked on the wards… that trial would NOT work.  There is no way those 
nurses have enough time” (N-106D) 
In summary nursing staff had concerns about all contexts, including PIC.  Designated support 
was the only facilitator identified.  
7.4 Mapping to I-PARIHS 
Using the integrated PARIHS framework (Harvey and Kitson, 2016) the key aspects for the 
nurses as ‘recipients’ have been mapped out in relation to the ‘innovation’ – the 
implementation of PK research studies.  Context extends from the local clinical area, to the 
wider organisation.   See Figure 46 below.  
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Figure 46: summary of nurses’ responses mapped to I-PARIHS 
 
7.5 Discussion 
7.5.1 Pharmacokinetic knowledge and experience  
Nurses play a pivotal role in current NHS care delivery to support and deliver evidence based 
practice (Department of Health, 2006).  Determining research acceptability or feasibility to 
clinical staff is therefore fundamental if successful implementation is to occur.  PRESCRIBE 
found that although nurses do not have experience of PK research studies, they have 
extensive experience from clinical management.  These experiences indicate there are 
significant issues related to the prescription and timely administration of medications, 
particularly related to patient acuity, competing requirements for IV access and ward 
demands.  These issues would be magnified in the context of a PK study and they raised 
concerns about the accuracy of current documentation, particularly if population PK 
methods of conduct were to be adopted.  There are very few studies conducted exploring 
health care professionals’ attitudes towards PK research with which to compare the findings.  
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A survey of attitudes towards unlicensed and off-label prescribing in paediatrics found 
paediatric nurses were relatively unconcerned about the safety and efficacy of unlicensed 
and off-label medicine use, and only 49.3% perceived there was a requirement for more 
clinical trials in CYP (Mukattash et al., 2011).   This is consistent with a study of Paediatricians 
which found that although 70% had concerns about safety associated with off-label use of 
medicines, only 50% believed that further trials were indicated (McLay et al., 2006).  These 
ambivalent attitudes are concerning given that medication errors are common within 
inpatient paediatric settings (Kaushal et al., 2001). In comparison participants within 
PRESCRIBE demonstrated a marked concern about the vulnerability of patients in their care 
and a desire for increased knowledge about the medications they utilised.  This concern 
translated into positivity towards the conduct of PK research, with 100% of participants 
agreeing they would be happy to care for a child in a PK study.  By contrast, only 27.7% of 
paediatric nurses (Mukattash et al., 2011) and 52% of Paediatricians (McLay et al., 2006) 
would be willing to be actively involved with a patient in a clinical research study.  The 
reasons for these differences in attitudes are not completely apparent, but one factor that 
differed was that 26/29 participants in PRESCRIBE worked in Paediatric Intensive Care; an 
area where 70% of the medications are unlicensed or are prescribed off label (Turner et al., 
1998) and multiple organ failure is common  (Leteurtre et al., 2006).    Nursing staff on PIC 
recounted experiences of feeling uncertainty in patient management in the face of liver and 
renal dysfunction or with the use of Extra-Corporeal Membranous Oxygenation (ECMO) and 
Continuous Veno-Venous Haemofiltration (CVVH).  In addition, non-medical prescribing is 
increasing within the organisation with the result that medication management is 
increasingly viewed as a multi-disciplinary issue (Buckley et al., 2006).  Reports from nurse 
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participants in PRESCRIBE therefore indicate a high level of support in principle for PK 
research, valuing the information for clinical management.  There were concerns about the 
inclusion of young infants and neonates, which is of concern as approximately 50% of 
admissions to BCH PIC are less than one year and neonatal patients are the most exposed 
group to unlicensed and off label drug use  (Conroy et al., 1999).  Further work may 
therefore be required to address concerns of nursing staff about those identified as 
‘vulnerable’.   
7.5.2 Roles and responsibility 
Nursing staff were supportive of PK research and in keeping with other published literature, 
highlighted the importance of research for clinical practice (Nilsson et al., 1998, Bjorkstrom 
and Hamrin, 2001).  However, they expressed concerns about the addition of extra work to 
an already stretched workforce, factors which have been identified in other intensive care 
studies (Siner et al., 2014, Browning et al., 2016).  Only 20% of participants in one study felt 
that the practicalities of a protocol on their workload had been considered (Smith et al., 
2016).  The risk is that adding to the workload of clinical staff will interfere with non-
research care (Alt-White and Pranulis, 2006). In recognition of this concern, nurses in 
PRESCRIBE were happy to share the responsibility for the conduct of the research with 
research staff.  However, their preference was for flexible support, including weekend 
support from research staff.  This would mean offering research cover seven days / week, at 
the very least 7.5 hours / day, ideally 12 hours / day.  This level of cover is not currently 
available within BCH or within many (if any) tertiary children’s Hospitals and would have 
huge implications for future resource planning and funding at the organisational level.   
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7.5.3 Research support 
In addition to the level of support, the nursing staff within PRESCRIBE also had preferences 
on who provided the support. Outreach support was regarded as beneficial but overall there 
was a preference for support from a department specific research team who understood the 
clinical environment and could provide practical assistance as needed by the clinical team.   
Smith et al (2016) highlight that positive relationships between researchers and clinicians 
were associated with favourable perceptions of research and research acceptability amongst 
nurses.  Indeed 81% of nurses who had cared for a patient in a multi-centre PICU study 
agreed that they felt part of the trial team (Browning et al., 2016).  Whilst the significance of 
good working relationships is highlighted by the published literature, there is little reference 
to who provides this research support or preferences on the provision.  What is known is 
that there needs to be significant investment of support prior to the commencement of a 
study (Smith et al., 2016), good communication about the ongoing progress of a study (Alt-
White and Pranulis, 2006) and also feedback about the results (Kahn, 2009).  These were all 
recognised by nurses within PRESCRIBE.  It is conceivable that good working relationship are 
more likely to happen when research staff are embedded within a unit.  Within the last ten 
years, however, there has been a move towards research nurse support from NIHR Research 
Networks (National Institute for Health Research, 2016b).  These resources are often not 
department specific and therefore staff may not be familiar with, or competent, within an 
environment such as PIC 
7.5.4 Research culture 
All 29 nursing participants were supportive of caring for future patients in PK studies, despite 
practical concerns about the impact on their workload.  This positivity towards research is 
suggested to develop when nurses work in research-active clinical areas (Hek and Shaw, 
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2006).  This is supported by Browning et al (2016) who report that nurses with at least 3 
years PIC experience were more likely to have positive perceptions of a trial they were 
supporting (THAPCA) than those with less experience.  Perceptions were also more positive 
for nurses who had cared for a patient in any research study versus those who had not.  In 
Smith et al (2016) 63% of participants had cared for patients in a research study over 5 times 
in the previous 12 months and 78% reported that research leads to improved care. The 
literature therefore seems to suggest that exposure and experience of research increase 
positive attitudes towards research.   This is supported by findings from PRESCRIBE, where 
many of the nurse participants (both PIC and non-PIC nurses) had experience of caring for 
patients in research studies. Even when there were significant concerns about their 
workload, staff still felt PK research was important.  However, when the context of the 
vignette moved to ward areas, staff became less supportive, even with the presence of 
outreach support.  Positivity therefore appears to be dependent on the local culture and 
practical support availability.  
7.6 Limitations 
With the majority of respondents working on PIC, the results are heavily oriented to the 
perspective of PIC.  The study protocol had specified recruitment through ward managers so 
when Ward Managers failed to respond, there were limited opportunities to recruit clinical 
nurses from ward areas. A future recruitment strategy would be wise to utilise multiple 
recruitment strategies to ensure recruitment is not limited by gatekeepers.  PRESCRIBE was 
focused on the issues surrounding the conduct of PK studies in critically ill children therefore 
the perspective of PIC nurses was the most important.   
 
 
224 
 
Nurses were not asked about whether they themselves were parents.  Three nurses did 
make reference to personal experiences of administering medications or their child requiring 
blood samples.  Overall staff focused on their professional, rather than personal experiences 
so this did not appear to be a significant influence on staff attitude.  
In a dynamic environment such as PIC which also experiences rapid staff turnover there is 
the possibility that staff attitudes have changed since the interviews were conducted in 
2013/14. A national report of PIC activity indicates that the acuity of PIC patients is 
increasing and many units are struggling to meet the recommended staffing levels (PICANet, 
2016).  It would therefore seem that staff concerns about workload and ability to support 
research activity are likely to remain valid.  
7.7 How does this qualitative work with nurses address the 
knowledge gap surrounding pharmacokinetic studies? 
This chapter set out to address gaps in knowledge associated with the health care 
professional perspective, specifically the perspective of nurses, the influence of context and 
facilitation and has addressed all three aspects.   
1. Health care professionals can play a pivotal role in influencing the success implementation 
of interventions or results from research  (Thompson, 2012, Rycroft-Malone et al., 2013).  
However, there are very few papers exploring the attitudes of nursing staff towards 
research. Only one published account of PK research within the PICU context was identified 
and this emphasised the challenging nature of this environment, particularly ensuring the 
accuracy of timing (Siner et al., 2014). However, this study was in abstract form only and the 
method of study was unclear so limited conclusions can be drawn. PRESCRIBE is the first 
study the researcher is aware of to explore attitudes of clinical nurses towards PK research 
 
 
225 
 
studies in the context of PICU.   Findings suggest that Paediatric Nurses are supportive of PK 
research but there are a number of barriers which need to be addressed in relation to the 
timely administration of medications, sampling and overall compliance with a study 
protocol.   
2. The influence of context on research conduct and staff attitudes is also an area where 
little research has been conducted.  Existing literature is also limited by the inclusion of 
participants from both PIC and Adult Intensive Care settings (Smith et al., 2016) and by the 
use of surveys, which limit further exploration of attitudes (Smith et al., 2016, Browning et 
al., 2016).   PRESCRIBE is one of only a few studies to explore PIC nurses’ attitudes 
specifically, using interactive methods and explore the influence of context on research 
conduct.  The findings provide evidence that nurses support the idea of PK research taking 
place in PIC but have serious concerns about the conduct within a ward area.  This is an 
important message for those funding, designing and approving the conduct of PK studies.  
3. The third gap in the knowledge this work addresses is the identification of facilitators for 
future study design and conduct.  Nurses value strategies that demonstrate safety for 
patients in their care, good communication between clinical and research teams as well as 
support from research personnel. Findings suggest that there is a discrepancy between staff 
preferences and current research provision, which may hinder future research conduct.   
7.8 Conclusion 
Although the term ‘pharmacokinetics’ was not necessarily one nurses were familiar with, 
they had a working understanding of the significance and could see the value of increased 
information for medicine management.  The nurse stakeholder group prided themselves on 
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prioritising the care of patients and their families and they had a strong sense of 
responsibility for patients in their care.  They were supportive of PK research overall but 
collectively they agreed that they would struggle significantly to adhere to a protocol such as 
the one in the vignette.  Facilitation was predominantly about having dedicated research 
support- ideally from a PIC specific research team who could work flexibly, dependent on 
unit needs.  The current NHS research infrastructure is often from generic teams of research 
personnel; however, this is not in line with clinical nurses’ preferences.  Funders and 
researchers must seek to address these concerns or risk alienating and losing the support of 
clinical staff and compromising the quality of research studies.  
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Chapter 8: Exploring the attitudes of 
research personnel towards 
Pharmacokinetics studies in critically ill 
children  
8.1 Introduction 
8.1.1 What is known about research personnel attitudes toward PK 
research? 
Setting up and running a clinical trial is a complex process that takes time, planning and 
resources (Pick et al., 2011). Whilst a variety of personnel are required to assist with the 
delivery and support of research (Tattersall, 2002, National Institute for Health Research, 
2016c) much of the day to day management is undertaken by Clinical Research Nurses (CRN) 
(Mori et al., 2007, Pick et al., 2011, National Institute for Health Research, 2016d).  The role 
is not exclusively the domain of nurses and there are a variety of other terms used within the 
published literature including Clinical Research Associate (Grunfeld et al., 2002, Tattersall, 
2002, Wright et al., 2002), Research Assistants (Cambron and Evans, 2003), Research 
Associates (Ulrich et al., 2010), and Clinical Research Coordinators (Rico-Villademoros et al., 
2004).  However, whilst the title and clinical background have varied in different settings 
what is consistent is the importance of a role in enrolling and following patients throughout 
the clinical trial process.  For the purposes of continuity and clarity henceforth the role is 
referred to as Clinical Research Nurse (CRN).  The role of the CRN is vital and the most 
common skills and responsibilities include screening, recruitment and obtaining informed 
consent from patients and/or relatives; administration of the intervention being studied; 
monitoring participants, collecting data and reporting any adverse events (Connolly et al., 
2004, Mori et al., 2007, Gibbs and Lowton, 2012).  In fact once a trial has been successfully 
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approved Principal Investigators have been described as having a relatively ‘hands-off role’, 
with research work only constituting about 5% of their workload (Lawton et al., 2012). The 
CRN with their key responsibilities for recruitment and involvement in trial implementation 
has a pivotal role for successful trial conduct (Connolly et al., 2004, Gibbs and Lowton, 2012, 
Lawton et al., 2012).    This highlights the value of understanding the experiences of the CRN, 
particularly in relation to recruitment.  A meta-synthesis of researchers and clinician’s 
perceptions of recruiting participants to clinical research was recently conducted (18 papers 
included) (Newington and Metcalfe, 2014).  However studies discussing the recruitment of 
patients unable to give informed consent, such as children and young people (CYP) and 
studies in intensive care setting were specifically excluded due to the additional ethical 
issues surrounding these populations.   One of the key findings from the meta-synthesis was 
that compromise was required to create study designs that were acceptable to all involved.  
Understanding the perspectives of all concerned in trial conduct is therefore invaluable 
(Tinkler et al., 2018).  Further research is warranted to ensure the experiences of those 
conducting research with populations such as CYP and in contexts such as intensive care is 
captured as this is missing from the current evidence-base.  
8.1.2 What is known about the approvals process for pharmacokinetic 
studies?  
In addition to permission from Research Ethics Committee (REC) approval to conduct 
research within the NHS, researchers must also have confirmation of management 
permission from each local site (National Institute for Health Research, 2016e).  A 
parliamentary report on clinical trials highlighted that separate local NHS Research and 
Development (R&D) approvals was one of the biggest barriers to initiating clinical trials in 
the UK and contributed to a 22% decline in the number of clinical trials conducted in the UK 
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between 2007 and 2011  (House of Commons Science and Technology Committee, 2013). 
The time taken for local R&D departments to approve the application has been the primary 
focus of criticism (Elwyn et al., 2005, Al-Shahi Salman et al., 2007, Hackshaw et al., 2008, 
Mallick and O'Callagan, 2009),   often with no explanation for delays (Al-Shahi Salman et al., 
2007, Hackshaw et al., 2008).  There are suggestions that REC members can have concerns 
about the conduct of research with CYP, particularly where there are additional invasive 
procedures  (Angell et al., 2010). However, little is known about the considerations R&D 
departments make when reviewing a research protocol or about their decision-making 
priorities.  Further research is required to understand more about the attitudes of R&D 
departments, particularly given the serious impact of delays on successful study conduct.    
Chapter 8 aims to address the gaps in knowledge related to research staff attitudes towards 
PK research, explore the influence of context on research staff attitudes and identify 
facilitators to research conduct (see Figure 47 below). 
Figure 47: gaps in the knowledge- research personnel 
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8.2 Research aims 
The aim of this work was to determine the attitudes of research staff (Clinical Research 
Nurses (CRN) and Research and Development (R&D) panel members) towards paediatric PK 
studies, identify what participants perceived to be a barrier or problematic about the 
conduct of paediatric PK research studies and identify what participants identified as 
enabling or facilitating the conduct of PK research studies.  Please see Chapter 2 for full 
details of the methods undertaken. 
8.3 Results 
8.3.1 Demographics 
Recruitment to focus groups and interviews took place between 01.04.2013 and 01.04.2014.  
47 Research staff participated in nine focus groups (FG) (n=42) and five interviews (n=5).  
One focus group (with 4 CRN West Midlands staff) was of too poor audio quality to be 
analysed, therefore, results from 43 research staff (8 FG and 5 interviews) are reported. 
 Ward specific (Birmingham Children’s Hospital (BCH))– Paediatric Intensive Care (PIC) 
(n=5) & Burns ward (n=1) = 6 
 Wellcome Trust Clinical Research Facility (WTCRF) (BCH): 13 
 Neonatal research team (Birmingham Women’s Hospital (BWH)): 3 
 National Institute Health Research (NIHR) Research Network (West Midlands (WM)): 8  
 National Institute Health Research (NIHR) Research Network (South West (SW)): 13 
Participants included Band 5 (n=5), Band 6 (n=33), Band 7 (n=5) (see Table 50 below). Table 
51 provides the codes for participants’ ages, paediatric experience and research experience. 
Despite person specifications within the NIHR Research Network posts being open to Allied 
Health Professionals, all staff were Registered Nurses.  The term Clinical Research Nurse 
(CRN) is therefore utilised.  CRN staff worked in a variety of areas and hospitals. 
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Table 50: recruited CRN staff participants’ demographics 
Participant Age Gender Band  Department Paeds 
experience  
Research 
experience 
Method 
45A* 2 F 6 PIC 3 2 FG 1 
45B* 3 F 6 PIC 4 2 FG 1 
45C* 3 F 6 PIC 3 2 FG 1 
45D* 4 M 5 PIC 3 2 FG 1 
45E* 5 F 6 PIC 5 3 FG 1 
48* 4 F 6 NIHR (WM) 5 3 Interview 
50A* 3 F 6 WTCRF 3 1 FG 2 
50B* 5 F 6 WTCRF 5 1 FG 2 
50C* 3 F 6 WTCRF 4 1 FG 2 
52A* 3 F 6 NIHR (WM) 4 1 FG 3 
52B* 5 F 7 NIHR (WM) 1 4 FG 3 
52C* 5 F 7 NIHR (WM) 5 2 FG 3 
52D* 5 F 6 NIHR (WM) 5 2 FG 3 
52E* 5 F 6 NIHR (WM) 5 3 FG 3 
52F* 4 F 6 NIHR (WM) 5 3 FG 3 
52G* 5 F 6 NIHR (WM) 5 3 FG 3 
67* 3 F 6 WTCRF 3 1 Interview 
68A* 2 F 5 WTCRF 2 1 FG 4 
68B* 1 F 5 WTCRF 1 1 FG 4 
68C* 1 F 5 WTCRF 1 1 FG 4 
72A* 5 F 6 WTCRF 5 1 FG 5 
72B* 2 F 5 WTCRF 2 1 FG 5 
72C* 3 F 7 WTCRF 4 3 FG 5 
72D* 3 F 6 WTCRF 4 3 FG 5 
77* 2 F 6 WTCRF 3 3 Interview 
78* 3 F 6 WTCRF 3 2 Interview 
79A* 3 F 6 Neonatal 4 3 FG 6 
79B* 5 F 6 Neonatal 5 2 FG 6 
79C* 5 F 6 Neonatal 5 2 FG 6 
88A* 5 F 6 NIHR (SW) 5 2 FG 7 
88B* 4 F 6 NIHR (SW) 5 3 FG 7 
88C* 2 F 6 NIHR (SW) 3 2 FG 7 
88D* 2 F 6 NIHR (SW) 3 1 FG 7 
88E* 5 F 7 NIHR (SW) 5 3 FG 7 
88F* 5 F 7 NIHR (SW) 5 3 FG 7 
88G* 3 F 6 NIHR (SW) 4 3 FG 7 
88H* 5 F 6 NIHR (SW) 5 3 FG 7 
88I* 4 F 6 NIHR (SW) 5 3 FG 7 
94* 4 F 6 Burns 4 2 Interview 
95A* 4 F 6 NIHR (SW) 5 2 FG 8 
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Participant Age Gender Band  Department Paeds 
experience  
Research 
experience 
Method 
95B* 3 F 6 NIHR (SW) 4 2 FG 8 
95C* 4 F 6 NIHR (SW) 5 2 FG 8 
95D* 5 F 6 NIHR (SW) 5 1 FG 8 
*= GCP trained 
Table 51: codes for age and experience of CRN participants  
Code: Age Experience 
1= 21-24 years 1= </=2 yrs 
2= 25-29 years 2= >2 years- 4.9 9yrs 
3= 30-35years 3= 5- 9.99yrs 
4= 36-40years 4= 10- 14.99 yrs 
5= 41-50 years 5= >/=15 yrs 
 
R&D participants included R&D Manager, representative from laboratories, a trials portfolio 
manager and Research administrator (see Table 52 below) (4/10 panel members). 
Table 52: summary of recruited R&D participants’ demographics  
Participant Age Gender Band  Department Paeds 
experience  
Research 
experience 
Method 
118* 3 F 8C R&D
1 
3 4 Interview 
119A* 5 M 8A R&D
2
 5 4 FG 1 
119B* 4 F 6 R&D
3
 3 3 FG 1 
119C* 5 F 6 R&D
4
 5 5 FG 1 
1
R&D manager, 
2
Laboratory Research Manager, 
3
Trial portfolio manager, 
4
Research administrator *= GCP 
trained 
 
Following introductory material all CRN and R&D staff stated they felt comfortable with the 
topic of pharmacokinetics.  When questioned for a definition, some provided a relatively 
detailed response, reflecting an understanding of what a PK trial would incorporate: 
“pharmacokinetics is what the body does to a drug as opposed to 
pharmacodynamics, which is what the drug does to the body. Obviously, it 
involves a child taking a drug, whether it be orally or an injection or intravenous, 
and then monitoring at set points, taking a sample of blood to see how the body’s 
metabolising the blood, toxicity levels, things like that, and it can be blood or urine 
as well” (CRN-48) 
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Other comments reflected a more practical, outcome-focused definition associated with 
getting the dose ‘correct’ for patients.  27/43 (63%) had experience of caring for a patient in 
a PK research study, particularly those working within the WTCRF (11/13).    
8.3.2 Themes 
Coding was condensed to the six core themes referred to within chapter 6. Quotes from CRN 
and R&D staff are cited as CRN- or RD- followed by their individual study number.  
8.3.3 Attitudes of research personnnel  
8.3.3.1 Attitudes of CRN 
CRN made large numbers of comments about the positive and negative aspects to 
conducting PK research (see Table 53 below).    
Table 53: summary attitudes towards PK research (CRN staff) 
Positive comments (56%) Negative comments (46%) 
 Inclusive approach 
 Families value choice & opportunity 
 Enhanced understanding of health 
condition for family 
 Age of CYP  
 Vulnerability  
 Health status  
 Burden on families 
 Influence of past experiences 
 Experimentation 
 Communication and comprehension 
difficulties 
 Age of CYP 
 Impact on staff 
CRN staff appeared to think positively about PK research with all CYP, but particularly in 
populations with rare diseases where there were limited treatment opportunities.  There 
was a feeling that research provided these families with some choices and the opportunity 
to gain knowledge and information about their child’s disease.  
“I think there's an element of as a research nurse... we’re in danger of thinking we 
know best.  And so, we might not ask a family or we might not let them know 
what's going on so as not to trouble them... But if you have a child with a chronic 
illness, even if you can't take part in a study, you like to know what's going on.  
You like to know what may be out there in the future.” (CRN-88E) 
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Negative comments reflected the challenges of approaching and conducting this type of 
research, with particular emphasis on the perceived vulnerability of the child, the distress of 
both the CYP and parents, the influence of the child’s health status, the burden of study 
requirements, the concept of experimentation and the challenge of communicating 
effectively with CYP and parents with comprehension and communication difficulties.  Age of 
the CYP was identified as both a positive and negative influence, reflecting the challenges 
associated with conducting research in both older and younger CYP. Staff made numerous 
references to how they felt parents and CYP would feel about participation in PK research. 
CRN attitudes therefore appeared to be heavily influenced by the risks: benefit assessment 
they felt CYP and parents would conduct, although there was also some recognition of the 
challenges of conducting PK research for staff.    Overall CRN staff demonstrated a positive 
attitude towards PK research, with 100% (of those asked) supportive to working on a PK 
study (see section 8.3.8.2.6). 
8.3.3.2 Attitudes of R&D staff  
Although R&D staff reported some of the same positive impacts of participation within PK 
studies as CRN staff, generally their attitude was more circumspect. They focused 
predominantly on the practicalities of service provision (see Table 54 below) and were less 
concerned about what a study involved.  This slightly indifferent attitude appeared to reflect 
the huge influence of organisational prioritisation. 
Table 54: summary of staff attitudes towards PK research (R&D staff) 
Positive comments (35%) Negative comments (65%) 
 Families value choice & opportunity 
 Enhanced understanding of health 
condition for family 
 
 Vulnerability  
 Health status  
 Impact on service provision 
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8.3.4 Recruitment                                
Similar to the accounts by CYP and parents, recruitment was by far the most discussed 
aspect of PK research conduct amongst R&D staff and the second most discussed area by 
CRN staff. Within this sub-theme many discussions focused on factors influencing the 
decision-making process.  
8.3.4.1 Research staff perspectives on parents’ decision making  
Overall there was congruence between CRN and R&D staff on the five most commented on 
factors (see Figure 48 below).   These included routine vs novel treatments, improving their 
own care, pain and distress, health status and helping others.  Where the two groups 
differed was that R&D staff identified less influential factors and made far fewer comments 
about parent decision-making. Instead they focused more on factors that influenced their 
decision-making (see 8.3.4.2). 
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Figure 48: number and distribution of comments made by CRN and R&D staff about parental decision-making 
 
 
1. Routine vs novel treatments 
Both groups of research personnel felt the type of study was one of the biggest influences on a family’s decision-making.  This was the 
most commented on aspect by both sets of participants. If the drug was novel, not normally available or there were few treatment 
options available families would be open to considering recruitment.  In fact, there were anecdotes of research staff being contacted by 
families internationally trying to access clinical trials and tales of families feeling torn when their chid wasn’t ‘sick enough’ to participate: 
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 “my colleague... received emails from India and all over the world, families who’d 
got her contact from websites and things, desperate to come on the trial. And that 
was hard to deal with, really, because you knew how desperate they were, we just 
had to pass them on to the consultant, really, and he’d have to explain that not 
everybody can be on it...” (CRN-48) 
If the trial was for a ‘routine treatment’ or where there was no direct benefit to the CYP, 
staff felt recruitment could be more challenging.  
2. Pain and distress 
Both sets of participants recognised that additional painful procedures for research purposes 
were likely to negatively influence decision making by CYP and parents:  
 “Even from being a patient yourself, you don’t want to have extra stuff stuck in 
you if you don’t need them or extra injections if you don’t need it. That’s from an 
adult’s perspective, let alone a child’s where it’s going to be difficult to get veins 
and would cause undue distress.” (RD-119B) 
CRN staff provided numerous examples of the impact that painful procedures had and felt 
that many CYP did decline participation due to extra invasive and painful procedures:  
“Oh yeah.  I’ve had children not take part in a study because of the possibility of 
having bloods done.  They're happy to have everything else done but they don't 
want bloods taken.  So, they can't carry on with the study because of that.” (CRN-
72A) 
3. Health status 
Both sets of participants felt parents’ decision making would be influenced by their child’s 
condition at the time of being approached.   Comments reflected parent’s struggle to make 
decisions in the face of an emergency or life-threatening episode and an admission to PIC: 
“If they are in for something more major, I don’t know, like meningitis or 
something, yes I think that it would be low down as a parent on your list of 
priorities to agree to doing something like that.” (CRN-95C)  
4. Help others 
The motivation to help others was referred to by 19 CRN staff. CRN staff felt there was a 
high level of altruistic feeling towards research which might benefit other people in the 
future amongst CYP and parents, particularly amongst those with life-limiting conditions:  
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 “...They may be aware that they have a limited life span but they still want to 
comply with some research and give something back…They just remember what it 
was like at the beginning for them and so they want to give something back.” 
(CRN-88C) 
Altruism as a motivator however was rarely mentioned by R&D staff, with only one of the 
interviewees making reference to it.   
In summary although the most commented on aspects of decision-making were similar 
between CRN and R&D staff, R&D staff focused on CYP and parents participating to improve 
or access treatments for their own benefit. Although CRN staff did show some congruence 
with those of CYP and parents (reported in chapter 6) their prioritisation differed.  
8.3.4.2 R&D staff decision-making 
In addition to discussing influences on CYP and parents’ decision making, R&D staff also 
discussed factors that influenced their decision making about research approval.  Comments 
focused on finance and funding, approvals, targets and capacity (see Figure 49 below). 
Figure 49: decision making priorities of R&D staff 
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“...our funding has been cut substantially over the last few years, we’ve gone from 
about one-and-half million down to about 600,000, that’s had a massive impact… 
It won’t get approved if it hasn’t got funding associated with it.” (RD-118) 
Staff were also critical of the approval process by Research Ethics Committees (RECs), with 
comments reflecting a lack of scrutiny of research of paediatric trials. The result was they felt 
studies were approved which placed excessive burden upon CYP and their families: 
“They seem to be approved almost too easily sometimes, particularly where there 
is a young age group and... they’re asking for a lot of blood from a very young 
child, but approval never seems to be a problem… once demands have been 
approved by Ethics Committees, it’s quite difficult for us to say, “Well actually, we 
don’t agree with that.” (RD-119A) 
As well as finding it challenging to contest REC approved protocols the R&D panel also found 
it challenging to question the internal approvals process. The team cited cases of researchers 
with numerous studies in a department with limited resources approving more studies.  
They were therefore concerned about capacity and felt a sense of powerlessness to request 
changes or to refuse a study if there were concerns: 
“We ask for the clinical lead’s approval and if the clinical lead says yes then we 
assume, rightly or wrongly, that they are aware of this study and they know the 
implications for their department.  We can’t make that judgment that’s why we 
have to ask them. So, we have to trust them when they say, “Oh yes, we can do 
this study.” (RD-119C). 
All four members of staff reported concerns the hospital had reached research capacity.  
Targets were therefore referred to and there was a clear dilemma about approving studies 
where targets were not achievable and a study could therefore be perceived to be ‘failing’.     
CRN staff did allude to recruitment targets but were less driven by these as a metric.  R&D 
Committee members were most concerned about a study having sufficient funding and 
having been costed appropriately rather than the specifics of what a study involved.   
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8.3.4.3 Barriers to recruitment  
The biggest barriers to decision-making about PK study participation R&D staff perceived to 
be studies with no personal benefit / no novel treatments, pain and distress and the health 
status of the CYP at the time of approach. Other barriers / issues were identified during 
discussions surrounding recruitment (see Table 55 below for a summary of barriers and 
facilitators). 
Table 55: summary of barriers / facilitators to recruitment (CRN & R&D staff) 
 Barriers Facilitators 
R
e
cr
u
it
m
e
n
t 
Infants 
Palliative patients 
 Personal benefit to research 
 Choice / opportunity 
 Helping others 
 Patient and Public Involvement (R&D) 
Severity of health status Deferred consent
1 
Pain / distress  Analgesia 
 Use of indwelling lines for sampling2 
Experimentation Access to novel treatments 
‘Routine’ medication  
 
 Personal benefit 
 Help others 
Past experiences  Engagement with clinical teams3 
 Communication 
 ‘The approach’ 
Lack of choice Access to novel treatments 
Extra hospital appts  Planning 
 Piggy-backed to clinical appts 
Missing school  Home visits 
 Overnight stay 
Travel  
Funding Approval procedure review 
Capacity CRN review 
Targets  Realistic targets set 
 CRN review  
1
See section 8.3.4.4.7 
2
See section 8.3.6.2.1 
3
See also 8.3.8.2.2 
8.3.4.3.1. Study subjects 
CRN staff worked in a variety of environments and with a variety of patient groups.  Despite 
these differences CRN staff were united in the need to be inclusive to approaching patients 
and their families:   
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 “I think everybody deserves the opportunity to be offered the research... I don’t 
think a certain patient group should be denied something or you make the 
decision that they shouldn’t be included” (CRN-95C)  
By comparison R&D staff made far fewer comments on this subject (see Figure 50 and 
Figure 51 below).    
Figure 50: vulnerable study participants (CRN staff comments) 
 
Figure 51: vulnerable study participants (R&D staff comments) 
 
Both groups of participants became more negative in their comments when inclusion in 
research extended to infants, although only two people (CRN staff) specifically stated to 
exclude them:  
“Our parents struggle, struggle so much to take in what has happened to them.  
Even if they were expecting it, they still struggle to take in what has happened” 
(CRN-79A, research staff on NICU)  
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There were some reservations about approaching families of a CYP on a palliative pathway 
by CRN staff, although the right of families to choose was recognised.   Some staff made 
comparisons between the right to choose about research participation and the organ 
donation movement: 
“It always puts me in mind of organ donation – that sort of scenario does – and 
there’s lots of evidence in organ donation that supports the fact that the families 
were glad to have been given that choice” (CRN-45A) 
There was also a recognition that palliative patients were not necessarily ‘dying’ immediately 
and research could also lead to optimisation in their care, such as in pain management. 
 “And the drugs that they might be taking... Morphine, for comfort – are they 
receiving enough?” (CRN-45D) 
8.3.4.3.2 Hospital appointments 
The subject of appointments specifically for research yielded a high number of comments 
from CRN staff on some aspects (see Figure 52 below).  
Figure 52: the impact of research appointments (CRN & R&D staff views) 
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Extra hospital visits were raised as a concern for families considering participation by both 
CRN staff and R&D staff, as these were often in addition to clinically required visits.  There 
were concerns this could affect recruitment:  
“Even if they’ve come into the hospital on a monthly basis, which is fairly frequent, 
studies that ask them to come every week for medicine, to them that’s too much.  
We’re had studies not recruit because of that.” (CRN-72D) 
Missing school was also recognised as an influential factor by 7 CRN Staff:  
“...school actually, is the big thing. It’s not so much parents work. I find a lot of 
them saying they already miss enough school as it is, so that’s the big one. So that 
can be a problem, when they’re having to take additional time off school...” (CRN-
48) 
In comparison this was only referred to by one participant from the R&D staff.  Both CRN 
and R&D staff recognised that travel might impact on decision-making by families, 
particularly as many patients already travelled significant distances for their care provision:  
 “...they tend to drop out.  And a lot of the reasons is because of the blood samples 
or they don’t want to travel back to the hospital.  That’s been some of the 
reasons, because they have to travel.” (CRN-94) 
However, in comparison to comments by parents in chapter 6, neither group recognised the 
extent of this as an influential factor.  
8.3.4.3.3 Summary: barriers to recruitment 
In summary, there were many issues surrounding recruitment to PK research for CRN staff. 
Decision-making was felt to be negatively influenced by a lack of personal benefit, the 
potential for pain and distress and the requirement to make decisions at a time of 
deteriorating health status. Although there were concerns about the approach of vulnerable 
populations, staff supported the concept of broad inclusion criteria. Additional hospital 
appointments were viewed as problematic, particularly because of the potential for CYP to 
miss school.  R&D staff were less focused on who and what the study involved and more 
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about unrealistic recruitment targets, the capacity of the department to support the study 
and the funding available.   
8.3.4.4 Facilitators to recruitment 
8.3.4.4.1 Having a choice 
Many CRN staff felt families valued having a choice and the opportunity to contribute to 
future health care as well as the potential for personal benefit, such as improved pain 
management. There were also comparisons to that of the organ donation movement; 
recognising that being approached about research could become more acceptable over 
time. 
8.3.4.4.2 Emphasise the benefit of personal participation 
Personal benefit was perceived to be the biggest influence for families on the decision to 
participate. Studies that offered access to novel treatments were felt to be a positive 
influence as they offered access to treatments not widely available.  For more ‘routine’ 
medication there was a recognition that these could be more difficult to recruit to.  Both 
CRN and R&D staff therefore highlighted the importance of offering some form of personal 
benefit or enhanced level of care or monitoring for the child from participation: 
“a lot of the families we have in the study are from quite specialist areas and very 
up on the knowledge of their disease... and they take part when they realise there 
is a benefit to them” (CRN-95A) 
8.3.4.4.3 Communication and ‘the approach’ 
The importance of getting the level and depth of communication with parents and with 
clinical staff was referred to by CRN personnel.  There was also reference to the importance 
of the initial approach and contact with families about a PK research study.  Key factors from 
the CRN perspective were sensitivity, timing and an ability to assess each individual situation 
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and circumstance.  There was also reference to the personal qualities of the individual 
carrying out the approach: 
“It’s one of those on-the-job things, isn't it?  Because you kind of learn how to 
manage it and I suppose get more confidence on the difficult conversations and 
not 'comfortable', but more able and confident to do it.” (CRN-95C) 
This congruence with CYP and parents indicates that both potential participants and 
research staff are aware of the importance of this early contact to facilitate the recruitment 
process.  
8.3.4.4.4 Reassurance of safety 
Similar to service users and nurses, research personnel recognised the importance of safety 
as an influential factor on recruitment and study retention.   Key components to reassure 
patients and staff about safety were good working relationships with clinical staff, reference 
to guidelines (see section 8.3.6.2.2) and the provision of training. Education for clinical staff 
helped them to understand their roles and responsibilities and how to troubleshoot, which 
was vital when there was no research cover: 
 “I did a similar study in <adult> intensive care… I mean, you can imagine how 
many nurses you’d need to train up because any one of those nurses could have 
ended up nursing one of these patients... I can’t say that everything went 
completely smoothly…. It was just a matter of being available to support those 
staff who had not done research before and mitigating for all those things that 
might go wrong” (CRN-52B) 
8.3.4.4.5 Analgesia and distraction techniques 
The pain and distress that painful procedures could cause were recognised by CRN and R&D 
staff to influence CYP and parents’ decision-making.  The use of topical analgesia and the use 
of distraction therapy were therefore identified as potential facilitators, although neither 
were regularly specified within a study protocol:  
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“It’s just down to things like applying an anaesthetic cream prior to sampling, 
that’s not always in the protocol.  I don’t know.  I just feel sometimes it’s written 
as, you can just do it there and then (clicks fingers), when you can’t. We’re dealing 
with children, not adults.” (CRN-78) 
However, for the scale of the problem there were relatively few facilitators identified by CRN 
staff and none from R&D staff.   
8.3.4.4.6 Avoid / combine research appointments  
Extra hospital visits and missing school were identified as barriers for families considering 
participation in PK research studies. Different methods to reduce the impact of these were 
discussed, see Figure 53 below.   
Figure 53: alternative approaches to research appointments (CRN staff) 
 
The top three methods are summarised in Table 56, although overall there were relatively 
few facilitators identified by CRN staff and almost no comments from R&D staff. 
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1. ‘Piggy-backed’ to clinical care 
Nine CRN staff made reference to research appointments being added onto routine 
appointments or clinical reviews being added to research appointments to reduce the 
requirement for ‘extra’ hospital attendance: 
“.. with a lot of my studies now, I’ve had a lot of people say to me, ‘We will do the 
research, but can you try and fit it on a day we’re already here?’ (CRN-48) 
CRN staff also referred to ‘piggy backing’ of research samples, so samples were only taken at 
the same time as routine clinical bloods.  This method of opportunistic sampling minimised 
infection risks and there was no additional pain or discomfort for participants: 
“And we did get parents that would refuse you know, unless they were done at 
the same time as other bloods. So, it was a big thing that they had to be done 
when the bloods were done.” (CRN-79B) 
All the comments related to this method of combining research and clinical care were 
positive and this definitely seemed to be viewed as a way of reducing recruitment 
difficulties: 
“Yeah, in every sense... I would say, if you can piggy back research to their clinical 
care as much as possible, it's better all round.” (CRN-88B) 
2. Home visits 
Home visits were spoken about positively by 4 CRN staff to aid patient recruitment and 
retention to studies.  Staff commented that avoiding hospital attendance was an incentive to 
some families.  However, very few staff had direct experience of this and questions were 
raised about how that would work for higher risk trials. 
3. Overnight stay 
A study which required CYP to stay overnight as an inpatient was identified as extremely 
challenging, with one site identifying this as impossible: 
 
 
248 
 
“there was a cardiology study that we had to close before we even opened to 
recruitment.  And one of the major factors was they needed a bed for PK 
overnight.  And, the way the hospital is, and currently continues to be, you know 
the PI had to make decisions that this is never going to happen.  We'll never have 
that bed to do it.” (CRN-88H) 
There were however comments about strategies that had been developed to overcome 
these issues such as the use of local hotels for overnight stays.  However, this was only 
feasible where the study was funded through industry.  
8.3.4.4.7 Consider different approaches to traditional PK approaches 
In order to overcome issues and concerns associated with the sampling requirements of a 
traditional PK study alternative approaches were discussed. Figure 54 below summarises 
CRN staff attitudes towards a number of alternative PK methods. Table 57 then summarises 
the top four approaches.  
Figure 54: alternative approaches to PK study conduct (CRN staff) 
 
Table 57: top 4 preferences for alternative approaches to PK study conduct (CRN staff) 
CRN staff preferences 
1. Levels available for routine care 
2. Opportunistic sampling 
3. Deferred consent 
4. Other bodily fluids 
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1. Make ‘research’ levels available for clinical care 
Similar to CYP and parents, CRN staff felt very positive about the concept of making levels 
obtained within a study available for clinicians to potentially optimise patient care:   
“I think it is a level of reassurance from both the clinical and the parental 
perspective because... you are taking this blood but you are getting the result and 
then you are acting on that, so I think that is reassuring for them” (CRN-45D) 
However, similar to nursing staff they were concerned if the results would not alter care 
delivery then clinical staff would not engage with the idea:  
“If the doctors or whoever is looking after them believe that it is a key factor in 
their care and actually having those levels could help them and alter their care, 
maybe change it, definitely.  But if it was seen as a bit wishy-washy… then it might 
not affect it” (CRN-78) 
2. Opportunistic sampling 
Opportunistic sampling reflected samples taken alongside routine or clinically indicated 
samples. Overall this was a popular approach amongst research staff, with comments 
reflecting a belief that this reduced unnecessary sampling and therefore reduced infection 
risks.  There was also a perception that parents would like this approach.  However, staff 
concerns reflected that there would need to be monitoring on the overall number of 
samples taken i.e. the maximum number of samples /volume to be taken:  
“I guess opportunistic sampling still has a number in terms of what we’re looking 
for, four samples or six samples.  So, it’s just managing that alongside all the other 
bloods that they might have taken” (CRN-77) 
3. Deferred consent 
Amongst the 24 participants where deferred consent was discussed, staff mostly favoured it 
as a positive contribution to PK research, particularly in emergency and critical care settings.  
Negative comments reflected anxieties about parents’ reactions related to consent: 
“I think it is so drilled into us that we don’t do anything until we have got consent 
in research… I don’t know why but it does not sit comfortably with me to do that” 
(CRN-95A) 
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4. Other bodily fluids 
There were a large number of comments about the use of other bodily fluids for measuring 
PK levels, either in a study comparing results to blood or as an alternative to blood.  Overall 
staff were positive towards this method, with comments reflecting that CYP and parents 
would prefer non-blood sampling as it was less invasive and there was no pain associated:  
<parents> “They're much happier if you put a pad in the nappy.  Or they're happy 
for you to just collect from a catheter bag.  They don’t seem to be watching you as 
much as when you were taking a blood sample” (CRN-94)  
Where this was felt to be difficult was with an adolescent population, if specimen collection 
needed to be at specific times (particularly if not catheterised) or if large volumes were 
required, particularly in a neonatal population.   Overall staff implied that this was not 
necessarily an easy option and there were concerns that it might actually be more time 
consuming for staff: 
“I'm just thinking about blood versus urine, it’s probably as time consuming as 
each other really, infection control procedures and such-like” (CRN-88H) 
Overall CRN staff valued approaches which could contribute to a population PK approach- 
such as scavenged samples, use of alternatives to blood and using research care to improve 
clinical management.  R&D staff made very few references to alternative methods, focusing 
more on the challenges of protocol design.   
8.3.4.4.8 Funding, capacity and target setting 
R&D staff were concerned about the capacity of departments to deliver research to time and 
target.  Adequate funding was therefore the crucial facilitator for approval, however there 
was also a recognition of utilising appropriate resources to support activity as well as 
ensuring that realistic targets were set at the beginning so a study could be seen to succeed:   
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“I think we’ve learned a lot from these types of studies and so whereas before in 
terms of targets setting, before we’d be you might have 10 patients within the 
department that would be eligible, we could get five of them.  We’re a lot smarter 
now, we would now probably say we can get one...” (RD-119B) 
8.3.4.4.9 Patient and Public Involvement (PPI) 
PPI was identified as a facilitator for PK research by R&D staff because it ensured that the 
study was both important and acceptable to CYP and parents: 
“I think that’s why consumer involvement is really important... because it’s about 
seeing actually what parents and what children want to see done” (R&D-118) 
 
This could also serve to address concerns associated with all stages of a research study.  
8.3.4.4.10 CRN protocol review 
In addition to involvement of PPI participants to review the acceptability of a study, there 
was also a recognition of the value of locally based CRN review. CRN staff described a vital 
role in reviewing a protocol to determine feasibility and acceptability in the local context:    
“.. sometimes you find yourself in these meetings going, “Your protocol is great. 
We can see what you’re trying to do but actually in reality this is not going to 
work” …. The two don’t always marry up very well; the nursing side of things and 
how we think and how somebody who writes the protocol might think.” (CRN-77) 
One of the main stumbling blocks was whether a study would clash with hospital policy or 
accepted local practice and there were several accounts from CRN staff of having to 
challenge the study sponsors over the study protocol: 
  “You do have to fit around your hospital policy.  Because if anything went wrong, 
the first thing you do when you analyse an incident is, well were you doing 
something according to how we want it done at the hospital? And if you blatantly 
haven't, then you are on a sticky wicket” (CRN-88G) 
Local CRN staff therefore played a vital role in determining the fit between a study protocol 
and local practices.  Once a study was established as acceptable then planning and 
organising the study to ensure it ran smoothly became a priority. 
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8.3.4.4.11 Summary of facilitators 
Many facilitators identified by CRN were similar to those identified by CYP and parents. 
Appropriate communication, consideration of ‘the approach’ and engagement with clinical 
staff professionals were all identified as positively enhancing the recruitment process. CRN 
staff also felt the optimum study design should offer some form of personal benefit and / or 
benefit to future CYP, samples would ideally be taken alongside clinically indicated samples 
or research samples would be used to inform clinical care and additional hospital 
appointments would be ‘piggy-backed’ to clinically indicated appointments.  Consideration 
of analgesia and the promotion of safety were important facilitators. R&D staff focused on 
the adequacy of funding for research, careful assessment of capacity and the setting of 
realistic targets.  CRN staff were recognised as being a valuable resource to assess the 
feasibility of research at the local level.   
8.3.5 Medication   
8.3.5.1 Barriers/ challenges with medicines 
Research personnel were asked about their experiences surrounding the administration of 
medications to CYP. Barriers and facilitators are summarised in Table 58. Overall most of 
their observations were negative, predominantly reflecting problems encountered in drug 
administration (see Figure 55).    
Table 58: summary of barriers and facilitators to administration of medications (CRN & R&D staff) 
 Barriers Facilitators 
Medications Accuracy with administration  
Tablets/ palatability / changing for research Pharmacy review 
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Figure 55: experiences and attitudes towards medications (CRN & R&D staff)  
   
 
CRN staff recognised that taking medications was a significant problem generally and was a 
significant consideration in the conduct of PK studies:  
“they fell at the first hurdle.  If you can't get the drug in, you can't really go into a 
PK study for it.” (CRN-72C) 
Staff commented on the level of planning that went into a study and the complications 
created when there was an issue with the medication itself or issues with fitting the 
medication into existing regimes: 
“It’s so much out of your control.  You think you’ve covered it all and you're like, 
“Yes, I've got folders full of instructions on how to do this... and damn! The child 
won't take the drug, I didn’t think about that!” (CRN-77) 
The issue of tablets was specifically referred to by 11 CRN staff and 4 R&D staff, with 
comments focusing on the size of tablets and children’s ability to swallow them:  
“Children don't suddenly become able to take or want to take tablets at once, like 
when they hit eight or something, you know" (CRN-88F) 
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Palatability was similarly raised as a problem, with comments about the taste and smell of 
medications inducing nausea and vomiting and an aversion to oral medications: 
 “I’ve known of a study, I haven’t worked on it.  But there was a study where the 
medicine was so awful to taste they literally couldn’t take it.” (CRN-78) 
R&D staff commented that consideration of an appropriate formulation was an aspect that 
was often neglected in trial development. These studies then experienced recruitment or 
retention issues which could have been avoided if earlier consultation with a paediatric 
pharmacist had occurred. However, in spite of this there were reflections on the difficulties 
of changing a medication for the purposes of a research study if the current medication was 
seen as ‘working’ and the child was accustomed to taking it: 
“...It is a tablet, whereas these families are used to these dissolvable tablets, it’s a 
classic example, they’re struggling to get parents to change that, even something 
as small as that. And they’re really unwilling, families are thinking, ‘No, I don’t 
want to have to do that’…” (CRN-48)  
8.3.5.2 Facilitators with medications 
The main facilitator identified from research personnel responses was for early pharmacist 
input to review formulation, administration and proposed regime.  
8.3.6 Sampling 
As with CYP, parents and nurses, research personnel made many comments about issues 
surrounding sampling for PK studies.  Barriers and facilitators are summarised in Table 59 
below.  
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Table 59: summary of barriers and facilitators related to sampling (CRN & R&D staff) 
 Barriers Facilitators 
Sampling Capillary 
Cannulas 
 Use of indwelling lines  
 Conduct on PIC 
Blood volumes & frequency  Guidelines 
 Engagement with clinical teams 
 Consider alternative methods to reduce sample volume 
and number
1
  
o opportunistic sampling  
o other bodily fluids 
Sampling regime  Training 
 Support from research teams 
1
See also section 8.3.4.4.7 
8.3.6.1 Barriers to sampling 
8.3.6.1.1 Vascular access 
The type of vascular access was frequently discussed by CRN staff but not by R&D staff.  (See 
Figure 56 below).   
Figure 56: opinions on vascular access (CRN & R&D staff)  
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experiences of  obtaining samples from them, there were large numbers of negative 
comments (70 negative comments) reflecting that they did not bleed back well or for very 
long, siting them and manipulating them was traumatic, it was challenging to get the 
required volumes of blood required,  siting two cannulas as specified in protocols was 
incapacitating, CYP often had ‘poor veins’; with restrictions in where vascular access can be 
sited or because they were acutely unwell, siting them and manipulating them required 
skilled personnel and there was often no clear guidance for the care and maintenance of 
cannulas in protocols: 
“...people I think have been misled by this simplification where they say, “Oh, it’s 
only a teaspoonful of blood.”  But actually, from a small vein in a young child’s 
arm, getting 5mls, a teaspoonful, is not as easy as it sounds. It’s not until they try 
it that they appreciate how difficult it can be.” (RD-119A) 
“Talking about PK studies... by definition, that involves taking blood and the big 
question is who’s going to take it and are they available?  Surprisingly few nurses 
are trained in venepuncture... Doctors are never available when you need them.  
And the phlebotomists, they’re always complaining that they are overloaded”. 
(CRN-77) 
There were therefore a large number of barriers associated with the use of cannulas. 
8.3.6.1.2 Obtaining samples 
Similar to nurses, CYP and parents, CRN staff commented on blood volume, the number of 
samples and the required regime or sampling protocol (see Figure 57 below).  There were 
low volumes of comments by R&D staff.  Similar to CYP, parents and nurses, research 
personnel commented more about the volume of blood being sampled, than the number of 
samples.  Negative comments reflected perceived parental and staff anxiety about the 
volumes being sampled and a concern that these samples were in addition to clinically 
indicated samples: 
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“...you know, you’re taking 20ml and you don’t realise that the phlebotomist has 
got a form for another ten, so it’s just on each patient, really weighing up how 
large they are, what problems they’ve got, is it safe to do so.” (CRN-68A) 
Figure 57: attitudes to study sampling requirements (CRN & R&D staff) 
 
 
There was also uncertainty amongst research staff about acceptable sampling volumes, 
particularly studies which did not differentiate between participants based on age or weight.  
19 /30 participants (64%) asked did not know of a protocol/ guideline to refer to:   
“Do you know what, I don’t, I just refer to the protocol and I hope … I suppose I 
have always presumed the protocol is right, that it has been through ethics and if 
they’ve approved the volume of blood then I go on that” (CRN-95B) 
Where sources of knowledge were referred to (n=36) NIHR guidelines were the most 
reported guideline (n=11, 31%). However, reliance on clinicians (n=14, 39%) and personal 
experience was evident (n=4, 11%) (see Figure 58 below). 
“I also go on a bit of judgement as well, if you are looking at something and you 
know, thinking oh well that’s actually quite a lot of blood… So, I think some of it 
has got to go with your clinical judgement as well.” (CRN-95C) 
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Figure 58: sources utilised to determine acceptability of sampling (CRN staff)  
 
Although there were fewer comments overall about the number of samples, all 31 
comments on the topic were negative.  Many of the comments reflected concerns that 
frequent samples exposed CYP to more pain and distress.  A trial sampling regime was one of 
the most discussed aspects by CRN staff, with 41 / 43 participants commenting negatively 
about protocol regimes (100 negative comments).  These reflected the specificity and 
inflexibility of many trial protocols: 
“it’s just all those unforeseen things, isn't it?  It’s the child that won't take the 
drug, it’s the cannula that won't go in, it’s the cannula that won't bleed back, it’s 
the sample that you can only get half of what we need, it’s the one that goes out 
of the window.  It’s the problem that crops up in labs when you forget to put the 
little sticker on that goes off to the companies…” (CRN-77) 
There were also numerous references to the challenge of matching staffing to the 
requirements of the protocol, particularly through the evening and overnight periods: 
 “And the timings of the sampling – the four hours, eight hours, 12 hours, 16, 24 – 
absolutely, I mean we don’t …  We haven’t got the provision to do the night time 
samples”. (CRN-95A) 
R&D staff were in agreement, highlighting the impact of the regime not only for CRN 
staffing, but also for the laboratories staff processing and storing samples.  Overall both sets 
of participants were concerned about the impact of blood sampling on patients, particularly 
the total volume of blood required and the required sampling regime.   
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8.3.6.2 Facilitators to sampling 
8.3.6.2.1 Use of indwelling, clinically indicated vascular access  
Similar to both service users and nurses, CRN staff also spoke positively about the concept of 
sampling from arterial and CVLs; referring to their ease of use and lack of pain or 
inconvenience to the patient: 
“It's easier if they've got central lines then you know that you're almost 
guaranteed to get your samples” (CRN-72D) 
However, with very few of the interviewed CRN staff assessed as competent to access 
arterial lines this was identified as a facilitator only in areas such as PIC or theatres.  
Similarly, staff were not necessarily competent to access all forms of CVL, for example 
vascuports or port-a-caths.  There were also concerns that accessing CVLs for research 
purposes placed the patient at increased risk of infection:   
“I think some parents are really funny about how many times the line's accessed”  
 (CRN-88D) 
Utilising indwelling, clinically indicated vascular access devices were therefore identified as a 
facilitator, however CRN staff cautioned that this was subject to staff having the right 
training and competence to be able to utilise the lines.  
8.3.6.2.2 Reference to guidelines  
As outlined in section 8.3.4.4.7, alternative approaches which reduced the requirement for 
samples or considered the use of non-blood sampling were viewed as potentially facilitative.  
Despite concerns about the total sampling volumes required few participants utilised or 
were aware of guidelines to assess acceptability.  Protocols which reference guidance on 
acceptable volumes are welcomed by many participants (28/ 30) (93%): 
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“We couldn’t get an answer... it was all over the place, and everyone was saying 
different things, it would be nice, yes, definitely, to have something to think, ‘Yes.’ 
You feel confident when you’ve got guidance and you’ve got boundaries” (CRN-48) 
Reference to guidelines therefore appeared to be a strategy valued by both parents and 
research personnel.  
8.3.7 Processing        
Similar to all the participant groups, CRN and R&D staff did not highlight large numbers of 
barriers with the processing of PK samples.  Barriers and facilitators are summarised in Table 
60 below.  
Table 60: summary of barriers and facilitators in relation to processing (CRN & R&D staff) 
 Barriers Facilitators 
Processing Documentation accuracy  Training 
 Trial related paperwork / documentation 
 Laboratory staff involvement 
 
Negative comments reflected similar issues to nursing staff related to problems with the 
opening times of laboratories or issues with the timeliness of feedback on levels: 
“Also, vancomycin being given and… when the level finally comes back it was high 
but because it didn’t come back in time they had already had another dose on top 
of that.” (CRN-45B) 
CRN staff also raised concerns that current documentation of sampling would be insufficient 
for studies utilising scavenged samples or opportunistic sampling: 
“Yes, you also then run the risk of them writing either the wrong time just to 
please you or not giving a time at all which we have found previously with 
samples.  There has been no time or date recorded” (CRN-45C) 
R&D staff also commented that funding cuts had severely affected laboratory resources 
which could impact on successful study conduct.  
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Key facilitators were therefore the training of clinical staff to ensure accuracy of 
documentation, the development of trial paperwork to aid documentation and the 
involvement and support of lab staff: 
“We’re always very well prepared with the labs…* [from labs] does some amazing 
labels for us as well that clearly show his staff, and us, what to do and that’s a 
massive help” (CRN-48) 
8.3.8 Outcomes            
8.3.8.1 Barriers to successful retention and completion of a trial 
Key barriers and facilitators are outlined below in Table 61.  
Table 61: summary of barriers and facilitators related to study outcomes (CRN & R&D staff) 
 Barriers Facilitators 
Outcomes Clinical nurse prioritisation and responsibility   Engagement with clinical teams 
 Research culture 
 Support: 
o Outreach support 
o Dept. specific team 
Research staffing levels 
Attitude to research  Research culture  
 
8.3.8.1.1 Clinical nurse prioritisation and responsibility 
Throughout the interviews and focus groups there were numerous references from research 
personnel about the existing workload of clinical staff and their ability to carry out ‘research 
care’: 
 “We can't get away from the fact that the nurses are over-stretched.  The 
clinicians are completely over-stretched and I think to take on any more, there's 
quite a lot, it's a big ask, a huge ask in this climate.  And actually, even if you just 
get us, get a designated research personnel doing those things, there's a huge 
sense, you get more support” (CRN-88B) 
CRN staff appreciated that clinical staff prioritised clinical care requirements and as a result 
research care was a lower priority:  
 “I remember a clinical study that was going on and there was you know, there 
was breaches in protocol and stuff but I didn't see that as the bedside nurse's fault 
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because her priority was, and quite rightly should have been, looking after the 
patient and not trying to reiterate protocol.” (CRN-88C) 
The frustration for research staff was trying to ensure that all the patients’ needs were met, 
particularly when time and energy had been invested in setting up and planning a study.  If 
research tasks were delegated to clinical nurses who were juggling multiple commitments 
there were concerns these would get missed or completed incorrectly:  
 “I think ideally if it could all be done by the research team that would be great 
because you’d have a fairly accurately followed protocol.  I think as you dilute it 
down and delegate roles, then you don’t get the protocol followed as much...” 
(CRN-45B) 
CRN staff wanted to be able to support staff by conducting the research components of the 
job, leaving clinical staff to provide ‘clinical’ care and there were examples of staff working 
long hours to try and cover all research activities.  The challenge was that this was not 
sustainable and many teams could not provide this level of support.  
8.3.8.1.2 Research staffing levels  
Research staffing requirements were one of the most discussed topics by both participant 
groups, with 73 comments from CRN staff and 23 comments from R&D staff.  Not 
surprisingly given their concern about clinical staff ability to undertake research activity as 
well as clinical care, the biggest concern was the provision of cover for PK studies outside of 
office hours- ‘out of hours cover’.  Even within designated facilities such as WTCRF, staff felt 
it was a challenge to facilitate PK research on an ad-hoc basis:  
“We do offer a 24/7 service as and when we need to.  But, if you said the patient 
is coming in tomorrow to start that drug and have PK sampling, the repercussions 
of that are quite big really… you potentially have maybe up to six staff to move 
around.” (CRN-77) (senior member of staff within WTCRF) 
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Flexible cover was an issue, even for a team which provided seven days-a-week cover such 
as the PIC Research team.  At the present time no team felt they would be able to provide 
the flexible 24/ 7 cover a PK study would require on their current staffing:   
“I think at the moment there’s not enough of us at the moment to cover a 24-hour 
service. I heard it mentioned and I thought, ‘There’s only seven of us, so to cover-,’ 
(laughter) I don’t quite know how you’d work that one out...” (CRN-48) 
There were also safety considerations with the administration of potentially novel 
medications as part of PK studies. Staff cited the importance of ensuring trial activity was 
planned as much as possible for office hours in the event of an emergency: 
“we don’t like to really be administering a drug in the middle of the night and that 
sort of thing. Particularly if it’s a drug that a child has never taken.  So, you want 
that kind of infrastructure around you and being able to yell on down the corridor 
‘just give me a hand with this’… so we always want our high-risk stuff to be in 
those daytime hours” (CRN-77). 
8.3.8.1.3 Attitude to research 
A number of CRN staff reflected on challenges they had encountered with obstruction and 
negativity from clinical colleagues: 
“It is a teaching hospital however, the archetypal nurse who's been qualified for 
40 years doesn't want a bead of it... honestly. They don't want to touch it with a 
barge pole because it's more work on top of their normal workload. “(CRN-88C) 
Research staff felt that the work they were doing was important but felt there were 
significant organisational barriers from small numbers of negative clinical staff.  
8.3.8.2 Facilitators for outcomes  
8.3.8.2.1 CRN role 
As described in section 8.3.4.4.10, a key facilitator was the early involvement of a CRN to 
review a study protocol and determine local acceptability.  This pivotal role extended 
beyond helping with recruitment. 25 CRN staff and 3 R&D staff made reference to successful 
study outcomes- medications given on time, samples taken, participants completed the 
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study- dependent on effective planning and organisation by CRN staff.  Anticipation of 
potential problems was felt to be a key responsibility, with consideration made to anything 
that could influence the study conduct, including conflicting medications, the timing of 
procedures, physical space as well staffing requirements: 
“Everything has to be planned, because obviously, it’s all different times... 
Planning is absolutely crucial.” (CRN-78) 
Precision was also a key factor for a successful PK study outcome, in particular the accuracy 
of medication administration, sampling and the accompanying documentation: 
“A lot of it is down to the second... we are looking to the clocks to the second... We 
do our very best to do it at the right time… I think on here, you just are aware of 
how important it is to be so precise” (CRN 72D)  
Staff felt huge pressure to avoid inaccuracies or missing data and there were accounts of 
staff working long hours on overtime to ensure a protocol was followed: 
“those weeks when I have had patients in outreach, I've been known to do 50 and 
60 hours... it’s my job.  I've got to make sure it’s okay, because ultimately if the 
sample is missed... ultimately we’re the ones that have to explain it and fill in 
those gaps” (CRN-77) 
These facilitating behaviours or roles CRN staff played in the set up and conduct of PK 
research were therefore felt to have a crucial impact on the outcome of a study.  These roles 
were not specific to PK studies, but staff identified that PK studies were dependent on a 
number of these factors.  These aspects are summarised in Figure 59.  
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Figure 59: pivotal roles of CRN staff in the set up and conduct of PK research 
 
8.3.8.2.2 Clinical engagement  
There were 83 comments from 24 CRN staff about the importance of engagement with 
clinical staff and the development of good working relationships.   When research staff were 
visible and interacted with clinical teams, this not only helped to promote safety but also 
promoted support for a study, mediated against ‘gatekeeping’ and helped with the portrayal 
of research to CYP and their families:  
“...If you have a clinical team that's signed up to something because they 
appreciate..., for evidence based care, you can't just carry on giving X drug willy 
nilly without knowing how it's working.  If that is part of the discussion with the 
family and the child, they see much clearer why there is a need for these type of 
PK studies” (CRN-88F) 
This was important at all stages of research conduct. 
 
8.3.8.2.3 Research culture 
Not surprisingly for people employed to work in research, most of the research staff felt 
conducting research was important.  Comments reflected the value in developing treatment 
options, that research led to improvements in patient care and that it generated income:  
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  “Any research means that you’re wanting to improve a certain service or certain 
area.  So, I think it’s worthwhile.  If it brings in the big bucks then obviously, it’s 
even higher on the agenda.” (RD-118) 
However, the crucial facilitating factor was that this positivity was part of a strong research 
culture, where staff valued the place of research alongside, or even as part of, everyday 
work:  
 “It should be part of normal care.  Research should be just something that 
everyone does.  I think in practice it’s a lot of work to make that happen.” (CRN-
94A).  
CRN staff viewed themselves as having an important role to play in contributing to this 
culture: 
“We go on about being a teaching hospital, as research nurses our responsibility is 
to teach research.  To promote research to all. To help them, to enable them, to 
take it on in their very, very busy work schedules.” (CRN-88B) 
8.3.8.2.4 Feedback from research 
As part of a strong research culture there was a recognition of the importance of providing 
feedback from research findings to not only study participants, but also to clinical staff:  
“They should be informed, because they’re contributing because they want to help 
other people and they want to know that it’s going to make improvements in the 
future so I think they need to be involved a bit more and not just left after we’ve 
got what we wanted.” (CRN-48) 
Feedback ensured that the contribution of everyone concerned with the conduct of a study 
was recognised and valued.  
8.3.8.2.5 Support 
The biggest facilitating factor for the conduct of a PK study from both CRN and R&D 
perspectives, was designated research staff support. When this support was provided on an 
external outreach basis, CRN staff identified different strategies to help synergistic working. 
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One strategy was to ‘join in’ with the clinical team to help them with routine care in between 
research jobs: 
“I used to end up making beds and checking drugs and doing everything with 
them, just so they could see I wasn’t going to just sit and point the finger.” (CRN-
88C) 
Alternatively, staff took on roles which were clinically indicated (but had research relevance), 
to reduce staff workload.  Adopting these strategies and becoming ‘accepted’ was an 
important step, not just for the individual research nurse, but for research activity:  
“It does feel like you’ve ‘broken in’ doesn't it?  When you've conquered an area 
and they accept you.  You do feel quite triumphant that research is taking place” 
(CRN-88E) 
Similar to the nursing staff, CRN staff recognised that although clinical staff were grateful for 
any support, there were challenges to utilising a model of outreach research support.  Some 
felt that clinical staff did not understand or respect their role and at times could experience 
being made to feel unwelcome and uncomfortable: 
“How we all do when there’s a foreigner on the ward!  They end up following you 
around the ward like, “Who are you?  What are you doing?”  You feel 
uncomfortable” (CRN-78) 
Staff were also daunted by having to go into different environments, particularly highly 
technical environments such as PIC when they were not trained in the speciality: 
 “I think I’d have to have more specific training, I wouldn’t want to go to and just 
access any random central line, and also it’s ITU!” (CRN-67) 
There was widespread support for a department specific research team, not only from those 
who worked in such a team (5 from PIC, 3 from NIC and 1 from Burns team) but also from 
those working for ‘generic’ research teams (NIHR and WTCRF staff).  Where this resource 
existed, it was felt to offer huge advantages to research delivery:  
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“if you’ve got research coordinators and research nurses embedded in different 
departments and they’re part of multi-disciplinary teams and they discuss the 
trials that are open and discuss responsibilities with people… if it was more like 
that, in all departments then you would have a better stream of communication 
and better delivered studies.” (RD-119B) 
8.3.8.2.6 Model of support 
There was widespread support from CRN staff for the conduct of PK research, with 41/43 
CRN staff stating they would look after a patient in a PK study (1 did not answer; 1 had to 
leave the interview early) and 3/4 R&D Committee participants were similarly supportive.  
With reference to the PK study within the vignette (sampling over 24 hour period), two 
participants (CRN) felt research staff should provide 100% cover, reflecting concerns about 
missing data: 
 “because they don’t see the data queries that come through, it doesn’t impact 
them… they don’t deal with the trials units… The importance of it is not always 
reinforced to them. You can say it is really important but they don’t get the extra 
workload and they don’t answer to them” (CRN-45B) 
59% of staff (both CRN and R&D staff) felt support should be offered at a minimum of 50:50 
shared responsibility between clinical and research staff, in order for the study to run 
successfully (see Figure 60 below).   
Figure 60: 'ideal' research: clinical staffing ratios for PK research (CRN & R&D participant responses combined) 
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8.3.8.2.7 Summary of facilitators for outcome 
To facilitate the successful conduct and completion of a PK research study, key factors were 
the cultivation of a research culture, engagement with clinical staff and crucially research 
support. R&D staff emphasised the benefit of utilising WTCRF facilities or obtaining support 
from outreach services to facilitate research activity.  However, CRN staff advocated 
wherever possible to utilise the support of an embedded research team.   
8.3.9 Context 
8.3.9.1 Barriers to context of research 
Participants’ comments on the conduct of PK studies reflected three main areas: inpatient 
wards, WTCRF and Paediatric or Neonatal Intensive care (see Table 62 below for a summary 
of barriers and facilitators and Figure 61 below for a summary of comments).  
Table 62: summary of barriers and facilitators to the context of research (CRN & R&D staff) 
 Barriers Facilitators 
Context Wards  WTCRF 
 PIC  
 
Figure 61: attitudes towards the context of PK research (CRN& R&D staff) 
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Neither CRN or R&D staff had a favourable view of conducting PK research within inpatient 
ward areas.  Concerns raised focused on a lack of space to conduct research, the noise and 
lack of privacy of ward areas and the challenge of complying with protocols within this 
environment: 
 “I bet there wasn’t a single patient that all samples were taken correctly on the 
ward.  Was there?  Throughout the study” (CRN-45A)  
No, probably not” (CRN-45C) (Exchange between two PIC CRN staff). 
The use of designated research facilities was recognised as being a logical context for PK 
study conduct.  However, research with hospital inpatients, studies which required sampling 
throughout the 24-hour period and studies which could not be advance planned were 
problematic. 
8.3.9.2 Facilitators to context  
CRN and R&D Participants overall were most positive about the idea of conducting PK 
studies in PIC or NIC environments.  Positive comments reflected the fact participants had 
vascular access for sampling, staffing ratios were 1:1 and staff perceived there to be time to 
talk to families: 
  “When I first read it, it struck me … if they were in intensive care this would be 
much more acceptable and easier (sounds of agreement) because you have got 
the arterial line, you have got the nurse there, one to one.  You know, they could 
just go through that on their shift and say they need these bloods then, then, then 
and then.  To me, in my head, being an ex-PICU nurse, it is much easier and 
achievable than on a ward” (CRN-95A) 
Despite concerns about the vulnerability of families and the nature of research in the 
context of emergency situations, there was support overall for PK research within the PIC 
context.  Conduct of PK studies within WTCRF was recommended for studies which could be 
conducted on an outpatient basis with advanced notice.   
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8.4 Mapping to I-PARIHS 
The key aspects for the CRN and R&D participants were mapped to the Integrated PARIHS 
framework (Harvey and Kitson, 2016). See Figure 62 and Figure 63 below. 
Figure 62: summary of CRN staff responses mapped to I-PARIHS 
 
Figure 63: summary of R&D staff responses mapped to I-PARIHS 
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8.5 Discussion 
8.5.1 Perception of families’ decision-making 
Staff from both participant groups felt parents’ decision-making about participation was 
influenced by the type of study they were being recruited to, particularly if it offered a novel 
treatment option, and the concept of improving their own health.  However, responses from 
CYP and parents, reported they were most motivated by the concept of helping others.  This 
suggests that research personnel perceptions of patients’ and families’ motivations are not 
aligned.  This could influence the way staff approach or discuss research with families, or 
even influence who they invite to participate, particularly if they are perceived as vulnerable   
(Kendall et al., 2007).  Research nurses can experience significant discomfort and difficulty 
approaching patients  to discuss recruitment, to the extent that eligible patients are not 
approached  (Donovan et al., 2014). Research staff also influence recruitment ‘cherry-
picking’ patients to increase the chances of good outcomes, and avoiding patients thought to 
be ‘unreliable’ (Lawton et al., 2012).  These issues were raised by participants in PRESCRIBE, 
who expressed concerns about approaching vulnerable groups, families in challenging 
situations such as an emergency / life-threatening situation and avoiding families who failed 
to comply with treatments. These findings are of concern because they indicate that CRN 
staff could restrict who they approach to participate in future PK studies.  This comes at a 
time when despite campaigns emphasising that the public can seek out research 
opportunities (National Institute for Health Research, 2013),  less than 21% of the public 
report they would feel confident to do so (National Institute for Health Research, 2015b).   
Researcher-initiated approach to recruitment therefore still dominates and this could be 
compromised if researchers limit the inclusive approach.  This approach is also not 
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welcomed by CYP and parents, who value the opportunity and choice to participate (as 
identified in chapter 6).  
8.5.2 Research personnel priorities 
When discussing perceptions of a PK study R&D participants were focused far more on 
aspects associated with finance, resources and targets.  This is perhaps not surprising in a 
backdrop of declining clinical trials in the UK and blame being attributed to local NHS R&D 
approvals processes (House of Commons Science and Technology Committee, 2013).  
Research in this area has focused on identifying the impact of delays from the R&D approval 
process (Al-Shahi Salman et al., 2007, Hackshaw et al., 2008, Mallick and O'Callagan, 2009, 
Snooks et al., 2012), rather than why there are delays within this process.  Despite the 
significance of the approval role R&D has, R&D participants within PRESCRIBE reported 
feeling relatively powerless.  They reported feeling dependent on clinicians to highlight the 
feasibility and capacity of the organisation to conduct a study, but felt the pressure fell on 
them when a study failed to deliver recruitment to time and target.  Recommendations from 
R&D staff reflected getting the right people or facilities on board and making sure that 
appropriate targets had been set so the study could ‘succeed’.  Little research has been 
conducted with those in a regulatory role at a local NHS Trust level so there is little with 
which to compare these responses.  The findings from PRESCRIBE indicate there are multiple 
competing demands for those in regulatory roles in R&D and further work to explore 
decision-making would be of benefit.  
8.5.3 Role of the CRN 
As with the other PRESCRIBE participants, key facilitators of effective communication and 
engagement with families and research staff, reduction in additional burden for families and 
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training and support for clinical staff were identified.  What was different was that research 
personnel encapsulated these aspects into the roles and responsibilities of the research 
nurse.  The CRN role was therefore highlighted as the pivotal facilitator for PK studies.  
Within the published literature there is a growing recognition of the role of the CRN in 
research delivery (Mori et al., 2007, Gibbs and Lowton, 2012).  Whilst some authors have 
emphasised the role of the CRN in writing protocols (Pick et al., 2011), there is a suggestion 
that their local expertise and knowledge is well-placed to review the enactment of a study 
protocol within the local organisational context.  Organisational features such as referrals, 
clinic sizes, previous experiences, as well as resources, staff time and institutional identity 
can significantly impact on local conduct (Krein et al., 2010, Lawton et al., 2012).   By 
reviewing protocols for acceptability, determining feasibility at the local site and identifying 
factors both congruent and incongruent to the organisation, difficulties associated with 
patient accrual could be overcome  (Grunfeld et al., 2002, Kasenda et al., 2014, Pica and 
Bourgeois, 2016).  The potential for CRN staff to contribute actively to discussions about the 
feasibility and acceptability of research is therefore apparent.  CRN’s have been identified as 
integral to the success of NHS research (UKCRC Subcommittee for Nurses in Clinical Research 
Workforce, 2007) and findings from PRESCRIBE support this.   
8.5.4 Role conflict 
As recruitment to clinical trials is increasingly placed in the hands of research nurses (Pick et 
al., 2011, National Institute for Health Research, 2016d) understanding their perspective 
becomes increasingly important  (Grunfeld et al., 2002). Participants within PRESCRIBE had 
all worked as nurses first before joining research teams and many identified themselves as 
paediatric nurses first; research nurses second.  Many research nurses, regardless of their 
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employment basis, saw research roles of lower status and asserted the primacy of their 
clinical or caring role (Donovan et al., 2014, Tinkler et al., 2018).  This could be challenging 
for those with split roles who continue to work as a member of the clinical workforce and as 
a CRN or for staff who work with populations with greater mortality/ morbidity.  Staff can 
feel conflicted about the impact of strict protocolised RCT requirements and the 
inconvenience trial participation brings for patients and jeopardise the integrity of the 
recruitment process (Lawton et al., 2012, Lawton et al., 2015).   It therefore follows that a 
strategy of CRN staff operating on an outreach basis could potentially reduce role conflict.  
However, PRESCRIBE participants were far more supportive of a department-specific CRN 
team.  Even staff who worked for the NIHR networks appreciated the value of staff 
embedded within a department with enhanced knowledge of the clinical speciality.  In light 
of the findings from PRESCRIBE further work to compare and contrast models of working and 
the impact of these on clinical and research staff satisfaction is warranted.   
8.5.5 Engagement with clinical teams 
With no research service able to offer 100% cover, research personnel identified that 
engagement with clinical teams was vital for recruitment, patient safety and successful study 
outcome.  This is supported by a recent meta-analysis, which identified that successful 
clinical research was dependent on the engagement of researchers, clinicians and patients 
(Newington and Metcalfe, 2014).  Good working relationships between research and clinical 
teams and minimising the burden on local collaborators leads to good working relationships 
(Campbell et al., 2007, French and Stavropoulou, 2016). These findings are evidenced in 
behaviours described by CRN staff in PRESCRIBE, who reported helping with clinical care, 
taking routine samples alongside research bloods and developing tools to assist clinical staff, 
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in order to create good working relationships. However, there were reports of feeling like an 
inconvenience and having to work hard to gain support from clinical colleagues and these 
challenges are also recognised within the published literature (Tinkler et al., 2018).  
Relationships with clinical colleagues are fundamental for success in recruitment and 
successful study completion. Ultimately with clinical staff working close to maximum 
capacity there is a danger that clinical staff will feel pressurised by additional requests and 
research staff in PRESCRIBE recognised this.  This must be reflected in future research 
resource planning and allocation.  
8.5.6 Research services planning 
The largest concern for CRN and R&D staff about staffing centred on the support of clinical 
colleagues and the provision of support outside of office hours. None of the interviewed 
teams were able to provide 24 hours a day research support, especially for a study design 
that did not permit advanced planning.  This has serious implications for the conduct of all 
clinical research activity, not just PK studies.   There are huge cost implications for low 
enrolling studies as well as the implication of no scientific benefit gained   (Kitterman et al., 
2011).   A study examining the recruitment success of Medical Research Council (MRC) and 
Health Technology Assessment (HTA) funded trials found only 55% of studies recruited their 
target sample size and 45% needed an extension of time or funding (Sully et al., 2013).  The 
discontinuation of trials raises ethical concerns and wastes scarce research resources 
(Kasenda et al., 2014).   Despite this there is little examination of the staffing resources 
required to undertake clinical research activity and no published evidence for staffing ratios 
or models of working.   Staff within PRESCRIBE recommended research cover for a PK study 
for an average of 57% of the time, including weekends.   The evidence from participants in 
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PRESCRIBE from across the West Midlands and South West England is that this resource is 
not available. This has the potential to significantly impact on successful study delivery.  
8.6 Limitations 
8.6.1 Participants 
The original plan to interview 7-8 CRN staff was rapidly revised, once the diversity of the CRN 
team was fully appreciated. The work then developed into a multi-site study to capture 
perspectives from teams working in emerging areas of interest, such as neonates and staff 
covering a wide geographical area.  This was of enormous benefit to the perspectives 
captured, however it did add significantly to the time required for study conduct with 
application for amendments through IRAS and negotiating NHS R&D approvals.   It also 
added significantly to the workload of transcription and analysis although this did mean that 
saturation was achieved.   
It took some time to determine the best representatives for staff identified within the PPI 
work as ‘Hospital Managers’.  Once this was established as members of the R&D Facilitation 
Committee, negotiating access proved challenging. Despite several personal discussions and 
emails, the sessions took over one year to set up and was then rescheduled twice.  
Negotiating with gatekeepers was challenging and for the future, a variety of methods and 
utilising the support of senior staff should be considered.  
Whilst some CRN staff (n=4) and R&D staff (n=1) did speak of their own experiences of being 
a parent of a CYP taking medications or experiencing invasive investigations, this information 
was not collected as part of the demographic data.  As there were low numbers of 
comments reflecting personal challenges it was felt unlikely to have compromised 
interpretation of staff attitudes. 
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8.6.2 Subject matter 
The interview schedule was tailored to each professional group and their roles, therefore 
there were some small differences in the questions posed to CRN and R&D participants, 
although the same vignette was utilised.  In 2013/ 2014 when the interviews and focus 
groups were being conducted there were widespread criticisms of the research governance 
system (House of Commons Science and Technology Committee, 2013).   Huge changes in 
the local R&D structure and staffing as well as in the Health Research Authority (HRA) 
funding and approvals process followed shortly after.   The interviews therefore span a 
period of significant change nationally and locally which might limit the applicability of the 
research in 2017.   
There were references from R&D participants’ to the place of commercial PK studies, for 
commercial value and income generation.  Some CRN staff also highlighted working on 
commercial studies, particularly the WTCRF.  However as participants’ did not differentiate 
between the design and conduct of commercial vs non-commercial studies this issue was 
not explored in detail.    
8.7 How does this qualitative work with research personnel 
address the gap in knowledge surrounding 
pharmacokinetic research? 
Chapter 8 set out to address gaps in knowledge associated with research personnel 
perspective, the influence of context and facilitation and has addressed all three aspects.   
1. The existing literature suggests CRN staff could play a pivotal role in the conduct of PK 
research, particularly with recruitment and obtaining informed consent (Connolly et al., 
2004, Nagel et al., 2010, Lawton et al., 2012).  However, there is a paucity of research 
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surrounding the attitudes of paediatric research staff and none undertaken to review 
attitudes towards PK research conduct. PRESCRIBE therefore makes an important 
contribution to the current evidence base with 43 representatives from embedded research 
teams, research department specific staff and NIHR research network staff from two of the 
largest UK Children’s Hospitals and a tertiary Neonatal Hospital.  With enhanced 
understanding, measures to assist with research conduct can address both PK recruitment 
and study retention.   
There has been very little work to explore the research approvals process at local NHS sites; 
known as R&D approval (National Institute for Health Research, 2016e), particularly 
surrounding decision making by R&D staff.  PRESCRIBE is the first study the researcher is 
aware of to conduct interviews with representatives at local NHS level to explore their views 
on the approval and conduct of paediatric research.  Although only four participants were 
interviewed this work makes an important step towards understanding more about the role 
of key personnel involved in the R&D approval process and factors influencing their decision 
making. 
2. There are suggestions that local context has a large influence on the conduct of research 
(Krein et al., 2010) and participant reports within this study support this.  However, little 
work has been undertaken to examine the impact of research configuration, staffing ratios 
and local context. PRESCRIBE provides important evidence that utilising designated research 
facilities is not a panacea for the challenges of conducting PK studies, although they are 
useful for the conduct of studies on an outpatient, Monday-Friday basis.  The study has also 
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established there is support from research staff for the conduct of PK studies within the PIC 
and high dependency context which has not been reported before.    
3. The third gap in the knowledge this work addresses is the identification of facilitators for 
future study design and conduct.  Key facilitators are the development of good working 
relationships between clinical and research personnel, working together to ensure successful 
trial conduct. Research support is fundamental for success, ideally from a department 
specific research team with minimal additional samples and hospital attendances.  Although 
these findings focus on PK studies, there are observations which appear to be relevant to all 
paediatric study designs which involve biological sampling, detailed protocolised care and 
timely interventions.   
8.8 Conclusion 
Research staff are a highly knowledgeable resource for the conduct of PK studies and have a 
multitude of experiences to draw upon.  They are supportive of future PK research but this is 
highly dependent on the context and type of study.  Studies in rare diseases which can be 
planned meticulously in advance can be accommodated within designated research facilities 
(where these exist). However, PK studies which have no personal benefit to participants are 
more problematic.  Where PK studies are conducted in clinical areas there are likely to be 
significant issues in study conduct, particularly in the context of ward areas.  Conducting 
research in PIC is a concern to many research staff, due to the acuity of the patient and 
concerns about parental anxiety (Siner et al., 2014).  Despite this, there is support for PK 
research at this time due to the availability of sampling lines and because analgesia is usually 
optimised.  A model of approximately 60% research staff cover is the preferred model for 
support, however there is a recognition that few research services are able to provide this.  
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In addition, there are concerns about the ability of outreach support in areas such as PIC to 
meet research requirements.  The current model of generic research cover is therefore at 
odds with service user and staff preference for embedded research teams and this renders 
supporting these studies challenging.  Given the huge problems that exist with studies 
discontinuing and failing to recruit (Kasenda et al., 2014, Pica and Bourgeois, 2016) a key 
requirement is to ensure studies are appropriately funded and resourced with appropriately 
trained research staff competent to practice within the study context. 
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Chapter 9: What is known about the 
attitudes towards and barriers and 
facilitators to pharmacokinetic research: 
discussion and conclusions 
9.1 Introduction 
The purpose of PRESCRIBE was to establish the perspectives of stakeholders and understand 
more about the barriers and facilitators to conducting PK research.   The aim of chapter 9 is, 
using an implementation science model, to collate, compare and contrast the results from 
chapters 3-8 and summarise participants’ attitudes towards PK research and the barriers and 
facilitators to conducting PK studies. From this, evidence-based guidelines for future 
researchers are developed (see Chapter 10).   
9.2 Implementation science 
Implementation science models are recognised as being useful to promote the systematic 
uptake of research findings and other evidence-based practices into routine practice (Eccles 
and Mittman, 2006).  One of the key ways they are used is to identify key constructs that 
serve as barriers or facilitators (Nilsen, 2015, Birken et al., 2017) and PRESCRIBE has adopted 
the I-PARIHS approach (Harvey and Kitson, 2016) to frame an evaluation.   
9.2.1 Evidence /Innovation 
Innovation is evidence derived from research, clinical and patient experience  (Harvey and 
Kitson, 2016).  The higher the level of evidence across all three aspects, the stronger the 
evidence is regarded as being and the more likely the implementation will be to succeed 
(Kitson et al., 1998a).  PRESCRIBE commenced with a scoping review of published PK 
literature with broad inclusion criteria to identify the existing knowledge base surrounding 
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PK research design. The evidence was found to be weak; with no systematic reviews of the 
topic, no identification of factors facilitating conduct and a lack of standardisation to PK 
reporting.  The scoping review therefore makes a major contribution to the knowledge 
surrounding barriers to PK conduct through the categorisation of 5 major themes and a 
crude indicator of the scale and magnitude of each problem (Chapter 3).  Following this a 
thorough exploration of who the stakeholders were, how to engage with them and the best 
methods to use was conducted (Chapter 4) before in-depth explorations of their 
perspectives (Chapters 5-8). The evidence has therefore been developed through a 
combination of explicit knowledge, tacit practice-based knowledge and patient experience.   
9.2.2 Recipients 
This construct considers the impact individuals can have in supporting or resisting an 
innovation though their views, beliefs and established ways of practice (Harvey and Kitson, 
2016).  In recognition of this, understanding the views of stakeholders, termed ‘recipients’ 
within I-PARIHS, was a central feature of PRESCRIBE, with 6 key groups of recipients 
included. Representation extended from lay CYP in the school setting to those with 
experience of emergency and critical care services (CYP and parents) as well as health and 
research personnel.  In total 240 participants contributed to PRESCRIBE, including 146 CYP, 
through both quantitative and qualitative methods. PRESCRIBE has therefore achieved 
representation from relevant personnel and established that service users, health and 
research personnel value medicines’ optimisation and appreciate the importance of PK 
research.   
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In the sections below the barriers and facilitators associated with core themes are reviewed 
for similarities and differences between the recipient groups and in relation to the evidence 
from the scoping review.  
9.2.2.1 Recipient responses compared by the number and distribution of 
comments 
The five participant groups had their responses coded to seven core themes, although the 
individual sub-themes varied for each group. Table 63 shows the number of comments per 
theme for each participant group as well as the total number of comments / group. There 
was large variation, with only 424 coded comments from R&D staff compared to 3169 
comments by CRN staff however this appears to be in keeping with the total number of 
participants per group (see column 2).  
Table 63: the number of comments per theme for each participant group in PRESCRIBE 
Using a stacked column chart (see Figure 64 below), the breakdown of how much each 
theme was discussed by each group is shown. 
 
 
 
 
 
 
 No. 
participants 
Recruitment Medication Sampling Processing Outcome Context Facilitation Total 
CYP 26 628 116 245 1 118 107 271 1486 
Parents 18 1041 130 251 8 178 116 547 2271 
Nurses 29 275 98 259 13 161 34 441 1281 
CRN  43 863 165 534 59 375 154 1019 3169 
R&D 4 203 28 54 17 61 26 35 424 
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Figure 64: participant group comments per theme (% of total number of comments made) 
 
Recruitment was a significant topic across participant groups. However, this was a priority 
area for discussion amongst CYP, parents and R&D staff, with 42%, 46% and 48% of their 
comments (respectively) coded to recruitment.   Nurses and CRN staff, by comparison made 
fewer comments overall on this topic (21% and 27% of their total comments), although 
there were still large numbers of comments from CRN staff (843).   Comments focused on 
medications, processing and outcomes were relatively consistent in number across 
participants groups.  Nurses and CRN made a large number of comments about sampling, 
20% and 17% respectively of their total comments were coded to aspects related to 
sampling. They also commented about factors that facilitated PK research (34% and 32% 
respectively of comments). R&D staff commented less overall than any other group. They 
also commented the least on facilitative factors, which fits with observations made about 
their slightly submissive approach.  However, they were also the smallest group (n=4).  
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9.2.3.2. Recipient responses reviewed by theme 
Each theme was also examined to allow review of contribution on a topic (see Table 64 
below). Using a stacked column chart (see Figure 65 below) the breakdown of how much 
each group contributed to discussion on each theme is shown. 
Table 64: comparison of all coded comments per theme by participant group (percentage) 
 Recruitment Medication Sampling Processing Outcome Context Facilitation
CYP 628 (21%) 116(22%) 245(18%) 1(1%) 118(13%) 107(24%) 271(12%) 
Parents 1041 (34%) 130 (24%) 251(19%) 8(8%) 178(20%) 116(27%) 547(24%) 
Nurses 275(9%) 98 (18%) 259(19%) 13(13%) 161(18%) 34(8%) 441(19%) 
CRN 863 (27%) 165 (31%) 534(40%) 59(60%) 375(42%) 154(35%) 1019(44%) 
R&D 203 (9%) 28 (5%) 54(4%) 17(18%) 61(7%) 26(6%) 35(1%) 
Total  3010 (100%) 537(100%) 1343(100%
) 
98(100%) 893(100%
) 
437(100%
) 
2313(100%
) 
Range 9-34% 5-31% 4-40% 1-60% 7-42% 6-35% 1-44% 
 
Figure 65: number of comments per theme (%) (by participant group) 
 
Contributions within themes were relatively consistent across participant groups for 
medication, sampling and outcomes.  R&D staff provided very low volumes of comments on 
all themes, apart from processing where they contributed 60% of the comments made.  CRN 
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staff made the largest contribution to all themes, reflecting the number of participants in 
this group (n=43) but also perhaps reflecting their expertise in research.  The exception was 
recruitment where 55% of the total number of comments came from CYP and parents, 
highlighting the importance of these topics to service users.   
In conclusion quantifying the comments by both the theme and the participant group helped 
triangulate the qualitative themes expressed and discussed by participants (Sandelowski, 
2000a, Moule and Hek, 2011, Parahoo, 2014).  Priority areas for CYP and parents were 
recruitment and context, nurses and CRN staff made the most comments on sampling and 
facilitation (although CRN staff spoke in volume on all aspects) and R&D staff were generally 
focused on recruitment, although with a different focus to other groups.  Barriers and 
facilitators from the scoping review and recipients’ perspectives (chapters 3,5,6,7 and 8) 
have been compiled in Table 65.   
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Table 65: summary of barriers & facilitators (from chapter 3,5,6,7,8) 
Theme Sub-theme Perceived barriers Perceived facilitators 
Recruitment ‘Vulnerable’ participants’/ families Infants 
Palliative patients 
Age of CYP (barrier & facilitator) 
Acuity of condition / situation 
Choice / opportunity 
Personal benefit 
Help others 
Age of CYP (barrier & facilitator) 
Levels made available for care 
No additional samples/ sampling procedures 
Deferred consent (emergency situations) 
 Communication / comprehension 
difficulties 
CYP incapacitated /additional needs 
Parental distress 
 
Preparation 
Communication 
Involve CYP 
Support joint decision-making 
 Pain / distress Additional painful procedures 
Blood sampling 
Negative past experiences 
Analgesia 
Distraction techniques 
Use of indwelling lines 
 Appointments ‘Extra’ appointments 
Missing school 
Missing work 
Additional travel 
Joint clinical / research appointments 
Flexibility with appointments 
Home visits 
 ‘Experimentation’ Trials of ‘routine’ medications 
Trials of innovative medications 
Uncertainty 
Perceived lack of choice 
Personal benefit 
Help others 
 
 Safety Patient / family concern 
Health professional concern 
Reference to guidelines 
Visible engagement clinical & research teams 
Education / training  
 Organisational  Insufficient funding 
Unfeasible / no capacity 
Unrealistic targets 
Feasibility review at local level 
Capacity review 
Realistic targets set 
Medication Accuracy Errors in preparation / administration 
Study requirements 
Research support 
Training 
Trial documentation 
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Theme Sub-theme Perceived barriers Perceived facilitators 
 Formulation Tablets 
Palatability 
Formulation issues 
PPI 
Pharmacist review 
Sampling Vascular access Additional cannula 
Capillary sampling 
Additional access to CVL / Arterial lines 
Avoid cannulas/ capillary samples 
Use indwelling vascular access 
 Blood volume 
Frequency 
Anaemia 
Patient stability 
Safety 
Reference to guidelines 
Engagement with clinical teams 
Consider population PK approaches- 
opportunistic sampling, scavenged samples, 
non-blood 
 Regime Infection risk 
Disturbing 
Precision 
Training 
Support from senior staff/ research team 
 
Processing Accuracy Inaccuracy in documentation 
Technical failure 
Training 
Trial-related documentation 
Involvement of lab staff 
 Storage / transportation Incorrect storage / transportation Clear guidelines 
Adequate staffing resources (Labs / CRN) 
Outcomes Clinical nurse workload Excessive nurse workload 
Lack of senior nurse support 
Clinical prioritisation 
Engage with clinical staff 
Senior clinical staff support 
Plan for ‘out of hours’ 
 Research staffing resources Research staff unavailability 
‘Unsocial hours’ cover 
Embedded research team 
Outreach research support 
 Organisational  Negative research culture Feedback results of research to staff 
Research culture 
Context Ward areas Lack of research infrastructure Use designated research facilities (outpatient) 
Use PIC (if an inpatient) 
Ward- ensure adequate staffing (clinical & 
research) 
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9.2.2.3 Barriers and facilitators by theme  
9.2.2.3.1 Recruitment: summary 
Despite the scoping review reported in Chapter 3 going back to 1990 only 38 papers were 
identified which reported recruitment rates to paediatric pharmacokinetic studies.  Only 
seven of these papers provided rationale for why participants and their families declined 
participation (Carlsson et al., 1997, Agertoft et al., 1999, Conway et al., 2004, Dupuis et al., 
2006, Kokki et al., 2006, McGregor et al., 2012, Altcheh et al., 2014).  Rationale focused on 
the requirements for additional blood sampling and additional hospital visits. The qualitative 
work undertaken in chapters 5-8 therefore adds significantly to what is known about 
barriers to recruitment.  This includes perspectives about those deemed ‘vulnerable’, as well 
as the influence of the CYP health status at the time of approach, the acuity of the situation, 
negative past experiences, the type of trial and nature of the medication being offered, 
wider impact of attendance on CYP and parents as well as organisational considerations 
such as departmental capacity and targets.  Overall the groups were similar in their 
recognition of barriers. The key difference was the impact of extra appointments on families 
was under estimated by health and research staff.  R&D staff emphasised the barriers of 
funding, capacity and unrealistic targets, rather than aspects specifically related to study 
design or participants.   
The scoping review identified no studies which featured strategies to promote recruitment 
to PK trials, however all participant groups contributed valuable observations about 
facilitation.  The groups were similar in being positive about the importance of an inclusive 
approach to recruitment, the importance of good communication and a sensitive approach 
and there was support for the use of a deferred consent model in time sensitive / 
emergency situations, which is consistent with the published literature (Morris et al., 2004, 
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Morris et al., 2006, Harron et al., 2015).  There was also agreement that additional research 
appointments should be avoided, or coordinated with clinical care and flexibility in times of 
day / day of the week offered. The importance  of being involved in decision-making was 
one of the most highlighted factors by CYP, both in the lay population and by those with 
health care experience, a finding supported by a recent study with adolescents (Ingersgaard 
et al., 2017). The strength of CYP desire to be involved in the process was however 
underestimated by clinical and research staff and even parents. Research personnel also 
underestimated the positive influence of altruism on decision-making for service users, 
emphasising instead the influence of personal benefit. Research staff need to ensure they 
are aligned with the perspectives of service users when designing and conducting research 
or risk poor recruitment and retention.  Unless future studies are designed with service 
users’ preferences or utilise strategies identified as facilitating  there is a risk that high 
declining rates of 41% and over will be perpetuated.  
9.2.2.3.2 Medication: summary 
CYP wtithin paediatric inpatient settings and particularly within the PIC setting are 
vulnerable to medication errors (Manias et al., 2013). The scoping review identified this 
situation can also occur in the context of a clinical trial and can result in the withdrawal of 
participants and their data from trial analysis. The issue of prescription or administration 
errors within research was not specifically reported within the qualitative work.  However 
health and research personnel did make references to the challenges of timeliness and 
accuracy.  The scoping review also identified problems related to adherence to the 
medication regime or problems associated with the trial formulation which were 
coroborated by service users, health and research personnel.  
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Nursing staff were the only group to discuss potential solutions to issues with medication 
delivery.  They emphasised the value of effective study documentation to promote 
accuracy, training on adherence to the trial protocol and adequate research support to 
assist with trial medication preparation and administration.  In keeping with a published 
study about the role of pharmacists (Girard et al., 2013), R&D staff suggested the early 
involvement of pharmacy staff to review and anticipate any issues associated with drug 
availability and formulation. They also highlighted the value of PPI to review CYP and 
parents’ priorities, views and preferences.  This was also emphasised by CYP and parents 
who stated the importance of ensuring the acceptability of study tablets and formulations 
prior to commencing a trial.  PRESCRIBE participants were all aware of problems 
surrounding the medicine management of CYP.  To minimise issues within a PK trial these 
must be considered early on in the design stage. 
9.2.2.3.3 Sampling: summary  
The scoping review identified that sampling issues from infants and children were the most 
reported problem within the published PK literature (n=112 studies).  These reflected 
studies which had experienced problems obtaining complete samples, missing samples or 
incorrect sampling.  This caused the loss of approximately 10% of patients’ data, although 
there were examples of studies which had lost 80% of data (Woloszczuk-Gebicka et al., 
2014).  This was corroborated through the qualitative work.  All participant groups were 
negative about capillary samples or sampling from a cannula, the frequency of sampling and 
were concerned about the safety of blood volumes and the specificity of study protocols; 
although there was some variance between groups on which were the most problematic 
issues.  
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Numerous facilitators were identified. Some worked to provide reassurance or personal 
benefit to families and health care professionals through reference to guidelines on 
acceptable blood sampling requirements, discussion about the individual patient between 
research and clinical staff or feedback of research findings to inform clinical management.  
Other facilitators fitted with strategies that reduced the emotional stress associated with 
sampling through the use of analgesia and distraction techniques.   Strategies to overcome 
the practical challenges of additional blood samples involved methods that informed a 
population PK approach, such as opportunistic sampling and scavenged samples; these were 
highly rated by families, health and research staff.   Studies which continue to utilise 
traditional PK approaches with high volume, high frequency sampling run the risk of failing 
to recruit or  retain participants or failing to adhere to the protocol, with the subsequent 
risk of missing or inaccurate data..   
9.2.2.3.4 Processing: summary 
Inaccuracies in documentation of sampling can impact on the processing and interpreting of 
samples.  This problem contributed to the loss of approximately 5% of participants’ data 
within the scoping review (n=16 studies).  This is correlated with comments from parents, 
nurses, CRN and R&D staff over the accuracy of sampling documentation. The scoping 
review also identified problems associated with technical aspects which related to the 
mishandling of samples as well as storage and transportation issues, aspects not widely 
reported on by participants in the qualitative work. This issue is perhaps more significant 
than consumer, health and research personnel perceived, possibly because the issue is only 
recognised on analysis which may take place several months or years after samples were 
taken.  Trial-related documentation and associated training were identified as the biggest 
facilitators to target accuracy.  However, staffing resources to ensure sample handling, 
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storage and transportation are essential. This is a concern at a time when R&D staff 
identified budget cuts to areas such as laboratories.  These must be considerations within 
the assessment of future PK trial capacity.   
9.2.2.3.5 Outcomes: summary 
Withdrawal of consent or loss to follow up were significant issues within the scoping review 
(n=43 papers), causing the loss of a median 8% of participants. Reasons for withdrawal 
(n=15/43 papers) reflected extra blood tests and extra hospital appointments.  Withdrawal 
was not identified as an issue within the qualitative work and so does not specifically 
feature as a barrier.  However, this does mean that conclusions drawn about influences on 
recruitment can also logically be applied to influences on study withdrawal or attrition.    
The key barrier to the success of a study participant having all the data collected at all the 
correct time points were the resources available to support the study.  Although clinical 
staff were well-placed to support research activity, all PRESCRIBE participants identified that 
they experienced a heavy workload and would struggle with prioritisation and responsibility 
for research requirements. There were also felt to be issues associated with the availability 
of research staff as the role has traditionally assumed a Monday-Friday, office hours basis. 
The culture of the organisation towards research was also widely acknowledged to be 
influential on the attitudes of patients, families and staff towards research; if this was 
negative then conduct would be challenging. Despite these barriers, there was a strong 
sense of support for PK research with  82% of  CYP,  94% parents, 100% nurses, 98% CRN 
and 75% R&D staff stating they would participate in or support a PK trial.   This is 
significantly higher than figures calculated within the scoping review of 59%,  however as 
the qualitative study was posed on a hypothetical basis it is likely consent rates would in 
reality be lower.   Consent rates from lay CYP were closer to the scoping review, with only 
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49% saying ‘Yes’ to participation, although only 19% would say No outright.   Overall the key 
facilitator for successful outcomes was appropriate research support.  Where the groups 
differed was that CYP and parents were less opinionated on where this support came from. 
Health and research staff however, emphasised the value of department specific research 
teams, operating on a minimum of 12 hours / day, 7 days a week basis.   
9.2.3 Context 
9.2.3.1 Local context 
The context is an integral part of all determinant frameworks (Nilsen, 2015) and  is well-
recognised as an influential factor on the success of an implementation (Kitson et al., 1998a, 
Kitson et al., 1998b).  The influence of where the research takes place was not a well-
reported factor within the papers included within the scoping review.  However, context 
was identified as extremely influential by qualitative participants (n=120).  Neither service 
users, health or research personnel had confidence in PK research being well-conducted in 
ward areas. Designated research facilities were favourably viewed, but best suited to those 
classed as outpatients.  PIC as a location for research was viewed positively by all 
participants due to the presence of intravascular devices, analgesia and the high staff to 
patient ratios.  However, PIC nurses had concerns about the acuity of patients and their 
ability to adhere to a PK protocol, despite the 1:1 ratio.  All participant groups were 
concerned about the workload of clinical staff and expressed concerns about the impact for 
trial conduct if staff were not adequately supported.   
9.2.3.2 Organisational context 
Whether research is delivered by a department specific or outreach service, nursing and 
CRN staff would like to see funded support for around 60% of the time, 7 days / week.  The 
preference is for this to be a locally based competent research team who are familiar with 
the clinical environment, rather than a generic outreach model.  It is also worth noting that 
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outreach teams are also wary of environments such as PIC and can be reluctant or unable to 
take an active role in research activities such as sampling.  At an organisational level, this 
requires strategic planning to ensure there is capacity to support approved studies and the 
refusal of studies which are not adequately funded.  The organisation also needs to devise a 
strategy for coordinating research and routine clinic appointments.  With recognition that 
additional appointments are unacceptable to CYP and parents, there is a requirement to 
formalise coordinated services as a research strategy. The organisation also has a 
responsibility to consider the development and sustainment of a research culture, with 
better preparation for families about on-going research, the provision of feedback from 
research and the use of social media to highlight the place of research.  
9.2.3.3 External health care context 
The outer context reflects the wider health care system and the influence of policy, 
regulatory and political infrastructures (Harvey and Kitson, 2016). Emerging themes from 
PRESCRIBE reflected work to be conducted at a national level, to cultivate the research 
culture and the acceptability of being approached, similar to the organ donation movement.  
There are also recommendations from the NIHR to improve the education to CYP about the 
purpose and conduct of research (National Institute for Health Research and GenerationR., 
2014, National Institute for Health Research, 2015c).  This would lead to improved 
knowledge and understanding of the public about the research and potentially increase 
engagement. From a policy perspective, many of the research staff worked for NIHR CRN 
research networks which provide research infrastructure and support across departments 
and institutions.  However, participants within PRESCRIBE emphasised a preference for 
embedded research staff within specific departments, which is at odds with the local and 
national research strategy.   Findings from the scoping review highlight a need for a change 
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in culture towards the reporting of PK studies.  Studies should be reported to the same 
standard as other studies with accuracy and transparency in reporting research (Simera and 
Altman, 2009).      
The influence of context on the conduct of PK research has not previously been reported. 
PRESCRIBE highlights issues at local, organisational and national level that influence the 
conduct of quality PK research. These principles were derived from consideration of PK 
research studies but could be relevant to the set up and conduct of other paediatric 
research studies.   
9.2.4 Facilitation 
Throughout the study facilitators have been identified. From these a simple facilitation 
model has been developed (see Figure 66 below), recognising that some aspects were 
applicable within several themes.   
Figure 66: summary of facilitation (from all participant groups) 
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All the findings from chapters 3-8, have been plotted into a summary I-PARIHS diagram (see 
Figure 67 below). 
Figure 67: I-PARIHS summary of PRESCRIBE 
 
9.3 Reflexivity 
As outlined in Chapter one, there were a number of influences on the author, JCM during 
the conduct of the project.  Being a nurse with experience of PIC, the lead nurse for the PIC 
research nursing team and a former research nurse within the NIHR networks offered useful 
insights, however it also involved juggling role demands or expected responses. This 
challenge of managing blurred role boundaries is recognised as a particular challenge within 
nursing (Gerrish, 2003).   Over time strategies and scripts developed to assist with managing 
these situations and supervision was used as a time to reflect on these situations. During the 
conduct of the PhD the researcher also became a parent to two children, both of whom 
were service users at a (different) children’s hospital and were themselves research 
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participants.  Being on the ‘other end’ of health and research care provided personal insight 
into decision-making about research, particularly decision-making for a previously fit and 
healthy child in an acute and time limited situation.  Ultimately these experiences helped 
with understanding participants’ perspectives whilst reflection and carefully documented 
audit trail helped to ensure transparency at all stages.  
9.4 Limitations to PRESCRIBE  
9.4.1 Pilot project 
The study as originally outlined, was going to culminate in a small pilot of a PK study of a 
medication, using the evidence gained to design the study protocol. However, with little 
existing knowledge on which to base this pilot, there was a rapid realisation that this would 
not be achievable within the timeframes of the project.  Instead the focus changed to 
gathering the highest quality data on which to base recommendations for PK conduct.  
Whilst this means that the recommendations generated have not been implemented into 
practice, the researcher is confident that they are grounded in evidence.  There are clear 
audit trials demonstrating the decision-making process and data is tracked to sources to 
emphasise the confirmability and credibility of themes and sub-themes (Lincoln and Guba, 
1985).  Simultaneous data triangulation of the five qualitative work-streams allowed 
constant comparison between participants of the same group and between participant 
groups (Sandelowski, 2000a, Moule and Hek, 2011, Parahoo, 2014).  This facilitated the 
exploration of similarities and also highlighted negative cases (Parahoo, 2014).  The 
recommendations are therefore felt to be grounded in credible and trustworthy analysis.  
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9.4.2 Subject areas 
Since the study was started in 2010, innovations within the field of pharmacokinetics have 
emerged or developed; such as methods for obtaining blood specimens by participants 
themselves ‘self-sampling’ (Leichtle et al., 2010), other alternatives to blood, urine and 
saliva such as analysis of hair samples (Roberts et al., 2015), the use of dried blood samples 
(Patel et al., 2010, Patel et al., 2013) as well as developments in pharmacometrics and 
pharmacokinetic pharmacodynamic modelling (Coppini et al., 2016, Standing, 2016).  It was 
not possible to review the acceptability and feasibility of all specific methods, however 
many avenues were reviewed and comparison across service user and health care 
professional participants was possible.  
9.4.3 The duration of the study 
The PhD funding was awarded in 2009 when research into children’s medicines was a high 
priority (Saint-Raymond and Seigneuret, 2005, Duffin, 2007, Sammons and Choonara, 2007, 
Choonara and Bauchner, 2008).  There were concerns whether eight years on in 2017 the 
results from PRESCRIBE would still be relevant. However, the answer appears to be yes.  The 
research climate and culture across the NHS is improving (Department of Health, 2015).  
Children and young people are recognised as one of the 30 core research specialities 
(National Institute for Health Research, 2017) and the number of participants recruited 
annually to NIHR CRN studies has increased ten-fold (Lythgoe et al., 2017). Medicines 
research is benefiting from advancing techniques to conduct early phase drug studies in 
children and Rieder and Hawcutt (2016) assert that there has never been a better time for 
conducting drug studies in children.  Paediatric patients are exposed to substantial 
polypharmacy and are at risk of drug-drug interactions, particularly those with rare diseases 
(Feudtner et al., 2012).  Knowledge of clinical pharmacology, pharmacokinetics and 
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pharmacodynamics to personalise a patient’s treatment is essential for the future (Bhatt-
Mehta, 2016). The value of this work, which was recognised in 2009, therefore remains valid 
in 2017. The output from PRESCRIBE will help inform future PK research studies, not only 
within PIC but across paediatric settings.  
9.5 Future research 
9.5.1 Improvements in PK reporting 
One of the key findings from the scoping review was the lack of standardisation of reporting 
across published pharmacokinetic studies. Complete, accurate and transparent reporting 
should be regarded as an integral part of good research and publication practice (Simera 
and Altman, 2009) and this review highlights that reporting within this field of health care 
research is currently inadequate.  Recommendations for pharmacokinetic research 
reporting have recently been developed through expert consensus (Kanji et al., 2015) and 
these are registered on the EQUATOR (Enhancing the QUAlity and Transparency Of health 
Research) website (EQUATOR Network, 2017).  Whilst this is an important step forward to 
improving the accuracy and transparency of publications, there is no evidence yet of the 
impact of these on reporting. In addition, this work was conducted without qualitative 
consultation with service users and health professionals.  Further examination is therefore 
required to ensure this captures all of the findings from PRESCRIBE.  
9.5.2 Patient and public involvement and engagement 
One of the most difficult aspects of the whole PhD project was trying to undertake PPI with 
parents with relevant experience.  The challenges of this experience led to the paper 
Menzies et al (2016).  PIC is a complex and expensive area with many types of service user, 
patient acuity and outcome.  Research in this area is challenging and researchers need to 
ensure that the public are engaged to ensure that future research is well designed and 
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acceptable to patients and their families. Moving on from this, national collaboration is 
required with discussions of how PIC clinicians and researchers as a whole undertake 
meaningful PI with this difficult-to-reach group.   
9.5.3 CYP and parents 
Conducting research with lay CYP within the school setting and those with experience of the 
hospital setting was challenging but rewarding.  Neither group is well represented within 
published research and future research must make efforts to engage directly with CYP who   
can participate if the right method and support is found (INVOLVE, 2016a, INVOLVE, 2016b). 
In the school setting, there would be value in distributing the questionnaire on a wider 
basis, to more schools and allow a wider perspective and enhance the transferability of 
results.  In addition, the study could be extended to those in year 8 and below to explore 
developing attitudes and views and allow further comparison across secondary school.  
Research with CYP with experience of hospital and participation in research has often 
focused on those with specific diseases, notably cancer.  There are no accounts the 
researcher is aware of about those who have participated in research within the PIC setting.  
This is particularly important given the emphasis CYP themselves placed on wanting to 
participate in decisions about consent, which is challenging in the face of acute illness or 
trauma.  Future  research could also extend beyond a single PIC to a multi-centre study and 
review the transferability of research findings to another setting (Moule and Goodman, 
2009).   
 
Parents were the hardest group of participants to engage with.  Reasons for this were 
attributed to the complex needs of their children and the responsibilities they have for care 
delivery, even within the hospital location. To overcome some of these the researcher 
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conducted 7 interviews (8 people) within the parent’s own home.  Future research could 
explore parents’ preferences using alternative methods of engagement such as on-line 
forums, on-line surveys and interviews via video-conference calling (VIPER, 2013, National 
Institute for Health Research and GenerationR., 2014, INVOLVE, 2016b). These methods 
might facilitate participation from people who otherwise might not have the time, energy or 
transportation means (Menzies et al., 2016).  Recruitment and attrition are known problems 
to the conduct of research (Shilling et al., 2011, Tishler and Reiss, 2011) and the 
identification of methods to increase accessibility and facilitate participation is vital to 
address these.   
9.5.4 Health and research personnel 
PRESCRIBE features 26 PIC nurses and 3 staff from high dependency wards.  In order to draw 
more conclusions a possibility is to extend recruitment to another PIC.  There are variations 
in acuity and speciality amongst PICs and staff in a different hospital might have different 
views about PK research conduct.   In addition, extending the work to more ward staff 
would offer more insight. 
Representatives from two NIHR paediatric networks participated with PRESCRIBE. In order 
to explore CRN staff attitudes on a wider scale there is the possibility of extending the work 
across the NIHR paediatric network.  Large sums of money are invested within the NHS 
Research infrastructure to support the conduct of research studies.  However, the findings 
from PRESCRIBE suggest that the current model is not optimal for the conduct of PK studies.  
Further debate could be enhanced by an exploration of the cost implications for different 
service models and heath economics evaluation.  In addition, further research could focus 
on evaluation and comparison of service users’ experiences to explore consumer 
preferences further.   
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It would also be interesting to conduct further work to explore the approvals processes 
further, both at local R&D level and also within the REC approval process.   With significant 
re-configuration to the research approvals process over the last two years, it would be 
interesting to review staff attitudes and perspectives on the challenges of decision-making 
now.   
9.5.5 Guideline development 
With draft recommendations now developed (see Chapter 10), the next stage is to obtain 
external review with experts within the pharmacology field. A recent study on deferred 
consent in trials of emergency treatment of critically ill children (CONNECT Advisory Group, 
2015, Woolfall et al., 2015a) developed their study findings into recommendations through 
a one day guideline development meeting  (Lyttle et al., 2014).  The plan is therefore to 
develop a working group to develop these guidelines further using expertise from the PK 
field.  This work will be conducted later in 2018 following on from the PhD submission.  
9.6 Conclusions 
In 2009 at the time the scholarship was awarded there was wide spread recognition that it 
was unacceptable to continue to use medications off label and off-license, particularly  in 
the most vulnerable patient groups (Conroy et al., 1999, Conroy et al., 2000).  Very little 
qualitative research concerning research design had taken place, despite the fact that 
researchers acknowledged paediatric research to be challenging (Caldwell et al., 2004). 
Within the field of pharmacokinetic research, barriers to recruitment and trial conduct are 
alluded to in the published literature (Anderson et al 2007), but the scale and magnitude of 
problems or the identification of solutions had never been classified.  Utilising principles of 
implementation science, PRESCRIBE has compiled evidence from a mixed methods 
approach, including a scoping review, public consultation and qualitative inquiry with 240 
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participants into stakeholders’ attitudes and perspectives, with the overall aim to explore 
acceptability and design of PK studies in paediatrics.  Importantly the work has established 
that the conduct of PK research is viewed as important by both service users and health 
professionals, with both groups recognising the importance of optimisation of medications. 
The biggest barriers to the conduct of PK research were found to be the requirement for 
blood sampling and additional painful procedures, additional ‘research’ appointments and 
the lack of resources to conduct PK research within inpatient facilities.  To address these, 
researchers must take action to ensure pain and distress are minimised, additional clinic 
appointments are avoided or minimised and there is sufficient support by trained research 
personnel.  Despite concerns about the timing and approach of families, the conduct of PK 
research within PIC was regarded by service users and health professionals as acceptable, 
due to the presence of intravascular access, analgesia and good staff: patient ratios. This is 
an important finding as patients within PIC have been identified as those most in need of 
studies for both efficacy and safety.  The output from all of this work is evidence-based 
recommendations to assist future researchers with future research conduct. It is envisaged 
that better designed studies which are more acceptable to CYP and their families as well as 
to the clinicians who implement them, will facilitate studies which recruit to target with 
minimum attrition.   
Not only does research design need to improve to reflect the concerns of service users and 
health professionals, but so does the quality of reporting about the conduct of PK studies. It 
is unacceptable to ask patients and their families to participate in poorly designed PK 
studies which then fail to adequately report all stages of the patient journey, fail to report 
problems encountered in research conduct and fail to highlight significant design flaws to 
future researchers.  Inadequate reporting hampers assessment of a study’s strengths, 
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weaknesses and generalisability (Von Elm et al., 2007).  Standards have recently been 
published to improve this situation (Kanji et al., 2015).  The impact of these has yet to be 
examined but it is hoped these will improve the transparency of PK research and overall will 
result in improved quality conduct and reporting of PK studies.  
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Chapter 10: Recommendations for PK 
study conduct 
10.1 Introduction 
Recommendations have been generated from the work conducted throughout PRESCRIBE 
as detailed in chapter 2-7.  Items were coded to ‘recommendations’- some generic and 
some very specific statements- and then compiled using the same themes utilised 
throughout the study. An additional category was created: ‘study set up’ reflecting factors 
that needed to be identified and dealt with before a study should open to recruitment. See 
Figure 68 below.   
Figure 68: 'new' category ‘study set up’ added 
 
The source(s) of evidence for the recommendations are coded alongside each point using 
the initials identified in Table 66 below.   
Table 66: summary of how recommendations were compiled from chapters  
Chapter Method 
Chapter 3: scoping review (SR)
1 
 Reviewed themes and sub-themes 
 Review papers identified during search reviewed (as 
additional reference material)  
Chapter 5: survey with school children (SC)
1 
 Questionnaire responses reviewed 
 Free text responses reviewed  
Chapter 6: qualitative descriptive study with 
Children (CYP)
1
 & parents (P)
1 
 NVivo 11: node created ‘recommendations’ 
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Chapter Method 
Chapter 7: qualitative descriptive study with 
nurses (N)
1 
 If there was an element of advice or caution material was 
also coded to recommendations (in addition to themes) 
 All coded material reviewed and added to themed 
recommendations 
Chapter 8: qualitative descriptive study with 
Clinical Research Nurses (CRN)
1
 and R&D staff 
(R&D)
1 
1
Abbreviations used in the recommendations below 
Where evidence was generated from multiple chapters, multiple codes are identified and 
where there is additional reference material to support this this is also indicated as a 
referenced source.  
The approach taken is in keeping with that of a post-doctoral paediatric research project to 
explore parent and research personnel views on consent in children’s critical care trials 
(Woolfall et al., 2015b).  The study utilised a similar mixed methods approach of surveys, 
interviews and focus groups and achieved recruitment of 23 parents (interview), 10 research 
nurses, 3 Doctors, 4 clinical trials research staff (focus groups) as well as 275 parents 
(questionnaire).  From PRESCRIBE there is survey data from 120 school children, focus 
groups and interviews with 28 CYP, 18 parents, 29 nurses, 43 Clinical Research Staff and 4 
R&D staff as well as findings from 203 published PK papers summarised within the scoping 
survey. This is felt to be a representative group from which to draw recommendations and 
the next step is to develop the recommendations further, using a similar approach to 
CONNECT of expert consultation and consensus (Lyttle et al., 2014). 
10.2 What type of trials are these recommendations useful 
for? 
This guidance has been developed for any study that features PK sampling within any topic 
area within paediatrics. The principles cover all research designs, although it is recognised 
that there are more restrictions in place within Phase I and Phase II studies.  Although the 
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recommendations have been developed to guide those involved in PK studies, they may be 
of use for the design and conduct of other studies within paediatrics that involve biological 
sampling. Recruitment to clinical trials with CYP has been said to be the one of the biggest 
challenges for researchers to overcome (Caldwell et al., 2004, Sammons et al., 2007a), 
particularly within the PIC setting (Kanthimathinathan and Scholefield, 2014). Therefore, 
practical guidance which reduces demand and burden on families may be of use. This 
guidance features advice which is in line with GCP guidelines (National Institute for Health 
Research, 2016a), but is not designed to replace them as these are a legislative requirement 
(Department of Health, 2005). 
10.3 Who are these recommendations written for? 
This guidance is for all those who have a role in the design and conduct of paediatric or 
neonatal trials that involve PK or blood sampling.  This may include Doctors, Nurses and 
Research Staff with a role to play in conducting research studies.  Those with a role in 
reviewing and approving research such as Patient and Public Involvement (PPI) 
representatives, members of NHS Research Ethics Committees (RECs) and Research & 
Development teams may also find this information useful.  It is anticipated these guidelines 
will be of interest to those who are involved in the design of research within Clinical Trials 
Units, Pharmaceutical companies and those who fund research studies.   
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10.4 Recommendations
Section 1: Study set up 
 
Section 1: study set up
Recommendation 1.1: Hospitals need to raise awareness that a hospital is research 
active 
 There needs to be a clear message that a hospital conducts research and that parents 
can expect to be approached about research if their child is eligible for a study (P, CRN)
 The message about research taking place needs to be reinforced through letters or 
information sent through with clinic appointments and correspondence from the 
Hospital, recognising research can occur at any stage of a patient journey (P, CRN) 
Recommendation 1.2: Preparation for CYP and families about PK research should take 
place as early as possible 
 Inform and prepare patients and their families wherever possible, about studies which 
are in set up or actively recruiting (P, CRN) 
 Written information sent out prior to hospital attendance will allow CYP and parents a 
chance to familiarise themselves with a PK research study. This could extend from 
receiving information the day before a child’s operation to receiving information 
during the antenatal period if this is appropriate to the study (SC, CYP, P, CRN) 
 Consider making information about trials such as posters or leaflets available in areas 
where families might see them, such as coffee rooms and waiting areas (CYP, P, CRN)
 Clinical staff should be adequately prepared with information about the study so they 
are facilitated to answer questions during this information-giving phase (P, N, CRN)
Recommendations 1.3: Planning and organisation is crucial to PK study set up 
 The researcher and / or research staff2 will be familiar with the protocol and conduct a 
thorough review of the feasibility of all stages at the local site (CRN, R&D) 
 There needs to be a period of education and training for clinical staff about the study, 
the aims and what the impact will be for clinical care (N, CRN) 
 A key aspect of the study launch is to identify key tasks with clear definition of who 
                                                          
2
 There are many different job titles used within research literature.  For continuity Research staff is used to 
represent ‘research nurses’, ‘research facilitators’, ‘trial managers’: all members of research staff who have a 
role to play in research study conduct and who have patient contact.
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Section 1: study set up 
will undertake each aspect (N, CRN, R&D)  
 Precision is a key element of PK studies and research staff will take responsibility for 
developing tools to facilitate accuracy in relation to both medication administration 
and accuracy in sample collection (N, CRN, R&D) 
 There should be a clear outline of the research support clinical staff can expect to 
receive and how to access it (CYP, P, N, CRN, R&D) 
 Where possible plan the study so there is a personal benefit to participation for CYP or 
parents, such as extra monitoring or extra clinical review (P, CRN) 
 Where there is no personal benefit to participation avoid unnecessary additional visits 
and / or procedures and highlight clearly what the benefits of the research are for 
other CYP and parents (P, CRN) 
Recommendation 1.4: Consider the model of consent, particularly for studies with a 
time-sensitive element or in a challenging environment 
 Researchers could consider a model of ‘pre-consent’, where CYP and parents’ consent 
in advance and then consent is re-affirmed on the day of the trial commencing (N,CRN) 
(Macrae et al., 2014) 
 Deferred consent or ‘research without prior consent’ (Morris et al., 2006, Harron et al., 
2015) could be considered if a PK study is targeting patients in the acute stages of an 
illness (CYP, P, N, CRN)  
 When samples are taken there should be some form of acknowledgement that 
samples are being taken and their consent will be sought at a later stage (P, N, CRN) 
Recommendation 1.5: Consider the use of social media as a resource for PK studies for 
CYP and parents 
 CYP and parents use social media for advice or support about clinical care and there is 
a suggestion this could extend to research studies, including PK studies (P)  
 Consider development of an on-line resource highlighting study participant’s 
experiences of participation within a PK study (P) 
Recommendation 1.6: Participant Information Sheet (PIS) need to be presented in a 
simple, clear format 
 The PIS needs to be written clearly and in a straightforward manner, explaining clearly 
what the study involves, particularly if there is a change in study medication involved 
(P, CRN) 
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Section 1: study set up 
 Consider recording the PIS in a different format, such as a video which can be watched 
or listened to on multiple occasions and facilitate understanding (P) 
Recommendation 1.7: Ensure the PK study has sufficient resources for successful 
recruitment 
 Appropriately trained research staff are a key factor in the successful conduct of PK 
studies. Funding must provide adequate staffing resources. (CRN, R&D) 
 Realistic recruitment targets need to be set which reflect recruitment rates for PK 
studies (CRN, R&D) 
 Researchers need to build in monitoring of study withdrawal and attrition.  This will 
facilitate early review of problems and allow for timely amendments (CRN, R&D)                                                                                        
 
Section 2: Recruitment 
 
 
Section 2: Recruitment 
Recommendation 2.1: Recruitment by clinicians and researchers should be inclusive and 
transparent 
 Clinicians and researchers should offer CYP of all ages and parents who are eligible for PK 
studies a choice about participation in PK studies, respecting their right to autonomy 
(CYP, P, N, CRN, R&D) 
 PK study recruitment should be transparent with reporting showing clearly who was 
invited to participate, rates of decline and clear participant flow throughout the study in 
the same manner as CONSORT guidelines (SR) (Schulz et al., 2010) 
 Non-invitation is not supported by CYP and parents, provided there is sensitivity in the 
manner and timing of approach invitation (CYP, P, N, CRN) 
 Where there are questions over eligibility or a concern about the safety of a study 
ensure there is timely communication between the research and clinical teams (P, N, 
CRN) 
Recommendation 2.2: Recognise the importance of the initial contact with CYP and 
parents 
 Parents are supportive of being approached by research staff provided staff are clearly 
identified, professional, courteous, display a clear ID badge and show tact in their timing 
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Section 2: Recruitment 
and sensitivity of approach (P, N, CRN) 
 Liaise with clinical staff to ensure research staff are fully informed about personal 
circumstances, parental responsibility and show sensitivity in timing (N, CRN)  
 Research staff require training to manage difficult conversations and develop confidence 
in the approach (CRN) 
 Parents value the opportunity to make decisions jointly; with their child where possible 
and with their partners/ spouses if applicable.  Strategies that promote involvement 
such as offering to meet with both parents and showing flexibility in availability are 
valued (P) 
Recommendation 2.3: sensitive and timely communication during and after recruitment is 
vital to the informed consent process 
 Be clear what the study outcomes are to enable parents to understand the relevance of 
the study to them (P, N, CRN) 
 Identify (where appropriate) to CYP and parents how research has informed current care 
(CYP, P, CRN) 
 Ensure there is a clear outline of what is uncertain or unknown without creating anxiety.  
Families can feel reassured by having what is ‘normal’ care and creating doubt about this 
is anxiety-provoking for them (P, CRN) 
 Ensure there are designated times for questions about research conduct (P, CRN) 
Recommendation 2.4: it is essential that CYP are involved as much as they would like 
throughout the whole research process 
 There are challenges to CYP joining in discussions about research when they are unwell 
and in hospital due to fatigue, feeling unwell and medications, particularly if they are in a 
high dependency or critical care area such as PIC.  The approach should (wherever 
possible) be at a time when the CYP is awake and able to join in discussions. Researchers 
should address them directly (SC, CYP, P, CRN) 
 Liaise with clinical staff and parents to determine the optimum time and manner for 
approach and whether there are any communication needs or tools that are required 
(SC, CYP, P) 
 Involvement should be assessed on an individual basis, rather than on age. There is a 
suggestion this could start from age 5 years. However best practice is to consider 
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involvement with all CYP (SC, CYP, P, CRN) 
Recommendation 2.5: researchers need to engage and collaborate with clinical staff 
 Visible engagement with clinical staff is important to families. They want to see their 
clinical team have had input to determine if the study is appropriate for their child (CYP, 
P, N, CRN) (See Recommendation 2.1) 
 This liaison needs to be evident throughout the PK research process from determination 
of eligibility, to timing of approach, to liaison over sample collection (P, N, CRN) 
 Parents find it helpful to understand which staff are undertaking what roles so it is clear 
whom to approach with questions. This clarity of roles is particularly important for 
research conducted during emergency situations (P) 
Recommendation 2.6: researchers need to consider influences on CYP and parents making 
decisions about participation in PK studies and address these where possible 
 Helping others was regarded as extremely important to CYP and parents in PRESCRIBE.  
Communication about the study needs to emphasise the benefits for future service 
users, particularly where there is little or no benefit to the individual themselves (see 
Recommendation 1.6) (SC, CYP, P, N, CRN) 
 There is a strong sense of group identity within some specialities so helping others might 
be a stronger motivation for some CYP and parents (P, CRN) 
 If there are few treatment options available, some families can be highly motivated to 
participate. This requires sensitive handling, particularly if there are issues about being 
ineligible after review (CRN) 
 Many PK studies are regarded as having ‘no benefit’ to the individual by researchers.  
However, researchers should avoid presumptions about what participants perceive as a 
benefit (P) 
 Recruiting CYP on ‘routine medications’ is felt to be more challenging.   This requires 
researchers to be realistic about recruitment targets (see Recommendation 1.7).  This 
also requires researchers to review if there are any benefits that can be added for the 
individual patient (P, CRN) 
 PK studies should allow the use of clinically indicated central venous lines (CVL) or 
arterial lines wherever possible to avoid the placement of additional cannulas (SC, CYP, 
P, N, CRN, R&D) (Errington et al., 2016) 
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 Preparation and advanced notice of research should be considered in research 
conducted in emergency situations (see Recommendation 1.2) (CYP, P, N, CRN) as can 
deferred consent (see Recommendation 1.4) (SC, CYP, P, N, CRN) (CONNECT Advisory 
Group, 2015, Woolfall et al., 2015a) 
Recommendation 2.7: extra ‘research’ appointments are not favourably viewed 
 Extra appointments are challenging for CYP and parents and need to be avoided.  
Consider how to add research activity to clinically indicated appointments or liaise with 
clinical colleagues to add clinical assessments into research appointments (SC, CYP, P, 
CRN) 
 Where appointments are required, researchers need to consider being flexible with 
appointments. Consider after school or weekend appointments or home visits to reduce 
the impact of missing school and parents having to take time off work. (SC, CYP, P, CRN) 
 Where extra appointments are required, researchers need to consider resources 
required to make them interesting or fun, such as DVDs, computer games, stickers, 
certificates (P) 
 If extra visits are required, the study should pay travel expenses or car parking to 
facilitate attendance (P, CRN) 
 The study should also consider subsistence support and child care if required (P, CRN) 
 Overnight stays should be avoided.  If these are unavoidable, consider the use of a 
(funded) hotel to facilitate the family’s attendance (CYP, P, CRN) 
Recommendation 2.8: researchers must consider analgesia and non-pharmacological 
interventions 
 Regardless of whether there is benefit to participants from participation researchers 
must consider reduction of pain and distress for CYP associated with blood sampling and 
make provision for the use of local anaesthetics, distraction and play therapy if required 
by service users (SC, CYP, P, CRN, R&D) 
 Analgesia and play therapy need to be addressed in study protocols and adequately 
funded through research resources (P, CRN)   
 
 
 
 
 
316 
 
Section 3: Medication 
 
 
 
Section 3: Medication 
Recommendation 3.1: researchers need to consider the trial formulation carefully 
 A pharmacist needs to be involved at the approval process to read and review the 
protocol for feasibility (CRN, R&D)   
 Participants need clear pictorial information so they are enabled to understand the 
actual size and shape of tablets or placebo medicines (P, CRN) 
 Palatability, colour and smell of medication can be significant problems for CYP. 
Formulation work is essential to ensure the drug can be administered and tolerated by 
the target participants (SR, CYP, P, N, CRN) (Kemper et al., 2011, Baguley et al., 2012) 
 Patient and public involvement (PPI) work would help with determining acceptability 
but this needs to be conducted early on to allow for changes to be made (R&D) 
 Researchers need to consider compatibility of medications with drinks or food and 
provide advice to families to allow them to make informed decisions.   Without this, 
parents may administer the medication in ways which could affect the PK data (P, CRN)  
 PPI is required to ensure there is support for a change in formulation before a trial 
opens to recruitment (CYP, P, N, CRN) 
 Ensure there are no safety issues for patients before approaching them with a change in 
preparation, for example that there are no contraindications to taking a tablet such as a 
poor swallow (CYP, N) 
 Medication delivery must be in accordance with Hospital policy unless there is a 
protocol variation which is approved by pharmacy and R&D, for example the use of a 
blinded trial medication (N, CRN)   
Recommendation 3.2: researchers should offer clear advice to CYP, parents and health 
care professionals about preparation and administration of medications   
 There needs to be clear guidelines on the prescription of trial medication to ensure 
there is clarity in dosing and what to do when levels are required to reduce the 
potential for error (SR, N) 
 There needs to be clear, succinct guidance for parents and nurses on how to administer 
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trial medication including (where appropriate): guidance on crushing of tablets, drug 
stability data, appropriate dilution (N, CRN) (Standing et al., 2005)  
 Researchers need to educate clinical staff regarding documentation of the time of drug 
administration and the time of sample collection.  It is vital to know the exact times 
medications were given (N, CRN)  (Brundage et al., 2004) 
 Study guidance needs to address the specifics about what to do in the event of a dosing 
error in a PK study as this will affect the reliability of the data (SR, N) 
 The study protocol needs to address what to do in the event of vomiting or expulsion 
(rectal route) as this will have a significant impact on PK measurements (SR)  
 The study protocol needs to provide guidance to staff on what to do in the event of 
being unable to administer medication at the designated time due to IV access 
unavailability, competing demands for access and a lack of appropriately trained staff. 
Guidance should include how this should be documented, whom they need to notify 
and what to do about subsequent PK measurements (N, CRN) 
Recommendation 3.3: a PK study needs to have the appropriate resources to facilitate 
timely medication administration 
 Ensure there are research staff available to support clinical staff in drug administration 
to ensure the correct dose is administered at the correct time (N, CRN) (Oliver et al., 
2004, Dupuis et al., 2006)   
 Ensure clinical staff have sufficient and appropriate resources to deliver the medication, 
particularly for intravenous (IV) delivery; for example, there are sufficient, appropriate 
IV pumps to avoid delays in trial medication administration (SR)  
 Provide clear documentation /study aids which enable staff to accurately and clearly 
document times of administration   Suggestions include slips attached to prescription 
charts. This is best developed on a study by study and site by site basis, informed by 
local practice (N, CRN)  
 Provide clear documentation / posters that a patient is in a study to reduce the 
potential for prescription errors or changes outside of protocol guidelines (N, CRN) 
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Section 4: Sampling 
Recommendation 4.1: wherever possible blood samples should be taken from clinically 
indicated intravascular catheters 
 Use of an intravascular catheter (arterial line /CVL3) is supported by service users and 
health professionals (SC, CYP, P, N, CRN, R&D) (Salazar, 2003) 
 Where a study protocol does not allow sampling from a CVL and requires placement of a 
peripheral cannula this should be clearly identified within the PIS, including visual aids to 
assist with understanding procedures and devices (CYP, P, CRN) 
 CVL or arterial lines should be accessed in accordance with hospital policy by staff 
trained and competent to do so (N, CRN)  
 Wherever possible additional sampling should be minimised to reduce the risk of 
infection (P, N, CRN)  
 Where possible strategies of opportunistic sampling (where samples are taken alongside 
clinical indicated samples) should be utilised (N, CRN) (Thomson and Elliott, 2011) 
Recommendation 4.2:  PK study protocols should consider the placement and care of 
cannulas 
 If additional cannulas are required for sampling, consider siting during anaesthesia (if 
applicable) to minimise pain from insertion or consider local anaesthetic cream to 
minimise discomfort from venepuncture (see Recommendation 2.8) (SC, CYP, P, CRN) 
(Abdel-Rahman et al., 2004, Vilo et al., 2008) 
 Consider the location of the cannulas, particularly if there is a requirement for two in 
contralateral limbs. Where possible, avoid incapacitating both hands (CYP, P, CRN)  
 Cannulas are the least preferred method for sampling for PK studies amongst CYP and 
parents.  Consider the use of capillary samples instead if samples are of a minimal 
volume and only a few samples are required (CYP, P) 
 Action to be taken in the event of a cannula failing to ‘bleed back’ should be outlined, 
                                                          
3
 CVL is used to represent all forms of central lines, including those inserted for long term use such as a port-a-
cath and those inserted for short terns used, such as those used on PIC.  
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particularly if there are restrictions on the sites where a cannula can be sited.  This needs 
to clarify the issue of documentation of times of the sample and what to do if the sample 
is outside of a sampling window (N, CRN) 
 The maximum number of attempts at resiting cannula should be discussed with CYP and 
families and documented clearly to help address anxiety amongst CYP (P, CRN) 
 Continuity of personnel siting cannulas should be offered wherever possible, particularly 
if there are issues surrounding cannulation (CYP, P) 
Recommendation 4.3: consider sampling volumes carefully 
 A protocol should identify individual and total amounts to be taken, i.e. the amount per 
sample plus a total volume to be sampled (N, CRN)  
 The PIS should provide clear information to indicate how much total volume is taken and 
how long it would take the individual to replace or regenerate this blood volume (SC, 
CYP, P, N, CRN) 
 Consider stratified guidelines; with different volumes for different age groups, 
particularly for neonates and infants (N, CRN) 
 Refer to guidelines within the study protocol and PIS to indicate the safety of sampling 
(CYP, P, N, CRN) 
 Safety for the individual participant is paramount.  Engage with clinician to determine if 
the sampling strategy poses any issues for the individual CYP (P, N, CRN, R&D) (see 
Recommendation 2.1) 
Recommendation 4.4: consider the sampling regime and care of the sampling line 
 If a cannula is to be used for sampling, consider preserving cannula patency through the 
use of saline or heparinised saline (CRN)  
 Educate and train clinical staff about the sampling regime through targeted education 
and training (N, CRN)  
 Support clinical staff with the sampling regime through allocated research staff to assist 
with or conduct sampling (at clinical staff discretion) (N, CRN, R&D) 
 Educate staff about the importance of accurate documentation of sampling time (N, 
CRN, R&D) 
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 Research staff should provide clinical staff with the correct bottles, correct forms and 
labels for the required PK samples (N, CRN, R&D) 
 If the research protocol allows the use of levels taken as part of routine therapeutic drug 
monitoring, ensure staff are educated to the importance of accuracy in the 
documentation (N)  
 Minimise sampling requirements outside of office hours (8-5pm), particularly if the CYP 
is not an inpatient (N, CRN) 
 Minimise requirement for overnight stay whenever possible by reducing sampling 
requirements at 12 hours (CYP, P, N, CRN) 
 Identify a designated clock so the same clock is used for timings and this should be 
documented clearly on the accompanying paperwork (CRN) 
 The time point '0 hours' will be defined as the pre-dose time. All the consecutive time 
points need to be calculated from the point of medication administration (CRN) 
 Samples will be taken at the defined time points following on from this. Paperwork 
should identify what these are, the sampling window available (if any) and allow space 
for documentation of what time the samples were actually taken (CRN) 
Recommendation 4.5: consider alternative strategies for the conduct of PK studies 
 Opportunistic sampling reduces unnecessary access to lines and potentially reduces 
infection risk (see Recommendation 4.6).  Researchers need to ensure monitoring of 
total blood sampling occurs to ensure safety of the individual patient (SC, CYP, P, N, CRN) 
 Researchers should consider the use of non-blood samples, such as urine or saliva which 
are perceived to be ‘less invasive’ by CYP and parents (SC, CYP, P, N, CRN) (Royal College 
Paedatrics and Child Health, 2004) 
 This approach could be considered if catheterised (for clinical indications).  If CYP are not 
catheterised or CYP cannot void on demand need to consider how samples would be 
collected (N, CRN) 
 There needs to be clear instructions within a study protocol on how to obtain saliva 
specimens and what to do for insufficient samples (CRN)  
 If sampling is to include scavenged samples (leftover clinical blood samples) education is 
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required to ensure there is accuracy in documentation (see Recommendation 4.4) (C, 
CYP, P, N, CRN, R&D) (Wade et al., 2008, Thomson and Elliott, 2011) 
 Randomised sampling windows where patients have the same number of samples taken 
but are randomised to different sampling frames are felt to be confusing for staff and 
parents (P, N, CRN) 
 Making results available for clinical care was popular amongst CYP, parents and research 
staff who participated in PRESCRIBE. This requires samples to be processed immediately 
so the results are available contemporaneously to inform clinical care givers (CYP, P, 
CRN) 
Recommendation 4.6: Safety of participants must be paramount 
 Reference to safety guidelines to indicate safe levels regarding volume of blood is 
supported by service users and health care providers (CYP, P, N, CRN) (see 
Recommendation 4.3 and Recommendation 4.5) 
 Stratified volumes, according to age or weight would be useful to demonstrate 
consideration of body size (see Recommendation 4.3) (N, CRN) 
 Variation in sampling practice is a concern, particularly in relation to scavenged sampling 
strategies. Education and training of clinical staff are required to reduce variability in 
sampling volume and discourage staff from taking more blood than required (N, CRN) 
 Researchers should engage with clinical colleagues to determine the appropriateness of 
a participant entering a study from a safety perspective on blood sampling and 
encourage review throughout the sampling period (P, N, CRN, R&D) (see 
Recommendation 2.1) 
 
Section 5: Processing 
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Recommendation 5:  researchers need to consider the storage, transportation and 
processing of samples 
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 Clinical staff need to be issued with clear guidance on the sampling bottles to be used, 
the volumes required and labels to be applied (see Recommendation 4.4) (SR, N, CRN, 
R&D) 
 There needs to be clear guidance on how and where to store samples and specific 
instructions on transportation, including accompany documentation.  Instructions need 
to cover what to do if there are problems with each of these steps and who to contact 
(SR, N, CRN, R&D) 
 The study assay needs to be thoroughly developed (SR) 
 Resources need to be allocated to the staffing required to process samples taken 
throughout the 24-hour period, including staff to transport samples to the labs at night-
time (CRN, R&D) 
Section 6: Outcomes 
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Recommendation 6.1: Conduct of PK studies require a positive attitude with value placed 
on the outcomes from the study 
 Positivity towards research needs to be evident from all personnel, not just research 
staff (P, N, CRN) 
 There needs to be evidence of the value an organisation places on research, with an 
emphasis that research is integral to improving clinical care (see Recommendation 1.1) 
Recommendation 6.2: results from PK studies should be fed back to participants 
 Ensure patients and their families receive feedback about study results, what was done 
with the samples they provided, what the outcome of the study was, what was the 
impact for clinical care and any research which will follow on from this (P, CRN) 
 Provide patients with staff contact details for questions or further information and how 
families can contact researchers if they would like to participate in any future research 
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(P, CRN) 
 Consider the use of social media to feedback about trial outcomes (see Recommendation 
1.5) (P) 
Recommendation 6.3: PK studies must be adequately resourced with staffing support and 
minimise additional work for clinical staff 
 Trial activity should be planned for office hours, wherever possible, and utilise 
designated research facilities where available (CYP, P, CRN) 
 Overnight stays should be avoided wherever possible (see Recommendation 2.7) (CYP, P, 
CRN) 
 Ensure senior staff in clinical areas are aware of sampling requirements so they can 
support their junior staff (N) 
 Research support should ideally cover at least 60% of research activity and should be 
flexible to accommodate busy periods and cover 7 days /week (N, CRN) 
 Support should be negotiated with the clinical nurses/ team to determine what help is 
required (N, CRN)  
 Extra workload for clinical staff should be minimised, even in areas where there are 1:1 
staffing ratios (SC, CYP, P, N, CRN, R&D) 
 Research support should ideally come from a department specific research team, fully 
trained and familiar with the specific context of research (N, CRN, R&D)   
 If a model of outreach support is utilised, staff need to be trained and assessed to have 
the skill sets required to support clinical staff (N, CRN, R&D) 
 Training of clinical staff by research staff is essential to ensure smooth running of the 
study (Recommendation 4.4 and Recommendation 4.6). This needs to cover key aspects 
of the study and signpost staff to where further information can be sought (see 
Recommendation 6.1) (N, CRN) 
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Recommendation 7: consider the location of the PK study at the outset and throughout 
the study 
 As an outpatient, CYP and parents are most supportive of research taking place in 
designated research facilities (CYP, P, CRN) 
 For inpatient studies avoid conduct within ward environments unless the study is 
adequately supported by research staff (P, N, CRN, R&D) 
 PIC is felt to be an appropriate place to conduct PK research, although research 
support must still be considered (see Recommendation 6.3) (CYP, P, N, CRN, R&D) 
 
10.5 Impact on PK design 
The scoping review established that the median number of participants in a PK study was 
23.  If this study was aiming to recruit and collect samples from 23 participants within 6 
months, (taking into account that 70% of potentially eligible participants and their data 
could be lost or excluded from analysis) this study would need up to 26.8 months to obtain 
complete data.  If these rates could be halved through tackling reasons for refusal / 
withdrawal, medication issues and sampling failures then this could have a significant 
impact on the ability of a study to recruit to time and target.  Implementing the 
recommendations into a study design is obviously highly dependent on the individual 
medication under investigation; however, an implementation guide has been developed 
(see Figure 69). 
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1. Appendix 1: Vignette and preparation material (CYP) 
Vignette and preparation material utilised with sessions with CYP.  This material was adjusted for 
each stakeholder group but the ‘typical’ PK study situation core components remained consistent 
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2. Appendix 2: Interview schedule: CYP  
 
FOCUS GROUP INTERVIEW SCHEDULE – Group 1b: children and young people (approved by REC) 
 
Aim:  
To explore the knowledge and attitudes that exists towards pharmacokinetic research amongst 
children and young people 
  
• To determine what knowledge children and young people have about pharmacokinetic 
research 
• To explore attitudes children and young people have towards PK research 
• To explore the barriers children and young people perceive towards participation in PK 
research 
• To explore the factors that facilitate PK research taking place 
 
Method: The aim is to pose the questions below in a focus group forum although there is the option 
of conducting the interview on a one to one basis, depending on individual preference.   The 
structure of the session is to some degree dependent on the interaction between participants 
therefore the schedule will be flexible according to the conversations generated.  The session 
facilitator will guide the session to ensure the areas below are covered as well as allowing new areas 
of enquiry to emerge.   
 
Ground rules will be outlined and then there will be some ice breaker games to allow the group to 
know a little about each other before the interview schedule formally begins.   
 
Opening: “You have been asked to take part today because you have visited Birmingham Children’s 
Hospital either via the Emergency Department, the Wellcome Clinical Research Facility or one of the 
wards and therefore you know a little bit about what happens when you come to hospital”.  
 
Question Rationale for asking the question Prompts 
1. Could you tell me how about your 
experiences of coming to Birmingham 
Children’s Hospital? 
 
This will start the flow of the interview 
and allow the participants an 
opportunity to express their level of 
experience.  This will help ensure I 
know who the respondents are so we 
can show sensitivity to their individual 
circumstances.    
 
The prompt questions will lead on from 
the main questions on the left and 
allow us to explore the experiences 
each participant has had and draw out 
the similarities between experiences. 
 
Although this will involve naming teams 
and Consultants this information will be 
anonymised in transcription.  It is of use 
to understand the experiences the 
individuals have had and to help them 
to open up about their own 
Do you know the name of the 
Consultant or team who usually 
manage your care? 
Do you know how long you’ve 
been seeing them?   
How often do you have to come 
to the hospital? 
Which departments do you 
usually visit?   
Have you had to stay in overnight 
or longer on one of the wards?   
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experiences.   
2. Can you describe the best bits about 
coming to hospital?   
This is a difficult concept to explore but 
I’m looking to determine if the 
participants have had positive 
experiences & demonstrate confidence 
in their care providers.  There is 
evidence in the literature that such 
relationships can influence recruitment 
to research and this is a theme I’d like 
to explore. 
What do you like about the team 
of people you see? 
Are there any people you 
especially like to see when you 
come to hospital?  
What is it about * that makes 
you feel positive about coming to 
hospital?   
3. Can you describe the worst bits 
about coming to hospital? 
I want to explore their perspective of 
the worst bits about a hospital visit 
because these will impact on their 
decision making about research.  The 
systematic review indicated that the 
biggest areas for refusal of research 
and withdrawal were additional blood 
sampling requirements and additional 
hospital visits.  We need to discuss this 
further with children and young people 
directly so we can clarify how much of a 
problem these are and then allow them 
to explore solutions/ ways of 
minimising these.   
 
 
How do these experiences make 
you feel?  
How do you / how did you cope 
with these experiences?   
How important is it to you that 
these episodes are kept to a 
minimum? 
 
4. What do you understand about the 
term ‘Research’?  
Do you think this is important in health 
care? 
 
As the group have had little 
introduction to the topic of PK research 
we’ll start by asking them about their 
understanding of ‘research’ and 
whether they feel this is important in 
health care.  From this we can then 
lead on to talking about the more 
specific area of PK research.  Without 
setting the context I think we would be 
endanger of losing their understanding 
and concentration. 
Have you ever taken part in a 
research study in health care? 
 
Have you ever heard of a type of 
research called ‘pharmacokinetic 
research’?     
 
Are you on any medicines that 
have ever had to have a level 
taken, for example medicines to 
help reduce or control ‘fits’?   
Using power point a simple vignette will be used.  If the schedule is being used in the context of a one to one interview 
then this will be printed out as a handout. 
Key points highlighted will be: 
 Usually of a medicine the child is already receiving. 
 Usually involves blood samples 
 Involves knowing exactly when a medicine is given 
 Involves knowing exactly when blood samples were taken 
 Often a protocol states in advance the times blood samples need to be taken (not flexible) 
 May involve sampling up to 24 hours but some studies have asked for samples at outpatient appointments for 
weeks and months afterwards.  
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4. What do you think about taking part 
in a study like this?  
 
Depending on the response we will 
then discuss issues in a step by step 
method: 
Medicines 
* How do you feel about taking your 
medicines at exact times?    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood samples 
* How do you feel about having blood 
taken to measure medicine levels? 
 
 
 
 
 
 
 
 
 
I want to know their initial reactions to 
a more ‘classic’ PK study design with a 
structured approach to the taking of 
the medicine and the sampling 
requirements.   
I want to know what their concerns 
would be and if there are any factors 
that make them say ‘No’ immediately.   
   
It is important to address the individual 
areas.  For example the issue of taking 
medicine at particular times might not 
at first seem a big issue but it might be 
if it meant it had to be dispensed by a 
health professional and taken at 8am 
on an empty stomach, so a number of 
variables can be controlled.   
Some studies might involve comparing 
two methods of delivery so children 
might be asked to take the medicine in 
a different formulation.  A small 
number of participants in the 
systematic review had to withdraw 
because they could not take the 
supplied formulation.   
 
Blood sampling is identified as the 
biggest issue affecting recruitment & 
withdrawal from PK studies but also the 
physical difficulties of obtaining 
sufficient blood and the right number 
of samples caused the loss of a large 
number of participants.  This area has 
not been explored directly with 
children & young people previously and 
it is vital that we explore these issues.   
How does the study design make 
you feel?  
Is there anything about this that 
makes you worry?   
 
Prompts to explore these areas 
further: 
Medicines 
If you’ve taken medicine have 
you always taken it at the exact 
time?   
What difficulties do you think 
there might be with this?   
Would it make a difference to 
you if you had to be admitted to 
hospital so they could give you 
the medicine at the exact times?  
How would you feel if you were 
asked to take part n a study 
which gave you the same 
medicine you’re usually on but in 
a different form such as a tablet?   
What if it involved you taking 
medicine at school in order to 
match the times?  Would this 
matter to you?  
Have you ever had any problems 
with taking a medicine such as 
the tablets being too big or not 
liking the taste?   
Have you ever been sick just 
after taking a medicine? If you 
have what did you do?   
Have you and your parents ever 
worried about whether you 
might need to alter your 
medicine dose?  
 
Blood samples 
If we could take blood samples 
from a cannula or from a central 
line (if you have one) would this 
affect your decision to take part?   
What if this was not possible, is 
there a limit on how many times 
you would agree to have blood 
taken?   
Would it matter to you if they 
didn’t tell you how much blood 
they were taking? 
Does it matter to you what times 
the blood samples are taken?   
Would you be happy to have 
blood taken even if it involved 
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Additional visits  
* How do you feel about having to 
come to hospital for extra 
appointments?   
being woken up in the night?  
   
Additional visits 
Would missing school be a 
concern for you or your parents? 
Do you think your parents would 
have worries about getting you 
to the appointments such as 
having to take time off work?   
 
 
 
 
 
 
 
 
Using power point there will be pictorial guides to some of the ideas the literature suggests could facilitate PK studies.  
Where the schedule is used in a one to one interview the slides will be printed out as a handout.  
 Population PK modelling 
 Randomised sampling windows 
 Sampling from a central line 
 Sampling from an arterial line 
 Dried blood spots 
5. We have some suggestions for ways 
to improve some of these factors.  
What are your thoughts on: 
Population PK 
* less samples per patient but we 
involve more patients and group all 
their data together? (population PK 
modelling) 
 
Sampling windows 
* another option is that different sets 
of patients have blood taken at 
different time periods  
eg group 1 have blood taken at 10 
mins, group2 have blood taken at 20 
mins.  Does that seem like a good idea 
to you?  
Using central lines / arterial lines 
* using ‘central lines’ in a big vein 
wherever possible?  
* Patients in intensive care often have a 
line in an artery so we can take bloods 
easily and quickly, do you think this 
would be a good time to measure 
medicine levels?  
 
 
 
 
Following on from the systematic 
review we have identified a number of 
facilitating factors which we are keen to 
explore.  The questions to the left 
reflect emerging themes from the 
literature which require lay discussion.   
 
Population PK modelling has become 
more common because it makes the 
most of sparse samples, particularly in 
vulnerable patient groups and sampling 
times can be flexible.    
 
Randomised sampling windows have 
been described in the literature 
alongside Population PK modelling but 
there has been no work to determine 
the acceptability of these with children 
and young people.   
 
In the literature there has been 
reluctance to use existing central lines, 
particularly if the drug is being 
administered via the line.  However 
there is some evidence to suggest that 
there is no difference in levels provided 
the naive lumen is used and this would 
seem to avoid the need for additional 
venepuncture. 
 
 
 
Population PK 
Would it seem better to you if 
you only had to give 2or 3 
samples and we could be flexible 
about what times we took them?  
 
Sampling windows 
Would a time ‘window’ eg 10-15 
minutes be preferable to an 
exact time?   
 
 
 
Using central lines / arterial lines 
If you had a ‘central line’ in a big 
vein and we didn’t use it to take 
bloods how would that make you 
feel?   
 
People in intensive care are 
usually very poorly or recovering 
from being very poorly. Does this 
affect what you think?  
 
How important is it to you that 
we take as little blood as 
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Dried blood spots 
* How would you feel about us using 
dried blood spots?  Although this might 
mean a finger or toe prick it would then 
only need a tiny volume of blood. 
Left over blood 
* At the moment any blood taken for 
‘routine purposes’ is put in a bin after 
use.  If there was any blood ‘left over’ 
would you be happy for us to use this 
to measure medicine levels?   
Other body fluids 
* Would you be happy to take part if 
we measured the medicine levels in a 
different body fluid, not blood such as 
spit or urine (wee)?  
 
 
possible?   
 
Would you prefer it if we took 
blood only at the same time as 
bloods taken for ‘routine 
purposes’?   
 
Dried blood spots 
Which is more important to you: 
the number of ‘stabs’ that take 
place or the amount of blood 
taken each time?   
 
Left over blood 
How would you feel about having 
leftover blood used if you hadn’t 
said yes to this being used?   
 
 
Other body fluids 
Would you feel happier if it was 
measured through urine (wee) or 
saliva (spit)?   
Would you be happy if we used 
any fluids that would otherwise 
go into a bin such as chest drain 
fluid?   
 
6. How important is it to you that there 
is a person you can contact with any 
questions about the study? 
Anecdotally staff report that a research 
study can fail if it is not appropriately 
staffed and resourced but this factor 
has not been explored within the 
context of PK research and not from 
the perspective of participants.   
Studies like this are ‘extra’ to 
normal care.  Would it worry you 
that the hospital staff might have 
extra work to do because of the 
study?  
 
Do you think that we should 
provide extra staff to do all the 
jobs involved such as taking the 
blood and sending it to the labs?  
 
Would it put you off taking part if 
there was not a names person / 
team of people to support you? 
 
7. Do you think it’s important for us to 
include all ages of children and young 
people in this type of research?   
In the papers included in the systematic 
review there was large variation in the 
age of the participants included in the 
study.  Neonates were only specifically 
included in 8% of the papers and 
infants < 1 year in 52%.  In other types 
of research there has often been a 
reluctance to invite groups such as 
those with a life limiting condition or 
those who are on intensive care.   We 
think this is a vital area to explore with 
Do you think there are any 
groups we shouldn’t ask?  What 
do you think about asking 
parents of premature babies?  
Parents of children who are very 
poorly and might die? 
What about if Mums and Dads 
are very upset.  Do you think we 
should ask them?   
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children and young people with direct 
experience of health care.   
What do you think we should do 
if parents do not speak or read 
English? 
Mums and dads who the Doctor 
thinks will say ‘No’   
What should we do about mums 
and dads who can’t visit the 
hospital very often because they 
live far away or because they 
have to stay at home and look 
after their other children?  
If we think Children are not 
taking their medicines properly 
do you think we should still ask 
them to take part?  
 
8. After everything you’ve heard about 
PK research would you say ‘yes’ if we 
asked you to take part in a PK study? 
I’ve left this as a closed question 
because I think it’s important to draw 
them into an answer before exploring 
why their immediate response is what 
it is.  It will be interesting to compare 
this to the responses we get on the 
questionnaire when they might not 
have fully understood what was 
involved.   
 
What would make you say ‘Yes’ / 
‘No’?   
What makes you worry about 
taking part?   
What is the biggest factor for you 
in deciding yes or no?   
Would there be anything that 
would make you change your 
mind?   
Do you think your view has 
changed since you’ve been taking 
part in this project and you’ve 
learnt more about it?   
Do you think you would have 
different worries to your mum or 
dad?   
Do you think research like this is 
important?   
How do you feel about the fact 
that there isn’t much research 
like this taking place at the 
moment?   
Do you think it’s ok for us to 
approach children and their 
parents to take part in PK 
studies?   
  
 
Thank you for taking part. 
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3. Appendix 3: Full list of Participant Information Sheets for all 
stakeholder groups, consent and assent forms 
 
For the purposes of space not all versions are included within this thesis. Forms highlighted in yellow 
are included below. 
1. Participant Information Sheet Schools; version 1.1, 07.03.14  
2. Participant Information Sheet 8-10yrs; version 2.0, 17.12.11 
3. Assent form child 8-10 yrs; version 2.0, 16.12.11 
4. Participant Information Sheet 11-16yrs; version 2.2, 10.04.14 
5. Assent form children and young people 11-16 yrs; version 2.0, 16.12.11 
6. Participant Information Sheet for parents (child & young person’s group); version 2.0, 16.12.11 
7. Consent form for parent (child & young person group); version 2.1, 23.01.12 
8. Participant Information Sheet; Parent Focus group; version 2.0 ,16.12.11 
9. Consent Form for Parent Focus Group; version 2.1, 23.01.12 
10. Participant Information Sheet for Nurses; version 2.0, 16.12.11 
11. Consent form for nurses; Version 2.1, 23.01.12 
12. Participant Information Sheet Clinical Research Staff- BCH; version 2.0, 16.12.11 
13. Participant Information Sheet Clinical Research Staff - BWH; version 2.0, 16.12.11 
14. Participant Information Sheet Clinical Research Staff –UHB; version 2.0, 16.12.11    
15. Consent form Clinical Research Staff- BCH; version 2.1, 23.01.12 
16. Consent form Clinical Research Staff - BWH; version 2.1, 23.01.12 
17. Consent form Clinical Research Staff –UHB; version 2.1, 23.01.12      
18. Participant Information Sheet Hospital Managers; version 2.0, 16.12.11 
19. Consent form Clinical Research Staff; version 2.1, 23.01.12      
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Appendix 3a: Participant information sheet for school children 
                                            
Birmingham Children’s Hospital 
Steelhouse Lane 
Birmingham 
B4 6NH 
07.03.2014 
 
PRESCRIBE: Pharmacokinetic RESearch in CRitically Ill children: 
facilitating the BEst design 
Dear parent, 
We are writing to you to ask if you’d be happy for your child to take part in a discussion group and 
complete a short questionnaire.   
This study is trying to determine the best way to carry out clinical trials in children by talking to 
children and young people and asking them what is important when we design a study.  We would 
like to speak to children who have little or no experience of being in hospital to understand how they 
might feel if approached when admitted to hospital when ill.   
Why are you asking my child?   
Your child’s school thinks it is important for children and young people to learn about medical 
research and has agreed to help the research team carrying out this study.   
What do they have to do?  
They will be asked to listen to a short talk about research into children’s medicines and then 
feedback their thoughts through discussion groups which will be tape recorded and completing a 
short questionnaire.      
 
The questions will ask about things such as:  
 Taking medicines in different forms  
 Having blood taken   
 Coming to hospital for appointments  
 
 
Participant Information Sheet Schools  
Version 1.1, 07.03.14 
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What are the benefits of taking part? 
The PRESCRIBE team want to ensure that children and young people’s views have been considered 
when designing research studies. The information we get from this work will help us to improve the 
design of studies for children in the future.   
 
Will the information my child gives be kept private? 
The questionnaire will not request any identifying information from your child such as their name so 
their responses will be anonymous.  If any names are used during the discussion groups they will be 
removed when they are transcribed.   
 
Who is involved in this research study? 
The session will be carried out by Julie Menzies, a research nurse undertaking a PhD with supervision 
by Professor Marriott at University of Birmingham & Dr’s Morris and Duncan at Birmingham 
Children’s Hospital.   The study has been reviewed and approved by National Research Ethics 
Committee South Central- Oxford A (12/SC/0051) and the Research & Development Department at 
Birmingham Children’s Hospital.    
 
Who can I get more information from? 
If you would like to anything more about this work please contact  or  
. If you would like any independent advice about how this study is being conducted please 
contact the Research and Development team at Birmingham Children’s Hospital on .  
                                     
I’m happy for my child to take part with this work during their visit, what do I need to do? 
No action needed.  Unless the school tells us you don’t want your child to take part then we will 
include all children in the discussion session and ask them to complete a questionnaire.   
 
I’m not happy for my child to take part, what do I need to do next?  
Please let your child’s teacher know and an alternative activity will be arranged on the day during the 
visit.  They would then attend the presentations but would miss the group discussion work and 
completion of the questionnaire.  
 
 
 
 
Participant Information Sheet Schools  
Version 1.1, 07.03.14 
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Appendix 3b: Participant information sheet and assent form CYP aged 8-
10years 
                            
 
PRESCRIBE: Pharmacokinetic RESearch in the CRitically Ill: 
facilitating the BEst design 
Dear  
We are asking if you’d like to take part in a discussion group (called a ‘focus group’).   
When children are sick they sometime have to have medicines.  The amount of medicine we 
give can be difficult to get right because all children are different and they are all growing at 
different rates.    We think it’s important that more of this type of work takes place so we 
want to ask children and young people what is OK and what is not OK when we do this kind of 
work.      
Why are you asking me?   
You’ve been asked because you have been to Birmingham Children’s Hospital and know a little bit 
about what happens when you come to the Emergency Department, outpatients department or if 
you get admitted to one of the wards.  
 
What do I have to do?  
We’d like you to come and meet up with a group of other children aged 8-16 years old to talk about 
your thoughts.    
The questions will ask about your thoughts on things such as: 
 Having blood taken   
 Coming to hospital for appointments  
 Ways of measuring the levels of medicine.  
 
The session will last between 45 minutes and an hour and a half depending on how 
much everyone talks!   
You will sign a form called an ‘assent form’ which says that you’re happy to take part and your 
parents will sign a form called a ‘consent form’ which says they’re happy for you to take part.  
We’ll give your parents money to pay for getting to the hospital or for parking the car and we’ll have 
some drinks and biscuits for you all.  
 Participant Information Sheet 8-10yrs  
Version 2.0 17.12.11 
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Your mum or dad are welcome to wait for you but the session is for children and young people only 
as we want to hear your views.   
We’ll run some other sessions for parents at a different time to talk to us as we want to know their 
thoughts too.   
Where will it be held? 
The group will be held at the Wellcome Clinical Research Facility, which is on the ground floor of the 
main hospital corridor at Birmingham Children’s Hospital.     
Do I have to say yes?  
No, not at all! It’s up to you!  It won’t affect any of your normal care. 
Is there any other way I can join in? 
We know that some people don’t like talking in front of other people.  If you would prefer to talk to 
our researcher on your own instead we would be happy to do this.  We can even come to your house 
if you would prefer.   
Will joining in this study help me? 
We cannot say that the study will help you.  We hope that the information we get will help other 
boys and girls in the future because we will improve how we do this type of study and get more 
information to help Doctors prescribe medicine.     
Will what I write be kept private? 
It will.  We won’t write anything in your notes or tell your Doctor.  The sessions will be tape recorded 
and then written out in full.  If any names are used during the focus group they won’t be written out.  
Also any other information such as ward names or places will be removed. 
Any information will be stored on a secure password protected computer and no one will have 
access to this apart from the team who are running this project.  
What will happen with the results of this work?  
When we have finished the study the results (what we find out) will be written up in special 
scientific magazines.  No one will know that they are your results because your name will not 
be in them.   
We can send you a summary of the results if you or your parents would like to read them. 
This information will help us make a guide for future researchers about the best way to do this 
type of study.      
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Contact details 
The name of the person running this study is Julie Menzies.   
If you or your mum or dad want to ask anything else about the study please contact 
                                          or by phone on  
 
I’m happy to take part, what do I need to do next?  
Your mum or Dad need to complete the form we’ve given to them so we know how best to contact 
you all to arrange the meeting.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant Information Sheet 8-10yrs  
Version 2.0 17.12.11 
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Appendix 3c: Assent form for CYP 8-10years 
                                
 
PRESCRIBE: Pharmacokinetic RESearch in the CRitically Ill: 
facilitating the BEst design 
Assent form for children 8-10 years (focus group)  
V2.0, 16.12.11  
Child (or if unable, parent on their behalf) to circle all they agree with: 
Has somebody explained the study to you?      Yes / No 
Do you understand what the study is about?      Yes /No 
Have you asked all the questions you want?      Yes / No 
Have you had your questions answered in a way you understand? Yes /No 
Do you understand it’s OK to stop taking part at any time?  Yes / No 
Are you happy to take part?      Yes /No 
If any answers are ‘No’ and you don’t want to take part don’t sign your name!  
If you do want to take part, please write your name and today’s date 
Your name:_______________________________________Date:___________________ 
Your parent or guardian must write their name here too if they are happy for you to do the study. 
_____________________   __________________________________ ______________ 
Print name   Signature           Date 
The researcher who explained the study to you needs to sign too: 
_____________________   __________________________________ ______________ 
Print name   Signature           Date 
Assent form child 8-10  
Version 2.0 16.12.11 
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Appendix 3d: Participant Information Sheet for Parents (for their child to 
participate) 
                             
 
PRESCRIBE: Pharmacokinetic RESearch in the CRitically Ill: 
facilitating the BEst design  
 
 Dear Parent 
Part 1: Invitation to participate 
We are inviting you to ask if your child could take part in a discussion group (‘focus group’).  
Why is this study needed? 
We are trying to determine the best way to carry out a type of research called 
‘pharmacokinetics’ in children.  Pharmacokinetic data helps Doctors to decide what dose of 
medicine to give children, how often to give it and how to alter the dose as children grow and 
develop.  This information is important to make sure that drug prescriptions are safe and the 
dose prescribed is not too high or too low.      
Why are you asking me? 
We’re asking you because you and your child recently attended or your child was an inpatient at 
Birmingham Children’s Hospital.  We want to talk to children to ask them what is important when we 
design a study like this.   
 
Part 2: what will happen if I say yes?  
Do I have to say yes? 
Taking part is completely voluntary.  If you think this is something your child would be interested in 
doing then we’d like to invite them to take part in a focus group.  We’ll provide them with an 
information sheet which has been written for their age group.  If you both agree then we would ask 
you to provide us with your contact details and we’ll contact you to arrange a date.  You will be asked 
to sign a consent form on the day of the focus group and your child will sign the form too.  You will 
be given a copy of the information sheet and signed consent form to keep.    
 
What happens during the study?   
 
 
 
Participant Information Sheet for parents (child & young person’s group) 
Version 2.0, 16.12.11 
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You will be asked to bring your child to attend the focus group. This focus 
group will be composed of 6-10 children who all have attended hospital at 
some point.  The session will last between 45- 90 minutes, depending on 
how much they talk!   
 
Refreshments will be provided and your travel costs will be reimbursed.  
The session will be for children and young people only but if you are 
interested in contributing to the topic we are running separate groups for parents which you would 
be welcome to join.   
 
If your child would like to take part but doesn’t like the idea of talking in a group setting or it would 
be difficult for you to bring them to hospital we can arrange for the researcher to come to your home 
and conduct a one to one interview there using the same questions.   
  
What kind of things will they be talking about?  
We want to know your child’s thoughts and experiences on having blood taken, how they might feel 
about research which measures levels of medicine and whether there is anything that would make 
them feel more positive about this type of research.  There aren’t any right or wrong answers and all 
we’re asking them to do is to join in the discussion. 
 
Where will it be held? 
The session will be held in the Wellcome Clinical Research Facility, which is on the 
ground floor of the main hospital corridor at Birmingham Children’s Hospital.    
What are the benefits of taking part? 
Taking part will not help your child directly but we expect that the information we get from this study 
will help us to improve the design of studies for children in the future.   
What are the possible disadvantages of taking part? 
There is minimal risk from taking part. If the discussions do bring up any distressing memories for 
your child of being in hospital or attending hospital we will put you in contact with BCH staff for 
further support, particularly if there is a team who you already know.  If the situation involves a 
complaint related to previous care we will refer you to the Patient Advice and Liaison Service (PALS).  
There is also a patient and family counselling service at BCH we can refer you to.  
 
 
 
 
Participant Information Sheet for parents (child & young person’s group) 
Version 2.0, 16.12.11 
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Who will know I took part? And is it confidential? 
The session will be private and only the other people who took part will know.  We won’t write 
anything in your child’s medical records notes.   
The focus groups will be tape recorded and then written out in full by the researcher.  If any names 
are used during the interviews then the researcher will remove them.  Also any other information 
such as ward names or places will be removed.  The audio-tapes and transcripts will be kept in a 
locked filing cabinet in a locked office. Only the researcher will have access to the audio-recorded 
data. The data will be collected and stored according to the Data Protection Act 1998. 
If you wish to withdraw your consent following the focus group this can be done up to a week after 
the session, before the researcher transcribes the session.  Please contact Julie Menzies on the 
contact details below if you decide you wish to withdraw. 
What will happen to the results of the study? 
We aim to publish the results of this research in a reputable medical journal and to share results at 
conferences.   Confidentiality will be ensured at all times and your child will not be identified in any 
publication.   
Who is involved in this research study? 
The University of Birmingham is sponsoring this study.  The Chief Investigator for this study is Julie 
Menzies.  The study is funded through a scholarship from the West Midlands Strategic Health 
Authority through a Nursing, Midwifery and Allied Health Research Fellowship.  All research in the 
NHS is looked at by an independent group of people called a Research Ethics Committee to ensure 
the interests of patients and their families is protected.  This study has been reviewed by National 
Research Ethics Committee South Central- Oxford A and approved. 
Who can I contact if I have any concerns about this study? 
The name of the person running this study is Julie Menzies.   
If you want to ask anything else about the study please contact  
                                          or by phone on  
If you have any concerns about this research project or want any independent 
advice about how this study is being conducted please contact the Patient Advice and Liaison Service 
at BCH on  or the Research and Development team at BCH on    
 
 
 
 
 
Participant Information Sheet for parents (child & young person’s group) 
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I’m happy for my child to take part, what do we do next?  
Please complete the form below which details your name, your child’s name, contact details and 
preferred way of being contacted.  We will then get in contact with you to arrange when the focus 
group will take place.   If you are unable to attend a focus group or your child would prefer a one to 
one interview then we can make arrangements to conduct this at your home instead 
 
 
Your name:                                                              
Your child’s name:                                                         
How would you like to be contacted?  Please tick your preferred method below and then add your details 
alongside.  
Post: my address is: 
                                                                                      
                                                                                      
Email: my preferred email address is:  
                                                                                      
Telephone: my phone number is: 
                                                                                      
My preferred day for the focus group would be: 
A weekday, preferably:  
Weekends  
During school holidays  
Not during school holidays  
Other:                                                                                 
My preferred time of day for the session would be: 
Mornings 
Afternoons  
Evenings  
Your signature:                                                              
 
 
 
 
Participant Information Sheet for parents (child & young person’s group) 
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Please return in the stamped addressed envelope.  If you misplace this please post to: 
Julie Menzies 
PICU Research Office, PICU, Birmingham Children’s Hospital,  
Steelhouse Lane, Birmingham. B4 6NH.   
Thank you 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant Information Sheet for parents (child & young person’s group) 
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Appendix 3e: Consent form for parents (CYP to participate) 
                              
 
PRESCRIBE: Pharmacokinetic RESearch in the CRitically Ill: 
facilitating the BEst design  
Consent form for Parents (child and young person focus group) 
V2.1, 23.01.12 
 Please initial box 
I confirm that I have read and understand the Participant Information 
Sheet dated 16.12.11 and version 2.0 for the above study.  I have had 
the opportunity to ask questions and have these answered 
satisfactorily 
 
I understand that participation is voluntary and that I am free to 
withdraw my consent from the study at any time without giving a 
reason although I understand that this is only possible for 7 days 
following the focus group 
 
I give consent for the researcher to audio-tape the focus groups  
I consent to the use of anonymous quotes  
I understand that relevant sections of my child’s medical notes may be 
looked at by responsible individuals from the research team, sponsor 
or from the NHS trust.  I give permission for these individuals to have 
access to my child’s records.   
 
I understand that my personal data will be processed for the purposes 
above in accordance with the Data Protection Act 1998. 
  
 
Based upon the above I agree to my child taking part 
 
 
 
 
 
 
 
 
 
 
 
Consent form for parent (child & young person group) 
Version 2.1, 23.01.12 
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____________________________________________ 
Name of Child 
 
________________________ __________________________________ ______________ 
 
Name of participant        Signature                Date 
 
________________________ __________________________________ ______________ 
 
Researcher         Signature                Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consent form for parent (child & young person group) 
Version 2.1, 23.01.12 
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4. Appendix 4: Summary of the coding process  
 
Figure 70 demonstrates the coding system in NVivo 11. The nodes are listed and sources and 
respondents are listed.  The pictures and screenshots are taken from interviews with research staff 
however the process was the same for all participant groups.  
Figure 70: screenshot of the coding system in NVivo 11 
 
The next step was to review the codes and try to classify them where possible, or re-code them, 
remove codes which were not fruitful or were subsumed in other codes.  All nodes were then 
exported into excel for review (see Table 67).   
Table 67: management & organisation of nodes. Deleted nodes in ‘grey’ 
Name Sources References 
access to novel treatments 8 27 
alternative approaches 0 0 
deferred consent 7 32 
dried blood spots 5 12 
levels available for care 10 34 
Opportunistic sampling 11 28 
other bodily fluids 12 95 
Population PK 13 59 
samples alongside routine samples 9 24 
Sampling windows 13 72 
Scavenged samples 13 86 
Barriers or problematic areas 0 0 
Blood volume 13 68 
changing meds for research purposes 12 38 
frequency of samples 7 19 
infection risk 7 15 
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Meds at correct times 13 63 
Problems obtaining samples in practice 11 36 
Problems with labs 8 28 
Vascular access 5 17 
A line 9 22 
cannulas 11 59 
Cannulas bleed back 12 50 
capillary samples 5 17 
central line 11 54 
blood sampling requirement 13 70 
children's attitudes towards research 10 28 
Communication 8 23 
compliance 8 21 
deleted nodes 0 0 
adherence 3 6 
'Guinea pig' 1 3 
child involvement 2 3 
non-nurses 2 3 
blood sampling requirements 1 1 
clinician decision 5 5 
Coordination of care 3 4 
preparation 1 2 
medical cover 1 4 
'Only treatment available' 2 2 
opt in, opt out 1 2 
Control 1 1 
retention to study 2 4 
Time 0 0 
resentment 2 6 
trust 1 1 
inconvenience 1 2 
assistance for vascular access 1 3 
Workload 2 2 
waste 3 3 
Blood transfusion 0 0 
prescription issues 0 0 
Probs with meds at right times ORAL 2 5 
Documentation 7 33 
engagement with clinical team 9 68 
experience 0 0 
example drugs 3 6 
Experience of PK in a study 13 57 
Experience of PK in clinical practice 10 30 
similar to PK studies worked on previously 8 15 
extra workload 11 46 
facilitating 0 0 
Guidelines 12 53 
relationship with clinical team 8 53 
support 9 50 
'outreach support' 11 82 
PIC research team 5 10 
families’ attitudes 13 106 
fear and pain 8 21 
gatekeepers 6 16 
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hospital policy 3 7 
Infiltrating the clinical area 6 20 
magic cream 3 4 
Not novel drugs, just routine 8 22 
parents comparing 4 12 
past experiences 7 18 
perceived benefit- parents 8 26 
piggy backed to clinical care 6 12 
precision 11 72 
preparation and organisation 13 59 
priorities 10 32 
protocol acceptability 7 47 
recruitment 13 69 
'research care' 8 18 
Research context 0 0 
location of study 13 108 
Regime 11 51 
Times of day 10 25 
vignette 9 23 
research facilities 10 36 
research features 0 0 
same clock 3 3 
delegation log 4 4 
tablet size 9 12 
missing school 6 12 
palatability 7 14 
Extra hospital visits 8 26 
avoid hospital 4 15 
responsibility 12 34 
staff knowledge and attitudes towards PK 1 1 
all ages included 13 33 
care for Pt in PK study 13 20 
feedback from research 3 10 
Further investigation 10 30 
groups to exclude 10 29 
Neonates 7 15 
inclusive 4 13 
Palliative 13 54 
PK definition 13 30 
research is important 9 18 
Research vs clinical ratio 13 67 
The approach 11 38 
staffing issues 11 70 
Training 11 39 
unsocial hours staffing 8 20 
valuing family’s choices 4 17 
'with my parent hat on' 3 16 
withdrawal from study 10 17 
 
The next stage was to condense these further into themes and this was achieved through mind 
maps.  Each node was mapped to the core themes and also to context and facilitation the 
underpinning factors in I-PARIHS.  Some nodes fitted into more than one category, so there was 
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some fluidity about their placement.  Using the list of themes and sub-themes as a template, a 
framework matrix for each participant was created (see example in Table 68 below).  
Table 68: participant 48 Framework  
Participant 48  
Definition of PK √ 
Experience of PK in a study √ 
In WTCRF 
Challenges extra visits and sampling. Pain from 
cannulas 
Experience of PK clinically  Not asked (has experience in a study) 
Similar to PK study in the vignette √ 
Problems with meds at right times √ Oral better than IV as then only need 1 
cannula 
 
Access to new treatments / phase 1 Important 
to families 
√ Volunteering for projects when no other 
options available. Good quote about 
desperation of people calling from all over the 
world about a study.  
Might be harder for studies where not novel 
treatment 
Families attitudes Motivated improve care for their child. Some 
altruistic but not as many  
Children’s attitudes Distress / pain. Removal of choice (i.e. 
preferred places have lines) 
Avoid / minimise hospital  Avoid overnight where possible- use of hotels 
option 
Piggy backing to clinical care wherever possible √ particularly bloods 
Preparation and organisation √ Key 
Research facilities Access to facilities important- WTCRF big help 
with this (if adopted) 
Priorities- ‘I’m a nurse first and then I’m a 
researcher’ 
Put parent and child first 
Changing meds for research purposes √ Problem for parents and children 
Problem with protocols (protocol acceptability) √ does it work locally? Review for individual pt. 
Doesn’t fit with actual practice  
Guidelines MCRN guidance  
PI decision  
Clinical experience in recognising acceptability 
Guidance Very little in protocol on care of cannula 
Flushes 
 
Problem with sampling requirements √ 
Vascular access Cannulas- pain, lack choice on location  
Capillary hurts more than cannula 
CVL if already sited √ although infection risk 
 
Left over blood (scavenged) √ slight concerns about ‘leftover’- why extra 
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taken? 
Population PK √ 
Levels available for routine care √ 
Sampling windows √ 
Other bodily fluids √ 
Opt in / opt out & deferred consent  √ 
Dried blood spots √ 
Ratio research: clinical  50:50 i.e. Mon-Fri 9-5 but needs to be more 
research team – up to 100% 
Staffing  Plan sampling to avoid overnight / unsocial hrs 
staffing  
Not able offer 24/7 cover  
Support Support staff in clinical areas to participate in 
research.  Workload crucial factor for them 
Context WTCRF √ 
Wards √ 
PIC families distressed but got lines in  
Wards- outpatients- nowhere appropriate 
 
Include all ages √? palliative an exclusion, healthy children 
exclude, those that don’t adhere to treatment 
Priority groups X 
Research feedback Feedback from research important to families 
Care for a patient in a PK study  √ 
Second stage Magnitudinal coding then took place to review attitudes (where appropriate). In Figure 
71 below each method of alternative approaches to PK studies was classified ‘positive’ or ‘negative’ 
with a frequency count for each.   
Figure 71: screenshot of NVivo 11- second line coding with magnitude coding 
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In the screenshot Figure 72 below ‘Levels available for care’ is highlighted, i.e. results from PK studies 
being made available to inform clinical care. This has been sub-coded to ‘positive to levels of care’. 
This features in 10 sources (out of 13 sources) and there were 30 positive comments.  The 19 people 
who stated positive comments are then listed in the side panel of the screenshot and the number 
below each indicates how many comments they each made. Below this are the comments 
themselves are listed below. The screenshot is on participants from focus group 45 and some of their 
quotes are visible in the screenshot.   
Figure 72: screenshot of NVivo 11- featuring 'positive' quotes from participants in FG 45 
 
The 19 participants who made 30 positive comments were then transferred onto paper records, with 
key messages summarised (as in the photograph Figure 73).   
Figure 73: levels available for care: positive and negative comments 
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The numerical data was then imported into excel to allow simple descriptive statistics to be 
calculated (see screenshot Figure 74).  This shows ‘Levels available for care’- 30 positive, 4 negative 
plotted alongside other strategies to allow comparison in a clustered bar chart.   
Figure 74: screenshot of excel and simple quantification of data 
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5. Appendix 5: Support algorithm (from Protocol V6.2, 
02.04.2014) 
If parents experience any distress we will refer to a support algorithm which we have developed: 
    
Step one: is to refer them to a Clinical Nurse Specialist within their area who are often familiar with 
individual families and their history  
Step two: particularly if the situation involves a complaint related to previous care would be to refer 
them to the Patient Advice and Liaison Service (PALS)  
Step three: would be to refer them to the Patient Counselling service within BCH.    
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6. Appendix 6: Data extraction Sheet for scoping review 
 
 
 
